var images_info;if (!images_info) images_info =[]; images_info["82"]={"82004":{"type":"graphic_table","displayName":"Pediatric ambulance equipment for basic life support","title":"Pediatric equipment for basic life support (BLS) ambulances in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric equipment for basic life support (BLS) ambulances in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Required*</td> </tr> <tr> <td class=\"subtitle2_single\">Airway and ventilation</td> </tr> <tr> <td class=\"indent2\">Portable and fixed suction with regulator and wide bore suction tubing</td> </tr> <tr> <td class=\"indent2\">Suction catheters: tonsil-tip and flexible (1 flexible between 6 and 10 F, 1 between 10 F and 16 F)</td> </tr> <tr> <td class=\"indent2\">Fixed and portable metered flow oxygen and oxygen tubing with variable flow regulator</td> </tr> <tr> <td class=\"indent2\">Oxygen masks (valveless and nonrebreathing): adult and child sizes</td> </tr> <tr> <td class=\"indent2\">Nasal cannulas: adult and child sizes</td> </tr> <tr> <td class=\"indent2\">Bag-valve-mask resuscitator: hand operated, self-reexpanding bag for adult (&#8805;1000 mL) and child (450-750 mL) with oxygen reservoir/accumulator, valve, and mask (neonatal, infant, child, and adult sizes)</td> </tr> <tr> <td class=\"indent2\">Airways: oropharyngeal (sizes 0-5); nasopharyngeal (16 F-34 F, adult and child sizes)</td> </tr> <tr> <td class=\"indent2\">Pulse oximeter with pediatric and adult probes</td> </tr> <tr> <td class=\"indent2\">Saline drops and infant nasal bulb syringe</td> </tr> <tr> <td class=\"subtitle2_single\">Monitoring and defibrillation</td> </tr> <tr> <td class=\"indent2\">Automatic external defibrillator with adult and pediatric pads and cables</td> </tr> <tr> <td class=\"subtitle2_single\">Immobilization devices</td> </tr> <tr> <td class=\"indent2\">Rigid cervical collars for children aged 2 years or older</td> </tr> <tr> <td class=\"indent2\">Head immobilization device, eg, firm padding or commercial device (not sand bags)</td> </tr> <tr> <td class=\"indent2\">Upper and lower extremity immobilization devices for children</td> </tr> <tr> <td class=\"indent2\">Backboards</td> </tr> <tr> <td class=\"subtitle2_single\">Obstetrical kit</td> </tr> <tr> <td class=\"subtitle2_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent2\">Access to pediatric protocols</td> </tr> <tr> <td class=\"indent2\">Length-based resuscitation tape OR reference material to guide pediatric drug dosing and equipment sizing based upon length OR age</td> </tr> <tr> <td class=\"indent2\">Pediatric sphygmomanometer</td> </tr> <tr> <td class=\"subtitle1_single\">Optional basic pediatric equipment</td> </tr> <tr> <td class=\"indent1\">Infant oxygen mask</td> </tr> <tr> <td class=\"indent1\">Infant self-inflating resuscitation bag</td> </tr> <tr> <td class=\"indent1\">Infant airways (nasopharyngeal 12 F, 14 F; oropharyngeal size 00)</td> </tr> <tr> <td class=\"indent1\">BP cuffs, neonatal and infant</td> </tr> <tr> <td class=\"indent1\">Pediatric stethoscope</td> </tr> <tr> <td class=\"indent1\">Infant cervical immobilization device</td> </tr> <tr> <td class=\"indent1\">Pediatric backboard and extremity splints</td> </tr> <tr> <td class=\"indent1\">Femur traction device for children</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">F: French.<br />* In addition to standard equipment and supplies as determined by state and local regulations.</div><div class=\"graphic_reference\">Data from: Joint policy statement--Equipment for ground ambulances. American Academy of Pediatrics, American College of Emergency Physicians, American College of Surgeons Committee on Trauma, Emergency Medical Services for Children, Emergency Nurses Association, National Association of EMS Physicians, National Association of State EMS Officials. Prehosp Emerg Care 2014; 18:92.</div><div id=\"graphicVersion\">Graphic 82004 Version 4.0</div></div></div>"},"82005":{"type":"graphic_table","displayName":"Foods better tolerated","title":"Foods and beverages that are better tolerated by irritable bowel syndrome (IBS) patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods and beverages that are better tolerated by irritable bowel syndrome (IBS) patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Water, ginger ale, Sprite&#174;, and Gatorade&#174;</td> </tr> <tr> <td>Soy milk or rice milk</td> </tr> <tr> <td>Soy or rice based products</td> </tr> <tr> <td>Plain pasta, plain noodles, white rice. No sauces or gravies.</td> </tr> <tr> <td>Potato: boiled or baked. No French Fries.</td> </tr> <tr> <td>Breads: French, Italian, whole white, English muffins, and white rolls</td> </tr> <tr> <td>Plain fish, plain chicken, plain turkey, or plain ham</td> </tr> <tr> <td>Eggs: soft-boiled, poached</td> </tr> <tr> <td>Cereals: plain cornflakes, Rice Krispies&#174;, Corn or Rice Chex&#174;, Cheerios&#174;; dry or with soymilk or rice milk</td> </tr> <tr> <td>Salads: lettuce, hard-boiled egg slices, oil and vinegar dressing</td> </tr> <tr> <td>Cooked peas, carrots (avoid raw vegetables)</td> </tr> <tr> <td>Margarine, jams, jellies, peanut butter</td> </tr> <tr> <td>In small amounts: applesauce, cantaloupe, watermelon, honeydew melon</td> </tr> <tr> <td>In small amounts: fruit cocktail, peaches, pears (canned, nondietetic)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Substitutes and alternatives are available for the foods and beverages that induce gastrointestinal symptoms. Listed above are examples of some of the foods and beverages that IBS patents have found to be well tolerated. It is important to use daily vitamins (multivitamin, calcium with vitamin D, folic acid, vitamin B complex, and vitamin C) when on a restricted diet.</div><div class=\"graphic_reference\">Data from: MacDermott RP. Treatment of irritable bowel syndrome in outpatients with inflammatory bowel disease using a food and beverage intolerance, food and beverage avoidance diet. Inflamm Bowel Dis 2007; 13:91.</div><div id=\"graphicVersion\">Graphic 82005 Version 3.0</div></div></div>"},"82006":{"type":"graphic_diagnosticimage","displayName":"Rounded atelectasis PA","title":"Rounded atelectasis in the right lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rounded atelectasis in the right lung</div><div class=\"cntnt\"><img style=\"width:393px; height:320px;\" src=\"images/PULM/82006_Rounded_atelectasis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest frontal radiograph shows a nodular mass in the right mid-lung (long arrow). A tail-like connection is seen between the mass and the hilum (short arrow).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82006 Version 4.0</div></div></div>"},"82007":{"type":"graphic_figure","displayName":"Pelvic floor muscles","title":"Muscles of the female pelvic floor","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Muscles of the female pelvic floor</div><div class=\"cntnt\"><img style=\"width:612px; height:432px;\" src=\"images/OBGYN/82007_Pelvic_floor_muscles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Muscles of the anterior pelvis and pelvic floor.</div><div class=\"graphic_reference\">Reproduced with permission from: Clay JH, Pounds DM. Basic Clinical Massage Therapy: Integrating Anatomy and Treatment. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82007 Version 2.0</div></div></div>"},"82008":{"type":"graphic_picture","displayName":"Hysteroscopic instruments","title":"Hysteroscopic instruments","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic instruments</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/OBGYN/82008_Hysteroscopic_instruments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Scissors. (B) Grasping forceps. (C) Rigid hysteroscopic biopsy forceps.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 82008 Version 1.0</div></div></div>"},"82011":{"type":"graphic_table","displayName":"Sulfonamide antimicrobials (sulfonylarylamines)","title":"Sulfonamide antimicrobials (sulfonylarylamines)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sulfonamide antimicrobials (sulfonylarylamines)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">G6PD risk*</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Systemic agents<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Sulfadiazine</td> <td>Low</td> <td>As single agent or in combination with pyrimethamine</td> </tr> <tr> <td class=\"indent1\">Sulfadoxine</td> <td>&nbsp;</td> <td>As single agent or in combination with pyrimethamine; long-acting<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Sulfaguanidine<sup>&#916;</sup></td> <td>Low</td> <td>Gastrointestinal antimicrobial</td> </tr> <tr> <td class=\"indent1\">Sulfamerazine<sup>&#916;</sup></td> <td>Low</td> <td>In combination with other sulfonamides or trimethoprim</td> </tr> <tr> <td class=\"indent1\">Sulfamethizole<sup>&#916;</sup></td> <td>&nbsp;</td> <td>Urinary tract antimicrobial</td> </tr> <tr> <td class=\"indent1\">Sulfamethazine (sulfadimidine)<sup>&#916;</sup></td> <td>High</td> <td>As single agent or in combination with other sulfonamides</td> </tr> <tr> <td class=\"indent1\">Sulfamethoxazole</td> <td>Variable</td> <td>In combination with trimethoprim or as single agent</td> </tr> <tr> <td class=\"indent1\">Sulfametopyrazine<sup>&#916;</sup></td> <td>&nbsp;</td> <td>In combination with pyrimethamine; long-acting<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Sulfamoxole<sup>&#916;</sup></td> <td>&nbsp;</td> <td>In combination with trimethoprim</td> </tr> <tr> <td class=\"indent1\">Sulfapyridine<sup>&#916;</sup></td> <td>&nbsp;</td> <td>Rarely used due to crystalluria risk</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine (salazosulfapyridine, salazopyrin)</td> <td>High</td> <td>Rheumatologic/gastrointestinal agent (nonantimicrobial); releases sulfapyridine in contact with gut flora</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sulfisoxazole (sulfafurazole)</td> <td>High</td> <td>As single agent or in combination with erythromycin</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Topical and ophthalmic agents</td> </tr> <tr> <td class=\"indent1\">Mafenide</td> <td>&nbsp;</td> <td>Topical solution or cream</td> </tr> <tr> <td class=\"indent1\">Silver sulfadiazine</td> <td>Low</td> <td>Topical cream or ointment</td> </tr> <tr> <td class=\"indent1\">Sulfacetamide</td> <td>High</td> <td>As single agent ophthalmic solution, ointment, various topicals, vaginal or in combination with sulfabenzamide, sulfathiazole, or prednisolone</td> </tr> <tr> <td class=\"indent1\">Sulfanilamide</td> <td>High</td> <td>As single agent vaginal or in combination with other antimicrobials</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">G6PD: glucose-6-phosphate dehydrogenase.<br />* Risk in G6PD deficiency may vary by type. See: <A href=\"http://www.g6pd.org/\" target=_blank>www.g6pd.org/</A>.<br />¶ The human immunodeficiency virus (HIV) protease inhibitors darunavir, fosamprenavir, and tipranavir, as well as the hepatitis C virus (HCV) protease inhibitor simeprevir contain sulfonamide moieties but lack one or both essential functional groups implicated in sulfonamide antibiotic hypersensitivity (ie, N4 arylamine or N-containing ring substitution at N1) and do not appear to cross-react. Refer to text.<br />Δ Not available commercially in United States.<br /><FONT class=lozenge>◊</FONT> Long-acting sulfonamides may be more frequently implicated in allergic reactions and are cleared slowly upon discontinuation.</div><div id=\"graphicVersion\">Graphic 82011 Version 7.0</div></div></div>"},"82012":{"type":"graphic_algorithm","displayName":"Rx psych side effects IFN","title":"Algorithm for pharmacological treatment of interferon-alfa-induced depression","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Algorithm for pharmacological treatment of interferon-alfa-induced depression</div><div class=\"cntnt\"><img style=\"width:599px; height:730px;\" src=\"images/GAST/82012_Rx_psych_side_effects_IFN.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Raison, Charles L, Demetrashvili, Marina, Capuron, Lucile, Miller, Andrew H. Neuropsychiatric adverse effects of interferon-[alpha]: Recognition and Management. CNS Drugs 2005; 19:105. Copyright &#169;2005 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 82012 Version 1.0</div></div></div>"},"82013":{"type":"graphic_table","displayName":"Influences on tests for IDA","title":"Confounding factors in laboratory tests for iron deficiency anemia in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Confounding factors in laboratory tests for iron deficiency anemia in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Expected value in pediatric patients with iron deficiency anemia*</td> <td class=\"subtitle1\">Confounding factors</td> </tr> <tr> <td>Hemoglobin<sup>[1]</sup></td> <td> <p>&#60;11 g/dL (6 months&nbsp;to&nbsp;&#60;5 years old)</p> <p>&#60;11.5 g/dL (5 to &#60;12&nbsp;years old)</p> <p>&#60;12 g/dL (12 to &#60;15 years, and non-pregnant females &#8805; 15 years)</p> <p>&#60;13 g/dL (Males 15 years and older)</p> </td> <td>Viral infections may cause a transient decrease in hemoglobin</td> </tr> <tr> <td>Mean corpuscular volume (MCV)</td> <td> <p>&#60;70 fL (1 to &#60;12 years old)<br /> &#60;80 fL (12 years and older)</p> </td> <td>Thalassemia trait; hemoglobin E</td> </tr> <tr> <td>Red cell distribution width (RDW)</td> <td>&#62;15.8 percent</td> <td>Infection or inflammation, hemolysis</td> </tr> <tr> <td>Erythrocyte protoporphyrin<sup>&#182;</sup></td> <td>&#62;70 to 80 &#181;g/dL</td> <td>Lead poisoning<sup>&#182;</sup></td> </tr> <tr> <td>Total iron-binding capacity (TIBC)</td> <td>&#62;450 &#181;g/dL</td> <td>Liver disease, inflammation, or hemolysis may lower TIBC; pregnancy or hormonal contraceptives may increase TIBC</td> </tr> <tr> <td>Transferrin saturation</td> <td>&#60;12 to 15 percent</td> <td>Infection or inflammation</td> </tr> <tr> <td>Serum ferritin<sup>[2]</sup></td> <td> <p>&#60;12 ng/mL (up to 5 years old)</p> <p>&#60;15 ng/mL (5 years and older)</p> </td> <td>Infection or inflammation; liver disease</td> </tr> <tr> <td>Soluble transferrin receptor (sTfR)</td> <td>&#62;27.3 nmol/L</td> <td>Increased in high turnover states</td> </tr> <tr> <td>Serum iron</td> <td>&#60;30 &#181;g/dL</td> <td>Diurnal variation; iron intake; infection or inflammation</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Reticulocyte hemoglobin content (CHr) or equivalent (Ret-He)<sup>[4]</sup></span>&nbsp;</td> <td>&#60;27 pg</td> <td>Also decreased in thalassemia and thalassemia trait</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>* These values are estimates for most children and adolescents with iron deficiency anemia. More precise standards for each age group are outlined in other UpToDate tables and topics on anemia in children. <br />¶ Erythrocyte protoporphyrin&nbsp;levels usually are not elevated until lead levels are markedly elevated. Thus,&nbsp;it is not a good screening test for mild lead toxicity and is not recommended for screening for pediatric lead poisoning. <br /></FONT></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI><FONT color=black>​DeBenoist, B, McLean, E, Egli, I, et al. Worldwide prevalence of anemia 1993-2005: WHO global database on anemia. World Health Organization, Geneva, 2008. Available at: <A href=\"http://www.who.int/vmnis/anaemia/prevalence/en/\">http://www.who.int/vmnis/anaemia/prevalence/en/</A></FONT></LI>&#xD;&#xA;<LI><FONT color=black>World Health Organization.&nbsp;Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations. Vitamin and Mineral Nutrition Information System. Geneva: World Health Organization; 2011. Publication No. WHO/NMH/NHD/MNM/11.2 [cited 2013 Feb 4]. Available from:http://www.who.int/vmnis/indicators/serum_ferritin.pdf.</FONT></LI>&#xD;&#xA;<LI><FONT color=black>Cogswell ME, Looker AC, Pfeiffer CM, et al. Assessment of iron deficiency in US preschool children and nonpregnant females of childbearing age: National Health and Nutrition Examination Survey 2003–2006. Am J Clin Nutr 2009; 89:1334.</FONT></LI>&#xD;&#xA;<LI>Ullrich C, Wu A, Armsby C, et al. Screening healthy infants for iron deficiency using reticulocyte hemoglobin content. JAMA 2005; 294:924.</LI></OL></div><div id=\"graphicVersion\">Graphic 82013 Version 11.0</div></div></div>"},"82014":{"type":"graphic_picture","displayName":"Gram-negative rods in urine","title":"Gram-negative rods in urine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gram-negative rods in urine</div><div class=\"cntnt\"><img style=\"width:366px; height:240px;\" src=\"images/ID/82014_Gramnegativerods.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of unspun urine (x1000) shows an inflammatory cell and numerous gram-negative bacilli. <EM>Escherichia coli</EM> grew from this specimen. The presence of one or more bacteria per oil immersion field of fresh, unspun urine usually indicates infection with 100,000 or more organisms per mL.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 82014 Version 7.0</div></div></div>"},"82015":{"type":"graphic_picture","displayName":"Deformity from Type III AC joint injury","title":"Deformity following Type III AC joint injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deformity following Type III AC joint injury</div><div class=\"cntnt\"><img style=\"width:396px; height:293px;\" src=\"images/EM/82015_AC_type_III_photo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 65-year-old masters cyclist and professional trombone player reports full, pain-free function after AC injury suffered when a dog ran out in front of him while cycling. Note the intact trapezius and anterior deltoid insertion on the clavicle, and drooped shoulder rather than elevated clavicle in the chronic state.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 82015 Version 4.0</div></div></div>"},"82016":{"type":"graphic_figure","displayName":"mBODE and survival postLVRS","title":"mBODE and survival post-LVRS","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">mBODE and survival post-LVRS</div><div class=\"cntnt\"><img style=\"width:605px; height:422px;\" src=\"images/PULM/82016_mBODE_and_survival_postLVRS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival curves (starting at 6 months after randomization [F06]) for the surgically treated patients in the National Emphysema Treatment Trial who survived and were able to provide data to calculate mBODE (<strong>m</strong>odified <strong>B</strong>ody mass index, airflow <strong>O</strong>bstruction, <strong>D</strong>yspnea, and <strong>E</strong>xercise capacity) 6 (F06) months after randomization. Survival curves are segregated by groups who experienced a decrease in mBODE &gt; 1 (<span class=blue>blue</span>), a rise in mBODE &gt; 1 (<span class=red>red</span>), no change in mBODE (-1 to 1 point change) (<span class=green>green</span>), or missing data (black) from baseline to the starting time point.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &#169; 2008 American Thoracic Society. Martinez, FJ, Han, MK, Andrei, AC, et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. American Journal of Respiratory and Critical Care Medicine 2008; 178:491. Official journal of the American Thoracic Society. Diane Gern, Publisher.</div><div id=\"graphicVersion\">Graphic 82016 Version 2.0</div></div></div>"},"82017":{"type":"graphic_figure","displayName":"Recurrence of insulinoma","title":"Recurrence rate of insulinoma","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Recurrence rate of insulinoma</div><div class=\"cntnt\"><img style=\"width:502px; height:334px;\" src=\"images/ENDO/82017_Recurrence_insulinoma_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Recurrence rate of insulinoma after initial curative surgery in 196 patients in the Mayo Clinic cohort (1927 to 1986). The likelihood of recurrence was greater in those patients with MEN1 (21 versus 7 percent at 20 years).</div><div class=\"graphic_footnotes\">MEN1: multiple endocrine neoplasia type 1.</div><div class=\"graphic_reference\">Courtesy of F John Service, MD.</div><div id=\"graphicVersion\">Graphic 82017 Version 2.0</div></div></div>"},"82018":{"type":"graphic_figure","displayName":"Classification of humeral shaft fractures","title":"Classification of humeral shaft fractures","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Classification of humeral shaft fractures</div><div class=\"cntnt\"><img style=\"width:461px; height:518px;\" src=\"images/EM/82018_Fractures_of_the_humeral_sh.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Müller AO Classification of Fractures/Long Bones (leaflet), Edition 2004/I, ISBN 3-905363-03-8. Copyright © 2004 AO Publishing, Switzerland.</div><div id=\"graphicVersion\">Graphic 82018 Version 2.0</div></div></div>"},"82019":{"type":"graphic_picture","displayName":"AC joint compression test - Part 1","title":"Acromioclavicular joint compression test: Part 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular joint compression test: Part 1</div><div class=\"cntnt\"><img style=\"width:432px; height:312px;\" src=\"images/EM/82019_AC_joint_compression_test1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pain elicited by compression of the acromioclavicular (AC) joint suggests an AC disorder. Testing is performed in two parts. Positioning for part one is pictured above.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 82019 Version 2.0</div></div></div>"},"82020":{"type":"graphic_waveform","displayName":"ST segment changes in MI tutorial","title":"Myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myocardial infarction</div><div class=\"cntnt\"><img style=\"width:416px; height:117px;\" src=\"images/CARD/82020_ST_changes_MI_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">J point and ST segment elevation are the hallmarks of acute myocardial infarction. The ST segment eventually becomes indistinguishable from the T wave.</div><div id=\"graphicVersion\">Graphic 82020 Version 3.0</div></div></div>"},"82021":{"type":"graphic_figure","displayName":"Construction of an ileostomy - suture to abdominal wall","title":"Construction of an ileostomy - suture to abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Construction of an ileostomy - suture to abdominal wall</div><div class=\"cntnt\"><img style=\"width:466px; height:505px;\" src=\"images/SURG/82021_Ileostomy-suture-to-abd-wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts suturing the proximal limb of the ileum to the dermis of the abdominal wall. Sutures are placed through the full thickness of the end of the ileum and through the seromuscular layer 3 cm proximal to the end.</div><div id=\"graphicVersion\">Graphic 82021 Version 1.0</div></div></div>"},"82023":{"type":"graphic_picture","displayName":"Traumatic cataract 2","title":"Traumatic cataract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic cataract</div><div class=\"cntnt\"><img style=\"width:396px; height:272px;\" src=\"images/PEDS/82023_Traumatic_cataract_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Traumatic cataract with opacification of the cortex and disruption of the iris due to a penetrating injury.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82023 Version 2.0</div></div></div>"},"82025":{"type":"graphic_picture","displayName":"Cutaneous lichen planus histopathology","title":"Cutaneous lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cutaneous lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:332px;\" src=\"images/DERM/82025_Cut_lichen_planus_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This specimen from a lesion of cutaneous lichen planus demonstrates a band-like lymphocytic infiltrate, saw-tooth rete ridges, multiple apoptotic keratinocytes, and wedge-shaped hypergranulosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82025 Version 1.0</div></div></div>"},"82026":{"type":"graphic_diagnosticimage","displayName":"Esophageal perf sclerotherapy","title":"Esophageal perforation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal perforation</div><div class=\"cntnt\"><img style=\"width:241px; height:288px;\" src=\"images/GAST/82026_Esophageal_perf_sclerothera.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This barium swallow study was performed in a 45-year old man who presented with severe chest pain following sclerotherapy for esophageal varicies. The study demonstrates two large perforations (arrows) arising from the distal esophagus (E).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 82026 Version 2.0</div></div></div>"},"82027":{"type":"graphic_waveform","displayName":"Advanced case 16","title":"Advanced case 16","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advanced case 16</div><div class=\"cntnt\"><img style=\"width:379px; height:240px;\" src=\"images/CARD/82027_Advanced_case_16.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82027 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"82028":{"type":"graphic_table","displayName":"Rx nonmeningeal crypto","title":"Antifungal treatment recommendations for nonmeningeal cryptococcosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antifungal treatment recommendations for nonmeningeal cryptococcosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Patient group</td> <td class=\"subtitle1\">Initial antifungal regimen</td> <td class=\"subtitle1\">Duration</td> </tr> <tr> <td>Immunosuppressed patients and immunocompetent patients with mild-to-moderate pulmonary cryptococcosis</td> <td>Fluconazole (400 mg per day)</td> <td>6 to 12 months</td> </tr> <tr> <td>Immunosuppressed patients* and immunocompetent patients with severe pulmonary cryptococcosis</td> <td>Same as CNS disease</td> <td>12 months</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Patients with nonmeningeal, nonpulmonary cryptococcosis</td> </tr> <tr> <td class=\"sublist1\">Patients with cryptococcemia</td> <td class=\"sublist_other\">Same as CNS disease</td> <td class=\"sublist_other\">12 months</td> </tr> <tr> <td class=\"sublist1\">Patients for whom CNS disease has been ruled out with no fungemia, with a single site of infection, and with no immunosuppressive risk factors</td> <td class=\"sublist_other\">Fluconazole 400 mg per day</td> <td class=\"sublist_other\">6 to 12 months</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.<br> * Should directly rule out CNS disease with lumbar puncture.</div><div class=\"graphic_reference\">Reproduced with permission from: Perfect JR, Disnukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291. Copyright © 2010 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 82028 Version 2.0</div></div></div>"},"82030":{"type":"graphic_diagnosticimage","displayName":"Pulm bronchogen cyst CT II","title":"Intrapulmonary bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intrapulmonary bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:207px;\" src=\"images/PULM/82030_Pulm_bronchogen_cyst_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan shows a thin-walled gas-filled cyst in right upper lobe.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82030 Version 3.0</div></div></div>"},"82031":{"type":"graphic_figure","displayName":"Simplified current view BMPR-II","title":"Signal transduction of the TGF-β superfamily","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Signal transduction of the TGF-&#946; superfamily</div><div class=\"cntnt\"><img style=\"width:504px; height:367px;\" src=\"images/PULM/82031_Simplified_current_view_BMP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A negative feedback loop is generated by the transcription of the inhibitory Smads by signaling from TGF-&#946; family of ligands (Smad6 preferentially inhibits the BMP/Smad1 pathways, whereas Smad7 appears to act as a more general inhibitor, at least in part by associating with activated type 1 receptors to prevent R-Smad binding). The orphan receptors ALK-1 and ALK-7 are illustrated at the site of their known Smad interactions. For clarity, many other regulatory and interacting pathways are not illustrated.</div><div class=\"graphic_footnotes\">* Endoglin interacts with several receptors.</div><div class=\"graphic_reference\">Reproduced with permission from Wilkins, MR, Gibbs, JS, Shovlin, CL, Lancet 2000: 356:1207. Copyright &#169; 2000 by The Lancet Ltd.</div><div id=\"graphicVersion\">Graphic 82031 Version 1.0</div></div></div>"},"82032":{"type":"graphic_picture","displayName":"Access needles and guidewire","title":"Access needles and guidewire","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Access needles and guidewire</div><div class=\"cntnt\"><img style=\"width:394px; height:554px;\" src=\"images/SURG/82032_Seldinger_kit_ed3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Top panel) Seldinger needle (left) with its sharp solid obturator in place, Potts-Cournand needle (center), with a hollow obturator that allows the operator to see blood flashback , and an 18-gauge thin-wall needle (right). The needles are surrounded by an 0.038-inch, 145-cm J-guidewire.<br> (Bottom panel) A Doppler-guided SmartNeedle.</div><div class=\"graphic_reference\">Reproduced with permission from: Baim DS. Grossman's Cardiac Catheterization, Angiography, and Intervention, Seventh Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82032 Version 2.0</div></div></div>"},"82034":{"type":"graphic_diagnosticimage","displayName":"Chronic thromboemoli US","title":"Chronic thromboemboli","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic thromboemboli</div><div class=\"cntnt\"><img style=\"width:360px; height:277px;\" src=\"images/PULM/82034_Chronic_thromboemoli_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiogram in chronic thromboembolic disease demonstrates marked enlargement of the right atrium and right ventricle with septal flattening.</div><div class=\"graphic_reference\">Courtesy of Peter F Fedullo, MD.</div><div id=\"graphicVersion\">Graphic 82034 Version 2.0</div></div></div>"},"82035":{"type":"graphic_picture","displayName":"Schneider tracheal stent","title":"Schneider tracheal wallstent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schneider tracheal wallstent</div><div class=\"cntnt\"><img style=\"width:348px; height:199px;\" src=\"images/PULM/82035_Schneider_tracheal_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schneider self-expanding tracheal Wallstent shown fully expanded.</div><div id=\"graphicVersion\">Graphic 82035 Version 2.0</div></div></div>"},"82036":{"type":"graphic_picture","displayName":"Auricular perichondritis with abscess","title":"Auricular perichondritis with abscess","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Auricular perichondritis with abscess</div><div class=\"cntnt\"><img style=\"width:599px; height:478px;\" src=\"images/EM/82036_Auricular_perichon_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient has a right ear perichondritis following a high ear piercing.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson MD.</div><div id=\"graphicVersion\">Graphic 82036 Version 6.0</div></div></div>"},"82037":{"type":"graphic_table","displayName":"Difficulty replicating","title":"Reasons for inability to replicate genetic associations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reasons for inability to replicate genetic associations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Possible reasons</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">True variation in the underlying association between genotype and outcome between populations studied</td> </tr> <tr> <td class=\"indent1\">Disease-causing allele is in linkage disequilibrium (ie, is associated) with a different allele at the marker locus (ie, the locus under study) in different groups</td> <td>Unlikely that allelic associations will vary much between continental populations, apart from when disease-causing variant is rare or has been subject to differential selection pressure</td> </tr> <tr> <td class=\"indent1\">Allelic heterogeneity exists between ethnic groups: different variants within the same gene contribute to disease risk</td> <td>Unlikely that much allelic heterogeneity will be present within continental populations, apart from when disease-causing variant is rare or has been subject to differential selection pressure</td> </tr> <tr> <td class=\"indent1\">The association is modified by other genetic or environmental factors that vary between the groups studied</td> <td>Effect modification by genes unlikely to account for failure to replicate studies in similar populations. Modification by environmental factors more likely, not especially when absolute risk of disease varies.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Biases vary between studies</td> </tr> <tr> <td class=\"indent1\">Selection bias: population at risk consists of strata that vary by allele frequencies at the marker locus, or the population is admixed, and the probability of being selected as a case or control varies by stratum</td> <td>Avoidable by careful sampling strategy</td> </tr> <tr> <td class=\"indent1\">Differential misclassification of exposure: for instance, when cases and controls have been genotyped in separate batches with genotyping error rates that vary between batches</td> <td>Easily avoided by appropriate laboratory procedures</td> </tr> <tr> <td class=\"indent1\">Differential misclassification of outcome: possible if genotype is known when outcome is classified</td> <td>Unlikely, because outcome is usually defined in advance of genotyping</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Confounding by population substructure</td> </tr> <tr> <td class=\"indent1\">Population is divided into strata that vary by disease risk and by allele frequencies at the marker locus</td> <td>Unlikely to be a serious problem in most studies: when confounding is a problem, it can be controlled in study design by restriction or use of family-based controls, or in the analysis by quantifying and controlling for substructure</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Absence of power leading to false-negative results in studies that do not replicate earlier positive findings</td> </tr> <tr> <td class=\"indent1\">Inadequate sample sizes, or differences in the efficiency of the sampling strategy (for instance sampling the entire distribution of a trait, instead of the tails of the distribution)</td> <td>Need to establish whether a negative study had adequate power to detect an association of the size originally reported</td> </tr> <tr> <td class=\"indent1\">Non-differential misclassification of outcome</td> <td>Even substantial misclassification of outcome can be compensated for by modest increases in sample size</td> </tr> <tr> <td class=\"indent1\">Failure to consider that the initial effect size reported is an inflation of the true effect size</td> <td>Replication studies should be powered to detect effect sizes that are smaller than the initial effect size reported, especially when the initial study had low power</td> </tr> <tr> <td class=\"indent1\">Case mix heterogeneity in an apparently homogenous outcome between populations studied: for instance in a study of stroke, mix of haemorrhagic and thrombotic subtypes may vary between populations</td> <td>Unlikely to be an explanation for failure to replicate studies in similar populations with similar case sampling strategies</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">False positive results by chance in initial positive studies</td> </tr> <tr> <td class=\"indent1\">Multiple testing and publication bias: multiple loci are assessed in each study, many statistical tests are done, and multiple studies are undertaken but only positive results are reported</td> <td>The most likely reason for failure to replicate</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Colhoun HM, McKeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361:865. Copyright &copy; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 82037 Version 4.0</div></div></div>"},"82039":{"type":"graphic_figure","displayName":"Schem reg glucose metab","title":"Schem reg glucose metab","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Schem reg glucose metab</div><div class=\"cntnt\"><img style=\"width:493px; height:571px;\" src=\"images/ENDO/82039_Schem_reg_glucose_metab.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cryer PE, Polonsky KS. Glucose homeostasis and hypoglycemia. In: Williams Textbook of Endocrinology, 9th ed, Wilson, JD, Foster, DW, Kronenberg, HM, Larsen, PR (Eds), WB Saunders Co., Philadelphia 1998. p.940. Copyright ©1998 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 82039 Version 2.0</div></div></div>"},"82041":{"type":"graphic_figure","displayName":"Exercise training in HF","title":"Efficacy of exercise training in HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Efficacy of exercise training in HF</div><div class=\"cntnt\"><img style=\"width:263px; height:245px;\" src=\"images/CARD/82041_ExercisetraininginHF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plot of individual values for the ventilatory anaerobic threshold (VO2) before and after exercise training in 12 patients with chronic heart failure. All but one patient improved and the rise in mean VO2 (shown in bold lines with 95 percent confidence intervals) was highly significant (p = 0.01).</div><div class=\"graphic_reference\">Data from: Sullivan MJ, Cobb FR, Chest 1992; 101:340S.</div><div id=\"graphicVersion\">Graphic 82041 Version 2.0</div></div></div>"},"82042":{"type":"graphic_figure","displayName":"Diverticulum PI","title":"Diverticulum","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Diverticulum</div><div class=\"cntnt\"><img style=\"width:588px; height:560px;\" src=\"images/PI/82042_Diverticulum_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the various parts of the colon (also known as the large intestine), the rectum, and the anus.</div><div class=\"graphic_reference\">Insert reproduced with permission from: Anatomical Chart Company. Copyright &#169; 2008 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 82042 Version 2.0</div></div></div>"},"82044":{"type":"graphic_picture","displayName":"Isometric jaw opening","title":"Isometric jaw opening","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Isometric jaw opening</div><div class=\"cntnt\"><img style=\"width:243px; height:375px;\" src=\"images/RHEUM/82044_Isometric_jaw_opening.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isometric jaw exercises are particularly useful for patients with temporomandibular joint dysfunction syndrome. These exercises are performed by applying resistance with an open or loosely fisted hand. In the isometric jaw opening exercise, the patient begins with her mouth open about an inch. The resistance and muscle contraction are held for 5 to 10 seconds before relaxing. This is repeated five times per session. Exercises can be performed with moderate resistance applied several sessions per day, or with maximum resistance 1 session per day.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 82044 Version 1.0</div></div></div>"},"82045":{"type":"graphic_table","displayName":"Coping with menopause PI","title":"Ways to cope with menopause symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ways to cope with menopause symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">What you can do</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Hot flashes and night sweats</td> <td>Dress in layers so you can take off clothes if you get hot.</td> </tr> <tr> <td>Keep the thermostat down and avoid hot drinks, such as coffee or tea.</td> </tr> <tr> <td>Put a cold, wet washcloth against your neck during hot flashes.</td> </tr> <tr> <td>Quit smoking, if you smoke. (Smoking makes hot flashes worse.)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Vaginal dryness</td> <td>Use lubricants before sex.</td> </tr> <tr> <td>Use a vaginal moisturizer, such as Replens or Lubrin.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Sleep problems</td> <td>Go to sleep and get up at the same time every day, even when you don't sleep well. (Taking naps can make the problem worse.)</td> </tr> <tr> <td>Avoid caffeine in the afternoon and don't drink much alcohol.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Depression</td> <td class=\"divider_top\">Try to stay active. Exercise helps ward off depression.</td> </tr> <tr> <td>Seek social support from women like you.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82045 Version 3.0</div></div></div>"},"82046":{"type":"graphic_table","displayName":"Rapid overview of hypertensive emergencies in children","title":"Hypertensive emergencies and urgencies in children - rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypertensive emergencies and urgencies in children - rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td class=\"sublist2_start\">Hypertensive emergency - symptomatic severe hypertension or rapid increase in blood pressure associated <strong>with </strong>one or more of the following signs of target-organ damage:</td> </tr> <tr> <td class=\"sublist2\">Seizures or encephalopathy</td> </tr> <tr> <td class=\"sublist2\">Papilledema and retinal hemorrhage or exudates</td> </tr> <tr> <td class=\"sublist2\">Heart failure</td> </tr> <tr> <td class=\"sublist2\">Renal insufficiency</td> </tr> <tr> <td class=\"indent1\">Hypertensive urgency - severe hypertension or rapid increase in blood pressure <strong>without </strong>the presence of severe target-organ damage or major symptoms</td> </tr> <tr> <td class=\"sublist2_start\">Other findings - findings suggesting a specific underlying etiology for hypertension include:</td> </tr> <tr> <td class=\"sublist2\">Hematuria, proteinuria, and edema (glomerulonephritis)</td> </tr> <tr> <td class=\"sublist2\">Ataxia, focal neurologic deficits, lethargy, coma (intracranial mass lesion or intracranial trauma)</td> </tr> <tr> <td class=\"sublist2\">Diminished femoral pulses or lower extremity BP (coarctation of the aorta)</td> </tr> <tr> <td class=\"sublist2\">Sympathomimetic overdose (eg, cocaine, amphetamine ingestion)</td> </tr> <tr> <td class=\"sublist2\">Pregnancy (ecclampsia)</td> </tr> <tr> <td class=\"sublist2\">Abdominal or flank bruit (renovascular disease)</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td class=\"indent1\">Confirm severely elevated blood pressure with strict attention to BP cuff size and placement*</td> </tr> <tr> <td class=\"indent1\">Measure 4 limb BP, especially in infants and young children</td> </tr> <tr> <td class=\"indent1\">Exclude other causes of severe hypertension (eg, primary head trauma, intracranial mass lesion, coarctation of the aorta, sympathomimetic ingestion<sup>&#182;</sup>)</td> </tr> <tr> <td class=\"indent1\">Blood studies: CBC with differential and reticulocyte count; serum electrolytes including calcium, blood urea nitrogen, and creatinine</td> </tr> <tr> <td class=\"indent1\">Urine studies: microscopic urinalysis and urine culture; urine pregnancy test in postmenarchal females, urine drug screen for cocaine, amphetamines, and PCP if drug use suspected</td> </tr> <tr> <td class=\"indent1\">Other diagnostic studies: EKG, chest radiograph (heart failure); Echocardiogram if rapidly available, Head CT if signs of trauma or intracranial mass lesion</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"indent1\">Assess airway and breathing. Perform endotracheal intubation as needed.</td> </tr> <tr> <td class=\"indent1\">Obtain vascular access</td> </tr> <tr> <td class=\"indent1\">Obtain intraarterial line for BP measurement or frequently measure BP by auscultation or rapidly cycling oscillometric BP</td> </tr> <tr> <td class=\"indent1\">Do not delay treatment for arterial cannulation</td> </tr> <tr> <td class=\"indent1\">For hypertensive emergencies, lower BP by no more than 25 percent of the planned total BP reduction over the first 8 hours using IV medication. Treatment should be started immediately. If possible, consult with pediatric nephrologist or other physician with expertise in managing pediatric hypertensive emergencies.<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">For hypertensive urgencies, use either an intravenous or oral medication depending on the clinical circumstances and desired rapidity of antihypertensive effect.<sup>&#916;</sup> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICP: intracranial pressure; BP: blood pressure; CBC: complete blood count; PCP: phencyclidine; EKG: electrocardiogram; CT: computed tomography.<br />* Auscultation is preferred. A BP cuff that is too small will artificially elevate BP.<br />¶ Mixed alpha and beta sympathomimetic ingestions may be accompanied by tachycardia, hypertension, hyperthermia, widened pulse pressure, delirium, seizures, dilated reactive pupils, diaphoresis, and pallor.<br />Δ Refer to UpToDate topics on approach to and management of hypertensive urgencies and emergencies in children. </div><div id=\"graphicVersion\">Graphic 82046 Version 6.0</div></div></div>"},"82047":{"type":"graphic_diagnosticimage","displayName":"Normal postoperative UGI series after sleeve gastrectomy","title":"Normal postoperative upper gastrointestinal (UGI) series after sleeve gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal postoperative upper gastrointestinal (UGI) series after sleeve gastrectomy</div><div class=\"cntnt\"><img style=\"width:432px; height:428px;\" src=\"images/SURG/82047_Norm_postop_UGI_sleeve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upside down &quot;7&quot; view in normal postoperative sleeve gastrectomy.</div><div id=\"graphicVersion\">Graphic 82047 Version 4.0</div></div></div>"},"82048":{"type":"graphic_picture","displayName":"Two-handed bag mask ventilation techniques","title":"Two-handed bag mask ventilation techniques","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Two-handed bag mask ventilation techniques</div><div class=\"cntnt\"><img style=\"width:545px; height:426px;\" src=\"images/EM/82048_Two_handed_tech.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are two ways to perform the two-handed technique. In the traditional method (picture A), both thumbs and index fingers hold pressure along the inferior and superior ridges of the mask. The other three fingers on each hand hold the mandible, in a fashion similar to the one-handed mask hold, and perform a simultaneous chin-lift and jaw-thrust maneuver. This position may not be comfortable to maintain for long periods of time. We recommend another method that uses the stronger thenar eminences to hold the mask in place (picture B). The thenar eminences are positioned parallel to each other along the long axis of each side of the mask, allowing the four remaining fingers to provide chin-lift and jaw-thrust maneuvers.</div><div id=\"graphicVersion\">Graphic 82048 Version 4.0</div></div></div>"},"82050":{"type":"graphic_figure","displayName":"Panniculectomy B","title":"Panniculectomy","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Panniculectomy</div><div class=\"cntnt\"><img style=\"width:531px; height:280px;\" src=\"images/SURG/82050_Panniculectomy_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An elliptical transverse incision is made extending from one flank to the other below the umbilicus.</div><div id=\"graphicVersion\">Graphic 82050 Version 3.0</div></div></div>"},"82052":{"type":"graphic_waveform","displayName":"EP study tracing RF ablation atrial tachycardia","title":"Electrophysiology (EP) study tracing obtained during radiofrequency catheter ablation of atrial tachycardia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Electrophysiology (EP) study tracing obtained during radiofrequency catheter ablation of atrial tachycardia</div><div class=\"cntnt\"><img style=\"width:540px; height:388px;\" src=\"images/CARD/82052_RF_ablation_atrial_tachycar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high posterior right atrium (HRA); posterior left atrium (USER1 and USER 3); proximal, mid, and distal coronary sinus (CS9-10, CS5-6, CS1-2); and right ventricular apex (RVA) in a patient with atrial tachycardia. Radiofrequency energy application at the left atrial site of earliest atrial activation (USER1) causes initial rate acceleration, consistent with heating of an automatic focus; this is followed by abrupt termination (*) of the atrial tachycardia, resulting in a junctional rhythm. The patient had no further tachycardia during follow-up and left ventricular function returned to normal within four months of the ablation procedure, confirming that the cardiomyopathy was tachycardia induced.</div><div id=\"graphicVersion\">Graphic 82052 Version 3.0</div></div></div>"},"82053":{"type":"graphic_figure","displayName":"Variation small saphenous vein anatomy","title":"Variation small saphenous vein anatomy","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Variation small saphenous vein anatomy</div><div class=\"cntnt\"><img style=\"width:534px; height:545px;\" src=\"images/SURG/82053_Small-saphenous-vein-var.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Based on information from Schweighofer G, M&#252;hlberger D, Brenner E. The anatomy of the small saphenous vein; fascial and neural relations, saphenofemoral junction, and valves. J Vasc Surg 2010; 51;982.</div><div id=\"graphicVersion\">Graphic 82053 Version 2.0</div></div></div>"},"82054":{"type":"graphic_picture","displayName":"SPTCL","title":"Subcutaneous panniculitis-like T cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Subcutaneous panniculitis-like T cell lymphoma</div><div class=\"cntnt\"><img style=\"width:584px; height:190px;\" src=\"images/HEME/82054_SPTCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lobular and septal pattern of subcutaneous infiltration.<br />(B) TIA-1 immunohistochemistry showing characteristic rimming about individual adipocytes.</div><div class=\"graphic_reference\">Reproduced with permission from: Elder DE, Elenitsas R, Johnson BL Jr, et al. Lever's Histopathology of the Skin, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82054 Version 7.0</div></div></div>"},"82057":{"type":"graphic_diagnosticimage","displayName":"Proximal phalanx distal fracture","title":"Fracture of the distal portion of the proximal phalanx","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Fracture of the distal portion of the proximal phalanx</div><div class=\"cntnt\"><img style=\"width:480px; height:410px;\" src=\"images/EM/82057_Prox_phalanx_distal_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiographs reveal a nondisplaced, nonangulated fracture (white arrow) of the proximal phalanx that does not appear to involve the proximal interphalangeal joint.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 82057 Version 2.0</div></div></div>"},"82058":{"type":"graphic_table","displayName":"Contraindications to bronchial challenge testing","title":"Contraindications to bronchial challenge testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to bronchial challenge testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Airflow limitation</td> </tr> <tr> <td class=\"indent1\">FEV<sub>1</sub> &#60;60% predicted (adults or children) or &#60;1.5 L (adults)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">FEV<sub>1</sub> &#60;75% predicted (adults or children) for exercise or eucapnic voluntary hyperpnoea challenge</td> </tr> <tr> <td class=\"subtitle1_single\">Spirometry quality</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Inability to perform acceptable and repeatable spirometry maneuvers throughout the test procedure</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular and other problems</td> </tr> <tr> <td class=\"indent1\">Myocardial infarction or stroke in last three months</td> </tr> <tr> <td class=\"indent1\">Uncontrolled hypertension</td> </tr> <tr> <td class=\"indent1\">Known aortic aneurysm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Recent eye surgery or intracranial pressure elevation risk</td> </tr> <tr> <td class=\"subtitle1_single\">General</td> </tr> <tr> <td class=\"indent1\">Inability to perform any of the testing maneuvers, such as inhaling the challenge agent consistently or exercising on treadmill or bicycle during an exercise challenge</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in one second.</div><div class=\"graphic_reference\">Reproduced with permission of the &copy; ERS 2018: European Respiratory Journal May 2017, 49 (5) 1601526; DOI: 10.1183/13993003.01526-2016.</div><div id=\"graphicVersion\">Graphic 82058 Version 5.0</div></div></div>"},"82060":{"type":"graphic_picture","displayName":"Gonorrhea purpura","title":"Disseminated gonococcal infection","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Disseminated gonococcal infection</div><div class=\"cntnt\"><img style=\"width:540px; height:363px;\" src=\"images/DERM/82060_Gonorrhea_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This adolescent girl developed tender purpuric papules on her right leg associated with fever and arthralgias. A cervical examination revealed cervical and adnexal tenderness, and a culture was positive for <em>Neisseria gonorrhoeae</em>.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 82060 Version 4.0</div></div></div>"},"82064":{"type":"graphic_figure","displayName":"Confounding in Mendelian randomization","title":"Confounding in Mendelian randomization","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Confounding in Mendelian randomization</div><div class=\"cntnt\"><img style=\"width:528px; height:672px;\" src=\"images/PC/82064_Confound_Mendel_rand_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Confounding by linkage disequilibrium occurs when loci in close proximity to the risk allele are predictors of the outcome.<br> (B) Confounding by population stratification occurs when ethnicity (or genetic ancestry) is associated with both the risk allele and the outcome.</div><div id=\"graphicVersion\">Graphic 82064 Version 3.0</div></div></div>"},"82065":{"type":"graphic_figure","displayName":"AP distal radius height","title":"Distal radius anatomy, antero-posterior (AP) view","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Distal radius anatomy, antero-posterior (AP) view</div><div class=\"cntnt\"><img style=\"width:544px; height:593px;\" src=\"images/EM/82065_AP_distal_radius_height.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Measurements performed on the AP view include radial inclination, radial height, and ulnar variance. Abnormal measurements are often found in the setting of distal radius fracture.</div><div id=\"graphicVersion\">Graphic 82065 Version 2.0</div></div></div>"},"82067":{"type":"graphic_figure","displayName":"Fatty alcohol cycle","title":"Fatty alcohol cycle","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Fatty alcohol cycle</div><div class=\"cntnt\"><img style=\"width:525px; height:400px;\" src=\"images/NEURO/82067_Fatty_alcohol_cycle.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82067 Version 1.0</div></div></div>"},"82069":{"type":"graphic_diagnosticimage","displayName":"Breast MRI for evaluating extent of disease - case 2","title":"Breast MRI for evaluating extent of disease - case 2","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Breast MRI for evaluating extent of disease - case 2</div><div class=\"cntnt\"><img style=\"width:514px; height:328px;\" src=\"images/SURG/82069_Br_MRI_eval_ext_dis_case2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast MRI can be used to determine the extent of disease in newly diagnosed cancer patient. Architectural distortion was detected in the central left breast on screening mammography. Diagnostic mammography confirmed persistence of the abnormality (A) and biopsy under ultrasound-guidance confirmed invasive ductal carcinoma. Preoperative MRI confirmed the large invasive cancer in the left breast (B) and a second suspiciously enhancing lesion in the outer right breast (C). Subsequent biopsy of the right breast finding revealed an invasive ductal cancer confirming contralateral disease.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 82069 Version 4.0</div></div></div>"},"82071":{"type":"graphic_picture","displayName":"Urothelial CIS H","title":"Urothelial carcinoma in situ (CIS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urothelial carcinoma in situ (CIS)</div><div class=\"cntnt\"><img style=\"width:432px; height:269px;\" src=\"images/ONC/82071_Urothelial_CIS_H.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 82071 Version 1.0</div></div></div>"},"82072":{"type":"graphic_diagnosticimage","displayName":"Reticular opacities PA","title":"Reticular opacities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reticular opacities</div><div class=\"cntnt\"><img style=\"width:371px; height:371px;\" src=\"images/PULM/82072_Reticular_opacities_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standard International Labor Office film for small irregular s opacities, less than 1.5 mm in diameter (reticular opacities).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82072 Version 3.0</div></div></div>"},"82073":{"type":"graphic_picture","displayName":"Seborrheic dermatitis ear","title":"Seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:346px; height:330px;\" src=\"images/DERM/82073_Seborrheicdermatitisear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient has involvement of the retroauricular area.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's photoguide of common skin disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82073 Version 3.0</div></div></div>"},"82074":{"type":"graphic_diagnosticimage","displayName":"Late acromegalic arthropathy","title":"Late acromegalic arthropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Late acromegalic arthropathy</div><div class=\"cntnt\"><img style=\"width:407px; height:288px;\" src=\"images/RHEUM/82074_Late_acromegalic_arthropath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain film of the hands shows the changes in late acromegalic arthropathy. The abnormalities include tufting of the terminal phalanges, widening of the joint spaces of the metacarpophalangeal joints, and degenerative changes, seen particularly in the thumb and first carpometacarpal joints and in the proximal interphalangeal joint of the right little finger.</div><div class=\"graphic_reference\">Courtesy of Verna Wright, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 82074 Version 2.0</div></div></div>"},"82075":{"type":"graphic_table","displayName":"Contraindications and precautions adult vaccines","title":"Contraindications and precautions to commonly used vaccines in adults*<sup>¶</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications and precautions to commonly used vaccines in adults*<sup>&para;</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine</td> <td class=\"subtitle1\">Contraindications</td> <td class=\"subtitle1\">Precautions</td> </tr> <tr class=\"divider_bottom\"> <td>Influenza, injectable trivalent (TIV)</td> <td>Severe allergic reaction (eg, anaphylaxis) after previous dose of any influenza vaccine or to a vaccine component, including egg protein</td> <td> <p>Moderate or severe acute illness with or without fever</p> History of Guillain-Barr&#233; syndrome (GBS) within six weeks of previous influenza vaccination</td> </tr> <tr class=\"divider_bottom\"> <td>Influenza, live attenuated (LAIV)<sup>&#916;</sup></td> <td> <p>Severe allergic reaction (eg, anaphylaxis) after previous dose of any influenza vaccine or to a vaccine component, including egg protein</p> <p>Immune suppression</p> <p>Certain chronic medical conditions such as asthma, diabetes, heart or kidney disease<sup>&#9674;</sup></p> Pregnancy</td> <td> <p>Moderate or severe acute illness with or without fever</p> <p>History of GBS within six weeks of previous influenza vaccination</p> Receipt of specific antivirals (ie, amantadine, rimantadine, zanamivir, or oseltamivir) 48 hours before vaccination; avoid use of these antiviral drugs for 14 days after vaccination</td> </tr> <tr class=\"divider_bottom\"> <td>Tetanus, diphtheria, pertussis (Tdap); tetanus, diphtheria (Td)</td> <td> <p>Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component</p> For Tdap only: Encephalopathy (eg, coma, decreased level of consciousness, or prolonged seizures) not attributable to another identifiable cause within seven days of administration of a previous dose of Tdap or diphtheria and tetanus toxoids and pertussis (DTP) or diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine</td> <td> <p>Moderate or severe acute illness with or without fever</p> <p>GBS within six weeks after a previous dose of tetanus toxoid-containing vaccine</p> <p>History of arthus-type hypersensitivity reactions after a previous dose of tetanus or diphtheria toxoid-containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus toxoid-containing vaccine</p> For Tdap only: Progressive or unstable neurologic disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized</td> </tr> <tr class=\"divider_bottom\"> <td>Varicella<sup>&#916;</sup></td> <td> <p>Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component</p> <p>Known severe immunodeficiency (eg, from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long-term immunosuppressive therapy<sup>&#167;</sup> or patients with human immunodeficiency virus (HIV) infection who are severely immunocompromised)</p> Pregnancy</td> <td> <p>Recent (&#8804;11 months) receipt of antibody-containing blood product (specific interval depends on product)<sup>&#165;</sup></p> <p>Moderate or severe acute illness with or without fever</p> Receipt of specific antivirals (ie, acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination; if possible, delay resumption of these antiviral drugs for 14 days after vaccination</td> </tr> <tr class=\"divider_bottom\"> <td>Human papillomavirus (HPV)</td> <td>Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component</td> <td> <p>Moderate or severe acute illness with or without fever</p> Pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td>Zoster</td> <td> <p>Severe allergic reaction (eg, anaphylaxis) to a vaccine component</p> <p>Known severe immunodeficiency (eg, from hematologic and solid tumors, receipt of chemotherapy, or long-term immunosuppressive therapy<sup>&#167;</sup> or patients with HIV infection who are severely immunocompromised)</p> Pregnancy</td> <td> <p>Moderate or severe acute illness with or without fever</p> Receipt of specific antivirals (ie, acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination; if possible, avoid use of these antiviral drugs for 14 days after vaccination</td> </tr> <tr class=\"divider_bottom\"> <td>Measles, mumps, rubella (MMR)<sup>&#916;</sup></td> <td> <p>Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component</p> <p>Known severe immunodeficiency (eg, from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long-term immunosuppressive therapy<sup>&#167;</sup> or patients with HIV infection who are severely immunocompromised)</p> Pregnancy</td> <td> <p>Moderate or severe acute illness with or without fever</p> <p>Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product)<sup>&#135;</sup></p> <p>History of thrombocytopenia or thrombocytopenic purpura</p> Need for tuberculin skin testing<sup>&#134;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Pneumococcal polysaccharide (PPSV)</td> <td>Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component</td> <td>Moderate or severe acute illness with or without fever</td> </tr> <tr class=\"divider_bottom\"> <td>Meningococcal, conjugate (MCV4); meningococcal, polysaccharide (MPSV4)</td> <td>Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component</td> <td>Moderate or severe acute illness with or without fever</td> </tr> <tr class=\"divider_bottom\"> <td>Hepatitis A (HepA)</td> <td>Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component</td> <td> <p>Moderate or severe acute illness with or without fever</p> Pregnancy</td> </tr> <tr> <td>Hepatitis B (HepB)</td> <td>Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component</td> <td>Moderate or severe acute illness with or without fever</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><sup></sup></div><div class=\"graphic_footnotes\">* Vaccine package inserts and the full Advisory Committee on Immunization Practices (ACIP) recommendations for these vaccines should be consulted for additional information on vaccine-related contraindications and precautions and for more information on vaccine excipients. Events or conditions listed as precautions should be reviewed carefully. Benefits of and risks for administering a specific vaccine to a person under these circumstances should be considered. If the risk from the vaccine is believed to outweigh the benefit, the vaccine should not be administered. If the benefit of vaccination is believed to outweigh the risk, the vaccine should be administered.<br />&#182; Regarding latex allergy: Some types of prefilled syringes contain natural rubber latex or dry natural latex rubber. Consult the package insert for any vaccine administered.<br />&Delta; LAIV, MMR, and varicella vaccines can be administered on the same day. If not administered on the same day, these live vaccines should be separated by at least 28 days.<br /><span class=\"lozenge\">&loz;</span> See Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010; 59(No. RR-8). Available at: <a href=\"http://www.cdc.gov/vaccines/hcp/acip-recs/index.html\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/acip-recs/index.html</a>.<br />&sect; Substantially immunosuppressive glucocorticoid dose is considered to be &ge;2 weeks of daily receipt of &ge;20 mg or &ge;2 mg/kg body weight of prednisone or equivalent.<br />&yen; Vaccine should be deferred for the appropriate interval if replacement immune globulin products are being administered.<br />&Dagger; See Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 60(No. RR-2). Available at: <a href=\"http://www.cdc.gov/vaccines/hcp/acip-recs/index.html\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/acip-recs/index.html</a>.<br />&dagger; Measles vaccination might suppress tuberculin reactivity temporarily. Measles-containing vaccine may be administered on the same day as tuberculin skin testing. If testing cannot be performed until after the day of MMR vaccination, the test should be postponed for &ge;4 weeks after the vaccination. If an urgent need exists to skin test, do so with the understanding that reactivity might be reduced by the vaccine.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Centers for Disease Control and Prevention. Contraindications and precautions to commonly used vaccines. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Morbidity and Mortality Weekly Report 2011; 60:40. </li>&#xD;&#xA;    <li>Atkinson W, Wolfe S, Hamborsky J (Eds). Epidemiology and prevention of vaccine preventable diseases, 12th Ed. Washington, DC: Public Health Foundation, 2011. Available at: <a href=\"http://www.cdc.gov/vaccines/pubs/pinkbook/index.html\" target=\"_blank\">http://www.cdc.gov/vaccines/pubs/pinkbook/index.html</a>. </li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted from: Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule - United States, 2012. MMWR Morbidity and Mortality Weekly Report 2012; 61:1.</div><div id=\"graphicVersion\">Graphic 82075 Version 3.0</div></div></div>"},"82076":{"type":"graphic_picture","displayName":"SIP blue abdomen distension","title":"Spontaneous intestinal perforation in a neonate with the classic features of abdominal distension and bluish discoloration of the abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spontaneous intestinal perforation in a neonate with the classic features of abdominal distension and bluish discoloration of the abdominal wall</div><div class=\"cntnt\"><img style=\"width:324px; height:294px;\" src=\"images/PEDS/82076_SIP_blue_abdomen_distension.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mary Brandt, MD.</div><div id=\"graphicVersion\">Graphic 82076 Version 2.0</div></div></div>"},"82077":{"type":"graphic_diagnosticimage","displayName":"Salter IV fracture","title":"Salter IV fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Salter IV fracture</div><div class=\"cntnt\"><img style=\"width:429px; height:544px;\" src=\"images/EM/82077_Salter_IV_fracture_Edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior posterior view of the right foot. Salter Harris type IV fracture of the proximal phalanx of the first toe with associated soft tissue swelling (arrow).</div><div class=\"graphic_reference\">Courtesy of David Mathison, MD and Dewesh Agrawal, MD.</div><div id=\"graphicVersion\">Graphic 82077 Version 4.0</div></div></div>"},"82078":{"type":"graphic_figure","displayName":"Colonic J-pouch rect reservoir","title":"Colonic J-pouch","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Colonic J-pouch</div><div class=\"cntnt\"><img style=\"width:486px; height:484px;\" src=\"images/ONC/82078_Colonic_J_pouch_rect_reservoir.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A colonic J-pouch is created by folding the distal colon on itself, followed by division of the septum and creation of a reservoir using a linear stapler. The pouch is suitable for either transanally sutured or stapled reconstructions.</div><div id=\"graphicVersion\">Graphic 82078 Version 8.0</div></div></div>"},"82081":{"type":"graphic_figure","displayName":"Electrolyte patterns PFTs","title":"The characteristic electrolyte secretory concentration patterns observed in pancreatic fluid in response to secretin administration","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">The characteristic electrolyte secretory concentration patterns observed in pancreatic fluid in response to secretin administration</div><div class=\"cntnt\"><img style=\"width:484px; height:403px;\" src=\"images/GAST/82081_Electrolyte_patterns_PFTs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sodium and potassium are maintained at stable concentrations and isotonic to plasma. There is a gradual rise in bicarbonate concentration to a peak of approximately 120 mEq/L. Chloride exhibits a reciprocal decrease in concentration.</div><div class=\"graphic_reference\">Courtesy of Cleveland Clinic Foundation.</div><div id=\"graphicVersion\">Graphic 82081 Version 1.0</div></div></div>"},"82082":{"type":"graphic_diagnosticimage","displayName":"Perirectal fistula EUS","title":"Perirectal fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perirectal fistula</div><div class=\"cntnt\"><img style=\"width:319px; height:319px;\" src=\"images/GAST/82082_Perirectal_fistula_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radial scanning endoscopic ultrasound image showing the relationship between a fistula and the external anal sphincter (EAS) and vagina. Air within the fistula makes it visible on the endoscopic ultrasound image.</div><div class=\"graphic_reference\">Courtesy of David A Schwartz, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 82082 Version 2.0</div></div></div>"},"82083":{"type":"graphic_table","displayName":"Clues RD young adult","title":"Clues to dyslexia in young adults and adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clues to dyslexia in young adults and adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Problems in speaking</td> </tr> <tr> <td>Persistence of earlier oral language difficulties</td> </tr> <tr> <td>The mispronunciation of the names of people and places, and tripping over parts of words</td> </tr> <tr> <td>Difficulty remembering names of people and places and the confusion of names that sound alike</td> </tr> <tr> <td>A struggle to retrieve words: \"It was on the tip of my tongue\"</td> </tr> <tr> <td>Lack of glibness, especially if put on the spot</td> </tr> <tr> <td>Spoken vocabulary that is smaller than listening vocabulary, and hesitation to say aloud words that might be mispronounced</td> </tr> <tr> <td class=\"subtitle1_single\">Problems in reading</td> </tr> <tr> <td>A childhood history of reading and spelling difficulties</td> </tr> <tr> <td>Word reading becomes more accurate over time but continues to require great effort</td> </tr> <tr> <td>Lack of fluency</td> </tr> <tr> <td>Embarrassment caused by oral reading: the avoidance of Bible study groups, reading at Passover seders, or delivering a written speech</td> </tr> <tr> <td>Trouble reading and pronouncing uncommon, strange, or unique words such as people's names, street or location names, food dishes on a menu (often resorting to asking the waiter about the special of the day or resorting to saying, \"I'll have what he's having,\" to avoid the embarrassment of not being able to read the menu)</td> </tr> <tr> <td>Persistent reading problems</td> </tr> <tr> <td>The substitution of made-up words during reading for words that cannot be pronounced--for example, <em>metropolitan</em> becomes <em>mitan</em>--and a failure to recognize the word <em>metropolitan</em> when it is seen again or heard in a lecture the next day</td> </tr> <tr> <td>Extreme fatigue from reading</td> </tr> <tr> <td>Slow reading of most materials: books, manuals, subtitles in foreign films</td> </tr> <tr> <td>Penalized by multiple-choice tests</td> </tr> <tr> <td>Unusually long hours spent reading school- or work-related materials</td> </tr> <tr> <td>Frequent sacrifice of social life for studying</td> </tr> <tr> <td>A preference for books with figures, charts, or graphics</td> </tr> <tr> <td>A preference for books with fewer words per page or with lots of white showing on a page</td> </tr> <tr> <td>Disinclination to read for pleasure</td> </tr> <tr> <td>Spelling that remains disastrous and a preference for less complicated words in writing that are easier to spell</td> </tr> <tr> <td>Particularly poor performance on rote clerical task</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">2/26/2008 - Fax permission request 10/10/2008--Permission granted for a 5-year period; figures to Terrence, invoices to Susan (JD). The total fee of $&amp;quot;110.00&amp;quot;was originally charged to Clues_RD_early_childhood Clues_RD_2nd_grade_and_up Clues_RD_young_adult</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51024&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reproduced with permission from: Shaywitz S. Overcoming Dyslexia: A New and Complete Science-Based Program for Reading Problems at Any Level. Copyright © 2003 by Sally Shaywitz, MD. Used with permission of Alfred A. Knopf, a division of Random House, Inc. For online information about other Random House, Inc. books and authors, see the internet website at www.randomhouse.com.</div><div id=\"graphicVersion\">Graphic 82083 Version 7.0</div></div></div>"},"82084":{"type":"graphic_table","displayName":"Ovulation induction in PCOS","title":"Comparison between laparoscopic ovulation induction and gonadotropin ovulation induction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison between laparoscopic ovulation induction and gonadotropin ovulation induction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Laparoscopic ovarian drilling</td> <td class=\"subtitle1\">Gonadotropin ovulation induction</td> </tr> <tr> <td>Advantages</td> <td> <p>One-time, minimally invasive procedure</p> <p>Normalizes endocrinologic and ultrasonographic abnormalities</p> <p>Restores ovulatory cycles for many years</p> <p>Pregnancy and live birth rates are comparable to gonadotropin ovulation induction with no increase in multiple pregnancy or OHSS</p> <p>Improves response to gonadotropin superovulation for IVF</p> <p>May improve acne and hirsutism</p> </td> <td> <p>Comparable pregnancy and live birth rates to ovarian drilling without surgery</p> <p>Widespread availability</p> </td> </tr> <tr> <td rowspan=\"2\">&nbsp;<br /> Disadvantages</td> </tr> <tr> <td> <p>Surgical risks inherent with laparoscopy</p> <p>Postoperative adhesions</p> <p>Diminished ovarian reserve versus normalization of elevated AMH and antral follicle counts</p> <p>Few clinicians in the United States offer it</p> </td> <td> <p>Significantly higher risk for multiple pregnancy</p> <p>Higher risk of OHSS</p> <p>Greater cost compared with ovarian drilling</p> <p>High patient inconvenience due to daily injections and frequent visits for monitoring</p> <p>No benefit beyond the treatment cycle</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OHSS: ovarian hyperstimulation syndrome; IVF: in vitro fertilization; AMH: anti-Müllerian hormone.</div><div id=\"graphicVersion\">Graphic 82084 Version 4.0</div></div></div>"},"82086":{"type":"graphic_waveform","displayName":"Hypercalcemia tutorial","title":"Hypercalcemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypercalcemia</div><div class=\"cntnt\"><img style=\"width:357px; height:107px;\" src=\"images/CARD/82086_Hypercalcemia_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A short QT interval (&lt;0.36 seconds), primarily secondary to a decrease in the ST segment duration, is characteristic of hypercalcemia. The initial portion of the T wave has an abrupt upslope.</div><div id=\"graphicVersion\">Graphic 82086 Version 2.0</div></div></div>"},"82087":{"type":"graphic_picture","displayName":"Mixed gonadal dysgenesis","title":"Mixed gonadal dysgenesis: Severe hypospadias","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Mixed gonadal dysgenesis: Severe hypospadias</div><div class=\"cntnt\"><img style=\"width:620px; height:231px;\" src=\"images/PEDS/82087_mixed_gonadal_dysgenesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two patients with mixed gonadal dysgenesis and severe hypospadias. Panel&nbsp;A is one patient and&nbsp;panels B and C are another.&nbsp;In panel C, the urethral opening is denoted by the arrow.</div><div class=\"graphic_reference\">Courtesy of Dr. Laurence Baskin.</div><div id=\"graphicVersion\">Graphic 82087 Version 5.0</div></div></div>"},"82088":{"type":"graphic_figure","displayName":"Anatomy of the cricothyroid membrane","title":"Anatomy of the cricothyroid membrane","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Anatomy of the cricothyroid membrane</div><div class=\"cntnt\"><img style=\"width:535px; height:505px;\" src=\"images/EM/82088_Cric_anatomy_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The cricothyroid muscle is bilateral and depicted on one side for illustrative purposes.</div><div id=\"graphicVersion\">Graphic 82088 Version 4.0</div></div></div>"},"82089":{"type":"graphic_figure","displayName":"Structure of bisphosphonates","title":"Biochemical structure of different bisphosphonates","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Biochemical structure of different bisphosphonates</div><div class=\"cntnt\"><img style=\"width:516px; height:118px;\" src=\"images/ENDO/82089_Structure_of_bisphosphonate.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82089 Version 1.0</div></div></div>"},"82091":{"type":"graphic_figure","displayName":"Indirect inguinal hernia B","title":"Indirect inguinal hernia","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Indirect inguinal hernia</div><div class=\"cntnt\"><img style=\"width:522px; height:266px;\" src=\"images/PEDS/82091_Indirect_inguinal_hernia_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse section of the anterior abdominal wall illustrates the herniation of peritoneal contents into the inguinal canal through the internal inguinal ring, along the course of the spermatic cord.</div><div class=\"graphic_reference\">Adapted from O'Rahilly. Abdominal walls. In: Basic Human Anatomy, W.B. Saunders Company, Philadelphia 1983. p.230.</div><div id=\"graphicVersion\">Graphic 82091 Version 1.0</div></div></div>"},"82093":{"type":"graphic_picture","displayName":"Medullary thyroid cancer","title":"Medullary thyroid cancer: Findings on surgical histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medullary thyroid cancer: Findings on surgical histology</div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/ENDO/82093_Medullary_thyroid_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen showing typical histologic appearance of medullary cancer.</div><div id=\"graphicVersion\">Graphic 82093 Version 3.0</div></div></div>"},"82094":{"type":"graphic_table","displayName":"Dietary fiber content of frequently consumed foods","title":"Dietary fiber content of frequently consumed foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary fiber content of frequently consumed foods</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">Fiber, g/serving</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fruits</td> </tr> <tr> <td class=\"indent1\">Apple (with skin)</td> <td>3.5/1 medium-sized apple</td> </tr> <tr> <td class=\"indent1\">Apricot (fresh)</td> <td>1.8/3 apricots</td> </tr> <tr> <td class=\"indent1\">Banana</td> <td>2.5/1 banana</td> </tr> <tr> <td class=\"indent1\">Cantaloupe</td> <td>2.7/half edible portion</td> </tr> <tr> <td class=\"indent1\">Dates</td> <td>13.5/1 cup (chopped)</td> </tr> <tr> <td class=\"indent1\">Grapefruit</td> <td>1.6/half edible portion</td> </tr> <tr> <td class=\"indent1\">Grapes</td> <td>2.6/10 grapes</td> </tr> <tr> <td class=\"indent1\">Oranges</td> <td>2.6/1 orange</td> </tr> <tr> <td class=\"indent1\">Peach (with skin)</td> <td>2.1/1 peach</td> </tr> <tr> <td class=\"indent1\">Pear (with skin)</td> <td>4.6/1 pear</td> </tr> <tr> <td class=\"indent1\">Pineapple</td> <td>2.2/1 cup (diced)</td> </tr> <tr> <td class=\"indent1\">Prunes</td> <td>11.9/11 dried prunes</td> </tr> <tr> <td class=\"indent1\">Raisins</td> <td>2.2/packet</td> </tr> <tr> <td class=\"indent1\">Strawberries</td> <td>3.0/1 cup</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Juices</td> </tr> <tr> <td class=\"indent1\">Apple</td> <td>0.74/1 cup</td> </tr> <tr> <td class=\"indent1\">Grapefruit</td> <td>1.0/1 cup</td> </tr> <tr> <td class=\"indent1\">Grape</td> <td>1.3/1 cup</td> </tr> <tr> <td class=\"indent1\">Orange</td> <td>1.0/1 cup</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vegetables</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Cooked</td> </tr> <tr> <td class=\"indent2\">Asparagus</td> <td>1.5/7 spears</td> </tr> <tr> <td class=\"indent2\">Beans, string, green</td> <td>3.4/1 cup</td> </tr> <tr> <td class=\"indent2\">Broccoli</td> <td>5.0/1 stalk</td> </tr> <tr> <td class=\"indent2\">Brussels sprouts</td> <td>4.6/7-8 sprouts</td> </tr> <tr> <td class=\"indent2\">Cabbage</td> <td>2.9/1 cup (cooked)</td> </tr> <tr> <td class=\"indent2\">Carrots</td> <td>4.6/1 cup</td> </tr> <tr> <td class=\"indent2\">Cauliflower</td> <td>2.1/1 cup</td> </tr> <tr> <td class=\"indent2\">Peas</td> <td>7.2/1 cup (cooked)</td> </tr> <tr> <td class=\"indent2\">Potato (with skin)</td> <td>2.3/1 boiled</td> </tr> <tr> <td class=\"indent2\">Spinach</td> <td>4.1/1 cup (raw)</td> </tr> <tr> <td class=\"indent2\">Squash, summer</td> <td>3.4/1 cup (cooked, diced)</td> </tr> <tr> <td class=\"indent2\">Sweet potatoes</td> <td>2.7/1 baked</td> </tr> <tr> <td class=\"indent2\">Zucchini</td> <td>4.2/1 cup (cooked, diced)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Raw</td> </tr> <tr> <td class=\"indent2\">Cucumber</td> <td>0.2/6-8 slices with skin</td> </tr> <tr> <td class=\"indent2\">Lettuce</td> <td>2.0/1 wedge iceberg</td> </tr> <tr> <td class=\"indent2\">Mushrooms</td> <td>0.8/half cup (sliced)</td> </tr> <tr> <td class=\"indent2\">Onions</td> <td>1.3/1 cup</td> </tr> <tr> <td class=\"indent2\">Peppers, green</td> <td>1.0/1 pod</td> </tr> <tr> <td class=\"indent2\">Tomato</td> <td>1.8/1 tomato</td> </tr> <tr> <td class=\"indent2\">Spinach</td> <td>8.0/1 cup (chopped)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Legumes</td> </tr> <tr> <td class=\"indent2\">Baked beans</td> <td>18.6/1 cup</td> </tr> <tr> <td class=\"indent2\">Dried peas</td> <td>4.7/half cup (cooked)</td> </tr> <tr> <td class=\"indent2\">Kidney beans</td> <td>7.4/half cup (cooked)</td> </tr> <tr> <td class=\"indent2\">Lima beans</td> <td>2.6/half cup (cooked)</td> </tr> <tr> <td class=\"indent2\">Lentils</td> <td>1.9/half cup (cooked)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Breads, pastas, and flours</td> </tr> <tr> <td class=\"indent1\">Bagels</td> <td>1.1/half bagel</td> </tr> <tr> <td class=\"indent1\">Bran muffins</td> <td>6.3/muffin</td> </tr> <tr> <td class=\"indent1\">Cracked wheat</td> <td>4.1/slice</td> </tr> <tr> <td class=\"indent1\">Oatmeal</td> <td>5.3/1 cup</td> </tr> <tr> <td class=\"indent1\">Pumpernickel bread</td> <td>1.0/slice</td> </tr> <tr> <td class=\"indent1\">White bread</td> <td>0.55/slice</td> </tr> <tr> <td class=\"indent1\">Whole-wheat bread</td> <td>1.66/slice</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Pasta and rice cooked</td> </tr> <tr> <td class=\"indent2\">Macaroni</td> <td>1.0/1 cup (cooked)</td> </tr> <tr> <td class=\"indent2\">Rice, brown</td> <td>2.4/1 cup (cooked)</td> </tr> <tr> <td class=\"indent2\">Rice, polished</td> <td>0.6/1 cup (cooked)</td> </tr> <tr> <td class=\"indent2\">Spaghetti (regular)</td> <td>1.0/1 cup (cooked)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Flours and grains</td> </tr> <tr> <td class=\"indent2\">Bran, oat</td> <td>8.3/oz</td> </tr> <tr> <td class=\"indent2\">Bran, wheat</td> <td>12.4/oz</td> </tr> <tr> <td class=\"indent2\">Rolled oats</td> <td>13.7/1 cup (cooked)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nuts</td> </tr> <tr> <td class=\"indent1\">Almonds</td> <td>3.6/half cup (slivered)</td> </tr> <tr> <td class=\"indent1\">Peanuts</td> <td>11.7/1 cup</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: the American Gastroenterological Association, Kim YI. AGA technical review: impact of dietary fiber on colon cancer occurrence. Gastroenterology 2000; 118:1235.</div><div id=\"graphicVersion\">Graphic 82094 Version 5.0</div></div></div>"},"82098":{"type":"graphic_diagnosticimage","displayName":"Lung abscess with empyema CT","title":"Lung abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lung abscess</div><div class=\"cntnt\"><img style=\"width:358px; height:236px;\" src=\"images/PULM/82098_Lung_abscess_with_empyema_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lung abscess in the right lower lobe with cavitation and narrow neck fistula leading to an empyema in the adjacent pleural space.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82098 Version 2.0</div></div></div>"},"82099":{"type":"graphic_picture","displayName":"Healed cutaneous ulcers","title":"Healed cutaneous ulcers caused by RV","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Healed cutaneous ulcers caused by RV</div><div class=\"cntnt\"><img style=\"width:329px; height:504px;\" src=\"images/RHEUM/82099_Healed_cutaneous_ulcers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Such lesions represent damage rather than active vasculitic disease.</div><div class=\"graphic_reference\">Courtesy of John Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 82099 Version 2.0</div></div></div>"},"82102":{"type":"graphic_figure","displayName":"Glaucomatous visual field progression","title":"Glaucomatous visual field progression","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Glaucomatous visual field progression</div><div class=\"cntnt\"><img style=\"width:488px; height:581px;\" src=\"images/PC/82102_Glaucomatous_visual_field.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An example of typical glaucomatous visual field progression, proceeding from early disease with focal deficits (top left) to diffuse, end-stage glaucoma (bottom right).</div><div class=\"graphic_reference\">Reproduced with permission from: Morrison JC, Pollack IP. Glaucoma: Science and Practice, Thieme Medical Publishers, New York, 2002. Copyright &#169; 2002 Thieme Medical Publishers, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 82102 Version 1.0</div></div></div>"},"82104":{"type":"graphic_figure","displayName":"BTK expression","title":"Peripheral blood flow cytometric analysis in XLA","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Peripheral blood flow cytometric analysis in XLA</div><div class=\"cntnt\"><img style=\"width:514px; height:360px;\" src=\"images/ALLRG/82104_BTK_expression.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top panels: BTK expression in B cells of a normal individual, a patient with XLA, and an individual who carries a BTK mutation. Bottom panels: BTK expression in monocytes of the same individuals as above.</div><div class=\"graphic_footnotes\">XLA: X-linked agammaglobulinemia; BTK: Bruton's tyrosine kinase.</div><div id=\"graphicVersion\">Graphic 82104 Version 2.0</div></div></div>"},"82107":{"type":"graphic_figure","displayName":"Early surgery and native valve endocarditis mortality","title":"Early surgery and native valve endocarditis mortality","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Early surgery and native valve endocarditis mortality</div><div class=\"cntnt\"><img style=\"width:564px; height:262px;\" src=\"images/CARD/82107_Early_surg_nat_val_endo_mor.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* p &lt;0.05 for difference between early surgery versus medical therapy for native valve endocarditis.</div><div class=\"graphic_reference\">Data from: Lalani T, Cabell CH, Benjamin DK, et al. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation 2010; 121:1005.</div><div id=\"graphicVersion\">Graphic 82107 Version 2.0</div></div></div>"},"82108":{"type":"graphic_picture","displayName":"Acitretin xerosis","title":"Acitretin-induced xerosis and desquamation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acitretin-induced xerosis and desquamation</div><div class=\"cntnt\"><img style=\"width:432px; height:404px;\" src=\"images/DERM/82108_Acitretin_xerosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse xerosis in a kidney transplant recipient who received 50 mg per day of acitretin.</div><div id=\"graphicVersion\">Graphic 82108 Version 1.0</div></div></div>"},"82109":{"type":"graphic_picture","displayName":"Episcleritis in RA","title":"Episcleritis in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Episcleritis in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:402px; height:264px;\" src=\"images/RHEUM/82109_Episcleritis_in_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Episcleritis in a patient with rheumatoid arthritis characterized by a patch of intense injection without scleral edema.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 82109 Version 2.0</div></div></div>"},"82111":{"type":"graphic_table","displayName":"Older adult activity counseling","title":"Physical activity counseling for older adults: An evidence-based quick guide","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical activity counseling for older adults: An evidence-based quick guide</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Recommendations:<sup>[1]</sup></td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Aerobic:</td> </tr> <tr> <td colspan=\"3\"> <ul> <li>&#8805;30 min or three bouts of &#8805;10 min/day </li> <li>&#8805;5 days/week </li> <li>Moderate intensity = 5 to 6 on a 10-point scale (where 0 = sitting, 5 to 6 = \"can talk,\" and 10 = all-out effort) </li> <li>In addition to routine ADLs </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Strength:</td> </tr> <tr> <td colspan=\"3\"> <ul> <li>8 to 10 exercises (major muscle groups), 10 to 15 repetitions </li> <li>&#8805;2 nonconsecutive days/week </li> <li>Moderate to high intensity = 5 to 8 on a 10-point scale (where 5 to 6 = \"can talk\" and 7 to 8 = short of breath) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Flexibility/balance:</td> </tr> <tr> <td colspan=\"3\"> <ul> <li>&#8805;10 min &#8805;2 days/week </li> <li>Flexibility to maintain/improve range of motion (ie, stretching of major muscle/tendon groups, yoga) </li> <li>Balance exercises for those at risk for falls (ie, tai chi, individualized balanced exercises) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Prevention:</td> </tr> <tr> <td colspan=\"3\"> <ul> <li>Create a single physical activity plan that integrates preventive and therapeutic treatment of chronic conditions </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" colspan=\"3\">Sample endurance (walking) and strength plan<sup>[2]</sup> </td> </tr> <tr> <td class=\"subtitle2\">Weeks</td> <td class=\"subtitle2\">Walking</td> <td class=\"subtitle2\">Strength</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Weeks 1 to 2:</strong></p> Introduction and acclimatization </td> <td> <ul> <li>Walk 10 minutes </li> <li>Three days/week </li> <li>Intensity level = 5 to 6 on a 10-point scale </li> </ul> </td> <td> <ul> <li>Four to five&nbsp;exercises for major muscle groups using weightbearing calisthenics, elastic bands, free weights, or weight machines </li> <li>One set of 10 to 15 repetitions on&nbsp;two nonconsecutive days/week </li> <li>Intensity level = 5 to 8 on a 10-point scale </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p><strong>Weeks 2 to 6:</strong></p> Begin progression</td> <td> <ul> <li>First increase to five days/week </li> <li>Gradually increase time to either 20 minutes or two bouts of 10 minutes/day </li> </ul> </td> <td> <ul> <li>Gradually add&nbsp;four to five&nbsp;exercises, totaling 8 to 10 major muscle group exercises </li> <li>One set of 10 to 15 repetitions on two nonconsecutive days/week </li> <li>Intensity level = 5 to 8 on a 10-point scale </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p><strong>Weeks 6+:</strong></p> Continued progression and exercise routine refining</td> <td> <ul> <li>Progress time to meet guideline of at least 30 minutes, in at least 10-minute bouts </li> <li>Five or more days/week </li> </ul> </td> <td> <ul> <li>Add a third nonconsecutive day/week </li> <li>Increase resistance by 2 to 10 percent depending on patient's progress and comfort level </li> <li>Emphasize pain-free exercising </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\"> <p>Recognize your role for PA advocacy</p> <em>Tips for physical activity counseling:</em></td> </tr> <tr> <td class=\"subtitle2_left\">If patient is:</td> <td class=\"subtitle2_left\" colspan=\"2\">Planned approach:</td> </tr> <tr> <td>Not ready to change</td> <td colspan=\"2\">Educate on benefits of exercise</td> </tr> <tr> <td>Ready to change</td> <td colspan=\"2\">Develop a specific physical activity plan</td> </tr> <tr class=\"divider_bottom\"> <td>Active</td> <td colspan=\"2\">Support continued activity</td> </tr> <tr> <td colspan=\"4\"> <ul> <li>Assess current physical activity (type, frequency, duration, intensity) </li> <li>Advise benefits relative to medical history </li> <li>Tailor realistic plan (consider chronic illness, current physical activity level, functional limits, and preferred activities) </li> <li>Specify <strong>what</strong> to do <strong>where</strong> and <strong>when</strong> </li> <li>Look for barriers and strategize solutions </li> <li>Encourage social support: <strong>who</strong> and <strong>how</strong> </li> <li>Confirm patient is <strong>\"very sure\"</strong> of physical activity success </li> <li>Chart plan and give written physical activity&nbsp;prescription to patient </li> <li>In follow-up, revise physical activity plan to enhance progress </li> <li>Reinforce positive behavior and activity documentation </li> <li>Reaffirm that more physical activity enhances benefits </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For more resources and handouts see:<br /><UL>&#xD;&#xA;<LI>American College of Sports Medicine. Exercise is Medicine website. Available at: <A href=\"http://www.exerciseismedicine.org/\">www.exerciseismedicine.org/</A>. (Accessed December 17, 2011). </LI>&#xD;&#xA;<LI>Veterans Health Administration Research and Development. Project LIFE Modules: Changing the PACE for Seniors. US Department of Veterans Affairs. Available at: <A href=\"http://www.research.va.gov/resources/pubs/LIFE-modules.cfm\" target=_blank>www.research.va.gov/resources/pubs/LIFE-modules.cfm</A>. (Accessed December 17, 2011). </LI>&#xD;&#xA;<LI>National Center for Health Promotion and Disease Prevention (NCP). MOVE! Handouts. US Department of Veterans Affairs. Available at: <A href=\"http://www.move.va.gov/handouts.asp\"target=_blank>www.move.va.gov/handouts.asp</A>. (Accessed December 17, 2011). </LI></UL></div><div class=\"graphic_footnotes\">ADLs: activities of daily living.</div><div class=\"graphic_reference\">References: <ol> <li>Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 2007; 116:1081. </li> <li>Morey MC. Celebrating 20 years of excellence in exercise for the older veteran. Federal Practitioner 2007; 24:38. </li> </ol></div><div id=\"graphicVersion\">Graphic 82111 Version 4.0</div></div></div>"},"82114":{"type":"graphic_picture","displayName":"Progressive Cushings obesity","title":"Progressive obesity in Cushing's syndrome","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Progressive obesity in Cushing's syndrome</div><div class=\"cntnt\"><img style=\"width:572px; height:158px;\" src=\"images/ENDO/82114_Progressive_Cushings_obesit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequence of pictures in a boy with Cushing's disease. <br />(A) Age six years, before apparent onset of Cushing's syndrome.<br />(B) Age seven years, still with little evidence of cushingoid appearance.<br />(C) Age eight years, with early facial rounding.<br />(D) Age nine years, with \"moon\" facies.<br />(E) Age 11 years, with florid Cushing's disease.</div><div class=\"graphic_reference\">Reproduced with permission from Williams Textbook of Endocrinology, 8th ed, Foster DW, Wilson JD (Eds), WB Saunders, Philadelphia, 1996.</div><div id=\"graphicVersion\">Graphic 82114 Version 3.0</div></div></div>"},"82115":{"type":"graphic_diagnosticimage","displayName":"CT scan ectopic parathyroid adenoma","title":"CT scan ectopic parathyroid adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan ectopic parathyroid adenoma</div><div class=\"cntnt\"><img style=\"width:432px; height:435px;\" src=\"images/SURG/82115_Ectopic_parathyroid_adenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of ectopic parathyroid adenoma. Small soft-tissue mass (arrow) in the anterior mediastinum.</div><div class=\"graphic_footnotes\">A: aorta; a: major branches of the aorta; v: brachiocephalic veins.</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg, RL. Clinical Imaging: An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82115 Version 4.0</div></div></div>"},"82116":{"type":"graphic_table","displayName":"DDx WM","title":"Differential diagnosis of Waldenstrom macroglobulinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of Waldenstrom macroglobulinemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Entity</td> <td class=\"subtitle1\">Bone marrow biopsy</td> <td class=\"subtitle1\">Monoclonal gammopathy</td> <td class=\"subtitle1\">Additional features</td> </tr> <tr> <td>Waldenstrom macroglobulinemia</td> <td>&#8805;10 percent infiltration by lymphoplasmacytic lymphoma</td> <td>Circulating monoclonal IgM of any size</td> <td>Anemia, hepatosplenomegaly, lymphadenopathy, and/or systemic symptoms</td> </tr> <tr> <td>Smoldering Waldenstrom macroglobulinemia</td> <td class=\"centered\" colspan=\"2\"> <p>Circulating monoclonal IgM &#8805;3.0 g/dL</p> <p>and/or</p> <p>&#8805;10 percent infiltration by lymphoplasmacytic lymphoma</p> </td> <td>No anemia, hepatosplenomegaly, lymphadenopathy, or systemic symptoms felt to be related to underlying lymphoplasmacytic proliferation</td> </tr> <tr> <td>IgM MGUS</td> <td>Minimal or no lymphoplasmacytic infiltration of the bone marrow; overall marrow involvement by such cells should be &#60;10 percent</td> <td>Circulating monoclonal IgM concentration &#60;3.0 g/dL</td> <td>No anemia, hepatosplenomegaly, lymphadenopathy, or systemic symptoms felt to be related to underlying lymphoplasmacytic proliferation</td> </tr> <tr> <td>Multiple myeloma</td> <td>Infiltration of plasma cells in the bone marrow</td> <td>IgM myeloma is rare; more commonly monoclonal protein is IgG, IgA, light chains only, or infrequently IgD</td> <td>Hypercalcemia, renal insufficiency, anemia, and bone lesions felt to be related to underlying lymphocyte proliferative disorder</td> </tr> <tr> <td>Chronic lymphocytic leukemia/small lymphocytic lymphoma</td> <td>Bone marrow infiltration with small mature appearing lymphocytes that express CD5; expression of CD20 and surface Ig is dim</td> <td>Monoclonal immunoglobulins can be seen in up to 15 percent</td> <td>Anemia, lymphadenopathy, hepatosplenomegaly, and/or systemic symptoms felt to be related to underlying plasma cell proliferative disorder</td> </tr> <tr> <td>Mantle cell lymphoma</td> <td>Bone marrow infiltration with monomorphous small to medium-sized B lymphocytes that overexpress cyclin D1</td> <td>IgM monoclonal protein may be present</td> <td>t(11;14)</td> </tr> <tr> <td>Amyloidosis</td> <td>Apple green birefringence under polarized light after staining with Congo red</td> <td>Usually have an associated monoclonal protein</td> <td>Nephrotic syndrome, restrictive cardiomyopathy, peripheral neuropathy, hepatomegaly, macroglossia, and purpura</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MGUS: monoclonal gammopathy of undetermined significance.</div><div id=\"graphicVersion\">Graphic 82116 Version 2.0</div></div></div>"},"82118":{"type":"graphic_figure","displayName":"Head circumference in a child with communicating hydrocephalus","title":"Head circumference in a child with communicating hydrocephalus","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Head circumference in a child with communicating hydrocephalus</div><div class=\"cntnt\"><img style=\"width:607px; height:782px;\" src=\"images/PEDS/82118_HCincommhydrocephalus.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Head circumference of a child with communicating hydrocephalus. A ventriculo-peritoneal shunt was placed at&nbsp;six months of age; it became nonfunctional at 15 months and was revised.</div><div class=\"graphic_reference\">Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000). <A href=\"https://www.cdc.gov/growthcharts/cdc_charts.htm\">https://www.cdc.gov/growthcharts/cdc_charts.htm</A>.</div><div id=\"graphicVersion\">Graphic 82118 Version 3.0</div></div></div>"},"82119":{"type":"graphic_figure","displayName":"Radial artery puncture","title":"Radial artery cannulation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radial artery cannulation</div><div class=\"cntnt\"><img style=\"width:402px; height:214px;\" src=\"images/PULM/82119_Radial_artery_puncture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Technique of radial artery cannulation. The radial artery is palpated between the distal radius and the tendon of the flexor carpi radialis.</div><div class=\"graphic_reference\">Redrawn from American Heart Association. Textbook of Advanced Cardiac Life Support, 1994.</div><div id=\"graphicVersion\">Graphic 82119 Version 1.0</div></div></div>"},"82124":{"type":"graphic_figure","displayName":"Elements of decision analysis","title":"Decision analysis elements","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Decision analysis elements</div><div class=\"cntnt\"><img style=\"width:463px; height:257px;\" src=\"images/PC/82124_Elements_of_decision_analys.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82124 Version 3.0</div></div></div>"},"82125":{"type":"graphic_picture","displayName":"Light microscopy Leydig tumor","title":"Leydig cell tumor","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Leydig cell tumor</div><div class=\"cntnt\"><img style=\"width:716px; height:536px;\" src=\"images/ONC/82125_Lght_mcrscpy_lydg_tmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a Leydig cell tumor of the testis. The tumor is well circumscribed and contains cells with round nucleoli and small prominent nucleoli, as well as moderate amounts of eosinophilic cytoplasm.&nbsp;No mitoses or necrosis are identified.&nbsp;Tumor cells would be immunoreactive for inhibin and calretinin.</div><div class=\"graphic_reference\">Courtesy of Dr. Michelle S. Hirsch, Department of Pathology, Brigham and Womens Hospital, Boston, MA.</div><div id=\"graphicVersion\">Graphic 82125 Version 2.0</div></div></div>"},"82127":{"type":"graphic_table","displayName":"Diuretic herbal ingredients","title":"Diuretic herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diuretic herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Drug</td>\n<td class=\"subtitle1\">Effect</td>\n</tr>\n<tr>\n<td>Agrimony</td>\n<td>Activity in vivo</td>\n</tr>\n<tr>\n<td>Artichoke</td>\n<td>Reputed action</td>\n</tr>\n<tr>\n<td>Boldo</td>\n<td>Irritant oil</td>\n</tr>\n<tr>\n<td>Broom</td>\n<td>Reputed action</td>\n</tr>\n<tr>\n<td>Buchu</td>\n<td>Reputed action</td>\n</tr>\n<tr>\n<td>Burdock</td>\n<td>Reputed action</td>\n</tr>\n<tr>\n<td>Celery</td>\n<td>Reputed action</td>\n</tr>\n<tr>\n<td>Cornsilk</td>\n<td>Human activity</td>\n</tr>\n<tr>\n<td>Couchgrass</td>\n<td>Activity in vivo</td>\n</tr>\n<tr>\n<td>Dandelion</td>\n<td>Activity in vivo</td>\n</tr>\n<tr>\n<td>Elder</td>\n<td>Activity in vivo</td>\n</tr>\n<tr>\n<td>Guaiacum</td>\n<td>Reputed action</td>\n</tr>\n<tr>\n<td>Juniper</td>\n<td>Reputed action; terpinen-4-ol</td>\n</tr>\n<tr>\n<td>Pokeroot</td>\n<td>Activity in vivo</td>\n</tr>\n<tr>\n<td>Shepherd's purse</td>\n<td>Activity in vivo</td>\n</tr>\n<tr>\n<td>Squill</td>\n<td>Activity in vivo</td>\n</tr>\n<tr>\n<td>Uva Ursi</td>\n<td>Reputed action</td>\n</tr>\n<tr>\n<td>Yarrow</td>\n<td>Activity in vivo</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals. The Pharmaceutical Press 1996, p. 277.</div><div id=\"graphicVersion\">Graphic 82127 Version 2.0</div></div></div>"},"82128":{"type":"graphic_picture","displayName":"Endosc targeted RFA Barrx90","title":"Endoscopic appearance of targeted ablation of the entire esophageal circumference for Barrett's esophagus at the top of the gastric folds using the Barrx90 system","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Endoscopic appearance of targeted ablation of the entire esophageal circumference for Barrett's esophagus at the top of the gastric folds using the Barrx90 system</div><div class=\"cntnt\"><img style=\"width:512px; height:294px;\" src=\"images/GAST/82128_Endosc_targeted_RFA_HALO90.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>(A, B)</STRONG> High-resolution white light inspection of the neosquamocolumnar junction after primary circumferential ablation. Differentiating Barrett's mucosa from cardia mucosa can be difficult.<BR><STRONG>(C)</STRONG> Corresponding image with narrow band imaging.<BR><STRONG>(D)</STRONG> To ensure eradication of all intestinal metaplasia at the top of the gastric folds, the entire circumference is ablated using the Barrx90 system. After the first ablation pass, whitish coagulum can be seen.<BR><STRONG>(E, F)</STRONG> After cleaning of the ablation zone and electrode surface, the entire neosquamocolumnar junction is ablated a second time.</div><div class=\"graphic_reference\">Reproduced with permission of www.endosurgery.eu. Copyright © 2010 Esophageal Research Foundation Amsterdam.</div><div id=\"graphicVersion\">Graphic 82128 Version 3.0</div></div></div>"},"82129":{"type":"graphic_diagnosticimage","displayName":"Cystic breast mass US","title":"Ultrasonography of a cystic breast mass in an adolescent patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasonography of a cystic breast mass in an adolescent patient</div><div class=\"cntnt\"><img style=\"width:396px; height:361px;\" src=\"images/PEDS/82129_Cystic_breast_mass_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Nirupama K De Silva, MD.</div><div id=\"graphicVersion\">Graphic 82129 Version 2.0</div></div></div>"},"82130":{"type":"graphic_picture","displayName":"Peripheral IV placement 6","title":"Peripheral IV placement: Completing insertion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral IV placement: Completing insertion</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/EM/82130_Peripheral_IV_placement_6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once the catheter is inserted, maintain pressure proximally to prevent bleeding and provide stability until IV tubing can be attached and the catheter secured.</div><div class=\"graphic_reference\">Courtesy of Robert Frank, MD.</div><div id=\"graphicVersion\">Graphic 82130 Version 2.0</div></div></div>"},"82132":{"type":"graphic_table","displayName":"Preventing lead exposure from soil","title":"Educational interventions to prevent exposure to lead in soil","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Educational interventions to prevent exposure to lead in soil</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td> Cover bare soil with grass, plants, gravel, or wood chips</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Do not let children play near walls of house or garage on bare soil</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Have children play in grassy area or sandbox that can be covered</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Wash children's hands after playing outside, or playing with pets</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Remove shoes before entering the house</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Use a doormat to reduce track-in of outdoor dust and soil</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Environmental Protection Agency. (http://www.epa.gov/lead/educationexesum.htm).</div><div id=\"graphicVersion\">Graphic 82132 Version 2.0</div></div></div>"},"82133":{"type":"graphic_table","displayName":"Differences between naïve and memory T cells","title":"Differences between naïve and memory T cells","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differences between naïve and memory T cells</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Na&#239;ve</td> <td class=\"subtitle1\">Effector</td> <td class=\"subtitle1\">Memory</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"5\">Surface phenotype&nbsp;&nbsp;&nbsp;&nbsp;</td> <td>CD45RA</td> <td>CD45RA/RO</td> <td>CD45RO</td> </tr> <tr> <td>CD44 lo</td> <td>CD44 hi</td> <td>CD44 hi</td> </tr> <tr> <td>Integrins lo</td> <td>Integrins hi</td> <td>Integrins hi</td> </tr> <tr> <td>CD29 lo</td> <td>CD29 hi</td> <td>CD29 hi</td> </tr> <tr> <td>CD25 lo</td> <td>CD25 hi</td> <td>CD25 lo</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Response to stimulation&nbsp;&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Antigen/APC</td> <td>Low</td> <td>&nbsp;</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Cytokine production</td> <td>Mainly IL-2</td> <td>&nbsp;</td> <td>Th1/Th2</td> </tr> <tr> <td class=\"indent1\">Low concentration anti-CD3 Ab</td> <td>No</td> <td>&nbsp;</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Anti-CD2 Ab</td> <td>Low</td> <td>&nbsp;</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Need for costimulation</td> <td>High</td> <td>&nbsp;</td> <td>Low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>CD: cluster of differentiation; CD45RA: marker of naïve (nonactivated) T cells; CD45RO: marker of memory (activated) T cells; lo: low expression; hi: high expression; </FONT><FONT color=black>APC</FONT>: antigen-presenting cell; IL-2: interleukin-2; Th1/Th2: T helper cell type 1/T helper cell type 2; Ab: antibody.</div><div id=\"graphicVersion\">Graphic 82133 Version 2.0</div></div></div>"},"82134":{"type":"graphic_figure","displayName":"Central line PI","title":"Central line","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Central line</div><div class=\"cntnt\"><img style=\"width:489px; height:432px;\" src=\"images/PI/82134_Central-line-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows a central line, which is a thin, flexible tube. One end is put into a large vein, usually in the neck. The other end stays outside the body.</div><div id=\"graphicVersion\">Graphic 82134 Version 1.0</div></div></div>"},"82136":{"type":"graphic_figure","displayName":"Model of basal ganglia dysfunction","title":"Model of basal ganglia dysfunction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Model of basal ganglia dysfunction</div><div class=\"cntnt\"><img style=\"width:368px; height:378px;\" src=\"images/NEURO/82136_Models_BG_dysfunction.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic drawing of the basal ganglia and their connections illustrates the main striato-fugal pathways. In Parkinson disease (PD), the indirect inhibitory pathway mediated via D2 striatal receptors is postulated to be overactive, whereas the direct inhibitory pathway mediated via D1 striatal receptors is underactive. As a result, the main pallidal-thalamic outflow pathway provides excessive inhibitory input to the thalamus, which causes suppression of thalamo-cortical-spinal pathway, manifested clinically by paucity and slowness of movement (bradykinesia). In contrast, altered function in the basal ganglia that occurs with hyperkinetic movement disorders presumably leads to disinhibition of the thalamo-cortical-striatal pathway, manifested clinically by abnormal involuntary movements such as chorea, hemiballism, tics (as seen in Tourette syndrome), and dystonia.</div><div class=\"graphic_footnotes\">Green: excitatory; Red: inhibitory; GPe: globus pallidus externa; GPi: globus pallidus interna; SNc: substantia nigra pars compacta; SNr: substantia nigra pars reticulata; STN: subthalamic nucleus; TH: ventrolateral nucleus of the thalamus.</div><div id=\"graphicVersion\">Graphic 82136 Version 4.0</div></div></div>"},"82137":{"type":"graphic_table","displayName":"Management myasthenic crisis","title":"Management of myasthenic crisis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of myasthenic crisis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Admit to intensive care unit</td> </tr> <tr> <td>Measure VC frequently, as often as every two hours if respiratory status is deteriorating</td> </tr> <tr> <td class=\"sublist1_start\">Consider elective intubation based upon overall clinical status, particularly&nbsp;in the presence of any of the following conditions:</td> </tr> <tr> <td class=\"sublist1\">Declines in serial measures of VC below 15 to 20 mL/kg ideal body weight</td> </tr> <tr> <td class=\"sublist1\">Declines in serial measurements of MIP less negative than -25 to&nbsp;-30 cmH<sub><span style=\"font-size: 10px;\">2</span></sub>O (ie,&nbsp;0 to -30 cmH<sub><span style=\"font-size: 10px;\">2</span></sub>O)</td> </tr> <tr> <td class=\"sublist1\">Clinical signs of respiratory distress</td> </tr> <tr> <td class=\"sublist1\">Evidence of progressive respiratory acidosis</td> </tr> <tr> <td class=\"sublist1\">Difficulty handling oral secretions</td> </tr> <tr> <td>Withdraw anticholinesterase medications to avoid excess airway secretions for patients who are intubated</td> </tr> <tr> <td>Seek and treat any precipitating or contributing factors, particularly infections</td> </tr> <tr> <td>Begin rapid therapy with plasma exchange&nbsp;or IVIG</td> </tr> <tr> <td>Begin immunomodulating therapy with high-dose glucocorticoids (eg, prednisone 60 to 80 mg per day); consider azathioprine, mycophenolate mofetil, or cyclosporine if glucocorticoids are contraindicated or previously ineffective</td> </tr> <tr> <td>After starting plasma exchange or IVIG treatment, consider weaning from mechanical ventilation when respiratory muscle strength is improving (ie, VC &#62;15 to 20&nbsp;mL/kg and MIP more negative than -25 to -30 cmH<sub>2</sub>O)&nbsp;in patients with an adequate cough and manageable respiratory secretions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VC: vital capacity; IVIG: intravenous immune globulin; MIP: maximal inspiratory pressure.</div><div id=\"graphicVersion\">Graphic 82137 Version 5.0</div></div></div>"},"82138":{"type":"graphic_table","displayName":"Diagnostic criteria HUVS","title":"Diagnostic criteria of hypocomplementemic urticarial vasculitis syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria of hypocomplementemic urticarial vasculitis syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Criteria</td>\r\n                    <td class=\"subtitle1\">Specifics</td>\r\n                    <td class=\"subtitle1\">Needed for the diagnosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"2\">Major criteria</td>\r\n                    <td>Urticaria for more than&nbsp;six months</td>\r\n                    <td rowspan=\"2\">The patient must have both major criteria.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hypocomplementemia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"6\">Minor criteria</td>\r\n                    <td>Venulitis of the dermis (established via biopsy)&nbsp;</td>\r\n                    <td rowspan=\"6\">The patient must have at least two of the minor criteria.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Arthralgia or arthritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Mild glomerulonephritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Uveitis or episcleritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Recurrent abdominal pain</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Positive C1q precipitin test by immunodiffusion with an associated suppressed C1q level</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 82138 Version 2.0</div></div></div>"},"82140":{"type":"graphic_picture","displayName":"Normal human band form","title":"Normal human band form","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal human band form</div><div class=\"cntnt\"><img style=\"width:448px; height:288px;\" src=\"images/HEME/82140_Normal_human_band_form.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear shows a normal human band form. The nucleus is nonsegmented and elongated resembling a horseshoe shape; there are no nuclear lobulations but a constriction is visible. The nuclear chromatin is aggregated into evenly arranged clumps. The cytoplasm is like the mature neutrophil with pink staining and fine azure bluish granules.</div><div class=\"graphic_reference\">Courtesy of Robert L Baehner, MD.</div><div id=\"graphicVersion\">Graphic 82140 Version 1.0</div></div></div>"},"82141":{"type":"graphic_picture","displayName":"Gross appearance MPM","title":"Gross appearance MPM","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross appearance MPM</div><div class=\"cntnt\"><img style=\"width:396px; height:293px;\" src=\"images/ONC/82141_Gross_appearance_MPM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical gross appearance of malignant peritoneal mesothelioma at operation; note the diffuse nodules on the peritoneal surfaces.</div><div class=\"graphic_reference\">Courtesy of Dr. H Richard Alexander, Jr., as published for the National Institutes of Health.</div><div id=\"graphicVersion\">Graphic 82141 Version 2.0</div></div></div>"},"82142":{"type":"graphic_figure","displayName":"Regions of back PI","title":"Regions of the back","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Regions of the back</div><div class=\"cntnt\"><img style=\"width:483px; height:600px;\" src=\"images/PI/82142_Regions_of_the_back_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the regions of the back.</div><div id=\"graphicVersion\">Graphic 82142 Version 4.0</div></div></div>"},"82144":{"type":"graphic_picture","displayName":"Calf stretch PI","title":"Calf stretch exercise","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Calf stretch exercise</div><div class=\"cntnt\"><img style=\"width:527px; height:302px;\" src=\"images/PI/82144_Calf_stretch_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sit with your legs straight and loop a towel around your foot. Then pull the top part of your foot towards you. Hold it like that for 10 to 30 seconds. Repeat this 5 times each session and do 2 sessions a day. You can also push the ball of your foot against the towel. This exercises and strengthens the muscles in your foot.</div><div id=\"graphicVersion\">Graphic 82144 Version 2.0</div></div></div>"},"82145":{"type":"graphic_figure","displayName":"COX 1 versus COX 2 inhibition","title":"Relative COX-1 and COX-2 selectivity of NSAIDs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relative COX-1 and COX-2 selectivity of NSAIDs</div><div class=\"cntnt\"><img style=\"width:420px; height:366px;\" src=\"images/RHEUM/82145_COX_1_vs_COX_2_inhibit_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Concentrations of various NSAIDs required to inhibit the activity of COX-1 and COX-2 by 50 percent (IC50) in assays of whole blood. The diagonal line indicates equivalence. Drugs plotted below the diagonal line are more potent inhibitors of COX-2 than of COX-1.</div><div class=\"graphic_footnotes\">COX: cyclooxygenase; NSAIDs: nonsteroidal antiinflammatory drugs; 6-MNA: 6-methoxy-2-naphthylacetic acid.</div><div class=\"graphic_reference\">Adapted from: FitzGerald GA, Patrono C. N Engl J Med 2001; 345:433.</div><div id=\"graphicVersion\">Graphic 82145 Version 7.0</div></div></div>"},"82146":{"type":"graphic_table","displayName":"Common causes violence","title":"Common and dangerous causes of violent behavior","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common and dangerous causes of violent behavior</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Toxicologic</td> </tr> <tr> <td>Alcohol intoxication or withdrawal</td> </tr> <tr> <td>Stimulant intoxication (eg, methamphetamine, phencyclidine, cocaine)</td> </tr> <tr> <td>Other drugs and drug reactions (eg, anabolic steroid, sedative-hypnotic)</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic</td> </tr> <tr> <td>Hypoglycemia</td> </tr> <tr> <td>Hypoxia</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td>Stroke</td> </tr> <tr> <td>Intracranial lesion (eg, hemorrhage, tumor)</td> </tr> <tr> <td>CNS infection</td> </tr> <tr> <td>Seizure</td> </tr> <tr> <td>Dementia</td> </tr> <tr> <td class=\"subtitle1_single\">Other medical conditions</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Shock</td> </tr> <tr> <td>AIDS</td> </tr> <tr> <td>Hypothermia; Hyperthermia</td> </tr> <tr> <td class=\"subtitle1_single\">Psychiatric</td> </tr> <tr> <td>Psychosis</td> </tr> <tr> <td>Schizophrenia</td> </tr> <tr> <td>Paranoid delusions</td> </tr> <tr> <td>Personality disorder</td> </tr> <tr> <td class=\"subtitle1_single\">Antisocial behavior</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82146 Version 2.0</div></div></div>"},"82147":{"type":"graphic_table","displayName":"Noncontraceptive benefits","title":"Potential noncontraceptive benefits of cyclic estrogen-progestin contraceptives","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential noncontraceptive benefits of cyclic estrogen-progestin contraceptives</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>&#8226; Reduction in dysmenorrhea</td> </tr> <tr> <td>&#8226; Reduction in pelvic pain related to endometriosis</td> </tr> <tr> <td>&#8226; Reduction of menorrhagia, with improvement in iron deficiency anemia related to blood loss</td> </tr> <tr> <td>&#8226; Reduction in risk of ectopic pregnancy</td> </tr> <tr> <td>&#8226; Reduction in symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder</td> </tr> <tr> <td>&#8226; Reduction in risk of benign breast disease</td> </tr> <tr> <td>&#8226; Reduction in development of new ovarian cysts (true for higher-dose estrogen pills only, which suppress ovulation), but no effect on existing ovarian cysts</td> </tr> <tr> <td>&#8226; Reduction in ovarian cancer, including some hereditary forms, such as those associated with mutations in the BRCA1 or BRCA2 gene, presumably due to inhibition of ovarian stimulation</td> </tr> <tr> <td>&#8226; Reduction in endometrial cancer, due to the progestin effect</td> </tr> <tr> <td>&#8226; Reduction in colorectal cancer in current users</td> </tr> <tr> <td>&#8226; Reduction in moderate acne</td> </tr> <tr> <td>&#8226; Reduction in hirsutism</td> </tr> <tr> <td>&#8226; More regular menstrual cycles</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In addition, there may be a reduction in postmenopausal hip fracture risk for women who use estrogen-containing contraceptives in their 40s. Also, extended cycle or continuous estrogen-progestin contraception can reduce symptoms of menstrual migraine.</div><div id=\"graphicVersion\">Graphic 82147 Version 2.0</div></div></div>"},"82148":{"type":"graphic_table","displayName":"Side effects of radiation therapy for cutaneous SCC","title":"Side effects associated with radiation therapy for cutaneous squamous cell cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Side effects associated with radiation therapy for cutaneous squamous cell cancer</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Short Term</td>\n\n      <td class=\"subtitle1\">Long Term</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Erythema, edema, and scaling</td>\n\n      <td>Cataracts</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vesicles/bullae formation</td>\n\n      <td>Infertility</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Erosions/ulceration</td>\n\n      <td>Chronic radiation dermatitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pain</td>\n\n      <td>Permanent alopecia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Infection</td>\n\n      <td>Delayed radiation necrosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>\"Comedo reaction\" </td>\n\n      <td>Thyroid cancer</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Appearance of pseudorecidives</td>\n\n      <td>Cutaneous malignancies</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Shedding of nails</td>\n\n      <td>Ulceration in fragile, atrophic skin that is prone to gangrene</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 82148 Version 2.0</div></div></div>"},"82149":{"type":"graphic_figure","displayName":"Laparoscopic mesh repair of parastomal hernia","title":"Laparoscopic mesh repair of parastomal hernia","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Laparoscopic mesh repair of parastomal hernia</div><div class=\"cntnt\"><img style=\"width:471px; height:569px;\" src=\"images/SURG/82149_PSH_lap_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parastomal hernia is repaired with mesh placed via the laparoscope. A. The mesh is prepared for placement prior to insertion into the abdominal cavity. Nonabsorbable sutures are placed on the edges of the mesh to later secure to the abdominal wall. An incision is made in a cruciate manner in the mesh to allow for a tension free construction and repair around the bowel. B. The mesh is rolled and applied to cover the defect. C. The mesh is secured to the abdominal wall and unrolled around the bowel. D. The mesh is fully opened and sutured to the bowel as well as the abdominal wall.</div><div id=\"graphicVersion\">Graphic 82149 Version 2.0</div></div></div>"},"82150":{"type":"graphic_picture","displayName":"Toxic epidermal necrolysis - bullae","title":"Toxic epidermal necrolysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toxic epidermal necrolysis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/82150_Toxicepidnecrolybullae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple bullae overlying diffuse erythema are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82150 Version 4.0</div></div></div>"},"82151":{"type":"graphic_table","displayName":"Prevention transmission HBV","title":"Recommendations for infected persons regarding prevention of transmission of HBV to others","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for infected persons regarding prevention of transmission of HBV to others</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1_single\">Persons who are HBsAg-positive should:</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Have sexual contacts vaccinated</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Use barrier protection during sexual intercourse if partner not vaccinated or naturally immune</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Not share toothbrushes or razors</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Cover open cuts and scratches</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Clean blood spills with detergent or bleach</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Not donate blood, organs or sperms</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">Children and adults who are HBsAg-positive:</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Can participate in all activities including contact sports</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Should not be excluded from daycare or school participation and should not be isolated from other children</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Can share food, utensils, or kiss others</td>\n\t  </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">6.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">9/21/2009--Requested permission. 9/22/2009--Permission granted; figures to Terrence (JD). 2/6/2010--Requested renewal (JD). 2/9/2010--Renewal granted (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=28014&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Prevention_transmission_HBV.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at http://publish.aasld.org/Pages/Default.aspx. Accessed September 8th 2009. Copyright © 2009 American Association for the Study of Liver Diseases.</div><div id=\"graphicVersion\">Graphic 82151 Version 9.0</div></div></div>"},"82153":{"type":"graphic_movie","displayName":"Apical 4 chamber effusion","title":"Apical 4 chamber view showing pericardial effusion","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Apical 4 chamber view showing pericardial effusion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82153_Apical4chambeffmovie.mp4\" style=\"width:496px;height:368px\"></div><img style=\"width:504px; height:388px;\" src=\"images/EM/82153_Apical4chambeffimage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows a pericardial effusion as seen from an apical four chamber view.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 82153 Version 1.0</div></div></div>"},"82155":{"type":"graphic_figure","displayName":"AR postoperative outcome","title":"Long-term postoperative survival in aortic regurgitation","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Long-term postoperative survival in aortic regurgitation</div><div class=\"cntnt\"><img style=\"width:482px; height:270px;\" src=\"images/CARD/82155_ARpostoperativeoutcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with aortic regurgitation who are in functional class I or II before surgery have a survival after surgery that is similar to that expected in an age and gender matched normal population. In contrast, the outcome among patients who are in functional class III or IV before surgery is worse than for those with functional class I and II.</div><div class=\"graphic_reference\">Data from Klodas E, Enriquez-Sarano M, Tajik AJ, et al, J Am Coll Cardiol 1997; 30:746.</div><div id=\"graphicVersion\">Graphic 82155 Version 2.0</div></div></div>"},"82156":{"type":"graphic_picture","displayName":"Light micrograph showing acute hypertensive nephrosclerosis","title":"Light micrograph showing acute hypertensive nephrosclerosis (formerly \"malignant nephrosclerosis\")","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing acute hypertensive nephrosclerosis (formerly \"malignant nephrosclerosis\")</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/82156_Malig_nephroscl_Light_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph reveals fibrinoid necrosis in the preglomerular afferent arteriole (arrow) in acute hypertensive nephrosclerosis (formerly \"malignant nephrosclerosis\"). The normal muscle layer of the media has been replaced by the fibrinoid material.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 82156 Version 3.0</div></div></div>"},"82157":{"type":"graphic_table","displayName":"Tests to diagnose UTI in children","title":"Test characteristics of tests used to diagnose urinary tract infections in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Test characteristics of tests used to diagnose urinary tract infections in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Sensitivity</td> <td class=\"subtitle1\">Specificity</td> <td class=\"subtitle1\">Positive likelihood ratio*</td> <td class=\"subtitle1\">Negative likelihood ratio<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Dipstick</td> </tr> <tr> <td class=\"indent1\">Leukocyte esterase (LE)</td> <td>84%</td> <td>78%</td> <td>4</td> <td>0.2</td> </tr> <tr> <td class=\"indent1\">Nitrite</td> <td>50%</td> <td>98%</td> <td>25</td> <td>0.5</td> </tr> <tr> <td class=\"indent1\">Nitrite or LE</td> <td>88%</td> <td>93%</td> <td>13</td> <td>0.1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nitrite and LE</td> <td>72%</td> <td>96%</td> <td>18</td> <td>0.3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Microscopy</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Uncentrifuged</td> </tr> <tr> <td class=\"indent2\">Pyuria (&#62;10/mm<sup>3</sup>) (all ages)</td> <td>77%</td> <td>89%</td> <td>7</td> <td>0.4</td> </tr> <tr> <td class=\"indent2\">Pyuria (&#62;10/mm<sup>3</sup>) (&#60;2 years)</td> <td>90%</td> <td>95%</td> <td>18</td> <td>0.1</td> </tr> <tr> <td class=\"indent2\">Bacteriuria (gram stained)</td> <td>93%</td> <td>95%</td> <td>19</td> <td>0.1</td> </tr> <tr> <td class=\"indent2\">Overall (P+B) = enhanced</td> <td>85%</td> <td>99.9%</td> <td>85</td> <td>0.1</td> </tr> <tr> <td class=\"indent2\">Overall (P or B)</td> <td>95%</td> <td>89%</td> <td>9</td> <td>0.1</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Centrifuged</td> </tr> <tr> <td class=\"indent2\">Pyuria (&#62;5/hpf)</td> <td>67%</td> <td>79%</td> <td>3</td> <td>0.4</td> </tr> <tr> <td class=\"indent2\">Bacteriuria</td> <td>81%</td> <td>83%</td> <td>5</td> <td>0.2</td> </tr> <tr> <td class=\"indent2\">Overall (P+B)</td> <td>66%</td> <td>99%</td> <td>7</td> <td>0.4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">P: pyuria; B: bacteriuria; hpf: high-power field.<br />* Positive likelihood ratio: The positive likelihood ratio is the probability that a child with a UTI will have a positive test divided by the probability that a child without a UTI will have a positive test (eg, true positive rate/false positive rate). The higher the positive likelihood ratio, the better the test.<br />¶ Negative likelihood ratio: The negative likelihood ratio is the probability that a child with a UTI will have a negative test divided by the probability that a child without a UTI will have a negative test (eg, false negative rate/true negative rate). The lower the negative likelihood ratio, the better the test (a perfect test has a negative likelihood ratio of zero).</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gorelick MH, Shaw KN. Screening tests for urinary tract infection in children: A meta-analysis. Pediatrics 1999; 104:e54. </li>&#xD;&#xA;    <li>Huicho L, Campos-Sanchez M, Alamo C. Metaanalysis of urine screening tests for determining the risk of urinary tract infection in children. Pediatr Infect Dis J 2002; 21:1. </li>&#xD;&#xA;    <li>Finnell SM, Carroll AE, Downs SM, the Subcommittee on Urinary Tract Infection. Technical Report--Diagnosis and Management of an Initial UTI in Febrile Infants and Young Children. Pediatrics 2011. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 82157 Version 8.0</div></div></div>"},"82158":{"type":"graphic_diagnosticimage","displayName":"TB pulmonary lesion","title":"Enlarged right-sided hilar lymph nodes with local infiltrate and atelectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enlarged right-sided hilar lymph nodes with local infiltrate and atelectasis</div><div class=\"cntnt\"><img style=\"width:396px; height:391px;\" src=\"images/ID/82158_TB_pulmonary_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enlarged right-sided hilar lymph nodes with local infiltrate and atelectasis caused by tuberculosis. This child was asymptomatic, this lesion having been discovered during a contact investigation conducted after this child's uncle was suspected of having pulmonary tuberculosis.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Starke, MD.</div><div id=\"graphicVersion\">Graphic 82158 Version 2.0</div></div></div>"},"82160":{"type":"graphic_figure","displayName":"Hooking maneuver","title":"Hooking maneuver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hooking maneuver</div><div class=\"cntnt\"><img style=\"width:366px; height:394px;\" src=\"images/RHEUM/82160_Hooking_maneuver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hooking maneuver is performed by hooking the fingers under the anterior costal margins and pulling the rib cage anteriorly.</div><div id=\"graphicVersion\">Graphic 82160 Version 2.0</div></div></div>"},"82161":{"type":"graphic_table","displayName":"Frequency heparin thrombocytopenia","title":"Patient population, frequency of HIT-IgG antibodies, and clinical HIT","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient population, frequency of HIT-IgG antibodies, and clinical HIT</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Patient population</td> <td class=\"subtitle1\" rowspan=\"2\">Days of treatment</td> <td class=\"subtitle1\" colspan=\"2\">Frequency heparin-induced antibodies</td> <td class=\"subtitle1\" rowspan=\"2\">Frequency of clinical HIT, percent</td> </tr> <tr> <td class=\"subtitle2\">Activation assay, percent</td> <td class=\"subtitle2\">Antigen assay, percent</td> </tr> <tr> <td>Cardiac, UFH</td> <td>5.1 &#177; 2.2 (SD)</td> <td>20.0</td> <td>50.0</td> <td>1.0</td> </tr> <tr> <td>Orthopedic, UFH</td> <td>9.2 &#177; 2.2</td> <td>9.3</td> <td>14.1</td> <td>4.9</td> </tr> <tr> <td>Orthopedic, LMWH</td> <td>9.5 &#177; 3.0</td> <td>3.2</td> <td>7.5</td> <td>0.9</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIT: heparin-induced thrombocytopenia; UFH: unfractionated heparin; LMWH: low molecular weight heparin.</div><div class=\"graphic_reference\">Modified from: Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96:1703.</div><div id=\"graphicVersion\">Graphic 82161 Version 6.0</div></div></div>"},"82162":{"type":"graphic_diagnosticimage","displayName":"Chondroblastoma humerus","title":"Chondroblastoma of the humerus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chondroblastoma of the humerus</div><div class=\"cntnt\"><img style=\"width:353px; height:480px;\" src=\"images/PEDS/82162_Chondroblastoma_humerus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Greater tuberosity of the humerus. Observe the oval, geographic lesion within the greater tuberosity apophysis (arrows). This is a characteristic location for chondroblastoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82162 Version 2.0</div></div></div>"},"82163":{"type":"graphic_figure","displayName":"Lateral approach for lumbar puncture","title":"Spinal needle access into the subarachnoid space by the median or lateral approach","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Spinal needle access into the subarachnoid space by the median or lateral approach</div><div class=\"cntnt\"><img style=\"width:538px; height:568px;\" src=\"images/PEDS/82163_Lateral_approach.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the lateral approach, the needle is inserted lateral to the upper border of the L3 or L4 spinous process. The needle is then directed slightly medially and cephalad. The lateral approach bypasses the supraspinal ligament (which can be calcified in older patients, causing deflection of the needle) and penetrates the ligamentum flavum, passing through the dura into the subarachnoid space.</div><div id=\"graphicVersion\">Graphic 82163 Version 3.0</div></div></div>"},"82167":{"type":"graphic_table","displayName":"Preoperative eval GERD","title":"Preoperative evaluation for gastroesophageal reflux disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preoperative evaluation for gastroesophageal reflux disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Detailed clinical history and physical examination to determine:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">A. Clinically significant GERD</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">B. Atypical GERD</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">C. Medical treatment failure/medication intolerance</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">D. Noncompliance</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">E. Prospect of lifelong medical therapy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">If work-up is indicated:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Endoscopy to assess degree/presence of esophagitis/Barrett's esophagus</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>24-48 continuous pH probe</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Esophageal manometry</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Optional additional evaluations:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Barium swallow to assess possible esophageal shortening</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Gastric emptying study to assess presence of delayed gastric emptying</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Impendence study to determine the presence of non-acid reflux</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 82167 Version 1.0</div></div></div>"},"82168":{"type":"graphic_figure","displayName":"Symptoms in ZES","title":"Presenting symptoms and signs in patients with Zollinger-Ellison syndrome","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Presenting symptoms and signs in patients with Zollinger-Ellison syndrome</div><div class=\"cntnt\"><img style=\"width:564px; height:606px;\" src=\"images/GAST/82168_Symptoms_in_ZES.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The presence or absence of clinical symptoms or signs at the initial assessment in 261 patients with Zollinger-Ellison syndrome (ZES). Prominent gastric body folds, esophageal stricture, and pyloric or duodenal scarring were determined by upper gastrointestinal endoscopy; a confirmed peptic ulcer was assessed by upper gastrointestinal endoscopy or radiographic studies.</div><div class=\"graphic_reference\">Data from: Roy PK, Venzon DJ, Shojamenesh H, et al, Medicine (Baltimore) 2000; 79:379.</div><div id=\"graphicVersion\">Graphic 82168 Version 5.0</div></div></div>"},"82169":{"type":"graphic_table","displayName":"Clinical features UV","title":"Clinical features of urticarial vasculitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of urticarial vasculitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Cutaneous features</td> <td class=\"subtitle1\">Systemic features</td> </tr> <tr> <td>Common </td> <td>Erythematous urticarial papules and plaques (wheals), angioedema, dermographism, annular erythema</td> <td>Musculoskeletal: arthralgia, arthritis</td> </tr> <tr> <td rowspan=\"3\">Less common</td> <td rowspan=\"3\">Urticarial lesions with residual hyperpigmentation and/or purpura</td> <td>Respiratory: cough, dyspnea, hemoptysis, COPD, asthma, pleural effusion<br /> </td> </tr> <tr> <td>Renal disease: proteinuria, hematuria, glomerulonephritis</td> </tr> <tr> <td>Gastrointestinal: substernal pain, abdominal pain, nausea, vomiting, diarrhea</td> </tr> <tr> <td rowspan=\"3\">Rare</td> <td rowspan=\"3\">Erythema multiforme-like lesions, livedo reticularis, Raynaud's phenomenon, laryngeal edema</td> <td>Cardiac: pericarditis, pericardial effusion, cardiac tamponade</td> </tr> <tr> <td>Ophthalmologic: conjunctivitis, episcleritis, uveitis, geographic serpiginous choroidopathy, visual loss</td> </tr> <tr> <td>Other: fever, splenomegaly, lymphadenopathy, cold sensitivity, reversible tracheal stenosis&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Very rare</td> <td rowspan=\"2\">&nbsp;</td> <td>CNS: pseudotumor cerebri, cranial nerve&nbsp;palsies, aseptic meningitis</td> </tr> <tr> <td>Miscellaneous: transverse myelitis, cardiac valve disease, optic atrophy, Jaccoud's arthropathy (chronic non-erosive, deforming arthropathy), peripheral neuropathy, pleuritis&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82169 Version 2.0</div></div></div>"},"82170":{"type":"graphic_table","displayName":"Fall risk assessment prevention","title":"Approach to fall risk assessment and targeted interventions to reduce falls","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to fall risk assessment and targeted interventions to reduce falls</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Risk factors</td>\n\n      <td class=\"subtitle1\">Interventions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Postural hypotension</td>\n\n      <td>Behavioral recommendation such as ankle pumps or hand clenching; elevate head of bed</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use of any benzodiazepines or other sedative-hypnotics</td>\n\n      <td>Education about appropriate use of these medications;\nnonpharmacologic treatment of sleep problems; medication taper and\ndiscontinuation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>At least four prescription drugs</td>\n\n      <td>Medication review with patient</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Unsafe tub and toilet transfers</td>\n\n      <td>Transfer training; environmental manipulations such as grab bars, raised toilet seats</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Environmental fall or tripping hazards</td>\n\n      <td>Appropriate manipulations such as hazard removal, safer furniture, structures such as grab bars or stair handrails</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Any gait impairment</td>\n\n      <td>Gait training, appropriate assistive device, balance or strengthening exercises if indicated</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Any transfer or balance impairment</td>\n\n      <td>Balance exercises, transfer training if indicated, environmental manipulations (walking devices, reachers, adaptive furniture such as higher chairs)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Impairment of lower and upper extremity muscle strength or joint range of motion</td>\n\n      <td>Resistive exercises</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 82170 Version 1.0</div></div></div>"},"82171":{"type":"graphic_table","displayName":"Indication thrombolytic therapy","title":"Potential indications for thrombolytic therapy in venous thromboembolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential indications for thrombolytic therapy in venous thromboembolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>High-risk (massive) PE; ie, presence of hypotension related to PE*</td> </tr> <tr> <td>Presence of severe hypoxemia (particularly in those with a contribution from concomitant cardiopulmonary disease)</td> </tr> <tr> <td>Patients with acute PE who appear to be decompensating but are not yet hypotensive</td> </tr> <tr> <td>Patients with severe right ventricular dysfunction and tachycardia due to PE</td> </tr> <tr> <td>Clot-in-transit (ie, right atrium or ventricle)</td> </tr> <tr> <td>Extensive deep vein thrombosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* This indication is widely accepted; the other potential indications require careful review of the risks of thrombolytic therapy and potential benefits.</div><div id=\"graphicVersion\">Graphic 82171 Version 2.0</div></div></div>"},"82172":{"type":"graphic_table","displayName":"Fluids for patients without dehydration","title":"Fluids for patients without signs of dehydration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fluids for patients without signs of dehydration</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acceptable</td> </tr> <tr> <td>Oral rehydration solution (optimal for both repletion and maintenance)</td> </tr> <tr> <td>Salted drinks (salted rice water or salted yogurt drink)</td> </tr> <tr> <td>Broth/soup (salted vegetable or meat soup)</td> </tr> <tr> <td>Water</td> </tr> <tr> <td>Rice water</td> </tr> <tr> <td>Coconut water (unsweetened)</td> </tr> <tr> <td>Weak tea (unsweetened)</td> </tr> <tr> <td>Fresh fruit juice (unsweetened)</td> </tr> <tr> <td class=\"subtitle1_single\">Unacceptable</td> </tr> <tr> <td>Carbonated beverages</td> </tr> <tr> <td>Sweetened juices</td> </tr> <tr> <td>Coffee</td> </tr> <tr> <td>Medicinal teas or infusions</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Fluids containing salt should be encouraged. Unacceptable fluids include carbonated beverages and sweetened juices; the sugar in these fluids may worsen diarrhea. Coffee and medicinal teas or infusions are also unacceptable since they can have diuretic and purgative effects.</div><div class=\"graphic_reference\">Data from: World Health Organization. The treatment of diarrhea: A manual for physicians and other senior health workers, 4th revision. WHO/FCH/CAH/05.1. World Health Organization, Geneva 2005. (Available at <a href=\"http://whqlibdoc.who.int/publications/2005/9241593180.pdf\" target=\"_blank\">http://whqlibdoc.who.int/publications/2005/9241593180.pdf</a>).</div><div id=\"graphicVersion\">Graphic 82172 Version 4.0</div></div></div>"},"82173":{"type":"graphic_picture","displayName":"Superficial spreading melanoma 2","title":"Superficial spreading melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial spreading melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/82173_Superficial_spread_melan_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lesion is asymmetric, has irregular borders, and more than three colors.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82173 Version 3.0</div></div></div>"},"82174":{"type":"graphic_table","displayName":"Skin manifestations PEG ribavir","title":"Potential dermatological manifestations associated with peginterferon and ribavirin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential dermatological manifestations associated with peginterferon and ribavirin</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">At injection site</td>\n</tr>\n<tr>\n<td>Erythema and induration</td>\n</tr>\n<tr>\n<td>Painful nodules with central vesiculation</td>\n</tr>\n<tr>\n<td>Ulceration and necrosis</td>\n</tr>\n<tr>\n<td>Contact allergy</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Distant from injection site</td>\n</tr>\n<tr>\n<td>Psoriasis</td>\n</tr>\n<tr>\n<td>Lichen planus</td>\n</tr>\n<tr>\n<td>Vitiligo</td>\n</tr>\n<tr>\n<td>Sarcoidosis</td>\n</tr>\n<tr>\n<td>Vasculitis</td>\n</tr>\n<tr>\n<td>Bullous pemphigus</td>\n</tr>\n<tr>\n<td>Raynaud's</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of Nezam H Afdhal, MD and T Barry Kelleher, MB, MRCPI.</div><div id=\"graphicVersion\">Graphic 82174 Version 2.0</div></div></div>"},"82175":{"type":"graphic_figure","displayName":"Sample ROC curve","title":"Receiver operating characteristic curve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Receiver operating characteristic curve</div><div class=\"cntnt\"><img style=\"width:355px; height:358px;\" src=\"images/OBGYN/82175_Smpl_ROC_crv.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The receiver operating characteristic curve (ROC) plots sensitivity against 1- specificity (ie, the false positive rate). Cutoff values for the diagnostic test vary along the length of the dashed curve, reflecting the interchange between sensitivity and specificity. The area under the ROC curve represents the accuracy of the test. A test that performs no better than chance would be represented by a straight line (solid line) with an area under the ROC of 0.5. A near perfect test would have a rectangular configuration (dotted line) with an area under the ROC approaching 1.00.</div><div id=\"graphicVersion\">Graphic 82175 Version 2.0</div></div></div>"},"82180":{"type":"graphic_diagnosticimage","displayName":"HIV associated dementia MRI","title":"MRI of the brain from a patient with HIV-associated dementia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of the brain from a patient with HIV-associated dementia</div><div class=\"cntnt\"><img style=\"width:295px; height:346px;\" src=\"images/ID/82180_HIV_encephalopathy_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral symmetrical high T2 signals without mass effect are present in the white matter of both frontal lobes, associated with subcortical atrophy.</div><div class=\"graphic_footnotes\">MRI: Magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 82180 Version 4.0</div></div></div>"},"82181":{"type":"graphic_table","displayName":"Causes of delayed passage of meconium","title":"Diagnoses to consider in infants and children with delayed passage of meconium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnoses to consider in infants and children with delayed passage of meconium</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Hirschsprung disease</td> <td>Abdominal distension and vomiting are common. On digital examination, typical findings are a tight anal canal with empty rectum, often with an explosive&nbsp;\"squirt\" of soft stool when the finger is withdrawn. On contrast enema, a transition zone may be seen, but often is not visible in newborns.</td> </tr> <tr> <td>Intestinal obstruction</td> <td>Consider atresia, webs, or volvulus. Obstruction may be present even in infants who pass meconium.</td> </tr> <tr> <td>Meconium ileus</td> <td>Symptoms often begin on second day of life. Most patients with meconium ileus have cystic fibrosis.</td> </tr> <tr> <td><span style=\"color: #0000ff;\"><span style=\"color: black;\">Meconium plug syndrome</span>&nbsp;</span></td> <td>Caused by&nbsp;c<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif'; color: #000000;\">olonic dysmotility or abnormal meconium consistency, leading to obstipation in the newborn. A contrast enema is both diagnostic and therapeutic. Some patients with meconium plug syndrome have Hirschsprung disease. </span></td> </tr> <tr> <td>Functional ileus</td> <td>Occurs in setting of prematurity, sepsis, respiratory distress, pneumonia, or electrolyte disturbances.</td> </tr> <tr> <td>Small left colon*</td> <td>Barium enema shows small-caliber left colon. Increased incidence with maternal diabetes.</td> </tr> <tr> <td>Drugs administered to mother before delivery</td> <td>Magnesium sulfate (MgSO4), opiates, or ganglionic blocking agents.</td> </tr> <tr> <td>Hypothyroidism</td> <td>Infants with hypothyroidism also may have prolonged jaundice, lethargy, and low body temperature.</td> </tr> <tr> <td>Other&nbsp;</td> <td>Rare disorders associated with&nbsp;intestinal pseudo-obstruction, including megacystis-microcolon-intestinal hypoperistalsis (Berdon) syndrome.&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Similar findings may occur in infants with Hirschsprung disease (HD), so affected infants should be observed closely and evaluated for HD if appropriate.</div><div class=\"graphic_reference\">Data from: Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.518.</div><div id=\"graphicVersion\">Graphic 82181 Version 7.0</div></div></div>"},"82182":{"type":"graphic_diagnosticimage","displayName":"Full thick quad tear","title":"Full thickness tear of the quadriceps tendon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Full thickness tear of the quadriceps tendon</div><div class=\"cntnt\"><img style=\"width:390px; height:390px;\" src=\"images/RHEUM/82182_Full_thick_quad_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sagittal proton density magnetic resonance image of the knee demonstrates complete discontinuity of the quadriceps tendon (arrow) consistent with full thickness tear.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 82182 Version 2.0</div></div></div>"},"82183":{"type":"graphic_diagnosticimage","displayName":"Pelvic endometriosis CT","title":"Endometriosis of the ovary","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endometriosis of the ovary</div><div class=\"cntnt\"><img style=\"width:327px; height:252px;\" src=\"images/ENDO/82183_Pelvic_endometriosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT scan of the pelvis in a 29-year-old woman demonstrates a well-circumscribed, low attenuation mass (arrow) in the left pelvis immediately posterior to the uterus. This mass was found to be an endometrioma of the left ovary at surgery.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 82183 Version 3.0</div></div></div>"},"82184":{"type":"graphic_waveform","displayName":"Intermediate case 1","title":"Intermediate case 1","html":"<div class=\"graphic normal\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Intermediate case 1</div><div class=\"cntnt\"><img style=\"width:478px; height:295px;\" src=\"images/CARD/82184_Intermediate_case_1.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82184 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"82186":{"type":"graphic_diagnosticimage","displayName":"MR fetal liver herniation","title":"Magnetic resonance imaging (MRI) of fetal liver position","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging (MRI) of fetal liver position</div><div class=\"cntnt\"><img style=\"width:504px; height:307px;\" src=\"images/OBGYN/82186_MR_fetal_liver_herniation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrafast fetal MRI using HASTE technique demonstrates (left) liver intraabdominal and (right) liver herniation into left chest.</div><div class=\"graphic_footnotes\">HASTE: half-Fourier acquisition single-shot turbo spin-echo.</div><div class=\"graphic_reference\">Courtesy of Holly L Hedrick, MD.</div><div id=\"graphicVersion\">Graphic 82186 Version 3.0</div></div></div>"},"82187":{"type":"graphic_figure","displayName":"Spectrum of CHD","title":"Spectrum of coronary heart disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spectrum of coronary heart disease</div><div class=\"cntnt\"><img style=\"width:430px; height:324px;\" src=\"images/PC/82187_Spectrum_of_CHD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MI: myocardial infarction; ACS: acute coronary syndrome.</div><div id=\"graphicVersion\">Graphic 82187 Version 2.0</div></div></div>"},"82188":{"type":"graphic_table","displayName":"Probability of thromboembolism","title":"Probability of thromboembolism in pregnant women with inherited thrombophilias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Probability of thromboembolism in pregnant women with inherited thrombophilias</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Lesion</td>\n\n      <td class=\"subtitle1\">Prevalence if no history of thrombosis, percent</td>\n\n      <td class=\"subtitle1\">Probability of thrombosis per pregnancy in carriers, percent</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Factor V Leiden</td>\n\n      <td>7.7</td>\n\n      <td>0.25</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Prothrombin gene mutation</td>\n\n      <td>1.3</td>\n\n      <td>0.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Both factor V Leiden and prothrombin gene mutation</td>\n\n      <td>0.1</td>\n\n      <td>4.6</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Antithrombin (ATIII) deficiency</td>\n\n      <td>1.5</td>\n\n      <td>0.4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Protein C deficiency</td>\n\n      <td>3.3</td>\n\n      <td>0.1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Protein S deficiency</td>\n\n      <td>6.6</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>No abnormality</td>\n\n      <td>&nbsp;</td>\n\n      <td>0.03</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from Gerhardt, AG, Scharf, RE, Beckmann, MW, et al, N Engl J Med 2000: 342:374.</div><div id=\"graphicVersion\">Graphic 82188 Version 1.0</div></div></div>"},"82191":{"type":"graphic_table","displayName":"Asthma education","title":"Delivery of asthma education by clinicians during patient care visits","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Delivery of asthma education by clinicians during patient care visits</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Assessment questions</td>\n<td class=\"subtitle1\">Information</td>\n<td class=\"subtitle1\">Skills</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_left\" colspan=\"3\">Recommendations for initial visit</td>\n</tr>\n\t\n<tr>\n\t<td class=\"subtitle3_left\">Focus on:</td>\n\t<td class=\"subtitle3_left\">Teach in simple language:</td>\n\t<td class=\"subtitle3_left\">Teach or review and demonstrate:</td>\n</tr>\n\n<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Expectations of visit</td>\n\t\t\t\t<td class=\"indent1\">&#8226; What is asthma? Asthma is a chronic lung disease. The airways are very sensitive. They become inflamed and narrow; breathing becomes difficult.</td>\n\t\t\t\t<td class=\"indent1\">&#8226; Inhaler and spacer or valved holding chamber (VHC) use. Check performance.</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Asthma control</td>\n\t\t\t\t<td class=\"indent1\">&#8226; The definition of asthma control: few daytime symptoms, no nighttime awakenings due to asthma, able to engage in normal activities, normal lung function.</td>\n\t\t\t\t<td class=\"sublist2_start\">&#8226; Self-monitoring skills that are tied to a written action plan:</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Patients' goals of treatment</td>\n\t\t\t\t<td class=\"sublist2_start\">&#8226; Asthma treatments: two types of medicines are needed:</td>\n\t\t\t\t<td class=\"sublist2\">- Recognize intensity and frequency of asthma symptoms.</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Medications</td>\n\t\t\t\t<td class=\"sublist2\">- Long-term control: medications that prevent symptoms, often by reducing inflammation.</td>\n\t\t\t\t<td class=\"sublist2\">- Review the signs of deterioration and the need to reevaluate therapy:</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Quality of life</td>\n\t\t\t\t<td class=\"sublist2\">- Quick relief: short-acting bronchodilator relaxes muscles around airways.</td>\n\t\t\t\t<td class=\"sublist3\">Waking at night or early morning with asthma</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"What worries you most about your asthma?\"</em></td>\n\t\t\t\t<td class=\"indent1\">&#8226; Bring all medications to every appointment.</td>\n\t\t\t\t<td class=\"sublist3\">Increased medication use</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"What do you want to accomplish at this visit?\"</em></td>\n\t\t\t\t<td class=\"indent1\">&#8226; When to seek medical advice. Provide appropriate telephone number.</td>\n\t\t\t\t<td class=\"sublist3\">Decreased activity tolerance</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"What do you want to be able to do that you can't do now because of your asthma?\"</em></td>\n\t\t\t\t<td rowspan=\"5\">&nbsp;</td>\n\t\t\t\t<td class=\"indent1\">&#8226; Use of a written asthma action plan that includes instructions for daily management and for recognizing and handling worsening asthma.</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"What do you expect from treatment?\"</em></td>\n\t\t\t\t<td rowspan=\"4\">&nbsp;</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"What medicines have you tried?\"</em></td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"What other questions do you have for me today?\"</em></td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"Are there things in your environment that make your asthma worse?\"</em></td>\n\t\t\t</tr>\n\t\t\t\n<tr>\n\t<td class=\"subtitle2_left\" colspan=\"3\">Recommendations for first followup visit (2 to 4 weeks or sooner as needed)</td>\n</tr>\n\n<tr>\n\t<td class=\"subtitle3_left\">Focus on:</td>\n\t<td class=\"subtitle3_left\">Teach in simple language:</td>\n\t<td class=\"subtitle3_left\">Teach or review and demonstrate:</td>\n</tr>\n<tr>\n\t<td class=\"indent1\">&#8226; Expectations of visit</td>\n\t<td class=\"indent1\">&#8226; Use of two types of medications.</td>\n\t<td class=\"indent1\">&#8226; Use of written asthma action plan. Review and adjust as needed.</td>\n</tr>\n<tr>\n\t<td class=\"indent1\">&#8226; Asthma control</td>\n\t<td class=\"indent1\">&#8226; Remind patient to bring all medications and the peak flow meter, if using, to every appointment for review.</td>\n\t<td class=\"indent1\">&#8226; Peak flow monitoring if indicated.</td>\n</tr>\n<tr>\n\t<td class=\"indent1\">&#8226; Patients' goals of treatment</td>\n\t<td class=\"indent1\">&#8226; Self-assessment of asthma control using symptoms and/or peak flow as a guide.</td>\n\t<td class=\"indent1\">&#8226; Correct inhaler and spacer or VHC technique.</td>\n</tr>\n<tr>\n\t<td class=\"indent1\">&#8226; Medications</td>\n\t<td rowspan=\"8\">&nbsp;</td>\n\t<td rowspan=\"8\">&nbsp;</td>\n</tr>\n<tr>\n\t<td class=\"indent1\">&#8226; Patient treatment preferences</td>\n</tr>\n<tr>\n\t<td class=\"indent1\">&#8226; Quality of life</td>\n</tr>\n<tr>\n\t<td class=\"indent1\">Ask relevant questions from previous visit and also ask:</td>\n</tr>\n<tr>\n\t<td class=\"indent1\"><em>\"What medications are you taking?\"</em></td>\n</tr>\n<tr>\n\t<td class=\"indent1\"><em>\"How and when are you taking them?\"</em></td>\n</tr>\n<tr>\n\t<td class=\"indent1\"><em>\"What problems have you had using your medications?\"</em></td>\n</tr>\n<tr>\n\t<td class=\"indent1\"><em>\"Please show me how you use your inhaled medications.\"</em></td>\n</tr>\n\t\t\t\t\t\t\n<tr>\n\t<td class=\"subtitle2_left\" colspan=\"3\">Recommendations for second followup visit</td>\n</tr>\n\n<tr>\n\t<td class=\"subtitle3_left\">Focus on:</td>\n\t<td class=\"subtitle3_left\">Teach in simple language:</td>\n\t<td class=\"subtitle3_left\">Teach or review and demonstrate:</td>\n</tr>\n\n<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Expectations of visit</td>\n\t\t\t\t<td class=\"indent1\">&#8226; Self-assessment of asthma control, using symptoms and/or peak flow as a guide.</td>\n\t\t\t\t<td class=\"indent1\">&#8226; Inhaler/spacer or VHC technique.</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Asthma control</td>\n\t\t\t\t<td class=\"sublist2_start\">&#8226; Relevant environmental control/avoidance strategies:</td>\n\t\t\t\t<td class=\"indent1\">&#8226; Peak flow monitoring technique.</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Patients' goals of treatment</td>\n\t\t\t\t<td class=\"sublist2\">- How to identify home, work, or school exposures that can cause or worsen asthma</td>\n\t\t\t\t<td class=\"indent1\">&#8226; Use of written asthma action plan. Review and adjust as needed.</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Medications</td>\n\t\t\t\t<td class=\"sublist2\">- How to control house-dust mites, animal exposures if applicable</td>\n\t\t\t\t<td class=\"indent1\">&#8226; Confirm that patient knows what to do if asthma gets worse.</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Quality of life</td>\n\t\t\t\t<td class=\"sublist2\">- How to avoid cigarette smoke (active and passive)</td>\n\t\t\t\t<td rowspan=\"8\">&nbsp;</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Ask relevant questions from previous visits and also ask:</td>\n\t\t\t\t<td class=\"indent1\">&#8226; Review all medications.</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"Have you noticed anything in your home, work, or school that makes your asthma worse?\"</em></td>\n\t\t\t\t<td rowspan=\"6\">&nbsp;</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"Describe for me how you know when to call your doctor or go to the hospital for asthma care.\"</em></td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"What questions do you have about the asthma action plan?\" \"Can we make it easier?\"</em></td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"Are your medications causing you any problems?\"</em></td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"Have you noticed anything in your environment that makes your asthma worse?\"</em></td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"Have you missed any of your medications?\"</em></td>\n\t\t\t</tr>\n\t\t\t\n<tr>\n\t<td class=\"subtitle2_left\" colspan=\"3\">Recommendations for all subsequent visits</td>\n</tr>\n\n<tr>\n\t<td class=\"subtitle3_left\">Focus on:</td>\n\t<td class=\"subtitle3_left\">Teach in simple language:</td>\n\t<td class=\"subtitle3_left\">Teach or review and demonstrate:</td>\n</tr>\n\n<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Expectations of visit</td>\n\t\t\t\t<td class=\"sublist2_start\">&#8226; Review and reinforce all:</td>\n\t\t\t\t<td class=\"indent1\">&#8226; Inhaler/spacer or VHC technique.</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Asthma control</td>\n\t\t\t\t<td class=\"sublist2\">- Educational messages</td>\n\t\t\t\t<td class=\"indent1\">&#8226; Peak flow monitoring technique, if appropriate.</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Patients' goals of treatment</td>\n\t\t\t\t<td class=\"sublist2\">- Environmental control strategies at home, work, or school</td>\n\t\t\t\t<td class=\"indent1\">&#8226; Use of written asthma action plan. Review and adjust as needed.</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Medications</td>\n\t\t\t\t<td class=\"sublist2\">- Medications</td>\n\t\t\t\t<td class=\"indent1\">&#8226; Confirm that patient knows what to do if asthma gets worse.</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">&#8226; Quality of life</td>\n\t\t\t\t<td class=\"sublist2\">- Self-assessment of asthma control, using symptoms and/or peak flow as a guide</td>\n\t\t\t\t<td rowspan=\"4\">&nbsp;</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Ask relevant questions from previous visits and also ask:</td>\n\t\t\t\t<td rowspan=\"3\">&nbsp;</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"How have you tried to control things that make your asthma worse?\"</em></td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\"><em>\"Please show me how you use your inhaled medication.\"</em></td>\n\t\t\t</tr>\t\t\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 82191 Version 1.0</div></div></div>"},"82192":{"type":"graphic_diagnosticimage","displayName":"Transverse patella fracture oblique view","title":"Transverse patella fracture from an oblique view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse patella fracture from an oblique view</div><div class=\"cntnt\"><img style=\"width:360px; height:362px;\" src=\"images/EM/82192_Transverse_patella_fx_obliq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain radiograph, taken from an oblique view,&nbsp;shows a&nbsp;transverse patella fracture (arrow).</div><div class=\"graphic_reference\">Courtesy of Jim Blount, MD.</div><div id=\"graphicVersion\">Graphic 82192 Version 4.0</div></div></div>"},"82193":{"type":"graphic_picture","displayName":"Actinic keratosis PI","title":"Actinic keratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Actinic keratosis</div><div class=\"cntnt\"><img style=\"width:432px; height:304px;\" src=\"images/PI/82193_Actinic_keratosis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Actinic keratosis causes rough, red, scaly spots on the skin.</div><div class=\"graphic_reference\">Reproduced from: Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D. Color Atlas and Synopsis of Clinical Dermatology. Common and Serious Diseases. (4th Ed), McGraw-Hill, New York 2001. p.220.</div><div id=\"graphicVersion\">Graphic 82193 Version 4.0</div></div></div>"},"82194":{"type":"graphic_diagnosticimage","displayName":"MRI of reactivated Chagas in the CNS","title":"MRI images from an HIV-infected patient with reactivated Chagas disease in the central nervous system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI images from an HIV-infected patient with reactivated Chagas disease in the central nervous system</div><div class=\"cntnt\"><img style=\"width:292px; height:576px;\" src=\"images/ID/82194_MRIreactivatedChagasedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Drs. Marcela Campo and Cesar Arias.</div><div id=\"graphicVersion\">Graphic 82194 Version 4.0</div></div></div>"},"82195":{"type":"graphic_figure","displayName":"Survival CHD LVEF","title":"Survival in coronary heart disease is related to left ventricular ejection fraction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival in coronary heart disease is related to left ventricular ejection fraction</div><div class=\"cntnt\"><img style=\"width:425px; height:259px;\" src=\"images/CARD/82195_Survival_CHD_LVEF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival analysis during medical therapy of 23,467 patients enrolled in the CASS trial who had one, two, or three vessel disease shows that the overall 12-year survival is related to the left ventricular ejection fraction.</div><div class=\"graphic_reference\">Data from Emond M, Mock MB, Davis KB, et al. Circulation 1994; 90:2645.</div><div id=\"graphicVersion\">Graphic 82195 Version 2.0</div></div></div>"},"82196":{"type":"graphic_table","displayName":"Cabazitaxel and prednisone for prostate cancer","title":"Cabazitaxel and prednisone for metastatic, castration-resistant prostate cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cabazitaxel and prednisone for metastatic, castration-resistant prostate cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cabazitaxel</td> <td>20 mg/m<sup>2</sup> IV*</td> <td>Dilute in 250 mL normal saline or 5% dextrose in water<sup>&#182;</sup> and administer over one hour; special equipment and preparation techniques needed<sup>&#916;</sup>.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Prednisone</td> <td>10 mg orally</td> <td>Daily.</td> <td>Days 1 to 21</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE (&#62;30 to 90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Severe hypersensitivity reactions may occur. Cabazitaxel is contraindicated in patients with a prior history of hypersensitivity to other drugs formulated with polysorbate 80. All patients should receive intravenous premedication with a corticosteroid (dexamethasone 8 mg or equivalent), an H1 receptor antagonist (diphenhydramine 25 mg or an equivalent), and an H2 receptor antagonist (ranitidine 50 mg IV or equivalent) at least 30 minutes prior to cabazitaxel administration. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not recommended&nbsp;for all patients (risk of febrile neutropenia 8%<sup>[1]</sup>). However, primary prophylaxis with G-CSF should be considered for all patients with high-risk clinical features: Age &#62;65 years, poor performance status, previous episodes of febrile neutropenia, extensive prior radiation, poor nutritional status, or other serious comorbidities. Bone marrow suppression is prominent with cabazitaxel, and deaths due to neutropenia are reported. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Reduce cabazitaxel dose for mild to moderate hepatic impairment. Cabazitaxel is not recommended in patients with severe hepatic impairment (total bilirubin &#62;3 times ULN). Cabazitaxel should be used with caution in patients with severe renal insufficiency requiring hemodialysis. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan=\"3\"> <ul> <li>Concurrent cabazitaxel administration with strong CYP3A4 inhibitors should be avoided due to potentially increased cabazitaxel plasma concentrations. </li> <li>If coadministration of cabazitaxel and a strong CYP3A4 inhibitor(s) is unavoidable, reduce cabazitaxel dose by 25%. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential weekly during the first cycle and at the start of each subsequent treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Renal and liver function testing at least every three weeks during treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor neurologic function and gastrointestinal toxicities prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Do not give if neutrophil count &#8804;1500/microL. For prolonged grade 3 or 4 neutropenia (greater than one week) despite appropriate medication including G-CSF for febrile neutropenia, delay treatment until improvement/resolution and neutrophil count is &#62;1500/microL, then reduce dose to 20 mg/m<sup>2</sup>. Use G-CSF for secondary prophylaxis.<sup>[2]</sup> Discontinue cabazitaxel if these toxicities recur at the lower dose level. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For grade 3 or higher diarrhea or persisting diarrhea despite appropriate medication and fluid and electrolyte replacement, delay treatment until improvement or resolution, then reduce dose to 20 mg/m<sup>2</sup>. For persistent diarrhea despite dose reduction, discontinue cabazitaxel therapy.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Peripheral neuropathy</strong></td> <td colspan=\"3\"> <ul> <li>For grade 2 peripheral neuropathy, delay treatment until improvement/resolution, then reduce dose to 20 mg/m<sup>2</sup>.<sup>[2]</sup> Discontinue cabazitaxel for grade 3 or grade 4 peripheral neuropathy. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony-stimulating factor; ULN: upper limit of normal; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CBC: complete blood count; PVC: polyvinyl chloride.<br />*A dose of 25 mg/m<SUP>2</SUP> can be used in select patients at the discretion of the treating health care provider.<br />¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Δ Do not use PVC infusion containers or polyurethane infusion sets for preparation or administration. The manufacturer requires that two dilutions are performed prior to administration. Cabazitaxel can be administered in normal saline or 5% dextrose in water at concentrations between 0.10 mg/mL and 0.26 mg/mL. Use an in-line filter of 0.22 micron nominal pore size during administration.<SUP>[2]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>de Bono JS, et al. Lancet 2010; 376:1147.</LI>&#xD;&#xA;<LI>Cabazitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 13, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 82196 Version 12.0</div></div></div>"},"82197":{"type":"graphic_diagnosticimage","displayName":"Langerhans histiocytosis PA I","title":"Pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:324px; height:360px;\" src=\"images/PULM/82197_Langerhans_histiocytosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph demonstrates the classic features of profuse ill-defined nodules, reticulondoular opacities, cysts, and costophrenic angle sparing in pulmonary Langerhans cell histiocytosis. There is a mild reduction in lung volumes.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 82197 Version 3.0</div></div></div>"},"82198":{"type":"graphic_picture","displayName":"Pansclerotic morphea","title":"Pansclerotic morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pansclerotic morphea</div><div class=\"cntnt\"><img style=\"width:307px; height:432px;\" src=\"images/DERM/82198_Pansclerotic_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sclerosis encompassing the majority of the body surface area, characteristically sparing the fingertips, is present.</div><div id=\"graphicVersion\">Graphic 82198 Version 2.0</div></div></div>"},"82199":{"type":"graphic_figure","displayName":"Pelvic ligaments anterior and posterior","title":"Pelvic ligaments: Anterior and posterior views","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Pelvic ligaments: Anterior and posterior views</div><div class=\"cntnt\"><img style=\"width:529px; height:191px;\" src=\"images/EM/82199_Pelvic_ligaments.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Gibbs, MA, Bosse, MJ. Pelvic Ring Fractures. In: Trauma Management: An Emergency Medicine Approach, Ferrara, PC, Colucciello, SA, Marx, JA, Verdile, VP, Gibbs, MA (Eds), Mosby, St. Louis 2001. p. 331. Illustrations used with permission of Elsevier Inc. All rights reserved. Copyright &#169;2001 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 82199 Version 2.0</div></div></div>"},"82200":{"type":"graphic_picture","displayName":"Neuropathology vanishing white matter disease","title":"Neuropathology of vanishing white matter disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neuropathology of vanishing white matter disease</div><div class=\"cntnt\"><img style=\"width:289px; height:432px;\" src=\"images/NEURO/82200_Neuropath_girl_age_16_VWM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal section of the left cerebral hemisphere shows the rarefaction of the white matter with microcystic changes in the periventricular area. The U-fibers, corpus callosum, and internal capsule are relatively spared (anti-MBP stain).</div><div class=\"graphic_reference\">Reproduced with permission from: Van der Knaap MS, Kamphorst W, Barth PG. Phenotypic variation in leukoencephalopathy with vanishing white matter. Neurology 1998; 51:540. Copyright © 1998 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82200 Version 13.0</div></div></div>"},"82201":{"type":"graphic_picture","displayName":"Rigid bronchoscope and forceps","title":"Rigid bronchoscope and forceps","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Rigid bronchoscope and forceps</div><div class=\"cntnt\"><img style=\"width:500px; height:366px;\" src=\"images/PULM/82201_Rigid_bronchoscp_forcep.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The distal end of rigid grasping forceps.<br />(B) The beveled distal tip of a rigid bronchoscope, showing the large working channel.</div><div id=\"graphicVersion\">Graphic 82201 Version 2.0</div></div></div>"},"82202":{"type":"graphic_diagnosticimage","displayName":"Rectal cancer BE","title":"Rectal cancer as seen on barium enema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rectal cancer as seen on barium enema</div><div class=\"cntnt\"><img style=\"width:247px; height:288px;\" src=\"images/GAST/82202_Rectal_cancer_BE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double-contrast barium enema shows an eccentric mass arising from the anterior wall of the rectum (arrow).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 82202 Version 3.0</div></div></div>"},"82203":{"type":"graphic_picture","displayName":"Megaloblastic marrow","title":"Megaloblastic erythropoiesis - bone marrow aspirate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Megaloblastic erythropoiesis - bone marrow aspirate</div><div class=\"cntnt\"><img style=\"width:419px; height:288px;\" src=\"images/HEME/82203_Megaloblastic_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with megaloblastic anemia secondary to vitamin B12 deficiency. This field shows a predominance of megaloblastic erythroid precursors (black arrows), two giant metamyelocytes (red arrows) and a mitotic figure (blue arrow). (Wright-Giemsa).</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 82203 Version 2.0</div></div></div>"},"82204":{"type":"graphic_picture","displayName":"CPAM type 1 histology","title":"Histology of a type 1 congenital pulmonary airway malformation (CPAM)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology of a type 1 congenital pulmonary airway malformation (CPAM)</div><div class=\"cntnt\"><img style=\"width:419px; height:276px;\" src=\"images/PEDS/82204_CCAM_type_1_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histology specimend from a congenital pulmonary airway malformation (CPAM) type 1, showing the large cystic component lined by columnar, ciliated epithelium. The wall of the cyst resembles pre-acinar airways. Frequent openings in the cyst wall extend into the adjacent acinar structures. The wall contains smooth muscle but not cartilage.</div><div class=\"graphic_reference\">Courtesy of Christopher M Oermann, MD, and Claire Langston, MD</div><div id=\"graphicVersion\">Graphic 82204 Version 5.0</div></div></div>"},"82206":{"type":"graphic_diagnosticimage","displayName":"Nasal encephalocele","title":"Nasal encephalocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasal encephalocele</div><div class=\"cntnt\"><img style=\"width:288px; height:287px;\" src=\"images/PEDS/82206_Nasal_encephalocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nasal cephaloceles are herniations of brain, meninges, and/or cerebrospinal fluid through a defect in the skull. Those containing brain tissue are termed encephaloceles. They may communicate with the subarachnoid space and, occasionally, the ventricular system. The arrow points to&nbsp;an encephalocele&nbsp;underneath the nasal dorsum.</div><div class=\"graphic_reference\">Courtesy of Marvin A Fishman, MD.</div><div id=\"graphicVersion\">Graphic 82206 Version 4.0</div></div></div>"},"82207":{"type":"graphic_diagnosticimage","displayName":"Giant bilateral bullae PA","title":"Chest radiograph of a giant bilateral bullae in young smoker","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a giant bilateral bullae in young smoker</div><div class=\"cntnt\"><img style=\"width:324px; height:315px;\" src=\"images/PULM/82207_Giant_bilateral_bullae_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows large bilateral collections of gas devoid of any vascular structures with a sharp edge concave laterally, which is a differentiating feature from pneumothorax. The functioning lung is retracted to the bases.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82207 Version 4.0</div></div></div>"},"82208":{"type":"graphic_diagnosticimage","displayName":"Septated empyema US","title":"Thoracic ultrasound of pleural empyema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic ultrasound of pleural empyema</div><div class=\"cntnt\"><img style=\"width:360px; height:266px;\" src=\"images/PULM/82208_Septated_empyema_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Empyema with multiple septations demonstrated on an ultrasonogram of the lower left hemithorax.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82208 Version 3.0</div></div></div>"},"82209":{"type":"graphic_figure","displayName":"Ixodes scapularis life cycle","title":"<em>Ixodes scapularis</em> life cycle","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\"><em>Ixodes scapularis</em> life cycle</div><div class=\"cntnt\"><img style=\"width:462px; height:472px;\" src=\"images/ID/82209_I_scapularis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">http://www.cdc.gov/ncidod/dvbid/lyme/images/TickLifeCycle_707.jpg.</div><div id=\"graphicVersion\">Graphic 82209 Version 2.0</div></div></div>"},"82210":{"type":"graphic_table","displayName":"Diagnostic studies for pediatric respiratory distress","title":"Diagnostic studies for evaluation of acute respiratory distress","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic studies for evaluation of acute respiratory distress</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Indications</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Bedside testing</td> </tr> <tr> <td class=\"indent1\">Pulse oximetry</td> <td>All patients with respiratory distress</td> <td> <p>Normal values despite hypoxia seen in patients with severe anemia, carboxyhemoglobin, or sickle cell disease</p> Falsely low values obtained in patients with pulse oximeter not correlating with pulse, poor peripheral perfusion, venous congestion, methemoglobinemia, certain nail polish colors, and in patients receiving vital dyes (eg, methylene blue) during surgical procedures</td> </tr> <tr> <td class=\"indent1\">End-tidal CO2 (ETCO2) measurement</td> <td> <p>Confirmation of successful endotracheal intubation</p> <p>Noninvasive monitoring of ventilation in intubated and non-intubated patients</p> Noninvasive monitoring for sedation in children</td> <td>Measurable in non-intubated and intubated patients</td> </tr> <tr> <td class=\"indent1\">Electrocardiogram</td> <td>Clinical suspicion of cardiac disease (eg, cardiac murmur, gallop, differential pulses or blood pressure between upper and lower extremities)</td> <td>Typically combined with chest radiograph to assess heart size and pulmonary vasculature in order to determine need for echocardiography</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Laboratory testing</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Arterial blood gas</td> <td rowspan=\"2\"> <p>Determine PaO2 for calculation of physiologic measures of oxygenation (eg, A-a gradient, PaO2/FiO2 ratio)</p> <p>Correlate pCO2 with end-tidal CO2 measurments</p> Measure pH and correlate with venous pH</td> <td>End-tidal CO2, pulse oximetry, and venous blood gases may be used as less invasive methods for ongoing monitoring of oxygenation, ventilation, and acid-base status if they correlate with arterial blood gas measurements</td> </tr> <tr> <td rowspan=\"2\">Assesses for the presence of an anion gap and renal dysfunction</td> </tr> <tr> <td class=\"indent1\">Electrolytes, blood urea nitrogen, creatinine</td> <td>Patients with metabolic acidosis</td> </tr> <tr> <td class=\"indent1\">Glucose</td> <td>Altered mental status</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ammonia</td> <td>Altered mental status and other findings suggestive of urea cycle defects</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Carboxyhemoglobin</td> <td> <p>Smoke inhalation</p> Altered mental status, headache, vomiting and possible exposure to carbon monoxide (eg, blocked furnace flue)</td> <td>Pulse oximetry is falsely elevated in the presence of carboxyhemoglobin</td> </tr> <tr> <td class=\"indent1\">Methemoglobin</td> <td> <p>Cyanosis in the presence of a normal PaO2 on arterial blood gas</p> Exposure to agents known to cause methemoglobinemia (eg, nitrites, benzocaine, aniline dyes)</td> <td>Oxygen saturation by cooximetry identifies the presence of an abnormal hemoglobin if specific measure of methemoglobin is not available</td> </tr> <tr> <td class=\"indent1\">D-dimer</td> <td>Clinical findings suggestive of pulmonary embolus (eg, low oxygenation, pleuritic chest pain, wedge-shaped infiltrate on chest radiograph, and predisposing condition [eg, sickle cell disease, thrombotic condition])</td> <td> <p>Pulmonary embolus is a rare cause of respiratory distress in children</p> Imaging options in patients with moderate to high clinical probability and elevated D-dimer include ventilation/perfusion scan, ultrasound of extremity veins and deep veins, CT pulmonary angiography, and pulmonary angiography</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Imaging</td> </tr> <tr> <td class=\"indent1\">Lateral neck radiograph</td> <td>Clinical findings suggestive of epiglottitis, retropharyngeal abscess, or ingested foreign body</td> <td>Croup can usually be diagnosed clinically without a radiograph</td> </tr> <tr> <td class=\"indent1\">Chest radiograph</td> <td>All children with significant respiratory distress and those with focal lung findings</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Forced expiratory or bilateral decubitus chest radiograph</td> <td>Suspected foreign body aspiration</td> <td>Hyperaeration noted on the side with the bronchial foreign body</td> </tr> <tr> <td class=\"indent1\">Unilateral decubitus chest radiograph</td> <td>Assess whether lung opacity is due to parenchymal disease or effusion</td> <td>Loculated effusions and very large effusions may not show evidence of layering</td> </tr> <tr> <td class=\"indent1\">Echocardiography</td> <td>Assess cardiac function and presence of structural heart disease</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Abdominal radiographs (supine and upright, or cross-table lateral)</td> <td>Significant abdominal tenderness and/or distension with concern for intestinal obstruction or perforation</td> <td>Other testing (eg, ultrasound, upper gastrointestinal contrast study, abdominal CT) may also be indicated depending upon clinical findings and likely etiologies</td> </tr> <tr> <td class=\"indent1\">Computed tomography (CT) of the head</td> <td>Clinical findings suggestive of increased intracranial pressure or intracranial mass lesion</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82210 Version 8.0</div></div></div>"},"82211":{"type":"graphic_picture","displayName":"P6 acupressure point","title":"P6 acupressure point","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">P6 acupressure point</div><div class=\"cntnt\"><img style=\"width:504px; height:376px;\" src=\"images/OBGYN/82211_P6_acupressure_point.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure or massage at the P6 acupressure point is reported in some studies to relieve motion sickness. The point is found three of the patient's fingerbreadths proximal to the proximal wrist fold, between the palmaris longus and flexor carpi radialis tendons, shown in this picture by the tip of the pen.</div><div class=\"graphic_reference\">Courtesy of Judith A Smith, Pharm D, BCOP, FCCP, FISOPP.</div><div id=\"graphicVersion\">Graphic 82211 Version 1.0</div></div></div>"},"82212":{"type":"graphic_picture","displayName":"Segmental hemangioma","title":"Segmental infantile hemangioma of the head and neck","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Segmental infantile hemangioma of the head and neck</div><div class=\"cntnt\"><img style=\"width:370px; height:277px;\" src=\"images/PEDS/82212_Segmental_hemangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segmental hemangiomas are usually plaquelike and demonstrate a linear and/or geographic presence over a specific cutaneous territory. Infants with segmental hemangiomas should also be evaluated for PHACE syndrome.</div><div class=\"graphic_reference\">Courtesy of Denise W Metry, MD.</div><div id=\"graphicVersion\">Graphic 82212 Version 3.0</div></div></div>"},"82213":{"type":"graphic_table","displayName":"Causes pleural eosinophilia","title":"Causes of pleural fluid eosinophilia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of pleural fluid eosinophilia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Exudative effusions</td> </tr> <tr> <td>Drugs</td> <td>Please refer to the&nbsp;UpToDate table&nbsp;on drug-induced pleural fluid eosinophilia</td> </tr> <tr> <td>Idiopathic</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"5\">Infection </td> <td>Bacteria (eg, parapneumonic effusion)</td> </tr> <tr> <td>Fungi (eg, Histoplasma capsulatum, Coccidioides immitis)</td> </tr> <tr> <td>Mycobacteria</td> </tr> <tr> <td>Parasites (eg, Amebiasis, Ascaria, Dracunculus, Echinococcosis, Filaria, Paragonimus, Strongyloides, Toxocara)</td> </tr> <tr> <td>Virus</td> </tr> <tr> <td rowspan=\"4\">Inflammatory </td> <td>Acute eosinophilic pneumonia</td> </tr> <tr> <td>Chronic eosinophilic pneumonia&nbsp;</td> </tr> <tr> <td>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</td> </tr> <tr> <td>Rheumatoid effusion</td> </tr> <tr> <td>Malignancy</td> <td>Lymphoma, mesothelioma, metastatic carcinoma&nbsp;</td> </tr> <tr> <td>Pulmonary embolism</td> <td>&nbsp;</td> </tr> <tr> <td>Toxin</td> <td>Benign asbestos effusion</td> </tr> <tr> <td rowspan=\"5\">Trauma</td> <td>Hemothorax</td> </tr> <tr> <td>Pneumothorax</td> </tr> <tr> <td>Thoracentesis</td> </tr> <tr> <td>Thoracic surgery</td> </tr> <tr> <td>Thoracoscopy</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Transudative effusions</td> </tr> <tr> <td>Cirrhosis</td> <td>&nbsp;</td> </tr> <tr> <td>Heart failure</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82213 Version 3.0</div></div></div>"},"82214":{"type":"graphic_picture","displayName":"Oral candidiasis - tongue","title":"Oral candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral candidiasis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/82214_Oral_candidiasis_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White plaques are present on the tongue.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82214 Version 3.0</div></div></div>"},"82218":{"type":"graphic_diagnosticimage","displayName":"Bronchial atresia CXR","title":"Bronchial atresia in infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchial atresia in infant</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PULM/82218_Bronchial_atresia_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows marked hyperexpansion and oligemia of the left upper lobe. A small suprahilar nodule is visible in the left upper lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82218 Version 2.0</div></div></div>"},"82220":{"type":"graphic_picture","displayName":"Inflammatory breast cancer appearance ","title":"Inflammatory breast cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory breast cancer</div><div class=\"cntnt\"><img style=\"width:432px; height:289px;\" src=\"images/ONC/82220_Inflammatory_breast_CA_ap1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sofia D Merajver, MD, PhD.</div><div id=\"graphicVersion\">Graphic 82220 Version 2.0</div></div></div>"},"82223":{"type":"graphic_figure","displayName":"Lichtenstein hernia repair","title":"Lichtenstein hernia repair","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Lichtenstein hernia repair</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/82223_Lichtenstein_hernia_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The upper&nbsp;illustrations depict the relationship of the&nbsp;mesh to the floor of the inguinal canal&nbsp;(A,B).&nbsp;A tangential view (C) of the mesh shows the inversion of a direct hernia sac with a purse string suture and the overlying attenuated transversalis fascia in Hasselbach’s triangle.</div><div id=\"graphicVersion\">Graphic 82223 Version 3.0</div></div></div>"},"82224":{"type":"graphic_diagnosticimage","displayName":"Adrenal mass CT","title":"Adrenal mass in disseminated histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adrenal mass in disseminated histoplasmosis</div><div class=\"cntnt\"><img style=\"width:432px; height:307px;\" src=\"images/ID/82224_Adrenal_mass_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adrenal computed tomography (CT) shows a markedly enlarged left adrenal gland. This patient had disseminated histoplasmosis with involvement of the lungs, liver, and bone marrow, and had a painful tongue ulcer that on biopsy showed <EM>H. capsulatum</EM> on methenamine silver stain.</div><div class=\"graphic_reference\">Courtesy of Carol A Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 82224 Version 3.0</div></div></div>"},"82225":{"type":"graphic_figure","displayName":"C-spine axial load","title":"Response of the cervical spine to applied axial load","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Response of the cervical spine to applied axial load</div><div class=\"cntnt\"><img style=\"width:485px; height:247px;\" src=\"images/PEDS/82225_C-spine_axial_load.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When the head is in the neutral position, with the normal cervical lordotic curve, forces transmitted to the head are dissipated in the cervical muscles and ligaments, as depicted in image A above. When the neck is flexed to 30 degrees, the cervical spine is straight and becomes collinear with the axial force which is directly transmitted from one vertebra to the next, as depicted in image B above. At the time of impact, the cervical spine buckles under the compressive load, as depicted in image C above.</div><div id=\"graphicVersion\">Graphic 82225 Version 1.0</div></div></div>"},"82226":{"type":"graphic_figure","displayName":"Anterior skull anatomy","title":"Anterior skull anatomy","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Anterior skull anatomy</div><div class=\"cntnt\"><img style=\"width:575px; height:454px;\" src=\"images/EM/82226_Skull_anat_ant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior view of the adult skull.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL,&#160;Dalley AF II. Clinical Oriented Anatomy, 4th Edition. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82226 Version 3.0</div></div></div>"},"82227":{"type":"graphic_picture","displayName":"SMAC agar stool with answer","title":"<EM>Escherichia coli</EM> on SMAC agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Escherichia coli</EM> on SMAC agar</div><div class=\"cntnt\"><img style=\"width:336px; height:240px;\" src=\"images/ID/82227_SMACagarstoolwithanswer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Culture of two <EM>Escherichia coli </EM>strains on sorbitol-MacConkey (SMAC) agar. Most <EM>E. coli </EM>utilize sorbitol (red colonies on right), but <EM>E. coli </EM>O157:H7 cannot (colorless colonies on left).</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 82227 Version 3.0</div></div></div>"},"82228":{"type":"graphic_table","displayName":"CT findings MPM","title":"Typical findings on contrast enhanced CT scan in patients with MPM","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical findings on contrast enhanced CT scan in patients with MPM</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Initial CT findings\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Frequency, percent\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ascites</td>\r\n  \r\n   <td>60 to 100</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Omental involvement</td>\r\n  \r\n   <td>66 to 91</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Peritoneal changes</td>\r\n  \r\n   <td>73 to 88</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Diaphragm or liver surface involvement</td>\r\n  \r\n   <td>77 to 82</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Small bowel or mesentery involvement</td>\r\n  \r\n   <td>60 to 82</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pleural changes*</td>\r\n  \r\n   <td>23 to 80</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pleural effusion*</td>\r\n  \r\n   <td>17 to 20</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Abdominal adenopathy</td>\r\n  \r\n   <td>12 to 27</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Discrete masses</td>\r\n  \r\n   <td>12 to 20</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=45875&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>CT_findings_MPM.htm</title></head></div><div class=\"graphic_footnotes\">CT: computed tomography; MPM: malignant peritoneal mesothelioma.<br />* Some studies additionally used plan radiographs for interpretations.</div><div class=\"graphic_reference\">References:<BR>1. Kebapci M, Vardareli E, Adapinar B, Acikalin M. CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur Radiol 2003; 13:2620.<BR>2. Ros PR, Yuschok TJ, Buck JL, et al. Peritoneal mesothelioma. Radiologic appearances correlated with histology. Acta Radiol 199; 32:355.<BR>3. Antman KH, Pomfret EA, Aisner J, et al. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1983; 1:386.<BR>4. Yan TD, Haveric N, Carmignani CP. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005; 103:839.<BR>5. Plaus WJ. Peritoneal mesothelioma. Arch Surg 1988; 123:763.</div><div id=\"graphicVersion\">Graphic 82228 Version 3.0</div></div></div>"},"82230":{"type":"graphic_figure","displayName":"Single vessel grafting","title":"Graphic representation of single vessel grafting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graphic representation of single vessel grafting</div><div class=\"cntnt\"><img style=\"width:449px; height:352px;\" src=\"images/CARD/82230_Single_vessel_grafting.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left internal mammary artery (LIMA) is anastomosed to the left anterior descending (LAD) artery. The coronary stabilizer prevents movement of the artery during the surgery.</div><div class=\"graphic_reference\">Redrawn from Stanbridge RD, Hadjinikolaou LK, cohen AS, et al. Ann Thorac Surg 1997; 65 (6 Suppl):S53.</div><div id=\"graphicVersion\">Graphic 82230 Version 2.0</div></div></div>"},"82231":{"type":"graphic_picture","displayName":"Syncytial form nodular sclerosis HL","title":"Syncytial form of nodular sclerosis Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Syncytial form of nodular sclerosis Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:502px; height:756px;\" src=\"images/HEME/82231_SyncyfrmndsclerosisHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sheets of lacunar cells are clustered around a center area of necrosis in the syncytial form of nodular sclerosis Hodgkin lymphoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al. Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82231 Version 8.0</div></div></div>"},"82234":{"type":"graphic_table","displayName":"Causes uvulitis","title":"Infectious and noninfectious causes of uvulitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious and noninfectious causes of uvulitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infectious causes</td> </tr> <tr> <td>Group A streptococcus (<em>Streptococcus pyogenes</em>)*</td> </tr> <tr> <td><em>Haemophilus influenzae</em> type b</td> </tr> <tr> <td><em>Fusobacterium nucleatum</em></td> </tr> <tr> <td><em>Prevotella intermedia</em></td> </tr> <tr> <td><em>Streptococcus pneumoniae</em></td> </tr> <tr> <td><em>Candida albicans</em></td> </tr> <tr> <td class=\"subtitle1_single\">Noninfectious causes</td> </tr> <tr> <td>Trauma (during airway or other instrumentation)</td> </tr> <tr> <td>Inhalation of irritants (including steam and cannabis)</td> </tr> <tr> <td>Vasculitis</td> </tr> <tr> <td>Allergic reaction</td> </tr> <tr> <td>Angioedema (Quincke's edema)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Most common cause. Other bacterial etiologies are from case reports.</div><div id=\"graphicVersion\">Graphic 82234 Version 4.0</div></div></div>"},"82235":{"type":"graphic_figure","displayName":"Radial head subluxation classic arm position","title":"Classic arm position in children with radial head subluxation (nursemaid's elbow)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classic arm position in children with radial head subluxation (nursemaid's elbow)</div><div class=\"cntnt\"><img style=\"width:327px; height:432px;\" src=\"images/PEDS/82235_RHS_classic_arm_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Children with radial head subluxation typically hold the affected arm close to the body with the elbow slightly flexed or extended and the forearm pronated.</div><div id=\"graphicVersion\">Graphic 82235 Version 2.0</div></div></div>"},"82236":{"type":"graphic_figure","displayName":"Plantar foot anatomy scheme: arteries and nerves","title":"Plantar foot anatomy scheme: arteries and nerves","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plantar foot anatomy scheme: arteries and nerves</div><div class=\"cntnt\"><img style=\"width:430px; height:507px;\" src=\"images/PC/82236_Plantar_foot_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The path of plantar arteries (red) and nerves (green) to the toes is shown. Each digit is innervated by four digital nerves; the dorsal arteries and nerves are not shown in this figure. In order to achieve a complete anesthetic effect, it is necessary to block all four nerves. For a complete block of the great toe, there are additional branches that come up the dorsal aspect of the great toe that can be missed if anesthetic is only injected laterally and medially. In general, foot injections are not performed in the plantar surface.</div><div id=\"graphicVersion\">Graphic 82236 Version 4.0</div></div></div>"},"82237":{"type":"graphic_diagnosticimage","displayName":"Honeycomb cysts in IPF CT","title":"Honeycomb cysts in IPF/UIP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Honeycomb cysts in IPF/UIP</div><div class=\"cntnt\"><img style=\"width:375px; height:283px;\" src=\"images/PULM/82237_Honeycomb_cysts_in_IPF_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">IPF/UIP with bilateral, small subpleural honeycomb cysts which are separated by normal parenchyma. The anterior segmental bronchus of the left upper lobe is slightly dilated, consistent with mild traction bronchiectasis.</div><div class=\"graphic_footnotes\">IPF: idiopathic pulmonary fibrosis; UIP: usual interstitial pneumonia.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82237 Version 3.0</div></div></div>"},"82239":{"type":"graphic_table","displayName":"Adult thoracic effective doses","title":"Adult thoracic effective doses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adult thoracic effective doses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Modality</td> <td class=\"subtitle1\">Average effective dose (mSv)</td> <td class=\"subtitle1\">Number of chest x-rays (PA/lateral) with equivalent radiation dose</td> </tr> <tr> <td>Chest radiograph (posteroanterior)</td> <td>Conventional radiography</td> <td>0.02</td> <td>0.2</td> </tr> <tr> <td>PA and lateral chest radiographs</td> <td>Conventional radiography</td> <td>0.1</td> <td>1</td> </tr> <tr> <td>Thyroid scan (iodine 123)</td> <td>Nuclear medicine</td> <td>1.9</td> <td>19</td> </tr> <tr> <td>Lung ventilation-perfusion scan</td> <td>Nuclear medicine</td> <td>2.2</td> <td>22</td> </tr> <tr> <td>Thoracic angiogram</td> <td>Conventional fluoroscopy or interventional radiology</td> <td>5</td> <td>50</td> </tr> <tr> <td>Parathyroid scan</td> <td>Nuclear medicine</td> <td>6.7</td> <td>67</td> </tr> <tr> <td>Conventional coronary angiogram</td> <td>Conventional fluoroscopy or interventional radiology</td> <td>7</td> <td>70</td> </tr> <tr> <td>CT chest </td> <td>Computed tomography</td> <td>8</td> <td>80</td> </tr> <tr> <td>Nuclear cardiac stress test</td> <td>Nuclear medicine</td> <td>9.4-12.8</td> <td>94-128</td> </tr> <tr> <td>Cardiac PET</td> <td>Nuclear medicine</td> <td>14.1</td> <td>141</td> </tr> <tr> <td>CT pulmonary embolism protocol </td> <td>Computed tomography</td> <td>15</td> <td>150</td> </tr> <tr> <td>Coronary angioplasty or stent</td> <td>Conventional fluoroscopy or interventional radiology</td> <td>15</td> <td>150</td> </tr> <tr> <td>CT coronary angiogram</td> <td>Computed tomography</td> <td>16</td> <td>160</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PET: positron-emission tomography.</div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Mettler, FA, Huda, W, Yoshizumi, TT, Mahesh, M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248:254. </li> <li>Smith-Bindman, R, Lipson, J, Marcus, R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009; 169:2078. </li> <li>Shrimpton, PC, Hillier, MC, Lewis, MA, Dunn, M. National survey of doses from CT in the UK: 2003. Br J Radiol 2006; 79:968. </li> <li>Diederich, S, Lenzen, H. Radiation exposure associated with imaging of the chest: comparison of different radiographic and computed tomography techniques. Cancer 2000; 89:2457. </li> </ol></div><div id=\"graphicVersion\">Graphic 82239 Version 4.0</div></div></div>"},"82240":{"type":"graphic_table","displayName":"Antibiotic regimens for tuboovarian abscess","title":"Antibiotic regimens for tuboovarian abscess","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic regimens for tuboovarian abscess</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimens</td> <td class=\"subtitle1\">Dose (adult)</td> </tr> <tr> <td class=\"subtitle1_start\" colspan=\"2\"><strong>First choice</strong>*<sup>[1-4]</sup></td> </tr> <tr> <td class=\"indent1\">Cefoxitin <strong>and</strong></td> <td>2 g IV every 6 hours</td> </tr> <tr> <td class=\"indent1\">Doxycycline</td> <td>100 mg orally or IV every 12 hours</td> </tr> <tr> <td class=\"sublist_other\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Cefotetan <strong>and</strong></td> <td>2 g IV every 12 hours</td> </tr> <tr> <td class=\"indent1\">Doxycycline</td> <td>100 mg orally or IV every 12 hours</td> </tr> <tr> <td class=\"sublist_other\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Clindamycin <strong>and</strong></td> <td>900 mg IV every 8 hours</td> </tr> <tr> <td class=\"indent1\">Gentamicin<sup>&#182;</sup></td> <td>2 mg/kg loading dose then 1.5 mg/kg every 8 hours IV or IM</td> </tr> <tr> <td class=\"sublist_other\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ampicillin <strong>and</strong></td> <td>2 g IV every 6 hours</td> </tr> <tr> <td class=\"indent1\">Clindamycin <strong>and</strong></td> <td>900 mg IV every 8 hours</td> </tr> <tr> <td class=\"indent1\">Gentamicin (3-antibiotic regimen)<sup>&#182;</sup></td> <td>2 mg/kg loading dose then 1.5 mg/kg every 8 hours IV or IM</td> </tr> <tr> <td class=\"sublist_other\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ampicillin-sulbactam <strong>and</strong></td> <td>3 g IV every 6 hours<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Doxycycline</td> <td>100 mg orally or IV every 12 hours</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Second choice</strong><sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Levofloxacin <strong>and</strong></td> <td>500 mg IV once daily</td> </tr> <tr> <td class=\"indent1\">Metronidazole</td> <td>500 mg IV every 8 hours</td> </tr> <tr> <td class=\"sublist_other\" colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Imipenem-cilastatin</td> <td>500 mg IV every 6 hours</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Outpatient oral regimens</strong> (<strong>only</strong> as continuation of therapy in select patients)<sup>&#9674;</sup><sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Levofloxacin <strong>or</strong> Ofloxacin <strong>and</strong></td> <td>500 mg orally once daily</td> </tr> <tr> <td class=\"indent1\">Metronidazole</td> <td>500 mg orally twice daily</td> </tr> <tr> <td class=\"sublist_other\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Amoxicillin-clavulanate XR</td> <td>2000 mg extended release orally twice daily</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table includes the United States Centers for Disease Control and Prevention (CDC) recommendations for antibiotic treatment of pelvic inflammatory disease, as extrapolated to treat tuboovarian abscess. There may be other reasonable options for antimicrobial agents. </div><div class=\"graphic_footnotes\">* Antibiotic doses should be adjusted appropriately for patients with renal insufficiency or other dose-related consideration.<br />¶ Alternatively gentamicin may be given 3 to 5 mg/kg IV once per day.<br />Δ 3 g ampicillin-sulbactam is equivalent to 2 g ampicillin with 1 gram sulbactam.<br /><FONT class=lozenge>◊</FONT> There are insufficient high quality data about this agent or regimen; coverage is theoretic.<br />§ In select patients in whom clinical improvement has been clearly documented, continuation of therapy as an outpatient may be appropriate. Direct communication with the patient and a plan for follow-up must also be confirmed.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Workowski KA, Berman S. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1. </li>&#xD;&#xA;    <li>Landers DV, Sweet RL. Tubo-ovarian abscess: contemporary approach to management. Rev Infect Dis 1983; 5:876. </li>&#xD;&#xA;    <li>Reed SD, Landers DV, Sweet RL. Am J Obstet Gynecol 1991; 164:1556. </li>&#xD;&#xA;    <li>Ginsburg DS, Stern JL, Hamod KA, et al. Am J Obstet Gynecol 1980; 138:1055. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 82240 Version 14.0</div></div></div>"},"82241":{"type":"graphic_table","displayName":"Pyogenic granuloma treatments and recurrence rates","title":"Treatments utilized for pyogenic granuloma and recurrence rates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatments utilized for pyogenic granuloma and recurrence rates</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">PG</td> <td class=\"subtitle1\">Recurrences (recurrence rate)</td> </tr> <tr> <td class=\"subtitle2_left\">Surgical management</td> <td class=\"subtitle2_left\">753</td> <td class=\"subtitle2_left\">38 (5.05%)</td> </tr> <tr> <td class=\"indent1\">Surgical excision</td> <td>510</td> <td>15 (2.94%)</td> </tr> <tr> <td class=\"indent1\">Curettage/shave excision +/- cautery/cautery alone</td> <td>199</td> <td>19 (9.55%)</td> </tr> <tr> <td class=\"indent1\">Shave excision + laser photocoagulation</td> <td>28</td> <td>2 (7.14%)</td> </tr> <tr> <td class=\"indent1\">Blunt removal + cauterization with silver nitrate</td> <td>13</td> <td>2 (15.38%)</td> </tr> <tr> <td class=\"indent1\">Punch excision/biopsy</td> <td>2</td> <td>0 (0%)</td> </tr> <tr> <td class=\"indent1\">Applying a suture around the base</td> <td>1</td> <td>0 (0%)</td> </tr> <tr> <td class=\"subtitle2_left\">Non-surgical management</td> <td class=\"subtitle2_left\">409</td> <td class=\"subtitle2_left\">15 (3.67%)</td> </tr> <tr> <td class=\"indent1\">Cryotherapy with liquid nitrogen</td> <td>185</td> <td>3 (1.62%)</td> </tr> <tr> <td class=\"indent1\">CO<sub>2</sub> laser ablation</td> <td>103</td> <td>5 (4.85%)</td> </tr> <tr> <td class=\"indent1\">Flashlamp pulsed dye laser</td> <td>69</td> <td>3 (4.35%)</td> </tr> <tr> <td class=\"indent1\">Nd-YAG laser</td> <td>2</td> <td>0 (0%)</td> </tr> <tr> <td class=\"indent1\">1064 nm laser + glycerin sclerotherapy</td> <td>1</td> <td>0 (0%)</td> </tr> <tr> <td class=\"indent1\">Sclerotherapy with monoethanolamine oleate</td> <td>9</td> <td>0 (0%)</td> </tr> <tr> <td class=\"indent1\">Sclerotherapy with monoethanolamine oleate</td> <td>15</td> <td>2 (13.33%)</td> </tr> <tr> <td class=\"indent1\">Topical imiquimod 5% cream</td> <td>17</td> <td>0 (0%)</td> </tr> <tr> <td class=\"indent1\">Systemic steroids</td> <td>1</td> <td>0 (0%)</td> </tr> <tr> <td class=\"indent1\">Diathermy</td> <td>1</td> <td>0 (0%)</td> </tr> <tr> <td class=\"indent1\">Radiation treatment</td> <td>1</td> <td>0 (0%)</td> </tr> <tr> <td class=\"indent1\">Intralesional bleomycin injection</td> <td>1</td> <td>0 (0%)</td> </tr> <tr> <td class=\"indent1\">Observation</td> <td>4</td> <td>0 (0%)</td> </tr> <tr class=\"divider_top\"> <td><strong>Total</strong></td> <td><strong>1162</strong></td> <td><strong>53 (4.56%)</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">From: Lee J, Sinno H, Tahiri Y, Gilardino MS. Treatment options for cutaneous pyogenic granulomas: A review. J Plast Reconstr Aesthet Surg 2011; 64:1216. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 82241 Version 1.0</div></div></div>"},"82242":{"type":"graphic_table","displayName":"Annual Lyme disease rate by state","title":"Reported cases of Lyme disease by state or locality in the United States, 2001-2010*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reported cases of Lyme disease by state or locality in the United States, 2001-2010*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"12\" width=\"7%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">State</td> <td class=\"subtitle1\" rowspan=\"2\">2001</td> <td class=\"subtitle1\" rowspan=\"2\">2002</td> <td class=\"subtitle1\" rowspan=\"2\">2003</td> <td class=\"subtitle1\" rowspan=\"2\">2004</td> <td class=\"subtitle1\" rowspan=\"2\">2005</td> <td class=\"subtitle1\" rowspan=\"2\">2006</td> <td class=\"subtitle1\" rowspan=\"2\">2007</td> <td class=\"subtitle1\" rowspan=\"2\">2008</td> <td class=\"subtitle1\" rowspan=\"2\">2009*</td> <td class=\"subtitle1\" colspan=\"3\">2010</td> </tr> <tr> <td class=\"subtitle2\">Confirmed</td> <td class=\"subtitle2\">Probable</td> <td class=\"subtitle2\">Incidence<sup>&#182;</sup></td> </tr> <tr> <td>Alabama</td> <td>10</td> <td>11</td> <td>8</td> <td>6</td> <td>3</td> <td>11</td> <td>13</td> <td>6</td> <td>3</td> <td>1</td> <td>1</td> <td>0.0</td> </tr> <tr> <td>Alaska</td> <td>2</td> <td>3</td> <td>3</td> <td>3</td> <td>4</td> <td>3</td> <td>10</td> <td>6</td> <td>7</td> <td>7</td> <td>0</td> <td>1.0</td> </tr> <tr> <td>Arizona</td> <td>3</td> <td>4</td> <td>4</td> <td>13</td> <td>10</td> <td>10</td> <td>2</td> <td>2</td> <td>3</td> <td>2</td> <td>0</td> <td>0.0</td> </tr> <tr> <td>Arkansas</td> <td>4</td> <td>3</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0.0</td> </tr> <tr> <td>California</td> <td>95</td> <td>97</td> <td>86</td> <td>48</td> <td>95</td> <td>85</td> <td>75</td> <td>74</td> <td>117</td> <td>126</td> <td>3</td> <td>0.4</td> </tr> <tr> <td>Colorado</td> <td>0</td> <td>1</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>2</td> <td>0</td> <td>1</td> <td>2</td> <td>0.0</td> </tr> <tr> <td>Connecticut</td> <td>3597</td> <td>4631</td> <td>1403</td> <td>1348</td> <td>1810</td> <td>1788</td> <td>3058</td> <td>2738</td> <td>2751</td> <td>1964</td> <td>1104</td> <td>55.0</td> </tr> <tr> <td>Delaware</td> <td>152</td> <td>194</td> <td>212</td> <td>339</td> <td>646</td> <td>482</td> <td>715</td> <td>772</td> <td>984</td> <td>656</td> <td>0</td> <td>73.1</td> </tr> <tr> <td>District of Columbia</td> <td>17</td> <td>25</td> <td>14</td> <td>16</td> <td>10</td> <td>62</td> <td>116</td> <td>71</td> <td>53</td> <td>34</td> <td>8</td> <td>5.7</td> </tr> <tr> <td>Florida</td> <td>43</td> <td>79</td> <td>43</td> <td>46</td> <td>47</td> <td>34</td> <td>30</td> <td>72</td> <td>77</td> <td>56</td> <td>28</td> <td>0.3</td> </tr> <tr> <td>Georgia</td> <td>0</td> <td>2</td> <td>10</td> <td>12</td> <td>6</td> <td>8</td> <td>11</td> <td>35</td> <td>40</td> <td>10</td> <td>0</td> <td>0.1</td> </tr> <tr> <td>Hawaii</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0.0</td> </tr> <tr> <td>Idaho</td> <td>5</td> <td>4</td> <td>3</td> <td>6</td> <td>2</td> <td>7</td> <td>9</td> <td>5</td> <td>4</td> <td>6</td> <td>3</td> <td>0.4</td> </tr> <tr> <td>Illinois</td> <td>32</td> <td>47</td> <td>71</td> <td>87</td> <td>127</td> <td>110</td> <td>149</td> <td>108</td> <td>136</td> <td>135</td> <td>0</td> <td>1.1</td> </tr> <tr> <td>Indiana</td> <td>26</td> <td>21</td> <td>25</td> <td>32</td> <td>33</td> <td>26</td> <td>55</td> <td>42</td> <td>61</td> <td>62</td> <td>16</td> <td>1.0</td> </tr> <tr> <td>Iowa</td> <td>36</td> <td>42</td> <td>58</td> <td>49</td> <td>89</td> <td>97</td> <td>123</td> <td>85</td> <td>77</td> <td>68</td> <td>17</td> <td>2.2</td> </tr> <tr> <td>Kansas</td> <td>2</td> <td>7</td> <td>4</td> <td>3</td> <td>3</td> <td>4</td> <td>8</td> <td>16</td> <td>18</td> <td>7</td> <td>3</td> <td>0.2</td> </tr> <tr> <td>Kentucky</td> <td>23</td> <td>25</td> <td>17</td> <td>15</td> <td>5</td> <td>7</td> <td>6</td> <td>5</td> <td>1</td> <td>5</td> <td>0</td> <td>0.1</td> </tr> <tr> <td>Louisiana</td> <td>8</td> <td>5</td> <td>7</td> <td>2</td> <td>3</td> <td>1</td> <td>2</td> <td>3</td> <td>0</td> <td>2</td> <td>1</td> <td>0.0</td> </tr> <tr> <td>Maine</td> <td>108</td> <td>219</td> <td>175</td> <td>225</td> <td>247</td> <td>338</td> <td>529</td> <td>780</td> <td>791</td> <td>559</td> <td>192</td> <td>42.1</td> </tr> <tr> <td>Maryland</td> <td>608</td> <td>738</td> <td>691</td> <td>891</td> <td>1235</td> <td>1248</td> <td>2576</td> <td>1746</td> <td>1466</td> <td>1163</td> <td>454</td> <td>20.1</td> </tr> <tr> <td>Massachusetts</td> <td>1164</td> <td>1807</td> <td>1532</td> <td>1532</td> <td>2336</td> <td>1432</td> <td>2988</td> <td>3960</td> <td>4019</td> <td>2380</td> <td>883</td> <td>36.3</td> </tr> <tr> <td>Michigan</td> <td>21</td> <td>26</td> <td>12</td> <td>27</td> <td>62</td> <td>55</td> <td>51</td> <td>76</td> <td>81</td> <td>76</td> <td>19</td> <td>0.8</td> </tr> <tr> <td>Minnesota</td> <td>461</td> <td>867</td> <td>474</td> <td>1023</td> <td>917</td> <td>914</td> <td>1238</td> <td>1046</td> <td>1063</td> <td>1293</td> <td>667</td> <td>24.4</td> </tr> <tr> <td>Mississippi</td> <td>8</td> <td>12</td> <td>21</td> <td>0</td> <td>0</td> <td>3</td> <td>1</td> <td>1</td> <td>0</td> <td>0</td> <td>0</td> <td>0.0</td> </tr> <tr> <td>Missouri</td> <td>37</td> <td>41</td> <td>70</td> <td>25</td> <td>15</td> <td>5</td> <td>10</td> <td>6</td> <td>3</td> <td>4</td> <td>0</td> <td>0.1</td> </tr> <tr> <td>Montana</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> <td>4</td> <td>6</td> <td>3</td> <td>3</td> <td>1</td> <td>0.3</td> </tr> <tr> <td>Nebraska</td> <td>4</td> <td>6</td> <td>2</td> <td>2</td> <td>2</td> <td>11</td> <td>7</td> <td>8</td> <td>4</td> <td>7</td> <td>1</td> <td>0.4</td> </tr> <tr> <td>Nevada</td> <td>4</td> <td>2</td> <td>3</td> <td>1</td> <td>3</td> <td>4</td> <td>15</td> <td>9</td> <td>10</td> <td>2</td> <td>0</td> <td>0.1</td> </tr> <tr> <td>New Hampshire</td> <td>129</td> <td>261</td> <td>190</td> <td>226</td> <td>265</td> <td>617</td> <td>896</td> <td>1211</td> <td>996</td> <td>830</td> <td>509</td> <td>63.0</td> </tr> <tr> <td>New Jersey</td> <td>2020</td> <td>2349</td> <td>2887</td> <td>2698</td> <td>3363</td> <td>2432</td> <td>3134</td> <td>3214</td> <td>4598</td> <td>3320</td> <td>392</td> <td>37.8</td> </tr> <tr> <td>New Mexico</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>3</td> <td>3</td> <td>5</td> <td>4</td> <td>1</td> <td>3</td> <td>2</td> <td>0.1</td> </tr> <tr> <td>New York</td> <td>4083</td> <td>5535</td> <td>5399</td> <td>5100</td> <td>5565</td> <td>4460</td> <td>4165</td> <td>5741</td> <td>4134</td> <td>2385</td> <td>1040</td> <td>12.3</td> </tr> <tr> <td>North Carolina</td> <td>41</td> <td>137</td> <td>156</td> <td>122</td> <td>49</td> <td>31</td> <td>53</td> <td>16</td> <td>21</td> <td>21</td> <td>61</td> <td>0.2</td> </tr> <tr> <td>North Dakota</td> <td>0</td> <td>1</td> <td>0</td> <td>0</td> <td>3</td> <td>7</td> <td>12</td> <td>8</td> <td>10</td> <td>21</td> <td>12</td> <td>3.1</td> </tr> <tr> <td>Ohio</td> <td>44</td> <td>82</td> <td>66</td> <td>50</td> <td>58</td> <td>43</td> <td>33</td> <td>40</td> <td>51</td> <td>21</td> <td>23</td> <td>0.2</td> </tr> <tr> <td>Oklahoma</td> <td>0</td> <td>0</td> <td>0</td> <td>3</td> <td>0</td> <td>0</td> <td>1</td> <td>1</td> <td>2</td> <td>0</td> <td>0</td> <td>0.0</td> </tr> <tr> <td>Oregon</td> <td>15</td> <td>12</td> <td>16</td> <td>11</td> <td>3</td> <td>7</td> <td>6</td> <td>18</td> <td>12</td> <td>7</td> <td>32</td> <td>0.2</td> </tr> <tr> <td>Pennsylvania</td> <td>2806</td> <td>3989</td> <td>5730</td> <td>3985</td> <td>4287</td> <td>3242</td> <td>3994</td> <td>3818</td> <td>4950</td> <td>3298</td> <td>507</td> <td>26.0</td> </tr> <tr> <td>Rhode Island</td> <td>510</td> <td>852</td> <td>736</td> <td>249</td> <td>39</td> <td>308</td> <td>177</td> <td>186</td> <td>150</td> <td>115</td> <td>66</td> <td>10.9</td> </tr> <tr> <td>South Carolina</td> <td>6</td> <td>26</td> <td>18</td> <td>22</td> <td>15</td> <td>20</td> <td>31</td> <td>14</td> <td>25</td> <td>19</td> <td>10</td> <td>0.4</td> </tr> <tr> <td>South Dakota</td> <td>0</td> <td>2</td> <td>1</td> <td>1</td> <td>2</td> <td>1</td> <td>0</td> <td>3</td> <td>1</td> <td>1</td> <td>0</td> <td>0.1</td> </tr> <tr> <td>Tennessee</td> <td>31</td> <td>28</td> <td>20</td> <td>20</td> <td>8</td> <td>15</td> <td>31</td> <td>7</td> <td>10</td> <td>6</td> <td>30</td> <td>0.1</td> </tr> <tr> <td>Texas</td> <td>75</td> <td>139</td> <td>85</td> <td>98</td> <td>69</td> <td>29</td> <td>87</td> <td>105</td> <td>88</td> <td>55</td> <td>87</td> <td>0.2</td> </tr> <tr> <td>Utah</td> <td>1</td> <td>5</td> <td>2</td> <td>1</td> <td>2</td> <td>5</td> <td>7</td> <td>3</td> <td>6</td> <td>3</td> <td>0</td> <td>0.1</td> </tr> <tr> <td>Vermont</td> <td>18</td> <td>37</td> <td>43</td> <td>50</td> <td>54</td> <td>105</td> <td>138</td> <td>330</td> <td>323</td> <td>271</td> <td>85</td> <td>43.3</td> </tr> <tr> <td>Virginia</td> <td>156</td> <td>259</td> <td>195</td> <td>216</td> <td>274</td> <td>357</td> <td>959</td> <td>886</td> <td>698</td> <td>911</td> <td>334</td> <td>11.4</td> </tr> <tr> <td>Washington</td> <td>9</td> <td>11</td> <td>7</td> <td>14</td> <td>13</td> <td>8</td> <td>12</td> <td>22</td> <td>15</td> <td>12</td> <td>4</td> <td>0.2</td> </tr> <tr> <td>West Virginia</td> <td>16</td> <td>26</td> <td>31</td> <td>38</td> <td>61</td> <td>28</td> <td>84</td> <td>120</td> <td>143</td> <td>128</td> <td>17</td> <td>6.9</td> </tr> <tr> <td>Wisconsin</td> <td>597</td> <td>1090</td> <td>740</td> <td>1144</td> <td>1459</td> <td>1466</td> <td>1814</td> <td>1493</td> <td>1952</td> <td>2505</td> <td>983</td> <td>44.0</td> </tr> <tr class=\"divider_bottom\"> <td>Wyoming</td> <td>1</td> <td>2</td> <td>2</td> <td>4</td> <td>3</td> <td>1</td> <td>3</td> <td>1</td> <td>1</td> <td>0</td> <td>0</td> <td>0.0</td> </tr> <tr> <td><strong>US total</strong></td> <td><strong>17,029</strong></td> <td><strong>23,763</strong></td> <td><strong>21,273</strong></td> <td><strong>19,804</strong></td> <td><strong>23,305</strong></td> <td><strong>19,931</strong></td> <td><strong>27,444</strong></td> <td><strong>28,921</strong></td> <td><strong>29,959</strong></td> <td><strong>22,561</strong></td> <td><strong>7597</strong></td> <td><strong>7.3</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Confirmed cases presented for all years except most recent.<br />&para; Confirmed cases per 100,000 population.</div><div class=\"graphic_reference\">Adapted from: Reported Lyme disease cases by state, 2000-2010. United States Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/lyme/stats/chartstables/reportedcases_statelocality.html\" target=\"_blank\">http://www.cdc.gov/lyme/stats/chartstables/reportedcases_statelocality.html</a>. Accessed on March 9, 2012.</div><div id=\"graphicVersion\">Graphic 82242 Version 4.0</div></div></div>"},"82244":{"type":"graphic_picture","displayName":"Fibrillary glomerulonephritis EM","title":"Fibrillary glomerulonephritis EM","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrillary glomerulonephritis EM</div><div class=\"cntnt\"><img style=\"width:378px; height:274px;\" src=\"images/NEPH/82244_Fibrillary_GN_EM_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in fibrillary glomerulonephritis showing intramembranous and subendothelial fibrillary deposits (arrows). The glomerular basement membrane (GBM) is markedly disrupted by the infiltrating fibrils and a distinct lamina densa cannot be seen.</div><div class=\"graphic_footnotes\">En: endothelial cell; Ep: epithelial cell.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 82244 Version 6.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"82245":{"type":"graphic_table","displayName":"Thoracolumbar spinal cord injury score","title":"The thoracolumbar spinal cord injury classification severity score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The thoracolumbar spinal cord injury classification severity score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"85%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">1. Morphology type</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Compression:</td> </tr> <tr> <td class=\"indent2\">Compression fracture</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent2\">Burst fracture</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Translational/rotational</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Distraction</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">2. Neurologic involvement</td> </tr> <tr> <td class=\"indent1\">Intact</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Nerve root</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Conus medullaris:</td> </tr> <tr> <td class=\"indent2\">Incomplete</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent2\">Complete</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Cauda equina</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">3. Posterior ligament complex</td> </tr> <tr> <td class=\"indent1\">Intact</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Injury suspected/indeterminate</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Injured</td> <td class=\"centered\">3</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Vaccaro AR, Zeiller SC, Hulbert RJ, et al. The thoracolumbar injury severity score: a proposed treatment algorithm. J Spinal Disord Tech 2005; 18:209.</div><div id=\"graphicVersion\">Graphic 82245 Version 4.0</div></div></div>"},"82246":{"type":"graphic_figure","displayName":"Dbl neg T cells","title":"Peripheral blood cytometric analysis in ALPS","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Peripheral blood cytometric analysis in ALPS</div><div class=\"cntnt\"><img style=\"width:480px; height:406px;\" src=\"images/ALLRG/82246_Dbl_neg_T_cells.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typically &lt;1 percent&nbsp;of TCR-alpha-beta+ T cells do not express CD4 or CD8. In ALPS, this population is greatly increased (top panels). In addition, these cells express B220 (bottom panels).</div><div class=\"graphic_footnotes\">ALPS: autoimmune lymphoproliferative syndrome; TCR: T cell receptor.</div><div id=\"graphicVersion\">Graphic 82246 Version 2.0</div></div></div>"},"82247":{"type":"graphic_figure","displayName":"Blood glucose record PI","title":"Blood glucose record","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Blood glucose record</div><div class=\"cntnt\"><img style=\"width:607px; height:778px;\" src=\"images/PI/82247_BG_record_PI.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82247 Version 2.0</div></div></div>"},"82248":{"type":"graphic_picture","displayName":"Malrotation at surgery","title":"Malrotation at surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malrotation at surgery</div><div class=\"cntnt\"><img style=\"width:447px; height:297px;\" src=\"images/PEDS/82248_Malrotation_at_surgery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With malrotation, Ladd's bands cross the duodenum, causing extrinsic obstruction. Here the Ladd's bands have been lifted up to expose the duodenum underneath.</div><div class=\"graphic_reference\">Courtesy of Mary L Brandt, MD.</div><div id=\"graphicVersion\">Graphic 82248 Version 1.0</div></div></div>"},"82249":{"type":"graphic_figure","displayName":"Sites of reentry in supraventricular tachyarrhythmias","title":"Sites of reentry in supraventricular tachyarrhythmias","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sites of reentry in supraventricular tachyarrhythmias</div><div class=\"cntnt\"><img style=\"width:421px; height:392px;\" src=\"images/CARD/82249_Sites_of_reentry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reentry may occur around a fixed anatomic obstacle or may be functional, developing in the absence of an anatomic obstacle and resulting from the intrinsic heterogeneity of electrophysiologic properties of the myocardial tissue. Reentrant circuits leading to a supraventricular tachyarrhythmia may develop in various parts of the heart: within and around the sinoatrial node (sinus node reentry); within the atrial myocardium (atrial tachycardia, atrial flutter, or atrial fibrillation); within the atrioventricular (AV) node due to the presence of a slow and fast pathway (atrioventricular nodal reentrant tachycardia); or involving the AV node and an accessory pathway (AP) (atrioventricular reentrant tachycardia) which include Kent, Mahaim, James, and atrio-Hisian (AH) fibers.</div><div id=\"graphicVersion\">Graphic 82249 Version 3.0</div></div></div>"},"82250":{"type":"graphic_picture","displayName":"TruViewEV01","title":"TruViewEV01","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TruViewEV01</div><div class=\"cntnt\"><img style=\"width:432px; height:255px;\" src=\"images/EM/82250_TruViewEV01.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Truview EVO video-laryngoscope in adult, pediatric and infant sizes for indirect laryngoscopy in routine and difficult airways, manufactured by Truphatek International Ltd., Israel. www.truphatek.com</div><div id=\"graphicVersion\">Graphic 82250 Version 2.0</div></div></div>"},"82254":{"type":"graphic_table","displayName":"Household cleaning measures to decrease lead exposure","title":"Household cleaning recommendations to decrease exposure to lead in dust","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Household cleaning recommendations to decrease exposure to lead in dust</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Hard surfaces</td> </tr> <tr> <td>Mop floors once per week with soapy water</td> </tr> <tr> <td>Clean window sills and wells once per week with soapy water</td> </tr> <tr> <td>Use paper towels or set aside a sponge for lead cleaning only</td> </tr> <tr> <td>Use separate buckets for wash and rinse water</td> </tr> <tr> <td>Lightly spray floors with water before sweeping</td> </tr> <tr> <td>Seal wood floors to provide a smooth cleanable surface</td> </tr> <tr> <td>Place a blanket or rug on bare floors where children play</td> </tr> <tr> <td>Keep children and their belongings away from windows</td> </tr> <tr> <td>Open double hung windows from the top</td> </tr> <tr> <td class=\"subtitle1_single\">Carpeted surfaces</td> </tr> <tr> <td class=\"sublist1_start\">Use a HEPA* vacuum for cleaning if possible, or</td> </tr> <tr> <td class=\"sublist1\">Use \"HEPA-type\" or \"allergy\" filter bag, or</td> </tr> <tr> <td class=\"sublist1\">Lightly coat new vacuum bags by spreading and vacuuming flour or cornstarch</td> </tr> <tr> <td>Use a vacuum with an agitator head</td> </tr> <tr> <td>Vacuum for an extended time</td> </tr> <tr> <td>Use care in removing older carpets that are heavily contaminated with lead dust</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* High-efficiency particulate air.</div><div class=\"graphic_reference\">Adapted from Environmental Protection Agency. (http://www.epa.gov/lead/educationexesum.htm)</div><div id=\"graphicVersion\">Graphic 82254 Version 4.0</div></div></div>"},"82255":{"type":"graphic_figure","displayName":"Hypospadias repair: Onlay island flap","title":"Hypospadias repair: Onlay island flap","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Hypospadias repair: Onlay island flap</div><div class=\"cntnt\"><img style=\"width:505px; height:320px;\" src=\"images/PEDS/82255_HypospadOnlayislandflap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Proximal hypospadias with the abnormal urethral meatus at the penile scrotal junction. A strip of tissue, \"the urethral plate,\" is outlined on the ventral aspect of the penile shaft, which will ultimately be the roof of the new urethra. The circumferential incision around the distal end of the penile shaft is placed in the normal position where a circumcision is performed. <br />(B) The urethral plate has been preserved and the penile skin dissected off the corporal bodies (this typically straightens the penis if there was any inherent curvature). The inner prepuce of the dorsal hooded foreskin has been outlined in preparation&nbsp;for creating a vascularized flap that will be patched onto the urethral plate.<br />(C) The vascularized inner prepuce is sewn to both sides of the urethral plate to create the new urethra. After completion of the new urethra the glans will be reconstructed and the extra dorsal penile shaft skin used to cover the penis and complete the repair.</div><div class=\"graphic_reference\">Reproduced from: Transverse Preputial Onlay Island Flap. In: Hinman's Atlas of Pediatric Urologic Surgery, 2nd ed, Hinman F, Baskin LS (Eds), Elsevier, Oxford 2008. Copyright © 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 82255 Version 5.0</div></div></div>"},"82257":{"type":"graphic_table","displayName":"Attenuation coefficient nodule","title":"Relative attenuation coefficients of nodule components (expressed in Hounsfield units, HU)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative attenuation coefficients of nodule components (expressed in Hounsfield units, HU)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Air</td>\n\n      <td>-1000</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fat</td>\n\n      <td>-50 to -100</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Water</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cyst</td>\n\n      <td>0 to 20</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fresh blood clot</td>\n\n      <td>40 to 60</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Noncalcified nodule</td>\n\n      <td>40 to 160</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Calcified nodule </td>\n\n      <td>&#62;200</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bone</td>\n\n      <td>1000</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 82257 Version 1.0</div></div></div>"},"82258":{"type":"graphic_figure","displayName":"Role of cholinergic system in asthma","title":"Role of cholinergic system in asthma","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Role of cholinergic system in asthma</div><div class=\"cntnt\"><img style=\"width:525px; height:667px;\" src=\"images/PULM/82258_Role_of_cholinergic_system_in_asthma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acetylcholine is released from preganglionic cholinergic nerves and acts on nicotinic receptors on parasympathetic ganglionic neurons. M<sub>1</sub> receptors in ganglia facilitate neurotransmission. M<sub>2</sub> receptors are feedback inhibitory receptors on postganglionic nerve terminals. Their stimulation inhibits ACh release. Stimulation of M<sub>3</sub> receptors in airway smooth muscle causes bronchoconstriction. Viral effects, which can induce asthma, may include inhibition of M<sub>2</sub>-ACh receptor binding.</div><div class=\"graphic_footnotes\">ACh: acetylcholine; N: nicotinic receptor; M<sub>1</sub>: muscarinic receptor type 1; M<sub>2</sub>: muscarinic receptor type 2; M<sub>3</sub>: muscarinic receptor type 3.<br />M<sub>1</sub> and M<sub>3</sub> receptors have stimulatory (+) bronchoconstrictive effects, whereas M<sub>2</sub> receptors have inhibitory (&ndash;) effects.</div><div id=\"graphicVersion\">Graphic 82258 Version 5.0</div></div></div>"},"82259":{"type":"graphic_picture","displayName":"Complete UCL tear","title":"Ulnar collateral ligament: Complete tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulnar collateral ligament: Complete tear</div><div class=\"cntnt\"><img style=\"width:432px; height:291px;\" src=\"images/EM/82259_Complete_UCL_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abduction stress placed upon the ulnar collateral ligament in this photograph reveals loss of a distinct endpoint and grossly abnormal motion, which are consistent with a complete ligament tear.</div><div id=\"graphicVersion\">Graphic 82259 Version 1.0</div></div></div>"},"82260":{"type":"graphic_picture","displayName":"Poison ivy 1 PI","title":"Poison ivy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Poison ivy</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PI/82260_Poison_ivy_1_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Green or green-reddish leaves grow in groups of three and have smooth, fine-toothed, or lobed margins, and small, yellow-green flowers form cream-colored fruit.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82260 Version 5.0</div></div></div>"},"82261":{"type":"graphic_figure","displayName":"Radical vaginectomy","title":"Radical vaginectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radical vaginectomy</div><div class=\"cntnt\"><img style=\"width:280px; height:515px;\" src=\"images/OBGYN/82261_Radical_vaginectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The assistant guides the application of the Zeppelin forceps to the paravaginal tissues from below, thereby protecting the vagina from inclusion in the clamp.</div><div id=\"graphicVersion\">Graphic 82261 Version 1.0</div></div></div>"},"82266":{"type":"graphic_diagnosticimage","displayName":"CT choanal atresia","title":"CT image of choanal atresia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT&nbsp;image of choanal atresia</div><div class=\"cntnt\"><img style=\"width:252px; height:365px;\" src=\"images/PEDS/82266_CT_choanal_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT image of choanal atresia. Note the bony narrowing of the posterior nose.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 82266 Version 5.0</div></div></div>"},"82268":{"type":"graphic_picture","displayName":"Eruptive xanthomata forearm","title":"Eruptive xanthomata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eruptive xanthomata</div><div class=\"cntnt\"><img style=\"width:259px; height:395px;\" src=\"images/PC/82268_Eruptive_xanthomata_forearm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Xanthomata are seen on the extensor surface of the forearm in a patient with severe hypertriglyceridemia.</div><div class=\"graphic_reference\">Reproduced with permission from: Durrington P. Dyslipidaemia. Lancet 2003; 362:717. Copyright © 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 82268 Version 2.0</div></div></div>"},"82269":{"type":"graphic_figure","displayName":"Distal clavicle fracture type II A","title":"Distal clavicle fracture type II A","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Distal clavicle fracture type II A</div><div class=\"cntnt\"><img style=\"width:454px; height:276px;\" src=\"images/EM/82269_Clav_fx_dist_type2a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture depicts a type II A distal clavicle fracture. In type IIA injuries, both conoid and trapezoid ligaments are attached to the distal segment, whereas the proximal segment without ligamentous attachments becomes displaced.</div><div class=\"graphic_reference\">Reproduced with permission from: Rockwood CA Jr, Green DP, Bucholz RW, Heckman JD (Eds). Rockwood and Green's Fractures in Adults, 4th ed, Lippincott-Raven, Philadelphia 1996. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82269 Version 5.0</div></div></div>"},"82275":{"type":"graphic_figure","displayName":"Cyber knife radiosurgery","title":"Cyber knife radiosurgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cyber knife radiosurgery</div><div class=\"cntnt\"><img style=\"width:384px; height:581px;\" src=\"images/ONC/82275_Cyber_knife_radiosurgery.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright © Accuray Incorporated.</div><div id=\"graphicVersion\">Graphic 82275 Version 7.0</div></div></div>"},"82276":{"type":"graphic_table","displayName":"CF supps bone health","title":"Dietary requirements relevant for bone health in cystic fibrosis, other than vitamin D","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary requirements relevant for bone health in cystic fibrosis, other than vitamin D</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Calcium*</td> <td class=\"subtitle1\">Phosphorus*</td> <td class=\"subtitle1\">Magnesium*</td> <td class=\"subtitle1\">Vitamin K<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Recommended daily intake</td> </tr> <tr> <td class=\"indent1\">0 to 6 months</td> <td>200 mg</td> <td>100 mg</td> <td>30 mg</td> <td>0.3 to 0.5 mg</td> </tr> <tr> <td class=\"indent1\">7 to 12 months</td> <td>260 mg</td> <td>275 mg</td> <td>75 mg</td> <td>0.3 to 0.5 mg</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>700 mg</td> <td>460 mg</td> <td>80 mg</td> <td>0.3 to 0.5 mg</td> </tr> <tr> <td class=\"indent1\">4 to 8 years</td> <td>1000 mg</td> <td>500 mg</td> <td>130 mg</td> <td>0.3 to 0.5 mg</td> </tr> <tr> <td class=\"indent1\">9 to 13 years</td> <td>1300 mg</td> <td>1250 mg</td> <td>240 mg</td> <td>0.3 to 0.5 mg</td> </tr> <tr> <td class=\"indent1\">14 to 18 years (boys)</td> <td>1300 mg</td> <td>1250 mg</td> <td>410 mg</td> <td>0.3 to 0.5 mg</td> </tr> <tr> <td class=\"indent1\">14 to 18 years (girls)</td> <td>1300 mg</td> <td>1250 mg</td> <td>360 mg</td> <td>0.3 to 0.5 mg</td> </tr> <tr> <td class=\"indent1\">Adults (men)</td> <td>1000 mg</td> <td>700 mg</td> <td>400 mg</td> <td>0.3 to 0.5 mg</td> </tr> <tr> <td class=\"indent1\">Adults (women)</td> <td>1000 mg</td> <td>700 mg</td> <td>310 mg</td> <td>0.3 to 0.5 mg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table outlines the dietary requirements of calcium, phosphorus, magnesium and vitamin K for individuals with cystic fibrosis, each of which is relevant for bone health. Dietary requirements of vitamin D for individuals with cystic fibrosis are presented in a separate table.</div><div class=\"graphic_footnotes\">* Dietary reference intakes (DRIs) for calcium, phosphorus and magnesium are the same as for a healthy population; these data are available at <a href=\"http://www.nap.edu/\" target=\"_blank\">www.nap.edu</a>. For these nutrients, the values shown for infants are adequate intakes (AIs), and the values for older children are recommended dietary allowances (RDAs).<br />&#182; Vitamin K intake recommendations for patients with cystic fibrosis from: Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002; 35:246.</div><div id=\"graphicVersion\">Graphic 82276 Version 8.0</div></div></div>"},"82277":{"type":"graphic_table","displayName":"RUTF","title":"Comparison of the F100 liquid diet with ready-to-use therapeutic food for treatment of malnutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of the F100 liquid diet with ready-to-use therapeutic food for treatment of malnutrition</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">F100<sup>[1]</sup></td> <td class=\"subtitle1\" colspan=\"2\">Ready-to-use therapeutic food (RUTF)<sup>[2]</sup></td> </tr> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle2\">Per 100 g&nbsp;</td> <td class=\"subtitle2\">Per 100 g</td> <td class=\"subtitle2\">Per sachet (92 g)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Macronutrients</td> </tr> <tr> <td class=\"sublist1\">Energy</td> <td class=\"sublist_other\">100 kcal (414 kJ)</td> <td class=\"sublist_other\"> <p>545 kcal (2281 kJ)</p> <p>&nbsp;</p> </td> <td class=\"sublist_other\">500 kcal (2070 kJ)</td> </tr> <tr> <td class=\"sublist1\">Protein (g)</td> <td class=\"sublist_other\">2.5</td> <td class=\"sublist_other\">13.6</td> <td class=\"sublist_other\">12.5</td> </tr> <tr> <td class=\"sublist1\">Lipid (g)</td> <td class=\"sublist_other\">5</td> <td class=\"sublist_other\">33</td> <td class=\"sublist_other\">30</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Minerals</td> </tr> <tr> <td class=\"sublist1\">Potassium (mg)</td> <td class=\"sublist_other\">212</td> <td class=\"sublist_other\">1111</td> <td class=\"sublist_other\">1022</td> </tr> <tr> <td class=\"sublist1\">Calcium (mg)</td> <td class=\"sublist_other\">58</td> <td class=\"sublist_other\">300</td> <td class=\"sublist_other\">276&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Phosphorus (mg)</td> <td class=\"sublist_other\">58</td> <td class=\"sublist_other\">300</td> <td class=\"sublist_other\">276&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Magnesium (mg)</td> <td class=\"sublist_other\">15</td> <td class=\"sublist_other\">92</td> <td class=\"sublist_other\">84.6&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Zinc (mg)</td> <td class=\"sublist_other\">2.1</td> <td class=\"sublist_other\">14</td> <td class=\"sublist_other\">12.9&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Copper (mg)</td> <td class=\"sublist_other\">0.3</td> <td class=\"sublist_other\">1.8</td> <td class=\"sublist_other\">1.6&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Iodine (microgram)</td> <td class=\"sublist_other\">14</td> <td class=\"sublist_other\">100</td> <td class=\"sublist_other\">92&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Selenium (microgram)</td> <td class=\"sublist_other\">4</td> <td class=\"sublist_other\">30</td> <td class=\"sublist_other\">27.6&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Iron (mg)</td> <td class=\"sublist_other\">0.4</td> <td class=\"sublist_other\">11.5</td> <td class=\"sublist_other\">10.6&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Vitamins</td> </tr> <tr> <td class=\"sublist1\">Thiamine (mg)</td> <td class=\"sublist_other\">0.1</td> <td class=\"sublist_other\">0.6</td> <td class=\"sublist_other\">0.55&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Riboflavin (mg)</td> <td class=\"sublist_other\">0.3</td> <td class=\"sublist_other\">1.8</td> <td class=\"sublist_other\">1.66&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Vitamin B-6 (mg)</td> <td class=\"sublist_other\">0.1</td> <td class=\"sublist_other\">0.6</td> <td class=\"sublist_other\">0.55&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Vitamin B-12 (microgram)</td> <td class=\"sublist_other\">0.3</td> <td class=\"sublist_other\">1.8</td> <td class=\"sublist_other\">1.7&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Vitamin C (mg)</td> <td class=\"sublist_other\">9.7</td> <td class=\"sublist_other\">53</td> <td class=\"sublist_other\">49&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Folic acid (microgram)</td> <td class=\"sublist_other\">39</td> <td class=\"sublist_other\">210</td> <td class=\"sublist_other\">193&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Niacin (mg)</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">5.3</td> <td class=\"sublist_other\">4.88&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Biotin (microgram)</td> <td class=\"sublist_other\">12</td> <td class=\"sublist_other\">65</td> <td class=\"sublist_other\">60&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Pantothenic acid (mg)</td> <td class=\"sublist_other\">0.6</td> <td class=\"sublist_other\">3.1</td> <td class=\"sublist_other\">2.85&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Retinol (microgram)</td> <td class=\"sublist_other\">154</td> <td class=\"sublist_other\">910</td> <td class=\"sublist_other\">840&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Vitamin D (microgram)</td> <td class=\"sublist_other\">2.9</td> <td class=\"sublist_other\">16</td> <td class=\"sublist_other\">15&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Vitamin K (microgram)</td> <td class=\"sublist_other\">2.9</td> <td class=\"sublist_other\">21</td> <td class=\"sublist_other\">19.3&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Vitamin E (mg)</td> <td class=\"sublist_other\">3.9</td> <td class=\"sublist_other\">20</td> <td class=\"sublist_other\">18.4&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Comparison of the nutritional composition of the F100 diet and solid ready-to-use therapeutic food (RUTF), used for the treatment of malnutrition in children. Nutrition information for RUTF based on Plumpy'Nut brand.<SUP innerHtml>[2] </SUP>Other preparations may have modest differences in nutritional content, but within ranges specified by the World Health Organization.<SUP>[3]</SUP></div><div class=\"graphic_footnotes\">F100: liquid, milk-based diet; RUTF: solid ready-to-use therapeutic food.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Diop el HI, Dossou NI, Ndour MM, et al. Comparison of the efficacy of a solid ready-to-use food and a liquid, milk-based diet for the rehabilitation of severely malnourished children: a randomized trial. Am J Clin Nutr 2003; 78:302. </LI>&#xD;&#xA;<LI>Nutrition information for Plumpy'Nut from manufacturer's website (Nutriset, Malaunay, France)&nbsp;</LI>&#xD;&#xA;<LI>Community-based management of severe acute malnutrition. A joint statement by the World Health Organization, the World Food Programme, the United Nations System Standing Committee on Nutrition, and the United Nations Children's Fund, 2007. Available at: http://www.who.int/nutrition/publications/severemalnutrition/978-92-806-4147-9_eng.pdf (Accessed on July 17, 2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 82277 Version 5.0</div></div></div>"},"82278":{"type":"graphic_picture","displayName":"Pregnancy gingivitis","title":"Gingivitis during pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gingivitis during pregnancy</div><div class=\"cntnt\"><img style=\"width:389px; height:252px;\" src=\"images/PC/82278_Pregnancy_gingivitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hormonal changes that occur with pregnancy significantly influence the bacterial flora, causing significant gingival inflammation and hypertrophy.</div><div class=\"graphic_reference\">Courtesy of Mark S Obernesser, DDS, MMSc.</div><div id=\"graphicVersion\">Graphic 82278 Version 1.0</div></div></div>"},"82280":{"type":"graphic_figure","displayName":"Spectrum of hypoplastic left heart syndrome","title":"Spectrum of hypoplastic left heart syndrome","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Spectrum of hypoplastic left heart syndrome</div><div class=\"cntnt\"><img style=\"width:587px; height:281px;\" src=\"images/PEDS/82280_Spectrhypoltheartsyndr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The spectrum of hypoplastic left heart syndrome (HLHS).<br />(Panel A) Aortic atresia with mitral atresia is the most extreme form of HLHS. The left ventricle (LV) is diminutive. The ascending aorta and arch are extremely hypoplastic, and flow is retrograde. Systemic output is ductal dependent.<br />(Panel B) Aortic atresia with a patent mitral valve. As in aortic atresia, the ascending aorta and arch are hypoplastic and all systemic output is ductal dependent. There is inflow without outflow. As a result, the LV is hypertensive with hypertrophy and endocardial fibroelastosis. The left ventricular mass can be greater than normal and result in distortion of the inflow of the right ventricle, resulting in tricuspid valve insufficiency.<br />(Panel C) Aortic valve stenosis with a patent mitral valve. The LV is hypoplastic, but antegrade flow through the aortic valve persists. The degree of aortic and arch hypoplasia is less than that observed with aortic atresia. This end of the spectrum of&nbsp;HLHS blends smoothly into critical aortic stenosis, and decision making concerning suitability for two-ventricle repair can be challenging.</div><div class=\"graphic_reference\">Reproduced with permission from: Tweddell J, Hoffman G, Ghanayem N, et al. Hypoplastic left heart syndrome. In: Moss and Adams' Heart Disease in Infants, Children and Adolescents: Including the Fetus and Young Adult, 7<SUP>th</SUP> ed, Allen H, Driscoll D, Shaddy R, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82280 Version 9.0</div></div></div>"},"82281":{"type":"graphic_picture","displayName":"Impetigo crusted lesions","title":"Impetigo","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Impetigo</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/82281_Impetigo_crusted_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crusted lesions in a patient with impetigo.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82281 Version 3.0</div></div></div>"},"82282":{"type":"graphic_table","displayName":"Risk factors ectopic pregnancy","title":"Risk factors for ectopic pregnancy compared with pregnant controls","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for ectopic pregnancy compared with pregnant controls</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Degree of risk</td> <td class=\"subtitle1\">Risk factors</td> <td class=\"subtitle1\">Odds ratio</td> </tr> <tr> <td rowspan=\"9\">High</td> <td>Previous ectopic pregnancy</td> <td>2.7 to 8.3</td> </tr> <tr> <td>Previous tubal surgery</td> <td>2.1 to 21</td> </tr> <tr> <td>Tubal pathology</td> <td>3.5 to 25</td> </tr> <tr> <td>Sterilization</td> <td>5.2 to 19</td> </tr> <tr> <td>IUD</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;- Past use</td> <td>1.7</td> </tr> <tr> <td>&nbsp;- Current use</td> <td>4.2 to 16.4</td> </tr> <tr> <td>&nbsp;- Levonorgestrel IUD</td> <td>4.9</td> </tr> <tr> <td>In vitro fertilization&nbsp;in&nbsp;current pregnancy</td> <td>4.0 to 9.3</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"9\">Moderate</td> <td>Current use of estrogen/progestin oral contraceptives</td> <td>1.7 to 4.5</td> </tr> <tr> <td>Previous sexually transmitted infections (gonorrhea, chlamydia)</td> <td>2.8 to 3.7</td> </tr> <tr> <td>Previous&nbsp;of pelvic inflammatory disease</td> <td>2.5 to 3.4</td> </tr> <tr> <td>In utero DES exposure</td> <td>3.7</td> </tr> <tr> <td>Smoking</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;- Past smoker</td> <td>1.5 to 2.5</td> </tr> <tr> <td>&nbsp;- Current smoker</td> <td>1.7 to 3.9</td> </tr> <tr> <td>Previous pelvic/abdominal surgery</td> <td>4.0</td> </tr> <tr> <td>Previous spontaneous abortion</td> <td>3.0</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Low</td> <td>Previous medical induced abortion&nbsp;</td> <td>2.8&nbsp;</td> </tr> <tr> <td>Infertility </td> <td>2.1 to 2.7</td> </tr> <tr> <td>Age &#8805;40 years</td> <td>2.9</td> </tr> <tr> <td>Vaginal douching</td> <td>1.1 to 3.1</td> </tr> <tr> <td>Age at first intercourse &#60;18 years</td> <td>1.6</td> </tr> <tr> <td>Previous appendectomy</td> <td>1.6</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><SUP></SUP>&nbsp;</div><div class=\"graphic_footnotes\">IUD: intrauterine device; DES: diethylstilbestrol.</div><div class=\"graphic_reference\">Data from: </P>&#xD;&#xA;<UL>&#xD;&#xA;<LI>Clayton HB, Schieve LA, Peterson HB, et al. Ectopic pregnancy risk with assisted reproductive technology procedures. Obstet Gynecol 2006; 107:595.</LI>&#xD;&#xA;<LI>Ankum WM, Mol BWJ, Van der Veen F, Bossuyt PMM. Risk factors for ectopic pregnancy: a meta-analysis. Fertil Steril 1996; 65:1093.</LI>&#xD;&#xA;<LI>Bouyer J, Coste J, Shojaei T, et al. Risk factors for ectopic pregnancy: a comprehensive analysis based on a large case-control, population-based study in France. Am J Epidemiol 2003; 157:185.</LI>&#xD;&#xA;<LI>Mol BWJ, Ankum WM, Bossuyt PMM, Van der Veen F. Contraception and the risk of ectopic pregnancy: a meta-analysis. Contraception 1995; 52:337.</LI>&#xD;&#xA;<LI>Li C, Zhao WH, Zhu Q, et al. Risk factors for ectopic pregnancy: a multicenter case-control study. BMC Pregnancy Childbirth 2015; 15:187.</LI>&#xD;&#xA;<LI>Cheng L, Zhao WH, Meng CX, et al. Contraceptive use and the risk of ectopic pregnancy: a multicenter case-control study. PLoS One 2014; 9:e115031.</LI>&#xD;&#xA;<LI>Hoover RN, Hyer M, Pfeiffer RM, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. New Engl J Med 2011; 365:1304.</LI></UL></div><div id=\"graphicVersion\">Graphic 82282 Version 6.0</div></div></div>"},"82283":{"type":"graphic_figure","displayName":"Patterns of response to platelet transfusion","title":"Patterns of response to platelet transfusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patterns of response to platelet transfusion</div><div class=\"cntnt\"><img style=\"width:441px; height:270px;\" src=\"images/HEME/82283_Patterns_of_platelet_respon.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two patterns can be seen in refractory patients. A normal increment at one hour following transfusion with return to the baseline count within 24 hours (green curve) is typical of the shortening of platelet survival seen with sepsis, hematopoietic cell transplantation, disseminated intravascular coagulation, and possibly in bleeding patients and those taking medications that interfere with platelet survival. The second pattern consists of little or no increment in platelet count, even within one hour of transfusion (red curve); this pattern is seen with alloimmunization.</div><div id=\"graphicVersion\">Graphic 82283 Version 2.0</div></div></div>"},"82285":{"type":"graphic_waveform","displayName":"Basic case 10","title":"Basic case 10","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Basic case 10</div><div class=\"cntnt\"><img style=\"width:450px; height:99px;\" src=\"images/CARD/82285_Basic_case_10.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82285 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"82286":{"type":"graphic_diagnosticimage","displayName":"SLS MRI 9 years","title":"Brain MRI of a 9-year-old with Sjogren-Larsson syndrome","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Brain MRI of a 9-year-old with Sjogren-Larsson syndrome</div><div class=\"cntnt\"><img style=\"width:468px; height:188px;\" src=\"images/NEURO/82286_SLS_MRI_9_years.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted MR images (3100/98 [TR/TE]).<br />(A and B) Mild signal-intensity changes of the periventricular white matter with predominant involvement of the occipital trigones.<br />(C) Small areas of unmyelinated subcortical association fibers.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Reproduced with permission from: Willemsen, MA, Van Der, Graaf M, Van Der, Knaap MS, et al. MR imaging and proton MR spectroscopic studies in Sjogren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004; 25:649. Copyright &copy;2004 American Society of Neuroradiology.</div><div id=\"graphicVersion\">Graphic 82286 Version 3.0</div></div></div>"},"82287":{"type":"graphic_picture","displayName":"Histol acral lentig melanoma","title":"Acral lentiginous melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acral lentiginous melanoma</div><div class=\"cntnt\"><img style=\"width:286px; height:578px;\" src=\"images/ONC/82287_Histol_acral_lentig_melanom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Low power light photomicrograph of an acral lentiginous melanoma shows a thickened stratum corneum, which is characteristic of acral sites. There is a lentiginous array of atypical melanocytes along the dermo-epidermal junction with foci of confluent melanocytic growth (black arrows). Panel B: Medium power photomicrograph shows extensive pagetoid spread of single cells into the epidermis (black arrows).</div><div class=\"graphic_reference\">Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.</div><div id=\"graphicVersion\">Graphic 82287 Version 1.0</div></div></div>"},"82288":{"type":"graphic_diagnosticimage","displayName":"LIP CXR and HRCT","title":"Lymphocytic interstitial pneumonitis (LIP)","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Lymphocytic interstitial pneumonitis (LIP)</div><div class=\"cntnt\"><img style=\"width:471px; height:404px;\" src=\"images/PEDS/82288_LIP_CXR_and_HRCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) In a 17-year-old with non-HIV-related LIP, frontal and lateral chest radiographs show bilateral ground glass abnormality.<br />(C, D) In the same patient, HRCT scans at two levels confirm widespread ground glass abnormality, with mosaic pattern, and some subpleural honeycomb cysts.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; LIP: lymphocytic interstitial pneumonitis; HRCT: high-resolution computerized tomography.</div><div class=\"graphic_reference\">Courtesy of Cynthia Epstein, MD and Leland L Fan, MD.</div><div id=\"graphicVersion\">Graphic 82288 Version 4.0</div></div></div>"},"82290":{"type":"graphic_figure","displayName":"Permanent teeth identification","title":"Conventional identification of the permanent teeth (United States)","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Conventional identification of the permanent teeth (United States)</div><div class=\"cntnt\"><img style=\"width:521px; height:407px;\" src=\"images/PEDS/82290_Permanent-teeth-identification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">By convention in the United States, general dentists identify the 32 permanent teeth by the numbers 1 through 32, as depicted above. Different identification systems are used in other countries.</div><div class=\"graphic_reference\">Redrawn from: Dentistry 2000 - Human Teeth Numbering Charts. http://www.dentistry2000.com/dentalhealthcare/teeth_numbering.html.</div><div id=\"graphicVersion\">Graphic 82290 Version 3.0</div></div></div>"},"82292":{"type":"graphic_figure","displayName":"Six months after RF treatment","title":"The \"Stretta\" procedure post treatment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The &quot;Stretta&quot; procedure post treatment</div><div class=\"cntnt\"><img style=\"width:367px; height:283px;\" src=\"images/GAST/82292_Six_months_after_RF_treatme.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram of the gastroesophageal junction at six months after the procedure illustrating lesion resorption and collagen contraction.</div><div class=\"graphic_reference\">Courtesy of George Triadafilopoulos, MD.</div><div id=\"graphicVersion\">Graphic 82292 Version 2.0</div></div></div>"},"82293":{"type":"graphic_table","displayName":"Lynch syndr CGC guidelines","title":"Lynch syndrome: Cancer Genetics Consortium management guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lynch syndrome: Cancer Genetics Consortium management guidelines</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"2\">\r\n  \r\n   Intervention\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" rowspan=\"2\">\r\n  \r\n   Recommendation\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Men and women\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Women\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>History and physical exam</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>Every year beginning at age 21 with review of systems, education, and counseling regarding Lynch syndrome</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Colonoscopy</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>Every 1-2 years beginning at age 20-25 years or 10 years younger than the youngest age at diagnosis in the family, whichever comes first.  For MSH6 families, begin at age 30.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Colorectal resection</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>Generally not recommended for primary prophylaxis, but if cancer diagnosed, subtotal colectomy is favored</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>Transvaginal ultrasound</td>\r\n  \r\n   <td>Every year beginning at age 30-35 years</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>Hysterectomy with bilateral salpingo-oophorectomy</td>\r\n  \r\n   <td>Offer as option after childbearing complete</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Urinalysis with cytology</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>Every 1-2 years beginning at age 25-35 years</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from: Lindor, NM, Petersen, GM, Hadley, DW, et al. Recommendations for the Care of Individuals With an Inherited Predisposition to Lynch Syndrome: A Systematic Review. JAMA 2006; 296:1507.</div><div id=\"graphicVersion\">Graphic 82293 Version 1.0</div></div></div>"},"82294":{"type":"graphic_table","displayName":"Clinical manifestations of HPV","title":"Clinical manifestations of human papillomavirus infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of human papillomavirus infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Benign</td> </tr> <tr> <td>Verrucous or acuminate wart</td> </tr> <tr> <td>Flat or intraepithelial condyloma</td> </tr> <tr> <td>Giant condyloma</td> </tr> <tr> <td class=\"subtitle1_single\">Premalignant</td> </tr> <tr> <td>Cervical intraepithelial neoplasia (CIN)</td> </tr> <tr> <td>Adenocarcinoma-in-situ of the cervix (AIS)</td> </tr> <tr> <td>Vaginal intraepithelial neoplasia (VAIN)</td> </tr> <tr> <td>Vulvar intraepithelial neoplasia (VIN)</td> </tr> <tr> <td>Anal intraepithelial neoplasia (AIN)</td> </tr> <tr> <td>Penile intraepithelial neoplasia (PIN)</td> </tr> <tr> <td class=\"subtitle1_single\">Malignant</td> </tr> <tr> <td>Invasive squamous and adenocarcinomas of the cervix</td> </tr> <tr> <td>Invasive squamous carcinoma of the vagina</td> </tr> <tr> <td>Invasive squamous carcinoma of the vulva</td> </tr> <tr> <td>Invasive squamous carcinoma of the anus</td> </tr> <tr> <td>Invasive squamous cell carcinoma of the penis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Pfister H. The role of human papillomavirus in anogenital cancer. Obstet Gynecol Clin North Am 1996; 23:579.</div><div id=\"graphicVersion\">Graphic 82294 Version 3.0</div></div></div>"},"82297":{"type":"graphic_figure","displayName":"Incision site","title":"Incision site for thyroid and parathyroid surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incision site for thyroid and parathyroid surgery</div><div class=\"cntnt\"><img style=\"width:443px; height:403px;\" src=\"images/SURG/82297_Incisionsite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Site of incision&nbsp;– 1 cm below cricoid. Surface anatomy with underlying anatomy shown to demonstrate why this location is optimal for thyroid and parathyroid surgery (underlying superior pole of thyroid and its blood vessels).</div><div class=\"graphic_reference\">Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82297 Version 12.0</div></div></div>"},"82298":{"type":"graphic_figure","displayName":"Middle thyroid vein","title":"Middle thyroid vein","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Middle thyroid vein</div><div class=\"cntnt\"><img style=\"width:549px; height:344px;\" src=\"images/SURG/82298_Middle_thyroid_vein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The middle thyroid vein is divided between clamps and tied with fine (3-0) silk sutures.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82298 Version 9.0</div></div></div>"},"82300":{"type":"graphic_table","displayName":"Td for multiple myeloma","title":"Thalidomide plus dexamethasone (Td) for multiple myeloma<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thalidomide plus dexamethasone (Td) for multiple myeloma<sup>[1,2]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 28 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Thalidomide*</strong></td> <td>200 mg by mouth</td> <td>Take with water on an empty stomach at least one hour after the evening meal.</td> <td>Daily on days 1 through 28</td> </tr> <tr> <td><strong>Dexamethasone</strong></td> <td>40 mg<sup>&#916;</sup> by mouth</td> <td>Take with food (after a meal or with food or milk) in the morning.</td> <td>Days 1, 8, 15, and 22</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> LOW or VERY LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for thrombosis:</strong> Without prophylaxis, the TD regimen is associated with thrombosis or embolism in up to 25 percent of patients<sup>[3]</sup>. As such, routine thromboprophylaxis is recommended for all patients<sup>[4]</sup>. Options for prophylaxis are discussed in detail separately. Refer to UpToDate topic on \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\", section on Thalidomide plus dexamethasone.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with G-CSF is not indicated (rate of severe neutropenia &#60;5 percent)<sup>[2]</sup>. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> Dose adjustments are not recommended for either drug in patients with preexisting renal or hepatic insufficiency<sup>[5,6]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pregnancy warning*:</strong> Thalidomide can result in severe, life-threatening human birth defects. Strict birth control regulations are in place for all patients taking thalidomide<sup>[5]</sup>. Pregnancy testing is required within 24 hours prior to initiation of thalidomide therapy.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential, serum electrolytes, and serum uric acid.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess fluid status, blood pressure, central nervous system status and dermatologic toxicity.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for signs of neuropathy monthly for the first three months, then periodically thereafter. Neuropathic complications include constipation. As such, many clinicians provide a prophylactic bowel regimen for patients taking thalidomide.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Pregnancy testing should be performed weekly during the first four weeks, and then every two to four weeks, depending upon menstrual cycle regularity.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Thalidomide should be withheld if the ANC falls below 750/microL. Restart after ANC recovers to &#62;1500/microL.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Rash:</strong> Thalidomide has been associated with rashes including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). If a rash develops, thalidomide should be discontinued and the rash further evaluated. Thalidomide should not be administered again if the rash is exfoliative, purpuric, bullous, or if SJS or TEN is suspected.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neuropathy:</strong> Thalidomide should be discontinued or dose reduced for pain, motor deficit, or interference with activities of daily living<sup>[7]</sup>. Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count; ANC: absolute neutrophil count.<br />* In the United States, the use of thalidomide is subject to the THALOMID REMS program (<A href=\"http://www.thalomidrems.com/\">www.THALOMIDREMS.com</A>) developed in an attempt to minimize the potential for pregnancy among patients taking this medication and associated birth defects.<br />Δ&nbsp;The dexamethasone dose is lower than what was used in the original studies, and is based on subsequent studies suggesting a higher mortality with high dose dexamethasone compared with low dose dexamethasone given in combination with the thalidomide analog, lenalidomide<SUP>[4]</SUP>.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Rajkumar SV, et al. J Clin Oncol 2006; 24:431.</LI>&#xD;&#xA;<LI>Rajkumar SV, et al. J Clin Oncol 2008; 26:2171.</LI>&#xD;&#xA;<LI>Palumbo A, et al. Leukemia 2008; 22:414. </LI>&#xD;&#xA;<LI>Lyman GH, et al. J Clin Oncol 2007; 25:5490. </LI>&#xD;&#xA;<LI>Thalidomide. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012). </LI>&#xD;&#xA;<LI>Dexamathasone tablet. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012).</LI>&#xD;&#xA;<LI>Delforge M, et al. Lancet Oncol 2010; 11:1086.</LI>&#xD;&#xA;<LI>Rajkumar SV, et al. Lancet Oncol 2010; 11:29.</LI></OL></div><div id=\"graphicVersion\">Graphic 82300 Version 17.0</div></div></div>"},"82303":{"type":"graphic_waveform","displayName":"ECG atrial flutter tutorial","title":"Single lead electrocardiogram (ECG) showing atrial flutter","html":"<div class=\"graphic normal\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Single lead electrocardiogram (ECG) showing atrial flutter</div><div class=\"cntnt\"><img style=\"width:459px; height:178px;\" src=\"images/CARD/82303_Atrial_flutter_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The atrial rate in this tracing of atrial waves is 300 beats per minute and the flutter waves, which are \"saw toothed,\" are uniform in morphology, amplitude, and cycle length. Impulse conduction to the ventricles is dependent upon the electrophysiologic characteristics of the atrioventricular node. Most commonly, every other atrial impulse is conducted and there is 2:1 block. However, when conduction through the atrioventricular node is impaired as a result of underlying disease, drugs, or increased vagal tone, there may be higher degrees of block, which may be variable, resulting in a regularly irregular ventricular rate.</div><div id=\"graphicVersion\">Graphic 82303 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"82306":{"type":"graphic_table","displayName":"Incidence mets neuroendocrine tumor by size","title":"Incidence of metastases related to the size of the primary gastroenteropancreatic neuroendocrine tumor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of metastases related to the size of the primary gastroenteropancreatic neuroendocrine tumor</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Tumor location and size, cm</td> <td class=\"subtitle1\">Total patient numbers</td> <td class=\"subtitle1\">Nodal metastases, number of patients (%)</td> <td class=\"subtitle1\">Distant metastases, number of patients (%)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Small intestine</td> </tr> <tr> <td class=\"indent1\">&#8804;1</td> <td>43</td> <td>5 (12)</td> <td>2 (5)</td> </tr> <tr> <td class=\"indent1\">1.1 to 1.9</td> <td>83</td> <td>58 (70)</td> <td>16 (19)</td> </tr> <tr> <td class=\"indent1\">&#8805;2</td> <td>59</td> <td>50 (85)</td> <td>28 (47)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Appendix</td> </tr> <tr> <td class=\"indent1\">&#8804;1</td> <td>431</td> <td>0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">1.1 to 1.9</td> <td>53</td> <td>4 (7.5)</td> <td>2 (4)</td> </tr> <tr> <td class=\"indent1\">&#8805;2</td> <td>33</td> <td>11 (33)</td> <td>4 (12)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Colon</td> </tr> <tr> <td class=\"indent1\">&#60;2</td> <td>11</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"indent1\">&#8805;2</td> <td>42</td> <td>26 (62)</td> <td>17 (40)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89:151. Copyright © 2005 Wiley-Liss. Permission from John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 82306 Version 5.0</div></div></div>"},"82307":{"type":"graphic_table","displayName":"Single gene defects associated with obesity","title":"Single gene defects associated with obesity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Single gene defects associated with obesity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Single gene disorder</td> <td class=\"subtitle1\">Chromosome</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr class=\"divider_bottom\"> <td>Leptin deficiency <em>(LEP)</em></td> <td>7q31.3<br /> (various <em>LEP</em> mutations interfering with synthesis or secretion of leptin)</td> <td>Severe, early onset obesity, hypometabolic rate, hyperphagia, pubertal delay, impaired glucose tolerance, hypothalamic hypogonadism, frequent infections. Leptin levels are very low or undetectable. Obesity and hyperphagia respond to replacement with exogenous recombinant leptin.<sup>[1]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Leptin receptor deficiency <em>(LEPR)</em></td> <td>1p31-p22</td> <td>Severe, early onset obesity, hypometabolic rate, hyperphagia, pubertal delay, hypothalamic hypogonadism. Leptin levels are high, but are proportional to the degree of obesity so they are not a useful marker for this defect. No response to treatment with exogenous leptin.<sup>[2,3]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Biologically inactive leptin, due to <em>LEP</em> mutation</td> <td>7q31.3<br /> (<em>LEP</em> p.D100Y)</td> <td>Severe, early onset obesity, hyperphagia. Leptin level are high (consistent with degree of obesity), but biologically inactive. Obesity and hyperphagia respond to treatment with exogenous recombinant leptin.<sup>[4]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Pro-opiomelanocortin deficiency <em>(POMC)</em></td> <td>2p23.3</td> <td>Adrenal insufficiency (typically presenting in the neonatal period); severe, early onset obesity, hyperphagia, and red hair in Caucasians.<sup>[5,6]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Proprotein convertase 1 (<em>PCSK1</em>, also known as prohormone convertase 1)</td> <td>5q15-q21</td> <td>Early onset obesity, diarrhea, abnormal glucose homeostasis, hypogonadotropic hypogonadism, hypocortisolism, elevated plasma proinsulin and POMC.<sup>[7]</sup></td> </tr> <tr> <td>Melanocortin receptor 4 haploinsufficiency <em>(MC4R)</em></td> <td>18q21.3-q22</td> <td>Early onset moderate-severe obesity, early onset hyperphagia, increased bone density, accelerated linear growth, severe hyperinsulinemia, mild central hypothyroidism.<sup>[8]</sup></td> </tr> <tr> <td>Melanocortin 2 receptor accessory protein 2 (<em>MRAP2</em>)&nbsp;&nbsp;</td> <td>6q14.2&nbsp;</td> <td>Severe nonsyndromic early-onset obesity (probably very rare).<sup>[9]</sup>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Farooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic function of human congenital leptin deficiency. J Clin Invest 2002; 110:1093. </LI>&#xD;&#xA;<LI>Clement K, Vaisse C, Lahlou N et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392:398.</LI>&#xD;&#xA;<LI>Farooqi IS, Wangensteen T, Collins S et al. Clinical and molecular spectrum of congenital deficiency of the leptin receptor. New Engl J Med 2007; 356:237.</LI>&#xD;&#xA;<LI>Wabitsch M, Funcke JB, Lennerz B et al. Biologically inactive leptin and early-onset extreme obesity. New Engl J Med 2015; 372:48.</LI>&#xD;&#xA;<LI>Krude H, Biebermann H, Luck W et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998; 19:155.</LI>&#xD;&#xA;<LI>Anisimova AS, Rubtsov PM, Akulich KA, et al. Late diagnosis of POMC deficiency and in vitro evidence of residual translation from allele with c.-11C&gt;A mutation. J Clin Endocrinol Metab 2017; 102:359.</LI>&#xD;&#xA;<LI>Jackson RS, Creemers JW, Ohaqi S et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997; 16:303.</LI>&#xD;&#xA;<LI>Farooqi IS, Keogh JM, Yeo GS et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. New Engl J Med 2003; 348:1085.</LI>&#xD;&#xA;<LI>Asai M, Ramachandrappa S, Joachim M, et al. Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. Science 2013; 341:275.</LI></OL>Farooqi IS. The severely obese patient - a genetic workup. Nat Clin Pract Endocrinol Metab 2006; 2:172.</div><div id=\"graphicVersion\">Graphic 82307 Version 10.0</div></div></div>"},"82308":{"type":"graphic_diagnosticimage","displayName":"Centrilobular emphysema","title":"Centrilobular emphysema pulmonary hypertension","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Centrilobular emphysema pulmonary hypertension</div><div class=\"cntnt\"><img style=\"width:597px; height:256px;\" src=\"images/RADIOL/82308_Centrilobular_emphysema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT images confirm the presence of centrilobular (centriacinar) emphysema (A) and pulmonary hypertension (B). The lung parenchyma shows lucent spaces of parenchymal destruction interspersed among normal lung tissue best appreciated in the right upper lobe (A). The main pulmonary artery (arrow) measures 3.8 cm (normal &lt;2.9 cm). The pulmonary artery and aorta should be about the same size and in this case the main pulmonary artery is larger than the companion ascending aorta.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 82308 Version 3.0</div></div></div>"},"82309":{"type":"graphic_picture","displayName":"RP dynamic collapse CT","title":"Relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:436px; height:276px;\" src=\"images/PULM/82309_RP_dynamic_collapse_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan shows tracheal narrowing and wall thickening that spares the posterior wall. Dynamic collapse is present during expiration (right).</div><div id=\"graphicVersion\">Graphic 82309 Version 1.0</div></div></div>"},"82310":{"type":"graphic_diagnosticimage","displayName":"Fibula fracture above lateral malleolus lateral view","title":"Fibula fracture above lateral malleolus: Lateral view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibula fracture above lateral malleolus: Lateral view</div><div class=\"cntnt\"><img style=\"width:390px; height:432px;\" src=\"images/EM/82310_Weber_C_lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral plain radiograph shows an oblique fracture (arrow) through the distal fibula.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 82310 Version 5.0</div></div></div>"},"82311":{"type":"graphic_picture","displayName":"Retinal neovascularization","title":"Early diabetic retinal neovascularization: Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early diabetic retinal neovascularization: Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:302px; height:288px;\" src=\"images/ENDO/82311_Retinal_neovascularization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diabetic retinopathy, showing irregular changes in venous caliber, tortuosity of blood vessels, and proliferation of networks of fragile new vessels, arising from both arteries and veins (arrows).</div><div class=\"graphic_reference\">Courtesy of David McCulloch, MD.</div><div id=\"graphicVersion\">Graphic 82311 Version 3.0</div></div></div>"},"82313":{"type":"graphic_picture","displayName":"Schatzki ring following balloon dilation","title":"Schatzki ring following balloon dilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schatzki ring following balloon dilation</div><div class=\"cntnt\"><img style=\"width:252px; height:263px;\" src=\"images/GAST/82313_Schatzki_ring_post_dilation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A wider distal esophageal lumen without the ring and a small amount of bleeding is seen following balloon dilation.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Douglas A. Horst, MD.</div><div id=\"graphicVersion\">Graphic 82313 Version 2.0</div></div></div>"},"82314":{"type":"graphic_picture","displayName":"ATL peripheral blood smear","title":"Adult T-cell leukemia/lymphoma peripheral blood smear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adult T-cell leukemia/lymphoma peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:432px; height:321px;\" src=\"images/HEME/82314_Leukemia_cells_feather_edge.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a view of the feather edge of a peripheral blood smear in a patient with Adult T-cell Leukemia/Lymphoma. The large malignant cells have accumulated in this region of the smear. The marked irregularity of the nuclear outlines is well seen, including their &quot;Flower-like&quot; appearance (arrows).</div><div class=\"graphic_reference\">Kindly provided by Dr. German Pihan, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 82314 Version 3.0</div></div></div>"},"82317":{"type":"graphic_diagnosticimage","displayName":"MRI findings Wernicke A","title":"MRI findings Wernicke's encephalopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI findings Wernicke's encephalopathy</div><div class=\"cntnt\"><img style=\"width:384px; height:539px;\" src=\"images/NEURO/82317_MRI_findings_Wernicke_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 20-year-old pregnant female with severe emesis and presumed Wernicke's encephalopathy. Flair images demonstrate typical findings of hyperintensity in the periaqueductal region of the midbrain (A), mammillary bodies (B), and thalamus (C). Additionally, the patient had bilateral symmetrical hyperintensity in the frontal-parietal cortices (D), which has also been reported in these patients.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Courtesy Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 82317 Version 4.0</div></div></div>"},"82318":{"type":"graphic_table","displayName":"Dose ranges adj analgesics","title":"Therapeutic dose ranges for commonly used adjuvant analgesics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic dose ranges for commonly used adjuvant analgesics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category based on conventional use</td> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Drugs</td> <td class=\"subtitle1\">Usual starting dose</td> <td class=\"subtitle1\">Usual effective dose range*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\">Multipurpose analgesics</td> <td rowspan=\"2\">Corticosteroids</td> <td>Dexamethasone</td> <td>Varies</td> <td>1 to 2 mg twice daily, orally or IV</td> </tr> <tr> <td>Prednisone</td> <td>Varies</td> <td>5 to 10 mg twice daily</td> </tr> <tr> <td rowspan=\"5\">Antidepressants</td> <td>Desipramine</td> <td>10 to 25 mg at bedtime</td> <td>50 to 150 mg at bedtime</td> </tr> <tr> <td>Duloxetine</td> <td>20 to 30 mg daily</td> <td>60 to 120 mg daily<sup>&#182;</sup></td> </tr> <tr> <td>Bupropion</td> <td>75 mg twice daily</td> <td>300 to 450 mg daily<sup>&#916;</sup></td> </tr> <tr> <td>Venlafaxine, sustained release</td> <td>75 mg once daily</td> <td>150 to 225 mg daily</td> </tr> <tr> <td>Nortriptyline</td> <td>10 to 25 mg at bedtime</td> <td>50 to 150 mg at bedtime</td> </tr> <tr class=\"divider_bottom\"> <td>Alpha-2 adrenergic agonists</td> <td>Tizanidine</td> <td>1 to 2 mg at bedtime</td> <td>2 to 8 mg twice daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Used for neuropathic pain</td> <td rowspan=\"2\">Anticonvulsants</td> <td>Gabapentin</td> <td>100 to 300 mg twice daily</td> <td>300 to 1200 mg three times daily</td> </tr> <tr> <td>Pregabalin</td> <td>25 to 75 mg twice daily</td> <td>150 to 300 mg twice daily</td> </tr> <tr class=\"divider_bottom\"> <td>GABA agonists</td> <td>Clonazepam</td> <td>0.5 mg at bedtime</td> <td>0.5 to 3 mg daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Used for bone pain</td> <td class=\"divider_bottom\" rowspan=\"3\">Osteoclast inhibitors</td> <td>Pamidronate</td> <td>&ndash;</td> <td>60 to 90 mg monthly, IV</td> </tr> <tr> <td>Zoledronic acid</td> <td>&ndash;</td> <td>4 mg monthly, IV</td> </tr> <tr class=\"divider_bottom\"> <td>Denosumab</td> <td>&ndash;</td> <td>120 mg monthly, subcutaneously</td> </tr> <tr> <td rowspan=\"2\">Used for bowel obstruction</td> <td>Anticholinergic drugs</td> <td>Glycopyrrolate</td> <td>0.1 mg daily</td> <td>0.1 to 0.2 mg three times daily, subcutaneously</td> </tr> <tr> <td>Somatostatin analogue</td> <td>Octreotide</td> <td>Varies</td> <td>0.1 to 0.3 mg twice daily, subcutaneously</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; GABA: gamma-aminobutyric acid.<br />* All doses shown are for adult patients, oral administration, unless otherwise noted.<br />¶ Randomized trials conducted in patients with diabetic peripheral neuropathy suggest no additional efficacy from 120 mg daily versus 60 mg daily.<br />Δ Bupropion doses ≥150 mg should be sustained release.</div><div id=\"graphicVersion\">Graphic 82318 Version 4.0</div></div></div>"},"82319":{"type":"graphic_diagnosticimage","displayName":"Chondroblastoma tibia","title":"Chondroblastoma of the proximal tibia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chondroblastoma of the proximal tibia</div><div class=\"cntnt\"><img style=\"width:432px; height:397px;\" src=\"images/PEDS/82319_Chondroblastoma_tibia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chondroblastoma (arrows) of the proximal tibia. The lesion has not crossed the physis.</div><div class=\"graphic_reference\">Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82319 Version 2.0</div></div></div>"},"82320":{"type":"graphic_diagnosticimage","displayName":"SCFE progression","title":"Progression from minimal stable/chronic to unstable/acute slipped capital femoral epiphysis (SCFE)","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Progression from minimal stable/chronic to unstable/acute slipped capital femoral epiphysis (SCFE)</div><div class=\"cntnt\"><img style=\"width:487px; height:192px;\" src=\"images/PEDS/82320_SCFE_progression.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior view of the hip (panel A) demonstrating minimal stable/chronic SCFE on the left. Widening, lucency, and irregularity of the physis and blurring of the junction between the physis and the metaphysis are present in Panel A. The child was sent home after these radiographs. Four days later, the patient returned with an unstable/acute SCFE (panel B), highlighting the importance of urgent management and avoidance of weight bearing until orthopedic evaluation.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 82320 Version 3.0</div></div></div>"},"82321":{"type":"graphic_picture","displayName":"Pseudomonal folliculitis","title":"Pseudomonal folliculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudomonal folliculitis</div><div class=\"cntnt\"><img style=\"width:396px; height:313px;\" src=\"images/PC/82321_Pseudomonal_folliculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hot tub folliculitis (\"hot tub buns\"). Multiple pruritic follicular papules and pustules occurred on the buttocks and trunk of this woman&nbsp;three days after she had bathed in a hot tub. Bacterial culture grew <EM>Pseudomonas aeruginosa</EM>.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82321 Version 3.0</div></div></div>"},"82322":{"type":"graphic_figure","displayName":"Squamous intraepithelial lesions","title":"Squamous intraepithelial lesions","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Squamous intraepithelial lesions</div><div class=\"cntnt\"><img style=\"width:533px; height:446px;\" src=\"images/ONC/82322_Schem_rep_squam_intra_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CIN: cervical intraepithelial neoplasia; AIN: anal intraepithelial neoplasia.</div><div class=\"graphic_reference\">Adapted from: Bonnez W. Papilloma virus. In: Clinical Virology, Richman DD, Whitley RJ, Hayden FG (Eds), 3rd Edition, ASM Press, Washington DC 2009, page 623.</div><div id=\"graphicVersion\">Graphic 82322 Version 1.0</div></div></div>"},"82323":{"type":"graphic_picture","displayName":"Ankle deformity child","title":"Ankle fracture with obvious deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ankle fracture with obvious deformity</div><div class=\"cntnt\"><img style=\"width:278px; height:360px;\" src=\"images/EM/82323_Ankledeformitychild.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe clinical deformity in a 14-year-old boy with an ankle fracture. It is obvious without x-rays that internal rotation will be needed to reduce this fracture.</div><div class=\"graphic_reference\">Reproduced with permission from: Shea KG, Frick SL. Ankle Fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82323 Version 10.0</div></div></div>"},"82324":{"type":"graphic_figure","displayName":"Onset menopausal transition","title":"Onset of the menopausal transition","html":"<div class=\"graphic\"><div style=\"width: 814px\" class=\"figure\"><div class=\"ttl\">Onset of the menopausal transition</div><div class=\"cntnt\"><img style=\"width:794px; height:478px;\" src=\"images/ENDO/82324_Onset_menopausal_transition.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Concentrations of FSH, LH, E2, and INH in a volunteer studied at the onset of menopausal transition. The vertical dashed lines represent the times of menses. The horizontal shaded bar represents the young-normal range for FSH. Note the marked fluctuations in hormone levels.</div><div class=\"graphic_footnotes\">E2: estradiol; FSH: follicle-stimulating hormone; INH: inhibin; LH: luteinizing hormone.</div><div class=\"graphic_reference\">Reproduced with permission from: Hee J, MacNaughton J, Bangah M, Burger HG. Perimenopausal patterns of gonadotropins, immunoreactive inhibin, estradiol and progesterone, Maturitas 1993; 18:9. Copyright © 1993 Elsevier.</div><div id=\"graphicVersion\">Graphic 82324 Version 4.0</div></div></div>"},"82327":{"type":"graphic_picture","displayName":"Myeloma kidney-immunofluorescence microscopy","title":"Myeloma kidney-immunofluorescence microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myeloma kidney-immunofluorescence microscopy</div><div class=\"cntnt\"><img style=\"width:378px; height:262px;\" src=\"images/NEPH/82327_Myeloma_kidney_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy with anti-human lambda antiserum showing variable staining of intratubular immunoglobulin light chain casts from a patient with multiple myeloma excreting monoclonal lambda light chains. The weaker staining casts presumably contain more Tamm-Horsfall mucoprotein.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 82327 Version 2.0</div></div></div>"},"82329":{"type":"graphic_figure","displayName":"Late potentials in diastole","title":"Late potentials bridging diastole","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Late potentials bridging diastole</div><div class=\"cntnt\"><img style=\"width:329px; height:501px;\" src=\"images/CARD/82329_Late_potentials_in_diastole.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are surface ECG leads I, II, III, V1, V4, and V6 and electrograms (a to h) recorded from the endocardial surface of the myocardium during ventricular tachycardia. There are presystolic signals in the area of slow myocardial conduction that can be traced through diastole to the preceding QRS complex. During sinus rhythm, late potentials can be recorded from these sites.</div><div id=\"graphicVersion\">Graphic 82329 Version 1.0</div></div></div>"},"82330":{"type":"graphic_table","displayName":"Drugs that alter phenytoin concentrations","title":"Common drugs that alter serum phenytoin concentrations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common drugs that alter serum phenytoin concentrations</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Drugs that increase the metabolism of phenytoin and decrease total and unbound plasma concentrations include:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Folic acid</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Dexamethasone</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Phenobarbital</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Diazepam</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Rifampin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Methadone</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Nitrofurantoin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Estrogens</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Drugs that decrease phenytoin metabolism and increase plasma concentrations include:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Valproic acid</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Carbamazepine</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Warfarin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Isoniazid</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cimetidine, ranitidine</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Omeprazole</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Ibuprofen</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Metronidazole</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Chloramphenicol</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Fluconazole</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Fluoxetine</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Risperidone </td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Amiodarone</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Allopurinol  </td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 82330 Version 2.0</div></div></div>"},"82332":{"type":"graphic_figure","displayName":"Alcohol consumption mortality","title":"Moderate alcohol intake reduces mortality","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Moderate alcohol intake reduces mortality</div><div class=\"cntnt\"><img style=\"width:351px; height:426px;\" src=\"images/CARD/82332_Alcohol_consumption_mortali.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a middle-aged and&nbsp;older adult&nbsp;population study of 490,000 subjects, all-cause mortality and cardiovascular mortality were reduced with moderate alcohol consumption. However, mortality increased with intake greater than two drinks per day due to death from alcohol-related conditions and cancer.</div><div class=\"graphic_reference\">Data from Thun MJ, Peto R, Lopez AD, et al. N Engl J Med 1997; 337:1705.</div><div id=\"graphicVersion\">Graphic 82332 Version 3.0</div></div></div>"},"82336":{"type":"graphic_figure","displayName":"Measurement of cervix","title":"Measurement of the cervix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Measurement of the cervix</div><div class=\"cntnt\"><img style=\"width:443px; height:301px;\" src=\"images/OBGYN/82336_Measurement_of_cervix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Funnel length should not be measured or recorded as it is not an independent predictor of preterm labor risk when the closed length of the cervical canal is considered.</div><div id=\"graphicVersion\">Graphic 82336 Version 3.0</div></div></div>"},"82340":{"type":"graphic_table","displayName":"Direct global costs burns","title":"Estimated direct costs of fires in 2006 as a percentage of the GDP","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated direct costs of fires in 2006 as a percentage of the GDP</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Country</td> <td class=\"subtitle1\" rowspan=\"2\">Currency</td> <td class=\"subtitle1\" colspan=\"3\">Direct losses</td> <td class=\"subtitle1\">Cost as percentage of GDP</td> </tr> <tr> <td class=\"subtitle2\">2007</td> <td class=\"subtitle2\">2008</td> <td class=\"subtitle2\">2009</td> <td class=\"subtitle2\">2007-2009</td> </tr> <tr> <td>Singapore</td> <td class=\"centered\">$S</td> <td class=\"centered\">110</td> <td class=\"centered\">110</td> <td class=\"centered\">115</td> <td class=\"centered\">0.04</td> </tr> <tr> <td>Slovenia</td> <td class=\"centered\">SIT</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.07 (2002-2004)</td> </tr> <tr> <td>Australia*</td> <td class=\"centered\">$AUS</td> <td class=\"centered\">905</td> <td class=\"centered\">1000</td> <td class=\"centered\">945</td> <td class=\"centered\">0.08</td> </tr> <tr> <td>Czech Republic</td> <td class=\"centered\">Kč</td> <td class=\"centered\">2450</td> <td class=\"centered\">3700</td> <td class=\"centered\">2450</td> <td class=\"centered\">0.08</td> </tr> <tr> <td>Spain<sup>&#182;</sup></td> <td class=\"centered\">&euro;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">910</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.08 (2008)</td> </tr> <tr> <td>Poland</td> <td class=\"centered\">zl</td> <td class=\"centered\">900</td> <td class=\"centered\">1450</td> <td class=\"centered\">1150</td> <td class=\"centered\">0.09</td> </tr> <tr> <td>United States</td> <td class=\"centered\">$US</td> <td class=\"centered\">16,500</td> <td class=\"centered\">17,500</td> <td class=\"centered\">14,000</td> <td class=\"centered\">0.11</td> </tr> <tr> <td>Japan</td> <td class=\"centered\">&#165;</td> <td class=\"centered\">600</td> <td class=\"centered\">615</td> <td class=\"centered\">605</td> <td class=\"centered\">0.12</td> </tr> <tr> <td>New Zealand</td> <td class=\"centered\">$NZ</td> <td class=\"centered\">180</td> <td class=\"centered\">240</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.12 (2007-2008)</td> </tr> <tr> <td>Germany</td> <td class=\"centered\">&euro;</td> <td class=\"centered\">2950</td> <td class=\"centered\">2850</td> <td class=\"centered\">3050</td> <td class=\"centered\">0.12</td> </tr> <tr> <td>United Kingdom</td> <td class=\"centered\">&#163;</td> <td class=\"centered\">1700</td> <td class=\"centered\">1950</td> <td class=\"centered\">1800</td> <td class=\"centered\">0.13</td> </tr> <tr> <td>Finland</td> <td class=\"centered\">&euro;</td> <td class=\"centered\">315</td> <td class=\"centered\">305</td> <td class=\"centered\">295</td> <td class=\"centered\">0.17</td> </tr> <tr> <td>Netherlands</td> <td class=\"centered\">&euro;</td> <td class=\"centered\">900</td> <td class=\"centered\">1050</td> <td class=\"centered\">925</td> <td class=\"centered\">0.17</td> </tr> <tr> <td>Sweden</td> <td class=\"centered\">kr</td> <td class=\"centered\">5400</td> <td class=\"centered\">5950</td> <td class=\"centered\">5550</td> <td class=\"centered\">0.18</td> </tr> <tr> <td>Denmark</td> <td class=\"centered\">kr</td> <td class=\"centered\">4050</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.20 (2005-2007)</td> </tr> <tr> <td>France</td> <td class=\"centered\">&euro;</td> <td class=\"centered\">3400</td> <td class=\"centered\">4550</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.20</td> </tr> <tr> <td>Italy</td> <td class=\"centered\">&euro;</td> <td class=\"centered\">2500</td> <td class=\"centered\">3150</td> <td class=\"centered\">3750</td> <td class=\"centered\">0.20</td> </tr> <tr> <td>Norway</td> <td class=\"centered\">kr</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.22 (2003-2005)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Fire losses include explosion losses following fire but exclude explosion losses where no fire occurs (for example, some acts of terrorism).</div><div class=\"graphic_footnotes\">GDP: gross domestic product.<br />* Australian data is calculated from figures provided in the Report on Government Services 2012 and may be influenced by specific methodological features of that publication.<br />&para; Spanish figures rely upon internal WFSC estimates derived from Spanish insurance data and have not had adjustments applied; consequently, this data should be regarded with caution.</div><div class=\"graphic_reference\">Reproduced with permission from: World Fire Statistics Newsletter 28. Information Bulletin of the World Fire Statistics Centre. Geneva Association Information Newsletter, Geneva, Switzerland, Oct 2012. Copyright &copy; 2013 The Geneva Association.</div><div id=\"graphicVersion\">Graphic 82340 Version 5.0</div></div></div>"},"82341":{"type":"graphic_figure","displayName":"Abdominal wall mesh placement","title":"Abdominal wall mesh placement","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Abdominal wall mesh placement</div><div class=\"cntnt\"><img style=\"width:520px; height:351px;\" src=\"images/SURG/82341_PSH_repair_lay_mesh_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Options for placement of mesh in the abdominal wall:<BR>(A) Onlay - mesh is placed anterior to the anterior rectus sheath.<BR>(B) Sublay - mesh is placed immediately above the posterior rectus sheath.<BR>(C) Intraperitoneal - mesh is placed directly beneath the peritoneum</div><div id=\"graphicVersion\">Graphic 82341 Version 5.0</div></div></div>"},"82343":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of abnormal axillary lymph node","title":"Ultrasound image of abnormal axillary lymph node","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound image of abnormal axillary lymph node</div><div class=\"cntnt\"><img style=\"width:392px; height:355px;\" src=\"images/SURG/82343_US_abnorm_ax_lymph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound of abnormal axillary lymph node. The arrow indicates nodular thickening of the cortex of the lymph node.</div><div id=\"graphicVersion\">Graphic 82343 Version 2.0</div></div></div>"},"82344":{"type":"graphic_figure","displayName":"SC central line infra mid","title":"Infraclavicular approach to the subclavian vein","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Infraclavicular approach to the subclavian vein</div><div class=\"cntnt\"><img style=\"width:542px; height:400px;\" src=\"images/EM/82344_SC_central_line_infra_mid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The midpoint approach to cannulation of the subclavian vein is most common. Insert the needle 2 to 3 cm inferior to the midpoint of the clavicle. Advance the needle aiming just deep to the suprasternal notch, keeping the needle parallel to the ground.</div><div id=\"graphicVersion\">Graphic 82344 Version 3.0</div></div></div>"},"82345":{"type":"graphic_table","displayName":"Morphologic abnormalities MDS","title":"Morphologic abnormalities in myelodysplastic syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Morphologic abnormalities in myelodysplastic syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Lineage </td> <td class=\"subtitle1\">Peripheral blood </td> <td class=\"subtitle1\">Bone marrow </td> </tr> <tr> <td rowspan=\"8\">Erythroid </td> <td>Ovalomacrocytes</td> <td>Megaloblastoid erythropoiesis</td> </tr> <tr> <td>Elliptocytes</td> <td>Nuclear budding</td> </tr> <tr> <td>Acanthocytes</td> <td>Ringed sideroblasts</td> </tr> <tr> <td>Stomatocytes</td> <td>Internuclear bridging</td> </tr> <tr> <td>Teardrops</td> <td>Karyorrhexis</td> </tr> <tr> <td>Nucleated erythrocytes</td> <td>Nuclear fragments</td> </tr> <tr> <td>Basophilic stippling</td> <td>Cytoplasmic vacuolization</td> </tr> <tr> <td>Howell-Jolly bodies</td> <td>Multinucleation</td> </tr> <tr> <td rowspan=\"6\">Myeloid </td> <td>Pseudo Pelger-Huet anomaly</td> <td>Defective granulation</td> </tr> <tr> <td>Auer rods</td> <td>Maturation arrest at myelocyte stage</td> </tr> <tr> <td>Hypogranulation</td> <td>Increase in monocytoid forms</td> </tr> <tr> <td>Nuclear sticks</td> <td>Abnormal localization of immature precursors</td> </tr> <tr> <td>Hypersegmentation</td> <td rowspan=\"2\">&nbsp; </td> </tr> <tr> <td>Ringed-shaped nuclei</td> </tr> <tr> <td rowspan=\"4\">Megakaryocyte </td> <td>Giant platelets</td> <td>Micromegakaryocytes</td> </tr> <tr> <td>Hypogranular or agranular platelets</td> <td>Large mononuclear forms</td> </tr> <tr> <td rowspan=\"2\">&nbsp; </td> <td>Hypogranulation</td> </tr> <tr> <td>Multiple small nuclei</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: List AF, Sandberg AA, Doll DC. Myelodysplastic Syndromes. Wintrobe's Clinical Hematology, 12th edition, Greer JP (Ed), Lippincott Williams &amp; Wilkins, Baltimore 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 82345 Version 13.0</div></div></div>"},"82348":{"type":"graphic_diagnosticimage","displayName":"Role of ultrasound","title":"Role of ultrasound in assessing extent of disease","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Role of ultrasound in assessing extent of disease</div><div class=\"cntnt\"><img style=\"width:591px; height:472px;\" src=\"images/PC/82348_Role_of_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound shows three additional cancers in the same breast. An irregular solid hypoechoic nodule in the 12:00 o'clock position (Panel A) corresponds to a nodule seen on mammogram and palpated on clinical examination. Three additional hypoechoic nodules (Panels B, C, and D) are seen between 2:00 and 11:00 o'clock positions that are non palpable. Presurgical knowledge of additional lesions is important in treatment planning.</div><div id=\"graphicVersion\">Graphic 82348 Version 2.0</div></div></div>"},"82350":{"type":"graphic_figure","displayName":"Normal puberty in girls","title":"Sequence of events during normal puberty in girls","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sequence of events during normal puberty in girls</div><div class=\"cntnt\"><img style=\"width:428px; height:278px;\" src=\"images/ENDO/82350_Timing_pubertal_milestones.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As this schematic shows, menarche is a relatively late event in puberty, occurring after both breast and pubic hair development are well-advanced. On average, menarche occurs at 12 and a half years in US Caucasian girls and at 12 years in African-American girls.</div><div class=\"graphic_reference\">Additional references:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Wu T, Mendola P, Buck GM. Ethnic Differences in the Presence of Secondary Sex Characteristics and Menarche Among US Girls: The Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics 2002; 110:752.</li>&#xD;&#xA;    <li>Herman-Giddens ME, Kaplowitz PB, Wasserman R. Navigating the Recent Articles on Girls' Puberty in Pediatrics: What Do We Know and Where Do We Go from Here? Pediatrics 2004; 113:911.</li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted from: Tanner JM. The development of the female reproductive system during adolescence. Clin Obstet &amp; Gynecol 1960; 3:135.</div><div id=\"graphicVersion\">Graphic 82350 Version 8.0</div></div></div>"},"82351":{"type":"graphic_table","displayName":"Types of effector systems","title":"Effector systems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effector systems</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Adenylyl cyclases - cAMP</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"1\">\r\n  \r\n   Phospholipases C and A<sub>2</sub> - IP<sub>3</sub>\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Guanylate cyclase - cGMP</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Potassium channels</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Calcium channels</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Others?</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">6.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=21379&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Types_of_effector_systems.htm</title></head></div><div class=\"graphic_lgnd\">Effector systems for GPCRs: the enzymes adenylyl cyclase, phospholipase C, and guanylate cyclase cause the production of specific second messengers, such as cAMP, IP3, or cGMP, which then mediate intracellular effects. Other effector systems, such as those involving ion channels, are more closely regulated by direct coupling with their G proteins. Effector systems of some GPCRs are unknown.</div><div class=\"graphic_footnotes\">GPCR: G protein-coupled receptor.</div><div id=\"graphicVersion\">Graphic 82351 Version 2.0</div></div></div>"},"82353":{"type":"graphic_table","displayName":"Poisons and drugs amenable to hemodialysis","title":"Poisons and drugs amenable to hemodialysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Poisons and drugs amenable to hemodialysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Barbiturates</td> </tr> <tr> <td>Bromides</td> </tr> <tr> <td class=\"sublist1_start\">Alcohols</td> </tr> <tr> <td class=\"sublist1\">Ethanol</td> </tr> <tr> <td class=\"sublist1\">Isopropanol</td> </tr> <tr> <td class=\"sublist1\">Acetone&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Methanol</td> </tr> <tr> <td class=\"sublist1\">Ethylene glycol</td> </tr> <tr> <td class=\"sublist1\">Propylene glycol&nbsp;</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>Procainamide</td> </tr> <tr> <td>Theophylline</td> </tr> <tr> <td>Salicylates</td> </tr> <tr> <td>Heavy metals (possible)</td> </tr> <tr> <td>Trichloroethanol/Chloral hydrate</td> </tr> <tr> <td>Atenolol</td> </tr> <tr> <td>Sotalol</td> </tr> <tr> <td>Biguanide (eg, metformin) when associated with lactic acidosis&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82353 Version 3.0</div></div></div>"},"82354":{"type":"graphic_picture","displayName":"Cauliflower ear in relapsing polychondritis","title":"Cauliflower ear in relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cauliflower ear in relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:360px; height:229px;\" src=\"images/RHEUM/82354_Cauliflower_ear_in_RPC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Auricular distortion in relapsing polychondritis induced by destructive changes in supporting structures of connective tissue.</div><div class=\"graphic_reference\">Courtesy of Jerome H Herman, MD.</div><div id=\"graphicVersion\">Graphic 82354 Version 3.0</div></div></div>"},"82355":{"type":"graphic_table","displayName":"Cytokine profile in RA","title":"Cytokine profile in rheumatoid arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytokine profile in rheumatoid arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">&nbsp;</td>\n<td class=\"subtitle1\">T cell derived</td>\n<td class=\"subtitle1\">Macrophage/fibroblast derived</td>\n</tr>\n<tr>\n<td>IL-1</td>\n<td>&nbsp;</td>\n<td>+</td>\n</tr>\n<tr>\n<td>IL-2</td>\n<td>-</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>IL-3</td>\n<td>-</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>IL-4</td>\n<td>-</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>IL-6</td>\n<td>&nbsp;</td>\n<td>+</td>\n</tr>\n<tr>\n<td>IL-8</td>\n<td>&nbsp;</td>\n<td>+</td>\n</tr><tr>\n      <td>IL-10</td>\n      <td>&nbsp;</td>\n      <td>+</td>\n    </tr>\n    <tr>\n      <td>IL-12</td>\n      <td>-</td>\n      <td>+</td>\n    </tr>\n    <tr>\n      <td>IL-15</td>\n      <td>+</td>\n      <td>+</td>\n    </tr>\n    <tr>\n      <td>TNF-alpha</td>\n      <td>-</td>\n      <td>+</td>\n    </tr>\n    <tr>\n      <td>TNF-beta</td>\n      <td>-</td>\n      <td>&nbsp;</td>\n    </tr>\n    <tr>\n      <td>IFN-gamma</td>\n      <td>-</td>\n      <td>&nbsp;</td>\n    </tr>\n    <tr>\n      <td>GM-CSF</td>\n      <td>-</td>\n      <td>+</td>\n    </tr>\n    <tr>\n      <td>G-CSF</td>\n      <td>&nbsp;</td>\n      <td>+</td>\n    </tr>\n    <tr>\n      <td>M-CSF</td>\n      <td>&nbsp;</td>\n      <td>+</td>\n    </tr>\n    <tr>\n      <td>TGF-beta</td>\n      <td>&nbsp;</td>\n      <td>+</td>\n    </tr>\n    <tr>\n      <td>IL-1ra</td>\n      <td>&nbsp;</td>\n      <td>+</td>\n    </tr>\n    <tr>\n      <td>MCP-1</td>\n      <td>&nbsp;</td>\n      <td>+</td>\n    </tr>\n    <tr>\n      <td>MIP-1</td>\n      <td>&nbsp;</td>\n      <td>+</td>\n    </tr>\n    <tr>\n      <td>ENA-78</td>\n      <td>&nbsp;</td>\n      <td>+</td>\n    </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">-: cytokine absent or present in very low concentration; +: cytokine readily detected.</div><div id=\"graphicVersion\">Graphic 82355 Version 1.0</div></div></div>"},"82356":{"type":"graphic_table","displayName":"Ways to get your ABCs under control PI","title":"Ways to get your ABCs under control","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ways to get your ABCs under control</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">What you can do</td> <td class=\"subtitle1\">Helps with A1C</td> <td class=\"subtitle1\">Helps with blood pressure</td> <td class=\"subtitle1\">Helps with cholesterol</td> </tr> <tr> <td>Take your medicines every day</td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> </tr> <tr> <td>Eat a diet low in saturated fat and cholesterol but rich in fruits and vegetables and low-fat dairy products</td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> </tr> <tr> <td>Limit the amount of salt (sodium) you eat</td> <td>&nbsp;</td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> <td>&nbsp;</td> </tr> <tr> <td>Be active</td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> </tr> <tr> <td>Lose weight if you are overweight</td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> </tr> <tr> <td>Avoid alcohol</td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> <td class=\"centered\"><span class=\"green\"><strong>X</strong></span></td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82356 Version 1.0</div></div></div>"},"82357":{"type":"graphic_waveform","displayName":"Doppler waveform within stented artery","title":"Doppler waveform within stented artery","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Doppler waveform within stented artery</div><div class=\"cntnt\"><img style=\"width:472px; height:350px;\" src=\"images/SURG/82357_Norm_periph_dopp_wave.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Duplex ultrasonography of a superficial femoral artery stent. Note the normal triphasic Doppler waveform within the stent, with a normal peak systolic velocity (78.6 cm per second). The bright white parallel lines represent the margins of the stent.</div><div class=\"graphic_footnotes\">DST: distal; M: mid; RT: right; SFA: superficial femoral artery; %: percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Topol EJ, Califf RM, et al. Textbook of Cardiovascular Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82357 Version 2.0</div></div></div>"},"82358":{"type":"graphic_picture","displayName":"Squamous cell carcinoma in situ","title":"Bowen's disease (cutaneous squamous cell carcinoma in situ) ","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Bowen's disease (cutaneous squamous cell carcinoma in situ) </div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/82358_Squam_cell_carcin_in_situ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous, scaly, thin plaque is present on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82358 Version 6.0</div></div></div>"},"82359":{"type":"graphic_table","displayName":"HCW prophylaxis recs I","title":"Postexposure prophylaxis for vaccine preventable diseases in healthcare workers - I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Postexposure prophylaxis for vaccine preventable diseases in healthcare workers - I</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Disease</td>\n\n\t\t\t<td rowspan=\"1\" colspan=\"2\" class=\"subtitle1\">Definition of</td>\n\n\t\t\t<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Prophylaxis</td>\n\n\t\t\t<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Work restrictions</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle2\">Susceptible</td>\n\n\t\t\t<td class=\"subtitle2\">Exposed</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td colspan=\"1\" rowspan=\"3\">Hepatitis B</td>\n\n\t\t\t<td colspan=\"1\" rowspan=\"3\">Never or incompletely vaccinated and never had an anti-HBs titer &#62;10 IU/mL</td>\n\n\t\t\t<td><p>Contact with contaminated blood or body fluid via percutaneous, membrane or non-intact skin exposure;</p>\n\t\t\t\t<p>\n\t\t\t<strong>Source</strong> - known HBsAg positive</p></td>\n\n\t\t\t<td><p><strong>Never vaccinated</strong> - HBIG 0.06 mL/kg x1 and initiate vaccine series</p>\n\t\t\t\t<p>\n\t\t\t<strong>Nonresponder</strong> - HBIG x2 Response unknown - test healthcare worker; HBIG x1 if not protected and boost or complete vaccination</p></td>\n\n\t\t\t<td colspan=\"1\" rowspan=\"3\"><p><strong>Acute infection</strong> - relieve from direct patient contact until jaundice resolves;</p>\n\t\t\t\t<p><strong>\n\t\t\tChronic infection</strong> - counsel healthcare worker on infection control practices - if transmission occurs, restrict from invasive procedures and direct contact with patient equipment until hepatitis B antigenemia resolves</p></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td><p>Contact with contaminated blood or body fluid via percutaneous, membrane or non-intact skin exposure;</p>\n\t\t\t\t<p>\n\t\t\t<strong>Source</strong> - known HBsAg negative</p></td>\n\n\t\t\t<td><p><strong>Never vaccinated</strong> - Initiate vaccine series</p>\n\t\t\t\t<p><strong>\n\t\t\tNonresponder or response unknown</strong> - no treatment needed</p></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td><p>Contact with contaminated blood or body fluid via percutaneous, membrane or non-intact skin exposure;</p>\n\t\t\t\t<p><strong>\n\t\t\tSource</strong> - unknown HBsAg</p></td>\n\n\t\t\t<td><p><strong>Never vaccinated</strong> - initiate vaccine series</p>\n\t\t\t\t<p><strong>\n\t\t\tNonresponder</strong> - treat as HBsAg positive if high risk source</p>\n\t\t\t\t<p><strong>\n\t\t\tResponse unknown</strong> - test healthcare worker; if not protected complete vaccination or begin revaccination.</p></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Influenza</td>\n\n\t\t\t<td>Did not recieve annual immunization</td>\n\n\t\t\t<td>Cohabiting confined air space or face to face contact in open area</td>\n\n\t\t\t<td>Catch-up immunization and consider amantidine or rimantidine 100 mg PO BID or oseltamivir 75 mg PO QD or BID</td>\n\n\t\t\t<td>Relieve from care of high risk patients</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Measles</td>\n\n\t\t\t<td>None of the following - documentation of diagnosis of measles by a physician, serologic evidence of immunity, two doses of MMR</td>\n\n\t\t\t<td>Cohabiting confined air space or face to face in open area</td>\n\n\t\t\t<td>Measles vaccine if no contraindications or immune globulin 0.25 mL/kg (maximum 15 mL) within 6 days or exposure</td>\n\n\t\t\t<td>Furlough from health-care facility until 4 days after rash appears or from day 5 after first exposure to day 21 after last exposure</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 82359 Version 1.0</div></div></div>"},"82362":{"type":"graphic_diagnosticimage","displayName":"Solitary enchondroma","title":"Solitary enchondroma of the femur","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Solitary enchondroma of the femur</div><div class=\"cntnt\"><img style=\"width:350px; height:466px;\" src=\"images/PEDS/82362_Solitary_enchondroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enchondroma of the distal femur demonstrates flocculent matrix resembling rings, or Cs and Os. Calcification is concentrated in the center of the lesion.</div><div class=\"graphic_reference\">Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82362 Version 2.0</div></div></div>"},"82363":{"type":"graphic_figure","displayName":"Short tandem repeats","title":"Short tandem repeats","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Short tandem repeats</div><div class=\"cntnt\"><img style=\"width:582px; height:341px;\" src=\"images/PC/82363_Short_tandem_repeats.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Example of a CAG short tandem repeat with genotype 4/6. (B) Slip mispairing: During DNA replication, nascent DNA copy (in purple) slips back one tandem repeat, resulting in duplicate replication of tandem repeat #5. Results in additional copy (total 7) on new strand. (C) Pedigree of Myotonic Dystrophy in three generations with anticipation. Grandmother has 75 tandem repeats at the DMPK gene, no symptoms. Mother has expansion of 530 repeats, with mild symptoms (no respiratory distress) at age 40. Grandson has progressive expansion to 1200 repeats, manifesting with myotonia and respiratory failure at one year of age.</div><div id=\"graphicVersion\">Graphic 82363 Version 1.0</div></div></div>"},"82365":{"type":"graphic_figure","displayName":"Bronchoprovocation test asthma","title":"Bronchoprovocation testing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoprovocation testing</div><div class=\"cntnt\"><img style=\"width:384px; height:268px;\" src=\"images/PULM/82365_Bronchoprovocation_test_ast.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of increasing the inhaled dose of methacholine in a healthy subject (red) and an asthmatic patient (blue). The provocative concentration is the amount of inhaled agonist required to drop the FEV<sub>1</sub> by 20 percent from the baseline (PC<sub>20</sub> FEV<sub>1</sub>) and is much less in the asthmatic than in the normal subject: 0.8 mg/mL versus 20 mg/mL. In general, a PC<sub>20</sub> &le;8 mg/mL is consistent with asthma; and a PC<sub>20</sub> ​&gt;16 mg/mL is considered a negative test. Thus, an increase in airway responsiveness is characterized by a decrease in the PC<sub>20</sub>.</div><div id=\"graphicVersion\">Graphic 82365 Version 2.0</div></div></div>"},"82366":{"type":"graphic_picture","displayName":"Lung biopsy EGPA (Churg-Strauss)","title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</div><div class=\"cntnt\"><img style=\"width:354px; height:245px;\" src=\"images/PULM/82366_Lung_biopsy_Churg_Strauss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power view of a lung biopsy from a patient with eosinophilic granulomatosis with polyangiitis (Churg-Strauss) showing well-established, necrotizing, and occlusing arterial lesions with obliteration of the arterial lumen. Dilatation of lymphatic channels in the arterial adventitia contributes significantly to the marked size discrepancy between the artery and its adjacent bronchiole. Other regions of the lung reveal marked intraalveolar eosinophilic infiltration in the parenchyma (Hematoxylin and eosin, x 10).</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 82366 Version 4.0</div></div></div>"},"82368":{"type":"graphic_table","displayName":"PROSTQA probabilities of erection after brachytherapy","title":"PROSTQA model-predicted probabilities of men having functional erections suitable for intercourse two years after brachytherapy for prostate cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PROSTQA model-predicted probabilities of men having functional erections suitable for intercourse two years after brachytherapy for prostate cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"5%\"></colgroup><colgroup span=\"5\" width=\"19%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age, y</td> <td class=\"subtitle1\" rowspan=\"2\">Race/ethnicity*</td> <td class=\"subtitle1\" rowspan=\"2\">BMI<sup>&#182;</sup></td> <td class=\"subtitle1\" colspan=\"3\">Predicted functional erections after treatment, percent (95% CI) (by pretreatment sexual HRQOL score)<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2\">67</td> <td class=\"subtitle2\">83</td> <td class=\"subtitle2\">100</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">60</td> <td class=\"divider_bottom\" rowspan=\"3\">African American</td> <td>&#60;25</td> <td>78 (48-94)</td> <td>92 (73-98)</td> <td>98 (89-99)</td> </tr> <tr> <td>25-&#60;35</td> <td>61 (35-83)</td> <td>83 (62-94)</td> <td>94 (83-98)</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;35</td> <td>28 (7-69)</td> <td>56 (18-88)</td> <td>81 (41-96)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">White/other</td> <td>&#60;25</td> <td>54 (33-74)</td> <td>79 (61-90)</td> <td>93 (83-97)</td> </tr> <tr> <td>25-&#60;35</td> <td>34 (22-48)</td> <td>62 (50-73)</td> <td>85 (75-91)</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;35</td> <td>11 (3-37)</td> <td>29 (9-63)</td> <td>58 (24-86)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">65</td> <td class=\"divider_bottom\" rowspan=\"3\">African American</td> <td>&#60;25</td> <td>73 (41-91)</td> <td>89 (67-97)</td> <td>97 (86-99)</td> </tr> <tr> <td>25-&#60;35</td> <td>54 (28-77)</td> <td>79 (54-92)</td> <td>93 (77-98)</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;35</td> <td>22 (5-62)</td> <td>48 (14-84)</td> <td>76 (33-95)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">White/other</td> <td>&#60;25</td> <td>46 (28-66)</td> <td>73 (55-86)</td> <td>90 (79-96)</td> </tr> <tr> <td>25-&#60;35</td> <td>27 (18-39)</td> <td>54 (44-65)</td> <td>80 (69-88)</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;35</td> <td>9 (2-30)</td> <td>23 (6-56)</td> <td>50 (18-82)</td> </tr> <tr> <td rowspan=\"6\">70</td> <td class=\"divider_bottom\" rowspan=\"3\">African American</td> <td>&#60;25</td> <td>66 (34-88)</td> <td>86 (60-96)</td> <td>95 (81-99)</td> </tr> <tr> <td>25-&#60;35</td> <td>46 (21-73)</td> <td>73 (45-90)</td> <td>90 (70-97)</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;35</td> <td>17 (3-56)</td> <td>40 (10-80)</td> <td>69 (25-94)</td> </tr> <tr> <td rowspan=\"3\">White/other</td> <td>&#60;25</td> <td>39 (22-58)</td> <td>67 (47-82)</td> <td>87 (72-95)</td> </tr> <tr> <td>25-&#60;35</td> <td>22 (13-33)</td> <td>47 (34-60)</td> <td>75 (60-86)</td> </tr> <tr> <td>&#8805;35</td> <td>6 (1-25)</td> <td>18 (4-50)</td> <td>42 (13-78)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PROSTQA: Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment; BMI: body mass index; HRQOL: health-related quality of life.<br />* White race/ethnicity included 3 percent of patients of other (non-African American) or unknown races/ethnicities.<br />¶ Calculated as weight in kilograms divided by height in meters squared.<br />Δ Specific values of pretreatment sexual functioning (Expanded Prostate Cancer Index Composite scores of 67, 83, and 100; range of 0-100, with a higher score representing better function) are tabulated to represent cohort distribution (25th, 50th, and 75th percentiles of scores among prostatectomy-treated patients) as well as to reflect a clinically relevant set of possible pretreatment sexual functioning. These values correspond to the 45th, 60th, and 85th percentiles among patients treated with brachytherapy. Across all treatment groups, these percentiles correspond to 358 patients (36 percent) with pretreatment sexual HRQOL scores of 67 or less, 441 (45 percent) with scores of 68-99, and 186 (19 percent) with scores of 100.</div><div class=\"graphic_reference\">Reproduced with permission from: Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306:1205. Copyright &copy; 2011 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 82368 Version 11.0</div></div></div>"},"82370":{"type":"graphic_figure","displayName":"Age of onset of infantile spasms","title":"Ages at onset of infantile spasms for 257 infants studied during the period 1963-1980","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Ages at onset of infantile spasms for 257 infants studied during the period 1963-1980</div><div class=\"cntnt\"><img style=\"width:457px; height:375px;\" src=\"images/PEDS/82370_Infantile_spasms_age_of_ons.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parents and physicians often do not recognize infantile spasms as seizures, particularly when they first occur, and it is probable that the age distribution should be shifted somewhat to the left.</div><div class=\"graphic_reference\">Data from: Kellaway, P, Frost, JD Jr, Hrachovy, RA, Infantile spasms. In: Antiepileptic Drug Therapy in Pediatrics, Morselli, PL, Pippenger, CE, Penry, JK (Eds), Raven Press, New York 1983.</div><div id=\"graphicVersion\">Graphic 82370 Version 2.0</div></div></div>"},"82371":{"type":"graphic_picture","displayName":"Crusted scabies hand","title":"Crusted scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crusted scabies</div><div class=\"cntnt\"><img style=\"width:396px; height:264px;\" src=\"images/PC/82371_Crusted_scabies_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crusted scabies in a patient with acquired immunodeficiency syndrome (AIDS). Note the crusted papules and the white, linear burrows.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82371 Version 3.0</div></div></div>"},"82372":{"type":"graphic_diagnosticimage","displayName":"Benign granuloma PET","title":"Benign granuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benign granuloma</div><div class=\"cntnt\"><img style=\"width:247px; height:273px;\" src=\"images/PULM/82372_Benign_granuloma_PET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal PET scan shows only very weak uptake of radionuclide in this benign lesion (arrow).</div><div class=\"graphic_footnotes\">PET: positron emission tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82372 Version 3.0</div></div></div>"},"82373":{"type":"graphic_picture","displayName":"Muscle histochemistry mitochondrial disorder","title":"Muscle histochemistry from a patient with a mitochondrial disorder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Muscle histochemistry from a patient with a mitochondrial disorder</div><div class=\"cntnt\"><img style=\"width:381px; height:510px;\" src=\"images/NEURO/82373_Muscle_histochemistry_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Succinate dehydrogenase (SDH) stain shows mitochondrial proliferation (&quot;ragged-blue&quot; fibers) and strongly SDH-reactive vessels (SSVs; arrow).<br> (B) Cytochrome c oxidase (COX) stain shows reduced enzyme activity in individual fibers (asterisk) and a COX-negative SSV (arrow); x20.</div><div class=\"graphic_reference\">Reproduced with permission from: Mancuso M, Filosto M, Mootha VK, et al. A novel mitochondrial tRNAPhe mutation causes MERRF syndrome. Neurology 2004; 62:2119. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82373 Version 6.0</div></div></div>"},"82374":{"type":"graphic_table","displayName":"CAD as first CV event","title":"Percentage of first atherosclerotic cardiovascular events as coronary heart disease in subjects in the Framingham study","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Percentage of first atherosclerotic cardiovascular events as coronary heart disease in subjects in the Framingham study</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">Age</td>\n\n      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Number of CV events, all types</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Percent as coronary heart disease</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">Men</td>\n\n      <td class=\"subtitle2\">Women</td>\n\n      <td class=\"subtitle2\">Men</td>\n\n      <td class=\"subtitle2\">Women</td>\n\n    </tr>\n\n    <tr>\n\n      <td>35 to 54</td>\n\n      <td>352</td>\n\n      <td>200</td>\n\n      <td>33.0</td>\n\n      <td>28.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>55 to 64</td>\n\n      <td>437</td>\n\n      <td>329</td>\n\n      <td>56.5</td>\n\n      <td>52.6</td>\n\n    </tr>\n\n    <tr>\n\n      <td>65 to 74</td>\n\n      <td>358</td>\n\n      <td>364</td>\n\n      <td>65.4</td>\n\n      <td>58.0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>75 to 94</td>\n\n      <td>199</td>\n\n      <td>312</td>\n\n      <td>57.3</td>\n\n      <td>48.1</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">44-year follow-up of cohort and 20-year follow-up of offspring.</div><div id=\"graphicVersion\">Graphic 82374 Version 2.0</div></div></div>"},"82376":{"type":"graphic_diagnosticimage","displayName":"Parenchymal brain lesions","title":"Parenchymal brain lesions associated with cerebral venous thrombosis","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Parenchymal brain lesions associated with cerebral venous thrombosis</div><div class=\"cntnt\"><img style=\"width:451px; height:289px;\" src=\"images/NEURO/82376_Parenchymal_brain_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Bilateral thalamic edema in a case of deep cerebral venous system thrombosis, identified in a T2-weighted FLAIR MRI. B) T2-weighted FLAIR MRI (coronal view) showing left temporal hemorrhagic infarct due to a thrombosis of left lateral sinus (arrow).</div><div class=\"graphic_footnotes\">Flair: fluid-attenuated inversion recovery; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 82376 Version 3.0</div></div></div>"},"82377":{"type":"graphic_picture","displayName":"Placental infarct","title":"Placental infarct (maternal origin)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Placental infarct (maternal origin)</div><div class=\"cntnt\"><img style=\"width:432px; height:270px;\" src=\"images/OBGYN/82377_Placental_infarct.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 82377 Version 1.0</div></div></div>"},"82379":{"type":"graphic_waveform","displayName":"Intermediate case 18","title":"Intermediate case 18","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Intermediate case 18</div><div class=\"cntnt\"><img style=\"width:540px; height:284px;\" src=\"images/CARD/82379_Intermediate_case_18.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82379 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"82381":{"type":"graphic_diagnosticimage","displayName":"Hypoechoic hypervascular nodule Doppler","title":"Hypoechoic hypervascular nodule Doppler","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Hypoechoic hypervascular nodule Doppler</div><div class=\"cntnt\"><img style=\"width:516px; height:357px;\" src=\"images/ENDO/82381_Hypoechoic_nod_Dopp_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A longitudinal image with Doppler interrogation of the left thyroid lobe that shows a hypoechoic, hypervascular nodule in its lower pole (N). Blood vessels are seen in the rest of the lobe (arrows).</div><div class=\"graphic_reference\">Courtesy of John Bonavita, MD, Department of Radiology, NYU Langone Medical Center.</div><div id=\"graphicVersion\">Graphic 82381 Version 3.0</div></div></div>"},"82383":{"type":"graphic_picture","displayName":"Corneal lacerations","title":"Two patients with obvious corneal lacerations with uveal prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two patients with obvious corneal lacerations with uveal prolapse</div><div class=\"cntnt\"><img style=\"width:298px; height:444px;\" src=\"images/EM/82383_Corneal_lacerations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Full thickness corneal laceration from a fragment of glass. Uveal tissue and aqueous are seen prolapsing through the wound. Subconjunctival hemorrhage is seen superiorly.<br> (B) Patient with full thickness corneal laceration. Brown uveal tissue (iris) is seen prolapsing through wound.</div><div id=\"graphicVersion\">Graphic 82383 Version 3.0</div></div></div>"},"82384":{"type":"graphic_table","displayName":"Helminths with marked eosinophilia","title":"Helminthic parasitic diseases causing marked eosinophilia (>3000/microL)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Helminthic parasitic diseases causing marked eosinophilia (&gt;3000/microL)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Parasite</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td>Angiostrongyliasis costaricensis</td> <td>&nbsp;</td> </tr> <tr> <td>Ascariasis</td> <td>Early transpulmonary larval migration, often absent when mature</td> </tr> <tr> <td>Hookworm infection</td> <td>Early transpulmonary larval migration, often mild when mature</td> </tr> <tr> <td>Strongyloidiasis</td> <td>&nbsp;</td> </tr> <tr> <td>Trichinellosis</td> <td>&nbsp;</td> </tr> <tr> <td>Visceral larva migrans</td> <td>Primarily in children</td> </tr> <tr> <td>Gnathostomiasis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Filariases:</td> </tr> <tr> <td class=\"sublist1\">Tropical pulmonary eosinophilia</td> <td class=\"sublist_other\">Especially in expatriates</td> </tr> <tr> <td class=\"sublist1\">Loiasis</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Onchocerciasis</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Flukes:</td> </tr> <tr> <td class=\"sublist1\">Schistosomiasis</td> <td class=\"sublist_other\">During early infection in nonimmunes (Katayama fever)</td> </tr> <tr> <td class=\"sublist1\">Fascioliasis</td> <td class=\"sublist_other\">During early infection</td> </tr> <tr> <td class=\"sublist1\">Clonorchiasis</td> <td class=\"sublist_other\">During early infection</td> </tr> <tr> <td class=\"sublist1\">Paragonimiasis</td> <td class=\"sublist_other\">During early infection</td> </tr> <tr> <td class=\"sublist1\">Fasciolopsiasis</td> <td class=\"sublist_other\">During early infection</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Weller PF. Eosinophilia in travelers. Med Clin North Am 1992; 76:1413.</div><div id=\"graphicVersion\">Graphic 82384 Version 4.0</div></div></div>"},"82386":{"type":"graphic_figure","displayName":"Pathogenic mechanisms PD","title":"Possible pathogenic mechanisms in Parkinson disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Possible pathogenic mechanisms in Parkinson disease</div><div class=\"cntnt\"><img style=\"width:375px; height:480px;\" src=\"images/NEURO/82386_Pathogenic_mechanisms_PD.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82386 Version 4.0</div></div></div>"},"82388":{"type":"graphic_table","displayName":"Common radioactive isotopes currently used","title":"Common radioactive isotopes currently used","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common radioactive isotopes currently used</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Radionuclides</td> <td class=\"subtitle1\" rowspan=\"2\">Half life</td> <td class=\"subtitle1\" rowspan=\"2\">Radiation emitted</td> <td class=\"subtitle1\" colspan=\"4\">Field of use</td> </tr> <tr> <td class=\"subtitle2\">Lab</td> <td class=\"subtitle2\">Industry</td> <td class=\"subtitle2\">Medical</td> <td class=\"subtitle2\">Nuclear Power</td> </tr> <tr> <td>Cerium, 144Cs</td> <td>285 days</td> <td>beta</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> <td>X</td> </tr> <tr> <td>Cesium, 137Ce</td> <td>30 years</td> <td>beta, gamma</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> <td>X</td> </tr> <tr> <td>Cobalt, 60Co</td> <td>5 years</td> <td>gamma</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td>Iodine, 131I, 125I</td> <td>8 days</td> <td>beta, gamma</td> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>X</td> </tr> <tr> <td>Iridium, 192Ir</td> <td>74 days</td> <td>gamma</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Phosphorous, 32P</td> <td>14 days</td> <td>beta</td> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Plutonium, 239Pu</td> <td>82x10(6) years</td> <td>alpha</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> </tr> <tr> <td>Radium, 226Ra</td> <td>1622 years</td> <td>alpha, beta, gamma</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Strontium, 90Sr</td> <td>28 years</td> <td>beta</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> <td>X</td> </tr> <tr> <td>Technetium, 99, 95Tc</td> <td>6 hours to 60 days</td> <td>gamma</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Tritium, 3H</td> <td>12 years</td> <td>beta</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> </tr> <tr> <td>Uranium, 234, 235, 238Ur</td> <td>2.5x10(6) to 4.5x10(9) years</td> <td>alpha, gamma</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>X</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Shannon BE, Jenkins JL, Braen GR. Radiation Injury. In: Manual of Emergency Medicine. Lippincott Williams &amp; Wilkins, Philadelphia, 2000. Copyright © 2000 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82388 Version 12.0</div></div></div>"},"82389":{"type":"graphic_table","displayName":"Normal urinary solute value in children random urine collection","title":"Normal urinary solute value in children based on measurements of solutes and creatinine from a single random urine collection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal urinary solute value in children based on measurements of solutes and creatinine from a single random urine collection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">mg/mg</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">mmol/mmol</td> </tr> <tr> <td rowspan=\"3\"><strong>Calcium/creatinine</strong></td> <td>0 to 6 mo</td> <td>&#60;0.8</td> <td>0 to 6 mo</td> <td>&#60;2.24</td> </tr> <tr> <td>6 to 12 mo</td> <td>&#60;0.6</td> <td>6 to 12 mo</td> <td>&#60;1.68</td> </tr> <tr> <td>2 to 18 yr</td> <td>&#60;0.2</td> <td>2 to 18 yr</td> <td>&#60;0.56</td> </tr> <tr class=\"divider_top\"> <td><strong>Cystine/creatinine</strong></td> <td>All ages</td> <td>&#60;0.02</td> <td>All ages</td> <td>&#60;0.01</td> </tr> <tr class=\"divider_top\"> <td><strong>Uric acid/glomerular filtration rate</strong>*</td> <td>&#62;3 yr</td> <td>&#60;0.56 mg uric acid/dL of glomerular filtrate</td> <td>&#62;3 yr</td> <td>&#60;0.03 mmol uric acid/dL of glomerular filtrate</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">mo: months; yr: years.<br />* Uric acid/glomerular filtration rate (GFR) calculated using the following equation, where UCr and PCr are the urine and plasma creatinine concentrations, respectively: Uric acid/GFR, mg/dL = Urine Uric Acid &divide; UCr x PCr.</div><div id=\"graphicVersion\">Graphic 82389 Version 10.0</div></div></div>"},"82390":{"type":"graphic_diagnosticimage","displayName":"Bilateral metaphyseal corner fractures distal tibia","title":"Bilateral metaphyseal corner (bucket handle) fractures of the distal tibia","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Bilateral metaphyseal corner (bucket handle) fractures of the distal tibia</div><div class=\"cntnt\"><img style=\"width:516px; height:414px;\" src=\"images/EM/82390_Bucket_handle_fx_distal_tib.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 3-month-old child with bilateral ankle swelling was found to have bilateral metaphyseal &quot;bucket-handle&quot; type fractures (black arrows).</div><div class=\"graphic_reference\">Courtesy of Eglal Shalaby-Rana, MD.</div><div id=\"graphicVersion\">Graphic 82390 Version 4.0</div></div></div>"},"82392":{"type":"graphic_algorithm","displayName":"Management of symptomatic anal fissure","title":"Management of symptomatic anal fissure","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Management of symptomatic anal fissure</div><div class=\"cntnt\"><img style=\"width:526px; height:672px;\" src=\"images/SURG/82392_Rx_anal_fiss.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Symptoms suggestive of Crohn-related fissures include multiple, nonhealing, recurring, painless, or unusually deep or wide fissures, and perianal skin tags that are hypertrophic, edematous, and tender.</div><div id=\"graphicVersion\">Graphic 82392 Version 5.0</div></div></div>"},"82393":{"type":"graphic_table","displayName":"Neurologic examination","title":"Organization of the neurologic examination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Organization of the neurologic examination</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">A. Mental status</td> </tr> <tr> <td>1. Level of alertness</td> </tr> <tr> <td class=\"sublist1_start\">2. Language</td> </tr> <tr> <td class=\"sublist1\">a. Fluency</td> </tr> <tr> <td class=\"sublist1\">b. Comprehension</td> </tr> <tr> <td class=\"sublist1\">c. Repetition</td> </tr> <tr> <td class=\"sublist1\">d. Naming</td> </tr> <tr> <td class=\"sublist1\">e. Reading</td> </tr> <tr> <td class=\"sublist1\">f. Writing</td> </tr> <tr> <td class=\"sublist1_start\">3. Memory</td> </tr> <tr> <td class=\"sublist1\">a. Immediate</td> </tr> <tr> <td class=\"sublist1\">b. Short-term</td> </tr> <tr> <td class=\"sublist1\">c. Long-term</td> </tr> <tr> <td class=\"sublist2\">i. Recent (including orientation to place and time)</td> </tr> <tr> <td class=\"sublist2\">ii. Remote</td> </tr> <tr> <td>4. Calculation</td> </tr> <tr> <td>5. Construction</td> </tr> <tr> <td>6. Abstraction</td> </tr> <tr> <td class=\"subtitle1_single\">B. Cranial nerves</td> </tr> <tr> <td>1. Olfaction (CN I)</td> </tr> <tr> <td class=\"sublist1_start\">2. Vision (CN II)</td> </tr> <tr> <td class=\"sublist1\">a. Visual fields</td> </tr> <tr> <td class=\"sublist1\">b. Visual acuity</td> </tr> <tr> <td class=\"sublist1\">c. Funduscopic examination</td> </tr> <tr> <td>3. Pupillary light reflex (CNs II, III)</td> </tr> <tr> <td>4. Eye movements (CNs III, IV, VI)</td> </tr> <tr> <td>5. Facial sensation (CN V)</td> </tr> <tr> <td class=\"sublist1_start\">6. Facial strength</td> </tr> <tr> <td class=\"sublist1\">a. Muscles of mastication (CN V)</td> </tr> <tr> <td class=\"sublist1\">b. Muscles of facial expression (CN VII)</td> </tr> <tr> <td>7. Hearing and vestibular function (CN VIII)</td> </tr> <tr> <td>8. Palatal movement (CNs IX, X)</td> </tr> <tr> <td>9. Dysarthria (CNs IX, X, XII)</td> </tr> <tr> <td>10. Head rotation (CN XI)</td> </tr> <tr> <td>11. Shoulder elevation (CN XI)</td> </tr> <tr> <td>12. Tongue movements (CN XII)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">C. Motor</td> </tr> <tr> <td>1. Gait</td> </tr> <tr> <td>2. Coordination</td> </tr> <tr> <td>3. Involuntary movements</td> </tr> <tr> <td>4. Pronator drift</td> </tr> <tr> <td class=\"sublist1_start\">5. Individual muscles</td> </tr> <tr> <td class=\"sublist1\">a. Strength</td> </tr> <tr> <td class=\"sublist1\">b. Bulk</td> </tr> <tr> <td class=\"sublist1\">c. Tone (resistance to passive manipulation)</td> </tr> <tr> <td class=\"subtitle1_single\">D. Reflexes</td> </tr> <tr> <td>1. Tendon reflexes</td> </tr> <tr> <td>2. Plantar responses</td> </tr> <tr> <td>3. Superficial reflexes</td> </tr> <tr> <td>4. \"Primitive\" reflexes</td> </tr> <tr> <td class=\"subtitle1_single\">E. Sensory</td> </tr> <tr> <td>1. Light touch</td> </tr> <tr> <td>2. Pain/temperature</td> </tr> <tr> <td>3. Joint position sense</td> </tr> <tr> <td>4. Vibration</td> </tr> <tr> <td>5. Double simultaneous stimulation</td> </tr> <tr> <td>6. Graphesthesia</td> </tr> <tr> <td>7. Stereognosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">With permission from: Gelb DJ. The Neurologic Examination. In: Introduction to Clinical Neurology. Woburn, MA, Butterworth-Heinemann 2000.</div><div id=\"graphicVersion\">Graphic 82393 Version 4.0</div></div></div>"},"82394":{"type":"graphic_table","displayName":"Integrative approach CAM","title":"Holistic pediatrics: Integrative approach to therapies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Holistic pediatrics: Integrative approach to therapies</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Biochemical therapies</td> </tr> <tr> <td>Medications</td> </tr> <tr> <td>Vitamins and minerals</td> </tr> <tr> <td class=\"sublist1_start\">Dietary supplements</td> </tr> <tr> <td class=\"sublist1\">Herbs</td> </tr> <tr> <td class=\"sublist1\">Amino acids</td> </tr> <tr> <td class=\"sublist1\">Hormones (melatonin, DHEA)</td> </tr> <tr> <td class=\"sublist1_start\">Other</td> </tr> <tr> <td class=\"sublist1\">Fish oil</td> </tr> <tr> <td class=\"sublist1\">Probiotics</td> </tr> <tr> <td class=\"subtitle1_single\">Biomechanical</td> </tr> <tr> <td>Massage and bodywork</td> </tr> <tr> <td>Chiropractic</td> </tr> <tr> <td>Osteopathy and other spinal adjustments</td> </tr> <tr> <td>Surgery and transfusions</td> </tr> <tr> <td class=\"subtitle1_single\">Bioenergetic</td> </tr> <tr> <td>Acupuncture</td> </tr> <tr> <td>Therapeutic Touch, Healing Touch</td> </tr> <tr> <td>Reiki, polarity therapy</td> </tr> <tr> <td>Prayer and ritual</td> </tr> <tr> <td>Homeopathy</td> </tr> <tr> <td>Radiation therapy</td> </tr> <tr> <td>Magnets and electromagnetic field therapies</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Lifestyle therapies</td> </tr> <tr> <td class=\"sublist1_start\">Diet</td> </tr> <tr> <td class=\"sublist1\">Vegetarian, vegan, organic</td> </tr> <tr> <td class=\"sublist1\">Low fat, high fiber</td> </tr> <tr> <td class=\"sublist1\">Gluten-free, casein-free</td> </tr> <tr> <td class=\"sublist1\">Paleolithic, Mediterranean</td> </tr> <tr> <td class=\"sublist1\">Low FODMAP</td> </tr> <tr> <td class=\"sublist1_start\">Exercise</td> </tr> <tr> <td class=\"sublist1\">Aerobic</td> </tr> <tr> <td class=\"sublist1\">Weight training</td> </tr> <tr> <td class=\"sublist1\">Yoga, tai chi, qigong</td> </tr> <tr> <td class=\"sublist1_start\">Environment</td> </tr> <tr> <td class=\"sublist1\">Light, music, vibration, heat, cold</td> </tr> <tr> <td class=\"sublist1\">Aromatherapy</td> </tr> <tr> <td class=\"sublist1\">Magnets</td> </tr> <tr> <td class=\"sublist1\">Media</td> </tr> <tr> <td class=\"sublist1\">Social</td> </tr> <tr> <td class=\"sublist1_start\">Mind-body</td> </tr> <tr> <td class=\"sublist1\">Hypnosis</td> </tr> <tr> <td class=\"sublist1\">Biofeedback</td> </tr> <tr> <td class=\"sublist1\">Meditation</td> </tr> <tr> <td class=\"sublist1\">Counseling, support groups</td> </tr> <tr> <td>Social/communication skills</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DHEA: dehydroepiandrosterone; FODMAP; fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.&nbsp;</div><div id=\"graphicVersion\">Graphic 82394 Version 3.0</div></div></div>"},"82395":{"type":"graphic_table","displayName":"Causes intractable hiccups","title":"Causes of persistent and intractable hiccups","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of persistent and intractable hiccups</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Central nervous system disorders</td> </tr> <tr> <td class=\"sublist2_start\">Vascular</td> </tr> <tr> <td class=\"sublist2\">Ischemic/hemorrhagic stroke*, AV malformations, temporal arteritis</td> </tr> <tr> <td class=\"sublist2_start\">Infections</td> </tr> <tr> <td class=\"sublist2\">Encephalitis*, meningitis, brain abscess, neurosyphillis, subphrenic abscess</td> </tr> <tr> <td class=\"sublist2_start\">Structural</td> </tr> <tr> <td class=\"sublist2\">Head trauma*, intracranial neoplasms, brainstem neoplasms, multiple sclerosis, syringomyelia, hydrocephalus</td> </tr> <tr> <td class=\"subtitle1_single\">Vagus and phrenic nerve irritation</td> </tr> <tr> <td class=\"indent1\">Goiter*, pharyngitis*, laryngitis, hair or foreign body irritation of tympanic membrane, neck cyst or other tumor</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal disorders</td> </tr> <tr> <td class=\"indent1\">Gastric distention, gastritis, peptic ulcer disease, pancreatitis, pancreatic cancer, gastric carcinoma, abdominal abscesses, gallbladder disease, inflammatory bowel disease, hepatitis, aerophagia, esophagael distention, esophagitis, bowel obstruction</td> </tr> <tr> <td class=\"subtitle1_single\">Thoracic disorders</td> </tr> <tr> <td class=\"indent1\">Enlarged lymph nodes secondary to infection or neoplasm*, pneumonia, empyema, bronchitis, asthma, pleuritis, aortic aneurysm, mediastinitis, mediastinal tumors, chest trauma, pulmonary embolism </td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular disorders</td> </tr> <tr> <td class=\"indent1\">Myocardial infarction, pericarditis</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic-metabolic</td> </tr> <tr> <td class=\"indent1\">Alcohol*</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Herpes zoster</td> </tr> <tr> <td class=\"indent1\">Hypocalcemia</td> </tr> <tr> <td class=\"indent1\">Hypocapnia</td> </tr> <tr> <td class=\"indent1\">Hyponatremia</td> </tr> <tr> <td class=\"indent1\">Influenza</td> </tr> <tr> <td class=\"indent1\">Malaria</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Uremia</td> </tr> <tr> <td class=\"subtitle1_single\">Postoperative</td> </tr> <tr> <td class=\"indent1\">General anesthesia</td> </tr> <tr> <td class=\"indent1\">Intubation (stimulation of glottis)</td> </tr> <tr> <td class=\"indent1\">Neck extension (stretching phrenic nerve roots)</td> </tr> <tr> <td class=\"indent1\">Gastric distention</td> </tr> <tr> <td class=\"indent1\">Traction on viscera</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td class=\"indent1\">Alpha methyldopa</td> </tr> <tr> <td class=\"indent1\">Short-acting barbituates</td> </tr> <tr> <td class=\"indent1\">Chemotherapeutic agents (eg, carboplatin)</td> </tr> <tr> <td class=\"indent1\">Dexamethasone</td> </tr> <tr> <td class=\"indent1\">Diazepam</td> </tr> <tr> <td class=\"subtitle1_single\">Psychogenic</td> </tr> <tr> <td class=\"indent1\">Anorexia nervosa</td> </tr> <tr> <td class=\"indent1\">Conversion reaction</td> </tr> <tr> <td class=\"indent1\">Excitement</td> </tr> <tr> <td class=\"indent1\">Malingering</td> </tr> <tr> <td class=\"indent1\">Schizophrenia</td> </tr> <tr> <td class=\"indent1\">Stress</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* More common causes.</div><div id=\"graphicVersion\">Graphic 82395 Version 6.0</div></div></div>"},"82396":{"type":"graphic_picture","displayName":"Solenopsis invicta worker (red imported fire ant)","title":"<EM>Solenopsis invicta </EM>worker (red imported fire ant)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Solenopsis invicta </EM>worker (red imported fire ant)</div><div class=\"cntnt\"><img style=\"width:297px; height:204px;\" src=\"images/PC/82396_Redimportedfireant.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from American Academy of Allergy and Immunology, Monograph on Insect Allergy, 3rd edition, Levine MI, Lockey RF (Eds), 1995.</div><div id=\"graphicVersion\">Graphic 82396 Version 3.0</div></div></div>"},"82397":{"type":"graphic_figure","displayName":"Thyroid nerves normal","title":"Nerve supply of the thyroid gland","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Nerve supply of the thyroid gland</div><div class=\"cntnt\"><img style=\"width:542px; height:527px;\" src=\"images/SURG/82397_Thyroid_nerves_normal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">It is critical that the superior and recurrent laryngeal nerves be routinely identified and protected in thyroid surgery to reduce the risk of injury.</div><div id=\"graphicVersion\">Graphic 82397 Version 3.0</div></div></div>"},"82398":{"type":"graphic_picture","displayName":"Antrum and pylorus","title":"Antrum and pylorus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Antrum and pylorus</div><div class=\"cntnt\"><img style=\"width:413px; height:181px;\" src=\"images/GAST/82398_Antrum_pylorus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic views of the antrum (left) and pylorus (right).</div><div id=\"graphicVersion\">Graphic 82398 Version 2.0</div></div></div>"},"82401":{"type":"graphic_table","displayName":"Strategies to improve adherence","title":"Strategies to improve adherence to antiretroviral therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies to improve adherence to antiretroviral therapy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>Establish readiness to start therapy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Provide education on medication dosing</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Review potential side effects</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anticipate and treat side effects</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Utilize educational aids including pictures, pillboxes,\nand calendars</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Engage family, friends</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Simplify regimens, dosing, and food requirements</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Utilize team approach with nurses, pharmacists, and\npeer counselors</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Provide accessible, trusting health care team</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=33246&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Strategies_to_improve_adher.htm</title></head></div><div class=\"graphic_reference\">http://aidsinfo.nih.gov/.</div><div id=\"graphicVersion\">Graphic 82401 Version 1.0</div></div></div>"},"82404":{"type":"graphic_table","displayName":"Diet CKD dyslipidemia child","title":"Dietary treatment recommendations for children with dyslipidemia and CKD stage 5 and kidney transplant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary treatment recommendations for children with dyslipidemia and CKD stage 5 and kidney transplant</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Macronutrient</td> <td class=\"subtitle1\">Serum LDL-C &#62;100 mg/dL</td> <td class=\"subtitle1\">Serum TG &#62;150 mg/dL</td> </tr> <tr> <td>Energy</td> <td>&nbsp;</td> <td>If associated with excess weight, energy balance + activity recommendations for weight loss</td> </tr> <tr> <td>Dietary fat</td> <td>&#60;30 percent of calories</td> <td>Low</td> </tr> <tr> <td>Dietary cholesterol</td> <td>&#60;200 mg/d</td> <td>&nbsp;</td> </tr> <tr> <td><em>Trans</em> fatty acids</td> <td>Avoid</td> <td>&nbsp;</td> </tr> <tr> <td>Saturated fatty acids</td> <td>&#60;7 percent of calories</td> <td>&nbsp;</td> </tr> <tr> <td>Carbohydrate</td> <td>&nbsp;</td> <td>Low simple carbohydrate</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides.</div><div class=\"graphic_reference\">Reproduced with permission from: National Kidney Foundation. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis 2009; 53:S11. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 82404 Version 3.0</div></div></div>"},"82405":{"type":"graphic_picture","displayName":"Bronchoscopic retrieval","title":"Bronchoscopic retrieval","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopic retrieval</div><div class=\"cntnt\"><img style=\"width:432px; height:247px;\" src=\"images/PULM/82405_Bronchoscopic_retrieval.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retrieval basket dedicated for endobronchial use greatly facilitates extraction of foreign bodies.</div><div id=\"graphicVersion\">Graphic 82405 Version 3.0</div></div></div>"},"82406":{"type":"graphic_table","displayName":"Rx options cardiogenic shock","title":"Treatment options for cardiogenic shock due to left ventricular dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment options for cardiogenic shock due to left ventricular dysfunction</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   General measures\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ventilation support to correct hypoxemia and, in part, acidosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Optimize intravascular volume</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sodium bicarbonate only for severe metabolic acidosis (arterial pH less than 7.10 to 7.15)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Aspirin</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Intravenous heparin</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Possible glycoprotein IIb/IIIa inhibitor with NSTEMI</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Insertion of pulmonary artery catheter</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Specific measures\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Pharmacologic support\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Sympathomimetic inotropes (eg, dopamine)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Norepinephrine (for refractory hypotension)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n  \r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Mechanical support\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   IABP, usually combined with percutaneous coronary intervention or coronary artery bypass graft surgery or possible thrombolytic therapy\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2_start\">\r\n  \r\n   Newer devices\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Left ventricular or biventricular assist devices\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Percutaneous cardiopulmonary bypass\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Reperfusion/revascularization\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Primary percutaneous coronary intervention\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Coronary artery bypass graft\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Thrombolytic therapy for patients not receiving PCI in a timely manner\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 82406 Version 1.0</div></div></div>"},"82411":{"type":"graphic_table","displayName":"Indications for VFA","title":"ISCD indications for VFA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ISCD indications for&nbsp;VFA</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Lateral spine imaging with standard radiography or densitometric VFA is indicated when T-score is &#60;&ndash;1.0 and one or more of the following is present:</td> </tr> <tr> <td class=\"indent1\">Women age &#8805;70 years or men age &#8805;80 years</td> </tr> <tr> <td class=\"indent1\">Historical height loss &#62;4 cm (&#62;1.5 inches)</td> </tr> <tr> <td class=\"indent1\">Self-reported but undocumented prior vertebral fracture</td> </tr> <tr> <td class=\"indent1\">Glucocorticoid therapy equivalent to &#8805;5 mg of prednisone or equivalent per day for &#8805;3 months</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ISCD: International Society for Clinical Densitometry; VFA: vertebral fracture assessment.</div><div class=\"graphic_reference\">Rosen, HN, Vokes TJ, Malabanan AO, et al. The Official Positions of the International Society for Clinical Densitometry: Vertebral fracture assessment. J Clin Densitom 2013; 16:482. doi: 10.1016/j.jocd.2013.08.003.</div><div id=\"graphicVersion\">Graphic 82411 Version 6.0</div></div></div>"},"82412":{"type":"graphic_figure","displayName":"OCT plaque characterization","title":"Intracoronary OCT plaque characterization","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Intracoronary OCT plaque characterization</div><div class=\"cntnt\"><img style=\"width:584px; height:586px;\" src=\"images/CARD/82412_OCT_plaque_characterization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Concentric fibrous plaque. Fibrous tissue appears signal rich, bright yellow. The signal-poor, dark media is not discernible anymore. The adventitial border as well as periadvential tissue can be seen.<BR>(B) Eccentric fibrous plaque in 9 to 12 o'clock position with focal calcification appearing as a signal poor, dark structure with sharply delineated borders (dotted line).<BR>(C) Eccentric fibrofatty plaque in 12 to 6 o'clock position showing typical gradual diminishing of the OCT signal towards the adventitia.<BR>(D) Eccentric lipid-rich plaque in 7 to 12 o'clock position. Typically a fibrous cap can be recognized as signal rich, yellow structure towards the lumen with a rapid drop in signal intensity towards the abluminal plaque side (arrows), caused by the high attenuation of lipid-rich tissue.</div><div class=\"graphic_footnotes\">IC: OCT imaging catheter in the center of the lumen; OCT: St. Jude/Lightlab Imaging C7XR.<br> * Angioplasty guide wire artefact.</div><div class=\"graphic_reference\">Courtesy of Dr. Evelyn Regar, Thoraxcenter.</div><div id=\"graphicVersion\">Graphic 82412 Version 4.0</div></div></div>"},"82413":{"type":"graphic_waveform","displayName":"Acute lateral MI tutorial","title":"Acute lateral transmural myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Acute lateral transmural myocardial infarction</div><div class=\"cntnt\"><img style=\"width:519px; height:230px;\" src=\"images/CARD/82413_Acute_lateral_MI_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ST elevation in leads I and aVL is characteristic of an acute lateral wall infarct. Reciprocal ST depression is evident in this case in the inferior leads (II, III, and aVF) and in V1.</div><div id=\"graphicVersion\">Graphic 82413 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"82415":{"type":"graphic_algorithm","displayName":"Optimal PD regimen and PET","title":"Optimal PD regimen and peritoneal equilibration test","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Optimal PD regimen and peritoneal equilibration test</div><div class=\"cntnt\"><img style=\"width:580px; height:234px;\" src=\"images/NEPH/82415_Optimal_PD_regimen_and_PET.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm showing how the results of the peritoneal equilibration test may help guide the choice of an optimal peritoneal dialysis regimen.</div><div class=\"graphic_footnotes\">NIPD: nightly intermittent peritoneal dialysis; DAPD: daytime ambulatory peritoneal dialysis; CIPD: chronic intermittent peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; CCPD: continuous cycler peritoneal dialysis; TPD: tidal peritoneal dialysis; BSA: body surface area; PD: peritoneal dialysis.</div><div id=\"graphicVersion\">Graphic 82415 Version 3.0</div></div></div>"},"82416":{"type":"graphic_table","displayName":"Retinal diseases that cause photopsias","title":"Retinal pathologies associated with elementary visual hallucinations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Retinal pathologies associated with elementary visual hallucinations</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Posterior vitreous detachment with retinal traction or retinal tear</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Retinal detachment</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cone dystrophies</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cancer-associated retinopathy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Melanoma-associated retinopathy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Autoimmune-associated retinopathy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Acute zonal occult outer retinopathies</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Other pathology causing mechanical changes in retina</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 82416 Version 2.0</div></div></div>"},"82417":{"type":"graphic_table","displayName":"Framingham risk score women","title":"Framingham risk score for women*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Framingham risk score for women*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Age</td> <td class=\"subtitle1\" colspan=\"3\">Diabetes</td> </tr> <tr> <td class=\"subtitle2\">Years</td> <td class=\"subtitle2\" colspan=\"2\">Points</td> <td class=\"subtitle2 subtitle2\">&nbsp;</td> <td class=\"subtitle2\" colspan=\"2\">Points </td> </tr> <tr> <td>30&nbsp;to 34</td> <td colspan=\"2\">-9</td> <td>No</td> <td colspan=\"2\">0</td> </tr> <tr> <td>35&nbsp;to 39</td> <td colspan=\"2\">-4</td> <td>Yes</td> <td colspan=\"2\">4</td> </tr> <tr> <td>40&nbsp;to 44</td> <td colspan=\"2\">0</td> <td class=\"subtitle1\" colspan=\"3\">Smoker</td> </tr> <tr> <td>45&nbsp;to 49</td> <td colspan=\"2\">3</td> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\" colspan=\"2\">Points </td> </tr> <tr> <td>50&nbsp;to 54</td> <td colspan=\"2\">6</td> <td>No</td> <td colspan=\"2\">0</td> </tr> <tr> <td>55&nbsp;to 59</td> <td colspan=\"2\">7</td> <td>Yes</td> <td colspan=\"2\">2</td> </tr> <tr> <td>60&nbsp;to 64</td> <td colspan=\"2\">8</td> <td rowspan=\"3\" colspan=\"3\">&nbsp;</td> </tr> <tr> <td>65&nbsp;to 69</td> <td colspan=\"2\">8</td> </tr> <tr> <td>70&nbsp;to 74</td> <td colspan=\"2\">8</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">LDL cholesterol</td> <td class=\"subtitle1\" colspan=\"3\">HDL cholesterol</td> </tr> <tr> <td class=\"subtitle2\">mg/dL</td> <td class=\"subtitle2\">mmol/L</td> <td class=\"subtitle2\">Points</td> <td class=\"subtitle2\">mg/dL</td> <td class=\"subtitle2\">mmol/L</td> <td class=\"subtitle2\">Points</td> </tr> <tr> <td>&#60;100</td> <td>&#60;2.59</td> <td>-2</td> <td>&#60;35</td> <td>&#60;0.90</td> <td><span style=\"font-weight: bold;\">5</span></td> </tr> <tr> <td>100&nbsp;to 129</td> <td>2.60&nbsp;to 3.36</td> <td>0</td> <td>35&nbsp;to 44</td> <td>0.91&nbsp;to 1.16</td> <td>2</td> </tr> <tr> <td>130&nbsp;to 159</td> <td>3.37&nbsp;to 4.14</td> <td>0</td> <td>45&nbsp;to 49</td> <td>1.17&nbsp;to 1.29</td> <td>1</td> </tr> <tr> <td>160&nbsp;to 190</td> <td>4.50&nbsp;to 4.92</td> <td>2</td> <td>50&nbsp;to 54</td> <td>1.30&nbsp;to 1.55</td> <td>0</td> </tr> <tr> <td>&#62;190</td> <td>&#62;4.92</td> <td>2</td> <td>&#62;60</td> <td>&#62;1.56</td> <td>-2</td> </tr> <tr> <td class=\"subtitle1\">Systolic blood pressure, mmHg</td> <td class=\"subtitle1\">Diastolic &#60;80 mmHg</td> <td class=\"subtitle1\">Diastolic 80 to 84</td> <td class=\"subtitle1\">Diastolic 85 to 89</td> <td class=\"subtitle1\">Diastolic 90 to 99</td> <td class=\"subtitle1\">Diastolic &#8805;100</td> </tr> <tr> <td>&#60;120</td> <td>-3</td> <td>0</td> <td>0</td> <td>2</td> <td>3</td> </tr> <tr> <td>120&nbsp;to 129</td> <td>0</td> <td>0</td> <td>0</td> <td>2</td> <td>3</td> </tr> <tr> <td>130&nbsp;to 139</td> <td>0</td> <td>0</td> <td>0</td> <td>2</td> <td>3</td> </tr> <tr> <td>140&nbsp;to 159</td> <td>2</td> <td>2</td> <td>2</td> <td>2</td> <td>3</td> </tr> <tr> <td>&#8805;160</td> <td>3</td> <td>3</td> <td>3</td> <td>3</td> <td>3</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"6\">CHD risk</td> </tr> <tr> <td class=\"subtitle2\">Total points</td> <td class=\"subtitle2\" colspan=\"2\">10-year CHD risk, percent </td> <td class=\"subtitle2\">Total points</td> <td class=\"subtitle2\" colspan=\"2\">10-year CHD risk, percent</td> </tr> <tr> <td>&#60;-2</td> <td colspan=\"2\">1</td> <td>8</td> <td colspan=\"2\">8</td> </tr> <tr> <td>-1</td> <td colspan=\"2\">2</td> <td>9</td> <td colspan=\"2\">9</td> </tr> <tr> <td>0</td> <td colspan=\"2\">2</td> <td>10</td> <td colspan=\"2\">11</td> </tr> <tr> <td>1</td> <td colspan=\"2\">2</td> <td>11</td> <td colspan=\"2\">13</td> </tr> <tr> <td>2</td> <td colspan=\"2\">3</td> <td>12</td> <td colspan=\"2\">15</td> </tr> <tr> <td>3</td> <td colspan=\"2\">3</td> <td>13</td> <td colspan=\"2\">17</td> </tr> <tr> <td>4</td> <td colspan=\"2\">4</td> <td>14</td> <td colspan=\"2\">20</td> </tr> <tr> <td>5</td> <td colspan=\"2\">5</td> <td>15</td> <td colspan=\"2\">24</td> </tr> <tr> <td>6</td> <td colspan=\"2\">6</td> <td>16</td> <td colspan=\"2\">27</td> </tr> <tr> <td>7</td> <td colspan=\"2\">7</td> <td>17</td> <td colspan=\"2\">32</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LDL: low-density lipoprotein; HDL: high-density lipoprotein; CHD: coronary heart disease; MI: myocardial infarction.<br />* Framingham risk scoring system for women. Use to calculate the risk of developing clinical CHD in women who do not have known CHD. Clinical CHD includes angina pectoris, recognized or unrecognized MI, coronary insufficiency (prolonged chest discomfort associated with transient repolarization abnormalities without criteria for MI), or CHD death.<br />To calculate the Framingham risk estimate, add points for age, presence of diabetes, smoking status, LDL cholesterol, HDL cholesterol, and blood pressure. Find the total point score on the bottom table to determine the 10-year risk of CHD.</div><div class=\"graphic_reference\">Adapted with permission from Wilson PW, D'Agostino R, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837. Copyright © 1998 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82417 Version 3.0</div></div></div>"},"82418":{"type":"graphic_diagnosticimage","displayName":"Interlobar fissures on HRCT","title":"Interlobar fissures on HRCT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interlobar fissures on HRCT</div><div class=\"cntnt\"><img style=\"width:379px; height:292px;\" src=\"images/PULM/82418_Interlobar_fissures_on_HRCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The curvilinear interlobar fissures have a thickness of 0.15 mm. The right minor fissure has a boomerang configuration (arrow); inside the boomerang, the middle lobe is visible, surrounded by the right upper lobe. The right major fissure appears as an oblique straight line, delineating the superior segment of the right lower lobe posteriorly.</div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82418 Version 3.0</div></div></div>"},"82419":{"type":"graphic_picture","displayName":"Central line J wire","title":"Guidewire with J tip for central venous catheter placement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Guidewire with J tip for central venous catheter placement</div><div class=\"cntnt\"><img style=\"width:432px; height:224px;\" src=\"images/EM/82419_Central_line_J_wire.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proper orientation of the J tip towards the superior vena cava helps prevent improper placement of central venous catheters. For subclavian catheters, the J tip is oriented caudally; for internal jugular catheters, the J tip is oriented medially.</div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 82419 Version 2.0</div></div></div>"},"82420":{"type":"graphic_picture","displayName":"PDR traction retinal detachment 1","title":"Severe traction retinal detachment in proliferative diabetic retinopathy: Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe traction retinal detachment in proliferative diabetic retinopathy: Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:396px; height:298px;\" src=\"images/ENDO/82420_PDR_traction_retin_detach-1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color fundus photograph of severe proliferative diabetic retinopathy with extensive traction retinal detachment of the macula due to fibrovascular proliferation along the arcades and across the macula with associated hemorrhage.</div><div id=\"graphicVersion\">Graphic 82420 Version 3.0</div></div></div>"},"82421":{"type":"graphic_figure","displayName":"Dx Barretts SCJ GEJ coincide","title":"Anatomic landmarks of the gastroesophageal junction","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Anatomic landmarks of the gastroesophageal junction</div><div class=\"cntnt\"><img style=\"width:516px; height:433px;\" src=\"images/GAST/82421_GEJ_Z_coincide.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration&nbsp;depicting the appearance when the squamocolumnar and gastroesophageal junctions coincide. In this situation, there is no apparent columnar-lined esophagus (ie, the entire esophagus is lined by squamous epithelium).</div><div class=\"graphic_footnotes\">GEJ: gastroesophageal junction.</div><div class=\"graphic_reference\">Modified from: Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology 1999; 117:218.</div><div id=\"graphicVersion\">Graphic 82421 Version 4.0</div></div></div>"},"82423":{"type":"graphic_table","displayName":"Hypertension awareness and treatment","title":"Trends in the awareness, treatment, and control of high blood pressure in adults in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Trends in the awareness, treatment, and control of high blood pressure in adults in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">NHANES II 1976 to 1980</td> <td class=\"subtitle1\">NHANES III 1988 to 1991</td> <td class=\"subtitle1\">NHANES III 1991 to 1994</td> <td class=\"subtitle1\">NHANES 1999 to 2000</td> <td class=\"subtitle1\">NHANES 2007 to 2008</td> </tr> <tr> <td>Awareness</td> <td>51</td> <td>73</td> <td>68</td> <td>70</td> <td>81</td> </tr> <tr> <td>Treatment</td> <td>31</td> <td>55</td> <td>54</td> <td>59</td> <td>72</td> </tr> <tr> <td>Control*</td> <td>10</td> <td>29</td> <td>27</td> <td>34</td> <td>50</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The data are for adults who are 18 to 74 years of age with a systolic pressure ≥140 mmHg and/or a diastolic pressure ≥90 mmHg.</div><div class=\"graphic_footnotes\">NHANES: National Health and Nutrition Examination Survey.<br />* Control is defined as a systolic pressure below 140 mmHg and a diastolic pressure below 90 mmHg.</div><div class=\"graphic_reference\">Adapted from: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, JAMA 2003; 289:2560, and from US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension 1988-2008, JAMA 2010; 303:2043.</div><div id=\"graphicVersion\">Graphic 82423 Version 7.0</div></div></div>"},"82429":{"type":"graphic_diagnosticimage","displayName":"Cardiac findings in hypereosinophilic syndrome","title":"Cardiac findings in hypereosinophilic syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardiac findings in hypereosinophilic syndrome</div><div class=\"cntnt\"><img style=\"width:324px; height:298px;\" src=\"images/ALLRG/82429_HES_cardiac_findings_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrow shows subendothelial fibrosis, appearing in white on magnetic resonance imaging (MRI).</div><div class=\"graphic_reference\">Kindly provided by Dr. Olivier Cappeliez, Department of Radiology, Erasme Hospital, Brussels, Belgium.</div><div id=\"graphicVersion\">Graphic 82429 Version 4.0</div></div></div>"},"82431":{"type":"graphic_table","displayName":"ACOG CPP Rx BC recs","title":"ACOG chronic pelvic pain level B and C recommendations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACOG chronic pelvic pain level B and C recommendations</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"2\" class=\"subtitle1\">Recommendations based on limited or inconsistent scientific evidence (level B)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2\">Intervention</td>\n\n      <td class=\"subtitle2\">Indication</td>\n\n    </tr>\n\n    <tr>\n\n      <td>GnRH agonists</td>\n\n      <td>CPP other than endometriosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Adhesiolysis</td>\n\n      <td>CPP attributed to dense bowel adhesions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hysterectomy</td>\n\n      <td>Reproductive tract symptoms</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sacral nerve stimulation</td>\n\n      <td>CPP</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Physical therapy</td>\n\n      <td>CPP</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nutritional supplementation with vitamin B1 or magnesium</td>\n\n      <td>Dysmenorrhea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Injection of trigger points</td>\n\n      <td colspan=\"1\" rowspan=\"2\">CPP</td>\n\n    </tr>\n\n    <tr>\n      <td>Application of magnets to trigger points</td>\n      \n    </tr>\n    <tr>\n\n      <td>Acupuncture, acupressor, transcutaneous nerve stimulation</td>\n\n      <td>Primary dysmenorrhea</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Recommendations based on consensus and expert opinion (level C)</td>\n\n\n    </tr>\n\n    <tr><td class=\"subtitle2\">Intervention</td><td class=\"subtitle2\">Indication</td></tr><tr>\n\n      <td>Antidepressants</td>\n\n      <td>CPP</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Opioids</td>\n\n      <td>CPP</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=21599&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>ACOG_CPP_Rx_BC_recs.htm</title></head></div><div class=\"graphic_reference\">Adapted and modified from Clinical Management Guidelines for Obstetrician-Gynecologists. Number 51, March 2004: Chronic Pelvic Pain. Obstet Gynecol 2004; 103:589.</div><div id=\"graphicVersion\">Graphic 82431 Version 5.0</div></div></div>"},"82432":{"type":"graphic_figure","displayName":"AHT drug and outcome ALLHAT","title":"Choice of antihypertensive monotherapy does not predict outcome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choice of antihypertensive monotherapy does not predict outcome</div><div class=\"cntnt\"><img style=\"width:422px; height:278px;\" src=\"images/NEPH/82432_AHT_drug_and_outcome_ALLHAT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the ALLHAT trial, cumulative event rates for the primary outcome (fatal coronary heart disease or nonfatal myocardial infarction) according to primary treatment with chlorthalidone, amlodipine, or lisinopril. Compared to chlorthalidone, there was no significant difference with amlodipine (relative risk 0.98) or lisinopril (relative risk 0.99 percent) at a mean of 4.9 years.</div><div class=\"graphic_reference\">Data from: The ALLHAT Officers, JAMA 2002; 288:2981.</div><div id=\"graphicVersion\">Graphic 82432 Version 3.0</div></div></div>"},"82433":{"type":"graphic_picture","displayName":"LCDD in bone marrow","title":"Bone marrow in light chain deposition disease","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Bone marrow in light chain deposition disease</div><div class=\"cntnt\"><img style=\"width:529px; height:251px;\" src=\"images/NEPH/82433_LCDD_in_bone_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunoperoxidase stain of a bone marrow biopsy from a patient with light chain deposition diesease shows the presence of cells with monoclonal kappa light chains (left panel) but not lambda light chains (right panel).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 82433 Version 1.0</div></div></div>"},"82436":{"type":"graphic_figure","displayName":"Kienbock disease stages","title":"Schematic representation of the stages of Kienbock disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic representation of the stages of Kienbock disease</div><div class=\"cntnt\"><img style=\"width:400px; height:524px;\" src=\"images/PEDS/82436_Kienbocks_disease_stages.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kienbock's disease is a progressive collapse of the lunate. There are four radiographic stages: 1) Normal radiograph. 2) Increased density, but the shape of the lunate remains intact. 3) Collapse of the lunate with proximal displacement of the capitate, rotation of the scaphoid, and negative ulnar variance. 4) Severe collapse, sclerosis, and osteophyte formation in the remaining wrist.</div><div id=\"graphicVersion\">Graphic 82436 Version 3.0</div></div></div>"},"82437":{"type":"graphic_picture","displayName":"Lateral luxation","title":"Lateral luxation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral luxation</div><div class=\"cntnt\"><img style=\"width:432px; height:318px;\" src=\"images/PEDS/82437_Lateral_Luxation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tooth is displaced laterally. The periodontal ligament is lacerated and fracture of the supporting bone occurs.</div><div class=\"graphic_reference\">Reproduced with permission from: McTigue, DJ. Managing traumatic injuries in the young permanent dentition. In: Pediatric Dentistry: Infancy through adolescence, 4th ed, WB Saunders, Philadelphia 2005. Copyright &#169; 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 82437 Version 1.0</div></div></div>"},"82438":{"type":"graphic_table","displayName":"St Johns wort quality criteria","title":"Examples of St John's Wort brands meeting specified quality criteria*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of St John's Wort brands meeting specified quality criteria*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Name of product (manufacturer) </td> </tr> <tr> <td>CVS Pharmacy St. John's Wort (CVS Pharmacy, Inc.)</td> </tr> <tr> <td>Kira&#174; St. John's Wort Lichtwer Pharma Exclusive LI 160&#174; Formula (ABKit Inc.)</td> </tr> <tr> <td>Nature's Way Perika St. John's Wort (Nature's Way Products, Inc.)</td> </tr> <tr> <td>Rite Aid St. John's Wort (Rite Aid Corporation)</td> </tr> <tr> <td>Vitamin Shoppe St. John's Wort Extract (The Vitamin Shoppe)</td> </tr> <tr> <td class=\"subtitle2_single\"> <p>Examples of products passing testing. Full report available at www.consumerlabs.com.</p> <p>* To pass testing, St. John's wort products had to meet all of the following criteria:</p> </td> </tr> <tr> <td class=\"indent1\">1. Meet its label claims for total hypericin and totalhyperforin (if claimed), with a minimum of 0.3 percent total hypericinsfor extracts and 0.1 percent total hypericins for dried raw herb. </td> </tr> <tr> <td class=\"indent1\">2. United States Pharmacopeia parameters for disintegration of vitamin supplements. </td> </tr> <tr> <td class=\"indent1\">3. Contain &#8804;2.0 mcg of lead in a daily recommended serving. </td> </tr> <tr> <td class=\"indent1\">4. Contain &#60;0.3 parts per million (micrograms per gram) of cadmium for dried raw herb or &#60;0.1 parts per million for extracts. </td> </tr> <tr> <td class=\"indent1\">5. Products must meet all FDA labeling requirements. </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82438 Version 2.0</div></div></div>"},"82439":{"type":"graphic_table","displayName":"Filamentous fungi MICs","title":"In vitro susceptibility of filamentous fungi to systemically active antifungal agents determined by CLSI M38-A2 broth microdilution methods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">In vitro susceptibility of filamentous fungi to systemically active antifungal agents determined by CLSI M38-A2 broth microdilution methods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"24%\"></colgroup><colgroup span=\"2\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Organism</td> <td class=\"subtitle1\" rowspan=\"2\">Antifungal agent</td> <td class=\"subtitle1\" rowspan=\"2\">Number tested</td> <td class=\"subtitle1\" colspan=\"2\">MIC (mcg/mL)</td> </tr> <tr> <td class=\"subtitle2\">50 percent*</td> <td class=\"subtitle2\">90 percent*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><em>Aspergillus fumigatus</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>1119</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Itraconazole</td> <td>1119</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Isavuconazole</td> <td>855</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Posaconazole</td> <td>1119</td> <td>0.12</td> <td>0.5</td> </tr> <tr> <td>Voriconazole</td> <td>1119</td> <td>0.25</td> <td>0.5</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>256</td> <td>0.03</td> <td>0.06</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><em>A. flavus</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>89</td> <td>1</td> <td>2</td> </tr> <tr> <td>Itraconazole</td> <td>89</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Isavuconazole</td> <td>444</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Posaconazole</td> <td>89</td> <td>0.25</td> <td>0.5</td> </tr> <tr> <td>Voriconazole</td> <td>89</td> <td>0.5</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>30</td> <td>0.03</td> <td>0.06</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><em>A. niger</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>101</td> <td>0.12</td> <td>1</td> </tr> <tr> <td>Itraconazole</td> <td>101</td> <td>1</td> <td>2</td> </tr> <tr> <td>Isavuconazole</td> <td>207</td> <td>1</td> <td>2</td> </tr> <tr> <td>Posaconazole</td> <td>101</td> <td>0.25</td> <td>0.5</td> </tr> <tr> <td>Voriconazole</td> <td>101</td> <td>0.5</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>29</td> <td>0.03</td> <td>0.06</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><em>A. versicolor</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>20</td> <td>1</td> <td>2</td> </tr> <tr> <td>Itraconazole</td> <td>20</td> <td>1</td> <td>2</td> </tr> <tr> <td>Isavuconazole</td> <td>75</td> <td>0.25</td> <td>0.5</td> </tr> <tr> <td>Posaconazole</td> <td>20</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Voriconazole</td> <td>20</td> <td>0.5</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>20</td> <td>0.03</td> <td>0.12</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><em>A. terreus</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>22</td> <td>2</td> <td>2</td> </tr> <tr> <td>Itraconazole</td> <td>22</td> <td>0.5</td> <td>0.5</td> </tr> <tr> <td>Isavuconazole&nbsp;</td> <td>384</td> <td>0.5</td> <td>0.5</td> </tr> <tr> <td>Posaconazole</td> <td>22</td> <td>0.25</td> <td>0.25</td> </tr> <tr> <td>Voriconazole</td> <td>22</td> <td>0.25</td> <td>0.5</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>16</td> <td>0.03</td> <td>0.06</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><em>Fusarium</em> spp</td> <td>Amphotericin B<sup>&#182;</sup></td> <td>67</td> <td>8</td> <td>32</td> </tr> <tr> <td>Itraconazole</td> <td>67</td> <td>16</td> <td>32</td> </tr> <tr> <td>Isavuconazole</td> <td>20</td> <td>16</td> <td>&#62;16&nbsp;</td> </tr> <tr> <td>Posaconazole</td> <td>67</td> <td>16</td> <td>32</td> </tr> <tr> <td>Voriconazole</td> <td>67</td> <td>16</td> <td>32</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>13</td> <td>&#62;8</td> <td>&#62;8</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><em>Scedosporium apiospermum</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>26</td> <td>2</td> <td>8</td> </tr> <tr> <td>Itraconazole</td> <td>26</td> <td>1</td> <td>32</td> </tr> <tr> <td>Isavuconazole&nbsp;</td> <td>16</td> <td>4</td> <td>4</td> </tr> <tr> <td>Posaconazole</td> <td>26</td> <td>0.25</td> <td>1</td> </tr> <tr> <td>Voriconazole</td> <td>13</td> <td>0.12</td> <td>0.25</td> </tr> <tr class=\"divider_bottom\"> <td>Micafungin</td> <td>36</td> <td>&#62;16</td> <td>&#62;16</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><em>S. prolificans</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>80</td> <td>16</td> <td>32</td> </tr> <tr> <td>Itraconazole</td> <td>80</td> <td>64</td> <td>64</td> </tr> <tr> <td>Isavuconazole</td> <td>6</td> <td>16</td> <td>-</td> </tr> <tr> <td>Posaconazole</td> <td>80</td> <td>16</td> <td>32</td> </tr> <tr> <td>Voriconazole</td> <td>55</td> <td>4</td> <td>4</td> </tr> <tr class=\"divider_bottom\"> <td>Micafungin</td> <td>17</td> <td>&#62;32</td> <td>&#62;32</td> </tr> <tr> <td rowspan=\"5\">Mucorales</td> <td>Amphotericin B<sup>&#182;</sup></td> <td>86</td> <td>0.25</td> <td>2</td> </tr> <tr> <td>Itraconazole</td> <td>86</td> <td>1</td> <td>32</td> </tr> <tr> <td>Isavuconazole&nbsp;</td> <td>45</td> <td>2</td> <td>16</td> </tr> <tr> <td>Posaconazole</td> <td>86</td> <td>0.5</td> <td>4</td> </tr> <tr> <td>Voriconazole</td> <td>86</td> <td>16</td> <td>128</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CLSI: Clinical and Laboratory Standards Institute; MIC: minimum inhibitory concentration.<br />* 50 percent and 90 percent; MIC encompassing 50 percent and 90 percent of isolates tested, respectively.<br />&#182; Amphotericin B MICs determined by Etest.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50:2009. </LI>&#xD;&#xA;<LI>Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41:3623. </LI>&#xD;&#xA;<LI>Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008; 46:2568. </LI>&#xD;&#xA;<LI>Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21:157. </LI>&#xD;&#xA;<LI>Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob Agents Chemother 2013; 57:3823.</LI>&#xD;&#xA;<LI>Guinea J, Pelaez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52: 1396.</LI></OL></div><div id=\"graphicVersion\">Graphic 82439 Version 8.0</div></div></div>"},"82440":{"type":"graphic_table","displayName":"Major causes of hypoaldosteronism","title":"Major causes of hypoaldosteronism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of hypoaldosteronism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Reduced aldosterone production</td> </tr> <tr> <td class=\"sublist2_start\">Hyporeninemic hypoaldosteronism</td> </tr> <tr> <td class=\"sublist2\">Renal disease, most often diabetic nephropathy</td> </tr> <tr> <td class=\"sublist2\">Nonsteroidal antiinflammatory drugs</td> </tr> <tr> <td class=\"sublist2\">Calcineurin inhibitors</td> </tr> <tr> <td class=\"sublist2\">Volume expansion, as in acute glomerulonephritis</td> </tr> <tr> <td class=\"indent1\">Angiotensin inhibitors, such as ACE inhibitors, angiotensin II receptor blockers, and direct renin inhibitors</td> </tr> <tr> <td class=\"indent1\">Chronic heparin therapy (impairs aldosterone synthesis)</td> </tr> <tr> <td class=\"indent1\">Primary adrenal insufficiency</td> </tr> <tr> <td class=\"indent1\">Severe illness</td> </tr> <tr> <td class=\"sublist2_start\">Inherited disorders</td> </tr> <tr> <td class=\"sublist2\">Congenital hypoaldosteronism (21-hydroxylase deficiency and isolated hypoaldosteronism)</td> </tr> <tr> <td class=\"sublist2\">Pseudohypoaldosteronism type 2 (Gordon's syndrome)</td> </tr> <tr> <td class=\"subtitle1_single\">Aldosterone resistance</td> </tr> <tr> <td class=\"sublist2_start\">Inhibition of the epithelial sodium channel</td> </tr> <tr> <td class=\"sublist2\">Potassium-sparing diuretics, such as spironolactone, eplerenone, amiloride, and triamterene</td> </tr> <tr> <td class=\"sublist2\">Antibiotics, trimethoprim, and pentamidine</td> </tr> <tr> <td class=\"indent1\">Pseudohypoaldosteronism type 1</td> </tr> <tr> <td class=\"sublist2_start\">Voltage defects</td> </tr> <tr> <td class=\"sublist2\">Markedly reduced distal Na delivery</td> </tr> <tr> <td class=\"sublist2\">Acquired or congenital defects in Na reabsorption by the distal tubule principal cells (obstructive uropathy), SLE, and sickle cell disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; SLE: systemic lupus erythematosus.</div><div id=\"graphicVersion\">Graphic 82440 Version 16.0</div></div></div>"},"82442":{"type":"graphic_form","displayName":"Visual analog pain scale","title":"Visual analog pain scale","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Visual analog pain scale</div><div class=\"cntnt\"><img style=\"width:411px; height:228px;\" src=\"images/ONC/82442_Vis_analog_pain_scale_edt.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82442 Version 5.0</div></div></div>"},"82443":{"type":"graphic_figure","displayName":"SCFE Kleins line","title":"Klein's line","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Klein's line</div><div class=\"cntnt\"><img style=\"width:507px; height:296px;\" src=\"images/PEDS/82443_SCFE_Kleins_line.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the normal AP view, a line drawn along the superior femoral neck (Klein's line) intersects the lateral portion of the femoral head. In a patient with SCFE, the line passes outside of the epiphysis or just at its superior edge.</div><div id=\"graphicVersion\">Graphic 82443 Version 2.0</div></div></div>"},"82446":{"type":"graphic_diagnosticimage","displayName":"Hiatal hernia after gastric banding","title":"Hiatal hernia after gastric banding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hiatal hernia after gastric banding</div><div class=\"cntnt\"><img style=\"width:404px; height:401px;\" src=\"images/SURG/82446_Hiatal_hernia_gastr_banding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This esophagram shows a subtle hiatal hernia in a patient who has undergone gastric banding. The arrow points to the hiatal hernia.</div><div id=\"graphicVersion\">Graphic 82446 Version 7.0</div></div></div>"},"82447":{"type":"graphic_figure","displayName":"PEG rHuMGDF in myelosuppression","title":"Benefit of PEG-rHuMGDF in myelosuppressed mice","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Benefit of PEG-rHuMGDF in myelosuppressed mice</div><div class=\"cntnt\"><img style=\"width:570px; height:256px;\" src=\"images/HEME/82447_PEG_rHuMGDF_in_myelosuppres.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of PEG-rHuMGDF (red lines) or placebo (blue lines) on the platelet, white blood cell (WBC), and red blood cell (RBC) counts in mice treated with a combination of carboplatin and sublethal irradiation. Mice treated with PEG-rHuMGDF had accelerated recovery of all blood cell lineages and reduced mortality (15 versus 94 percent).</div><div class=\"graphic_reference\">Data from Hokom, MM, Lacey, D, Kinstler, OB, et al, Blood 1995; 86:4486.</div><div id=\"graphicVersion\">Graphic 82447 Version 1.0</div></div></div>"},"82448":{"type":"graphic_figure","displayName":"Mechanisms hereditary hypophosphatemic rickets","title":"Pathways of renal phosphate wasting in hereditary hypophosphatemic rickets and tumor-induced osteomalacia","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Pathways of renal phosphate wasting in hereditary hypophosphatemic rickets and tumor-induced osteomalacia</div><div class=\"cntnt\"><img style=\"width:539px; height:200px;\" src=\"images/PEDS/82448_Mech_hypophos_rickets.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Levels of FGF-23 are increased by inactivating mutations in PHEX (as in XLH) or DMP1 (as in ARHR), by activating mutations in FGF-23 (as in ADHR), or by tumor production of FGF-23 (as in TIO). Each of these disorders leads to excessive activity of FGF-23, which suppresses the Na/Pi cotransporter and causes renal phosphate wasting. In HHRH the renal phosphate wasting is caused by a mutation in the Na/Pi cotransporter itself.</div><div class=\"graphic_footnotes\">XLH: X-linked hypophosphatemic rickets.<br>ADHR: Autosomal dominant hypophosphatemic rickets.<br>ARHR: Autosomal recessive hypophosphatemic rickets.<br>TIO: Tumor-induced osteomalacia.<br>HHRH: Hereditary hypophosphatemic rickets with hypercalcuria.<br>PHEX: Phosphate regulating endopeptidase on the X chromosome.<br>DMP1: Dentin matrix protein 1.<br>FGF-23: fibroblast growth factor 23.</div><div id=\"graphicVersion\">Graphic 82448 Version 2.0</div></div></div>"},"82449":{"type":"graphic_figure","displayName":"Incidence rates of syncope","title":"Incidence rates of syncope according to age and sex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incidence rates of syncope according to age and sex</div><div class=\"cntnt\"><img style=\"width:429px; height:295px;\" src=\"images/CARD/82449_Incidence_rates_of_syncope.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The incidence rates of syncope per 1000 person-years of follow-up increased with age among both men and women. The increase in the incidence rate was steeper starting at the age of 70 years. Syncope rates were similar among men and women.</div><div class=\"graphic_reference\">Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002; 347:878.</div><div id=\"graphicVersion\">Graphic 82449 Version 2.0</div></div></div>"},"82452":{"type":"graphic_diagnosticimage","displayName":"Nondisplaced olecranon fracture","title":"Nondisplaced olecranon fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nondisplaced olecranon fracture</div><div class=\"cntnt\"><img style=\"width:277px; height:586px;\" src=\"images/EM/82452_Nondisplacedolecranonfrac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anteroposterior view of the elbow. (B) Lateral view of the elbow. A linear greenstick fracture line is evident on both views (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from:&nbsp;Erickson M,&nbsp;Garg S. Radial Neck and Olecranon Fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins.&nbsp;<A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82452 Version 9.0</div></div></div>"},"82453":{"type":"graphic_figure","displayName":"Mortality rates for esophageal perforation","title":"Imapct of delay in diagnosis on mortality rates for patients with an esophageal perforation","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Imapct of delay in diagnosis on mortality rates for patients with an esophageal perforation</div><div class=\"cntnt\"><img style=\"width:457px; height:398px;\" src=\"images/SURG/82453_Mort_rates_esoph_perfor.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure represents the effect of delay in diagnosis on mortality rates for patients with an esophageal perforation. The overall mortality rate of an early diagnosis made within 24 hours is lower compared with a delay in diagnosis greater than 24 hours (14 versus 27 percent). Patients treated with a primary closure within 24 hours had a lower mortality rate compared with those repaired after 24 hours (4 versus 14 percent).</div><div class=\"graphic_reference\">Data from: Brinster CJ, Singhal S, Lee L, et al. Evolving options in the management of esophageal perforation. Ann Thorac Surg 2004; 77:1475.</div><div id=\"graphicVersion\">Graphic 82453 Version 1.0</div></div></div>"},"82454":{"type":"graphic_figure","displayName":"Serum prolactin in pregnancy","title":"Serum prolactin concentrations increase during pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum prolactin concentrations increase during pregnancy</div><div class=\"cntnt\"><img style=\"width:371px; height:282px;\" src=\"images/ENDO/82454_Serum_prolactin_in_pregnanc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum prolactin concentrations as a function of time of gestation, showing the increase in prolactin as pregnancy progresses. The zone lines represent the range of values that can be seen.</div><div class=\"graphic_reference\">Data from Tyson JE, Ito P, Guyda H, et al. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972; 113:14.</div><div id=\"graphicVersion\">Graphic 82454 Version 2.0</div></div></div>"},"82456":{"type":"graphic_picture","displayName":"Barrx360 sizing balloon","title":"Barrx360 sizing balloon","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Barrx360 sizing balloon</div><div class=\"cntnt\"><img style=\"width:540px; height:350px;\" src=\"images/GAST/82456_HALO360_sizing_balloon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sizing catheter for radiofrequency ablation.</div><div class=\"graphic_reference\">Reproduced with permission from: BÂRRX Medical Inc. Copyright © 2011. All rights reserved.</div><div id=\"graphicVersion\">Graphic 82456 Version 4.0</div></div></div>"},"82457":{"type":"graphic_figure","displayName":"Simpson uterine sound","title":"Malleable callibrated Simpson uterine sound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malleable callibrated Simpson uterine sound</div><div class=\"cntnt\"><img style=\"width:434px; height:392px;\" src=\"images/OBGYN/82457_Simpsonuterinesound.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82457 Version 1.0</div></div></div>"},"82460":{"type":"graphic_table","displayName":"Grading HFSR","title":"Grading severity of hand-foot skin reaction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading severity of hand-foot skin reaction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Symptoms</td> </tr> <tr> <td>Grade 1</td> <td>Numbness, dysesthesia, paresthesia, tingling, painless swelling, erythema or discomfort in the hands and feet, not affecting the patient's activities of daily living</td> </tr> <tr> <td>Grade 2</td> <td>Painful erythema, swelling of the hands or feet, and/or discomfort affecting the patient's activities of daily living</td> </tr> <tr> <td>Grade 3</td> <td>Peeling, blistering, erosions, or severe pain of the hands and feet, or severe discomfort that causes the patient to be unable to work or perform activities of daily living</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multi-targeted kinase inhibitors sorafenib and sunitinib. The Oncologist 2008; 13:1001.</div><div id=\"graphicVersion\">Graphic 82460 Version 2.0</div></div></div>"},"82463":{"type":"graphic_picture","displayName":"Chronic GVHD tongue","title":"Oral chronic graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral chronic graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/82463_Chronic_GVHD_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple white plaques are present on the tongue.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>.&nbsp;Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82463 Version 3.0</div></div></div>"},"82464":{"type":"graphic_picture","displayName":"Tinea versicolor chest PI","title":"Tinea versicolor on the chest","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor on the chest</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PI/82464_Tinea_versicolor_chest_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tinea versicolor can appear as dark patches on the skin.</div><div class=\"graphic_reference\">Photo courtesy of Paul S Matz, MD. Reproduced from: Chung EK, Boom JA, Datto GA, Matz PS (Eds). Visual Diagnosis in Pediatrics. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006.</div><div id=\"graphicVersion\">Graphic 82464 Version 3.0</div></div></div>"},"82465":{"type":"graphic_picture","displayName":"Tongue reconstruct STSG","title":"Tongue after reconstruction with split-thickness skin graft (STSG)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tongue after reconstruction with split-thickness skin graft (STSG)</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/ONC/82465_Tongue_reconstruct_STSG.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Neil D Gross, MD.</div><div id=\"graphicVersion\">Graphic 82465 Version 2.0</div></div></div>"},"82466":{"type":"graphic_table","displayName":"Syndromes associated with OSA","title":"Syndromes that have obstructive sleep apnea as a finding and the factors that contribute to the obstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Syndromes that have obstructive sleep apnea as a finding and the factors that contribute to the obstruction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Micro- gnathia</td> <td class=\"subtitle1\">Maxillary Hypoplasia (Small Nasal Capsule)</td> <td class=\"subtitle1\">Choanal Atresia or Stenosis</td> <td class=\"subtitle1\">Cranial Base Anomalies</td> <td class=\"subtitle1\">Hypotonia of Pharynx</td> <td class=\"subtitle1\">Macro-glossia</td> <td class=\"subtitle1\">Other Anomalies</td> </tr> <tr> <td>Achondroplasia</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Apert</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Beckwith-Wiedemann</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>CNS anomalies</td> </tr> <tr> <td>Camptomelic and dysplasia</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Tracheal, bronchial cartilage anomalies;</td> </tr> <tr> <td>Cerebro- costo- mandibular</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Charge association</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>CNS anomalies</td> </tr> <tr> <td>Crouzon</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Tracheal ring anomalies</td> </tr> <tr> <td>De Lange</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>CNS anomalies</td> </tr> <tr> <td>Diastrophic dysplasia</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Femoral dysgenesis</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Fetal alcohol</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>CNS anomalies</td> </tr> <tr> <td>Fetal hydantoin</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>CNS anomalies</td> </tr> <tr> <td>Freeman-Sheldon</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Multiple contractures</td> </tr> <tr> <td>Fronto- metaphyseal dysplasia</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Cranial overgrowth; scoliosis</td> </tr> <tr> <td>Hallermann-Streiff</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hemifacial microsomia</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>Pharyngeal asymmetry</td> </tr> <tr> <td>Holo- prosencephaly sequence</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>CNS anomalies</td> </tr> <tr> <td>Larsen's</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Connective tissue dysplasia</td> </tr> <tr> <td>Marshall- Smith</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>CNS anomalies</td> </tr> <tr> <td>Nager</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Otopalato- digital</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Pfeiffer</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Tracheal ring anomalies</td> </tr> <tr> <td>Prader-Willi</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>CNS anomalies</td> </tr> <tr> <td>Pykno- dysostosis</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Robin sequence (isolated)</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Rubinstein-Taybi</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>CNS anomalies</td> </tr> <tr> <td>Shprintzen</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>Laryngeal web; retrognathia</td> </tr> <tr> <td>Shprintzen-Goldberg</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Spondylo- epiphyseal dysplasia</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Stickler</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Short genioglossus; soft tracheal cartilage</td> </tr> <tr> <td>Storage disorders (lysosomal, etc)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Steinert</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>Myotonia</td> </tr> <tr> <td>Townes</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Treacher Collins</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Turner</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Short neck</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"8\">Chromosome disorders</td> </tr> <tr> <td class=\"sublist1\"> <p>Down syndrome</p> <p>(Trisomy 21)</p> </td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">CNS anomalies</td> </tr> <tr> <td class=\"sublist1\">Trisomy 18</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">CNS anomalies</td> </tr> <tr> <td class=\"sublist1\">Trisomy 13</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">CNS anomalies; holoprosencephaly</td> </tr> <tr> <td class=\"sublist1\">Trisomy 4p</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">CNS anomalies; short neck</td> </tr> <tr> <td class=\"sublist1\">6q-deletion</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">CNS anomalies; laryngeal dysfunction</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Sher AE. Obstructive sleep apnea syndrome: a complex disorder of the upper airway. Otolaryngol Clin North Am 1990; 23:593. Copyright ©1990 Elsevier.</div><div id=\"graphicVersion\">Graphic 82466 Version 3.0</div></div></div>"},"82467":{"type":"graphic_table","displayName":"Diag considerations nocturia","title":"Summary of important diagnostic considerations in the evaluation of the patient with nocturia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of important diagnostic considerations in the evaluation of the patient with nocturia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Element </td> <td class=\"subtitle1\">Specific aspect </td> <td class=\"subtitle1\">Rationale </td> </tr> <tr> <td rowspan=\"6\">History </td> <td>Review of medical history</td> <td>Heart failure, diabetes mellitus, hypertension, obstructive sleep apnea, and peripheral edema particularly relevant; narrow angle glaucoma is a contraindication for bladder relaxant therapy</td> </tr> <tr> <td>Fluid intake</td> <td>Evaluation for excessive fluid intake (psychogenic polydypsia, health belief)</td> </tr> <tr> <td>Medications, especially for diuretics</td> <td>Late afternoon or evening diuretic use may cause nocturia</td> </tr> <tr> <td>Sleep and related conditions</td> <td>Information about nighttime pain, depression, or insomnia or difficulty with sleep maintenance is important</td> </tr> <tr> <td>Dizziness, low blood pressure or orthostasis, or history of accidental falls</td> <td>May be a contraindication for nonselective alpha-blocker therapy</td> </tr> <tr> <td>Dementia or mild cognitive impairment</td> <td>May be contraindication, use antcholinergic drugs with caution</td> </tr> <tr> <td rowspan=\"5\">Physical examination </td> <td>Supine and orthostatic blood pressure</td> <td>Particularly if alpha-blocker therapy (for men) is considered</td> </tr> <tr> <td>Cardiovascular and pulmonary examination</td> <td>Examination for fluid overload or heart failure</td> </tr> <tr> <td>Abdominal examination</td> <td>Evaluation for suprapubic distention and tenderness (insensitive, but highly specific if found)</td> </tr> <tr> <td>Rectal examination</td> <td>Evaluation for prostate size, rectal masses, or fecal impaction; analysis of resting and volitional contraction (useful for employing behavioral therapy, including urge suppression strategies)</td> </tr> <tr> <td>Neurologic examination</td> <td>Neurologic conditions (spinal cord injury or multiple sclerosis)</td> </tr> <tr> <td rowspan=\"2\">Laboratory studies </td> <td>Urinalysis</td> <td>Urinary tract pathology, hematuria</td> </tr> <tr> <td>Electrolyte panel</td> <td>Evaluation for abnormal renal function; check for glycemic control in patients with diabetes mellitus; examination for low serum sodium (especially for consideration of&nbsp;desmospressin therapy or monitoring)</td> </tr> <tr> <td>Frequency volume chart</td> <td>Nocturnal polyuria, functional bladder capacity, total 24-hour urine output</td> <td>More accurate description of patient nocturnal urinary patterns</td> </tr> <tr> <td rowspan=\"2\">Additional studies </td> <td>Noninvasive uroflowometry (in men)</td> <td>Low urine flow rate (4 to 15 mL/sec) more suggestive of BPH; very low flow rate (&#60;4 mL/sec) may indicate need for surgical treatment</td> </tr> <tr> <td>PVR by ultrasound</td> <td>PVR&nbsp;over 200 mL may be causative of nocturia or may prevent use of a bladder relaxant</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">PVR: post-void residual; BPH: benign prostatic hyperplasia.</div><div id=\"graphicVersion\">Graphic 82467 Version 2.0</div></div></div>"},"82468":{"type":"graphic_picture","displayName":"Lymphocytic thymoma Low","title":"Predominantly lymphocytic thymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Predominantly lymphocytic thymoma</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/PULM/82468_Lymphocytic_thymoma_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immature lymphocytes are predominant, compared to the epithelial cells that are hardly seen on hematoxylin and eosin stain.</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 82468 Version 1.0</div></div></div>"},"82469":{"type":"graphic_diagnosticimage","displayName":"2D TTE Parasternal short axis LV papillary muscles","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis view showing the papillary muscles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis view showing the papillary muscles</div><div class=\"cntnt\"><img style=\"width:380px; height:257px;\" src=\"images/CARD/82469_Short_axis_LV_papillary_mus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short axis image was taken at the same level of the minor axis of the left ventricle (LV); the posteromedial (PMPM) and anterolateral papillary muscles (ALPM) can be seen. The cut through the posteromedial papillary muscle is closer to its tip than the one through the anterolateral.</div><div id=\"graphicVersion\">Graphic 82469 Version 3.0</div></div></div>"},"82471":{"type":"graphic_picture","displayName":"Southern black widow","title":"Southern black widow","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Southern black widow</div><div class=\"cntnt\"><img style=\"width:504px; height:329px;\" src=\"images/EM/82471_Southern_black_widow_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In addition to the red hourglass mark on the ventral portion of the abdomen, the southern black widow also has a red dot just dorsal to the anal region.</div><div class=\"graphic_reference\">Courtesy of Richard Vetter, MS.</div><div id=\"graphicVersion\">Graphic 82471 Version 1.0</div></div></div>"},"82473":{"type":"graphic_figure","displayName":"Incarcerated uterus","title":"Incarcerated gravid uterus","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Incarcerated gravid uterus</div><div class=\"cntnt\"><img style=\"width:497px; height:570px;\" src=\"images/OBGYN/82473_Incarcerated_uterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sacculation originating from the anterior lower segment faces the maternal umbilicus, while the uterine fundus remains in the lower posterior pelvis below the sacral promontory (inverted polarity). Concomitantly, both the bladder and the cervix are pulled into the abdominal cavity, towards the umbilicus. The cervix can be stretched to 10 cm in length or more, with the internal os located above the symphysis pubis and occasionally above the bladder.</div><div id=\"graphicVersion\">Graphic 82473 Version 3.0</div></div></div>"},"82474":{"type":"graphic_picture","displayName":"Pelosi cesarean technique 1","title":"Abdominal incision in the Pelosi technique","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Abdominal incision in the Pelosi technique</div><div class=\"cntnt\"><img style=\"width:546px; height:510px;\" src=\"images/OBGYN/82474_Pelosi_abdominal_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A low transverse suprapubic skin incision is made with a scalpel. The subcutaneous tissue and rectus fascia are incised transversely with electrocautery knife; the subcutaneous tissue is not stripped from the fascia beyond what is needed to expose the cut edges of the fascia.<br />(B) The linea alba is exposed by pulling up the superior edge of the abdominal incision. The traditional dissection of the superior and inferior aspects of the fascia from underlying rectus and pyramidal muscles is not routinely performed.<br />(C) To expose the peritoneum the rectus muscles are separated in the midline by vertical digital dissection.<br />(D) The peritoneum is opened by finger perforation.<br />(E) The peritoneal opening is then extended digitally by vertical and lateral traction. When the peritoneum can not be perforated or stretched digitally, a scalpel or scissors can be used.<br />(F) The full thickness of the abdominal incision is then stretched transversely using the surgeon's fingers.</div><div class=\"graphic_reference\">Courtesy of Marco Pelosi, MD and Marco Pelosi III, MD.</div><div id=\"graphicVersion\">Graphic 82474 Version 4.0</div></div></div>"},"82475":{"type":"graphic_figure","displayName":"IRA patency and mortality","title":"Patent IRA decreases mortality after thrombolysis for acute MI","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Patent IRA decreases mortality after thrombolysis for acute MI</div><div class=\"cntnt\"><img style=\"width:488px; height:341px;\" src=\"images/CARD/82475_IRA_patency_and_mortality.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early and long-term mortality according to infarct-related coronary artery patency following thrombolysis in five different trials. Mortality at both time periods was lower in the patients with a patent infarct-related artery (IRA).</div><div class=\"graphic_footnotes\">WWICSK: Western Washington Intracoronary Streptokinase Trial; TAMI: Thrombolysis and Angioplasty in Myocardial Infarction; TIMI: Thrombolysis in Myocardial Infarction; TEAM: Thrombolysis with Eminase in Myocardial Infarction.</div><div id=\"graphicVersion\">Graphic 82475 Version 1.0</div></div></div>"},"82476":{"type":"graphic_diagnosticimage","displayName":"Right lung atelectasis CT","title":"CT scan of right lung atelectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of right lung atelectasis</div><div class=\"cntnt\"><img style=\"width:360px; height:231px;\" src=\"images/PULM/82476_Right_lung_atelectasis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan of the chest with mediastinal window setting shows the rotational shift of the mediastinum to the right with complete opacification and loss of volume of the right lung. A small posteromedial pleural effusion is present (arrow) and is less&nbsp;opaque than the adjacent collapsed lung. The effusion is probably due to the decreased relative pleural pressure in the right hemithorax following the collapse of the right lung.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82476 Version 3.0</div></div></div>"},"82477":{"type":"graphic_diagnosticimage","displayName":"Zanca view radiograph of acromioclavicular joint","title":"Zanca view radiograph of acromioclavicular joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Zanca view radiograph of acromioclavicular joint</div><div class=\"cntnt\"><img style=\"width:277px; height:514px;\" src=\"images/EM/82477_Zanca_view_radiogr_AC_joint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph of the acromioclavicular joint using the Zanca view (bottom image) provides a clearer view of the joint, without overlapping bone, compared to a standard AP view of the shoulder (top image).</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 82477 Version 3.0</div></div></div>"},"82478":{"type":"graphic_picture","displayName":"Buffalo hump in Cushings syndrome","title":"Buffalo hump in Cushing's syndrome","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Buffalo hump in Cushing's syndrome</div><div class=\"cntnt\"><img style=\"width:468px; height:469px;\" src=\"images/ENDO/82478_Buffalo_hump_Cushings_syndr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Side view of a patient with Cushing's syndrome showing a dorsocervical fat pad (&quot;buffalo hump&quot;).</div><div class=\"graphic_reference\">Reproduced with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 82478 Version 6.0</div></div></div>"},"82479":{"type":"graphic_table","displayName":"Categories of increased risk for diabetes","title":"Categories of increased risk for diabetes (prediabetes)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categories of increased risk for diabetes (prediabetes)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>FPG 100 to 125 mg/dL (5.6 to 6.9 mmol/L) (IFG)</td> </tr> <tr> <td>Two-hour&nbsp;post-load glucose&nbsp;on the 75 g OGTT 140 to 199 mg/dL (7.8 to 11.0 mmol/L) (IGT)</td> </tr> <tr> <td>A1C 5.7 to 6.4% (39 to 46 mmol/mol)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FPG: fasting plasma glucose; IFG: impaired fasting glucose; OGTT: oral glucose tolerance test;&nbsp;IGT: impaired glucose tolerance;&nbsp;A1C: glycated hemoglobin.<br />* For all three tests, risk is continuous, extending below the lower limit of the range and becoming disproportionately greater at higher ends of the range.</div><div class=\"graphic_reference\">Reprinted with permission from the American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care 2011; 34:S11. Copyright © 2011 American Diabetes Association. Table also published in: American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 2013; 36 Suppl 1:S11. The content within this table is still current as of the 2018 version of the Standards of Medical Care in Diabetes.</div><div id=\"graphicVersion\">Graphic 82479 Version 13.0</div></div></div>"},"82480":{"type":"graphic_picture","displayName":"Torsion of fallopian tube","title":"Tubal torsion demonstrating severe distension of the distal tube","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Tubal torsion demonstrating severe distension of the distal tube</div><div class=\"cntnt\"><img style=\"width:468px; height:356px;\" src=\"images/OBGYN/82480_Torsionoffallopiantube.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82480 Version 13.0</div></div></div>"},"82481":{"type":"graphic_table","displayName":"Marrow asp bx available tests","title":"Available tests: bone marrow aspirates and biopsies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Available tests: bone marrow aspirates and biopsies</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Standard tests</td>\n</tr>\n<tr>\n<td>Aspirate smear/ particle crush smear</td>\n</tr>\n<tr>\n<td>Buffy coat smear</td>\n</tr>\n<tr>\n<td>Bone marrow biopsy section</td>\n</tr>\n<tr>\n<td>Iron stain</td>\n</tr>\n<tr>\n<td>Clot section</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Other tests applied selectively</td>\n</tr>\n<tr>\n<td>Reticulin and/or collagen stains for suspected fibrosis</td>\n</tr>\n<tr>\n<td>Enzyme cytochemical stains</td>\n</tr>\n<tr>\n<td>Immunophenotyping/ flow cytometry</td>\n</tr>\n<tr>\n<td>Cytogenetic analysis</td>\n</tr>\n<tr>\n<td>Fluorescence in situ hybridization (FISH)</td>\n</tr>\n<tr>\n<td>Molecular genetic analysis</td>\n</tr>\n<tr>\n<td>Culture for mycobacteria, leishmania, histoplasma</td>\n</tr>\n<tr>\n<td>Acid fast staining for mycobacteria</td>\n</tr>\n<tr>\n<td>Congo Red stain for suspected amyloidosis</td>\n</tr>\n<tr>\n<td>Cell culture assays</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 82481 Version 1.0</div></div></div>"},"82484":{"type":"graphic_diagnosticimage","displayName":"Short pancreas ERCP","title":"Endoscopic retrograde cholangiopancreatography (ERCP) showing short pancreas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic retrograde cholangiopancreatography (ERCP) showing short pancreas</div><div class=\"cntnt\"><img style=\"width:432px; height:290px;\" src=\"images/PEDS/82484_Short_pancreas.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK 1997. Copyright ©1997 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 82484 Version 3.0</div></div></div>"},"82485":{"type":"graphic_figure","displayName":"Benefit of pravastatin post-MI in the CARE trial","title":"Benefit of pravastatin post-myocardial infarction in the CARE trial","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benefit of pravastatin post-myocardial infarction in the CARE trial</div><div class=\"cntnt\"><img style=\"width:368px; height:237px;\" src=\"images/CARD/82485_Pravastatin_CARE_trial.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier analysis of the incidence of coronary death or nonfatal myocardial infarction in post-MI patients who had average levels of cholesterol and were randomized to therapy with pravastatin or placebo. The incidence of these endpoints was significantly reduced by therapy with pravastatin (p = 0.003). A similar percent benefit was seen in the subgroup of patients with near normal levels of LDL cholesterol (125 to 150 mg/dL [3.2 to 3.9 mmol/L]).</div><div class=\"graphic_footnotes\">MI: myocardial infarction; LDL: low-density lipoprotein.</div><div class=\"graphic_reference\">Redrawn from: Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001.</div><div id=\"graphicVersion\">Graphic 82485 Version 5.0</div></div></div>"},"82487":{"type":"graphic_table","displayName":"Symptoms of acute HIV infection","title":"Frequency of common symptoms in acute HIV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of common symptoms in acute HIV infection</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Symptom</td>\n<td class=\"subtitle1\">No. patients</td>\n<td class=\"subtitle1\">Percent</td>\n</tr>\n<tr>\n<td>Fever</td>\n<td>200</td>\n<td>96</td>\n</tr>\n<tr>\n<td>Adenopathy</td>\n<td>154</td>\n<td>74</td>\n</tr>\n<tr>\n<td>Pharyngitis</td>\n<td>146</td>\n<td>70</td>\n</tr>\n<tr>\n<td>Rash</td>\n<td>146</td>\n<td>70</td>\n</tr>\n<tr>\n<td>Myalgia/arthralgia</td>\n<td>112</td>\n<td>54</td>\n</tr>\n<tr>\n<td>Diarrhea</td>\n<td>67</td>\n<td>32</td>\n</tr>\n<tr>\n<td>Headache</td>\n<td>66</td>\n<td>32</td>\n</tr>\n<tr>\n<td>Nausea/vomiting</td>\n<td>56</td>\n<td>27</td>\n</tr>\n<tr>\n<td>Neuropathy</td>\n<td>13</td>\n<td>6</td>\n</tr>\n<tr>\n<td>Encephalopathy</td>\n<td>12</td>\n<td>6</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Niu, MT, Stein, DS, Schnittman, SM, J Infect Dis 1993; 168:1490.</div><div id=\"graphicVersion\">Graphic 82487 Version 1.0</div></div></div>"},"82488":{"type":"graphic_figure","displayName":"HCO3 reabsorption plasma K","title":"Relation between plasma potassium and bicarbonate reabsorption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relation between plasma potassium and bicarbonate reabsorption</div><div class=\"cntnt\"><img style=\"width:367px; height:258px;\" src=\"images/NEPH/82488_HCO3_reabsorption_plasma_K.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal tubular reabsorption of HCO<SUB>3</SUB><SUP>–</SUP> as a function of the plasma K concentration. There is an inverse relationship with HCO<SUB>3</SUB><SUP>–</SUP> reabsorption, rising with hypokalemia and falling with hyperkalemia.</div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate.</div><div class=\"graphic_reference\">Data from: Fuller GR, MacLeod MB, Pitts RF. Am J Physiol 1956; 182:111.</div><div id=\"graphicVersion\">Graphic 82488 Version 6.0</div></div></div>"},"82490":{"type":"graphic_table","displayName":"Localized cutaneous blistering disorders","title":"Select examples of localized cutaneous blistering disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Select examples of localized cutaneous blistering disorders</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Disorder</td>\r\n            <td class=\"subtitle1\">Clinical features</td>\r\n            <td class=\"subtitle1\">Diagnostic tests</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong>Dermatitis</strong></td>\r\n            <td>Linear configuration if contact dermatitis.</td>\r\n            <td>H&#38;E: spongiosis</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td><strong>Bullous tinea pedis</strong></td>\r\n            <td>Vesicles on soles of feet or between the toes.</td>\r\n            <td>KOH examination demonstrating hyphae or positive fungal culture</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td><strong>Fixed drug eruption</strong></td>\r\n            <td>Dusky violaceous patch, hemorrhagic bulla; may recur at same location with future drug exposures.</td>\r\n            <td>\r\n            <p>History</p>\r\n            <p>H&#38;E: lichenoid or interface dermatitis</p>\r\n            </td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td><strong>Erythema multiforme</strong></td>\r\n            <td>Targetoid papules on extremities and acral locations; hemorrhagic vesicles/bullae; intermittent recurrences usually associated with HSV infection.</td>\r\n            <td>H&#38;E: vacuolar interface dermatitis; positive confirmation of concurrent HSV outbreak</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td><strong>Friction blisters</strong></td>\r\n            <td>Most commonly seen on soles of feet or palms of hands at sites of friction.</td>\r\n            <td>\r\n            <p>History</p>\r\n            <p>H&#38;E: intraepidermal blister</p>\r\n            </td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td><strong>Coma blisters</strong></td>\r\n            <td>Tense blisters at sites of pressure in comatose patients.</td>\r\n            <td>\r\n            <p>History</p>\r\n            <p>H&#38;E: subepidermal blister and eccrine gland necrosis</p>\r\n            </td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td><strong>Bullous insect bites</strong></td>\r\n            <td>Intense pruritus and erythematous papules.</td>\r\n            <td>History</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td><strong>Bullous disease of diabetes (bullous diabeticorum)</strong></td>\r\n            <td>Tense blisters found predominately on lower extremities. Lack of erythema or inflammation. Rare manifestation of diabetes.</td>\r\n            <td>\r\n            <p>H&#38;E: pauci-inflammatory subepidermal blister</p>\r\n            <p>DIF: negative</p>\r\n            </td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td><strong>Grover's (transient acantholytic dermatosis)</strong></td>\r\n            <td>Keratotic eroded papules and vesicles on the abdomen, chest, back. Male predominance. Often worsens with heat, exercise, hospitalization.</td>\r\n            <td>\r\n            <p>H&#38;E: dyskeratosis and acantholysis</p>\r\n            <p>DIF: negative</p>\r\n            </td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin pathology stain; DIF: direct immunofluorescence; KOH: potassium hydroxide; HSV: herpes simplex virus.</div><div id=\"graphicVersion\">Graphic 82490 Version 2.0</div></div></div>"},"82491":{"type":"graphic_picture","displayName":"Core stability rehabilitation for tennis","title":"Core muscle stability rehabilitation for tennis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Core muscle stability rehabilitation for tennis</div><div class=\"cntnt\"><img style=\"width:331px; height:360px;\" src=\"images/EM/82491_Tenniscorestabilityrehab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Core muscle weakness&nbsp;may contribute to extremity injuries such as epicondylitis. For this reason, exercises to develop core muscle strength and stability are often incorporated into rehabilitation programs.</div><div class=\"graphic_reference\">Reproduced with permission from: Jayanthi N, Subbarao JV. Racket sports injuries. In: Sports Medicine and Rehabilitation: A Sports Specific Approach. Buschbacher R, Prahlow N, Dave SJ (eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82491 Version 12.0</div></div></div>"},"82492":{"type":"graphic_figure","displayName":"Technique for oocyte recovery","title":"Follicle aspiration","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Follicle aspiration</div><div class=\"cntnt\"><img style=\"width:578px; height:590px;\" src=\"images/ENDO/82492_Technique_for_oocyte_recove.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematized representation of transvaginal ultrasound-guided follicle aspiration. The ultrasound probe is covered with a sterile plastic sheath.</div><div class=\"graphic_reference\">Reproduced with permission from: Paulson RJ, Sachs J. Rewinding Your Biological Clock: Motherhood Late in Life, WH Freeman and Company, New York 1998. Copyright &copy; 1998.</div><div id=\"graphicVersion\">Graphic 82492 Version 2.0</div></div></div>"},"82493":{"type":"graphic_figure","displayName":"Anatomy of tetralogy of Fallot","title":"Anatomy of tetralogy of Fallot","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Anatomy of tetralogy of Fallot</div><div class=\"cntnt\"><img style=\"width:530px; height:605px;\" src=\"images/PEDS/82493_Anatomy_of_tetralogy_of_Fal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tetralogy of Fallot is characterized by a large ventricular septal defect (VSD), an aorta that overrides the left and right ventricles, obstruction of the right ventricular outflow tract, and right ventricular hypertrophy. As a result of the substantial obstruction of the right ventricular outflow tract, there is right-to-left shunting through the VSD resulting in cyanosis.</div><div id=\"graphicVersion\">Graphic 82493 Version 8.0</div></div></div>"},"82494":{"type":"graphic_figure","displayName":"Adult mosquito heads","title":"Adult Anopheline and Culicine mosquito heads","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Adult Anopheline and Culicine mosquito heads</div><div class=\"cntnt\"><img style=\"width:542px; height:585px;\" src=\"images/ID/82494_Adult_mosquito_heads.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The head appendages of the adult mosquito consist of one proboscis (a serrated appendage used by female mosquitoes for extracting blood), a pair of antennae, and a pair of maxillary palps; these features require a microscope for visualization. The unique palp characteristics are the most reliable for differentiation between Anopheline and Culicine mosquitoes. Anopheline female palps are about the same length as the proboscis, while Anopheline male palps are club-shaped at the ends. Culicine female palps are shorter than the proboscis, and Culicine male palps are long with a tapered point.</div><div class=\"graphic_reference\">Modified from figures courtesy of Cheryl Whitehorn, MSc.</div><div id=\"graphicVersion\">Graphic 82494 Version 3.0</div></div></div>"},"82495":{"type":"graphic_table","displayName":"Parenteral agents for moderate to severe foot infection","title":"Parenteral agents for empiric treatment of moderate to severe diabetic foot infections*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral agents for empiric treatment of moderate to severe diabetic foot infections*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Dosing (for adults with normal renal function)<sup>&#182;</sup></td> <td class=\"subtitle1\">Activity against <em>Pseudomonas</em><sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Beta-lactam/beta-lactamase inhibitors</td> </tr> <tr> <td class=\"indent1\">Ampicillin-sulbactam</td> <td>3 g every 6 hours</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Piperacillin-tazobactam<sup>&#9674;</sup></td> <td>3.375 g every 6 hours or 4.5 g every 6 to 8 hours</td> <td>Yes, when dosed 4.5 g every 6 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Carbapenems</td> </tr> <tr> <td class=\"indent1\">Imipenem-cilastatin<sup>&#9674;</sup></td> <td>500 mg every 6 hours</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Meropenem<sup>&#9674;</sup></td> <td>1 g every 8 hours</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ertapenem</td> <td>1 g every 24 hours</td> <td>No</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Combination&nbsp;regimens</td> </tr> <tr> <td class=\"sublist2_start\">Metronidazole PLUS one of the following:</td> <td class=\"sublist_other_start\">500 mg every 8 hours</td> <td class=\"sublist_other_start\">No</td> </tr> <tr> <td class=\"sublist2\">Ceftriaxone</td> <td class=\"sublist_other\">1 to 2 g every 24 hours</td> <td class=\"sublist_other\">No</td> </tr> <tr> <td class=\"sublist2\">Ceftazidime<sup>&#9674;</sup></td> <td class=\"sublist_other\">2 g every 8 to 12 hours</td> <td class=\"sublist_other\">Yes</td> </tr> <tr> <td class=\"sublist2\">Cefepime<sup>&#9674;</sup></td> <td class=\"sublist_other\">2 g every 8 to 12 hours</td> <td class=\"sublist_other\">Yes, when dosed every 8 hours</td> </tr> <tr> <td class=\"sublist2\">Ciprofloxacin<sup>&#167;</sup></td> <td class=\"sublist_other\">400 mg IV every 8 to 12 hours</td> <td class=\"sublist_other\">Yes, when dosed every 8 hours<sup>&#165;</sup></td> </tr> <tr> <td class=\"sublist2\">Levofloxacin</td> <td class=\"sublist_other\">750 mg IV every 24 hours</td> <td class=\"sublist_other\">Yes<sup>&#165;</sup></td> </tr> <tr> <td class=\"sublist2\">Moxifloxacin</td> <td class=\"sublist_other\">400 mg every 24 hours</td> <td class=\"sublist_other\">No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">Aztreonam<sup>&#167;</sup></td> <td class=\"sublist_other\">2 g every 6 to 8 hours</td> <td class=\"sublist_other\">Yes, when dosed every 6 hours<sup>&#165;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">PLUS one of the following if MRSA coverage is warranted</td> </tr> <tr> <td class=\"indent1\">Vancomycin<sup>&#135;</sup></td> <td>15 to 20 mg/kg every 8 to 12 hours</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Linezolid<sup>&#134;</sup></td> <td>600 mg every 12 hours</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Daptomycin</td> <td>4 to 6 mg/kg every 24 hours</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These regimens do not have activity against carbapenem-resistant Enterobacteriaceae. Patients who have suspected or documented infection with a carbapenem-resistant organism should be managed in consultation with an expert in infectious diseases.<br />¶&nbsp;Many of these agents require adjustment of the dose in the setting of renal dysfunction.<br />Δ&nbsp;Empiric coverage for<EM> Pseudomonas aeruginosa</EM> may not be necessary except in severe cases or when the patient has particular risk for involvement with this organism, such as a macerated wound or one with significant water exposure.<br />◊ These antibiotics can be given as a prolonged infusion over 3 to 4 hours. Patients who have a high risk of infection with drug-resistant pathogens or who are critically ill in the setting of a severe infection are most likely to benefit from prolonged infusion dosing. For additional information, refer to other UpToDate content on prolonged infusions of beta-lactams.<br />§&nbsp;These agents should be used in combination with an agent that has good gram-positive coverage, such as vancomycin, linezolid, or daptomycin.<br />¥&nbsp;Variable activity against <EM>Pseudomonas</EM>. Consult local susceptibility data before use.<br />‡&nbsp;Maximum 2 grams per dose. Adjust dose to maintain vancomycin serum concentrations of 15 to 20 mg/dL. Total daily doses above ≥4 g per day have been associated with increased risk of nephrotoxicity.<br />†&nbsp;Because of the toxicity associated with long-term linezolid use, we do not recommend this agent for treatment of osteomyelitis.</div><div class=\"graphic_reference\">Data courtesy of authors with additional data from: Lipsky BA, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 54:e132.</div><div id=\"graphicVersion\">Graphic 82495 Version 8.0</div></div></div>"},"82497":{"type":"graphic_figure","displayName":"Nephron anatomy PI","title":"Anatomy of the nephron","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Anatomy of the nephron</div><div class=\"cntnt\"><img style=\"width:542px; height:569px;\" src=\"images/PI/82497_Nephron_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the structure of the nephron, which filters waste from the body's blood supply. Each nephron is composed of a glomerulus and a tubule. The glomerulus filters wastes and excess fluids, while the tubules modify the waste to form urine.</div><div id=\"graphicVersion\">Graphic 82497 Version 4.0</div></div></div>"},"82498":{"type":"graphic_table","displayName":"LR of Down syndrome based on presence of an isolated soft marker","title":"Likelihood ratio of Down syndrome based on the presence of an isolated soft marker (pooled results)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Likelihood ratio of Down syndrome based on the presence of an isolated soft marker (pooled results)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Sensitivity Down syndrome,<br /> percent</td> <td class=\"subtitle1\">False positive rate<br /> (ie, marker detected in euploid karyotype), percent</td> <td class=\"subtitle1\">Positive likelihood ratio if the marker is isolated,<br /> percent*</td> </tr> <tr> <td>Absent or hypoplastic nasal bone</td> <td class=\"centered\">48.9 to 69.9</td> <td class=\"centered\">1.9 to 4.0</td> <td class=\"centered\">6.58</td> </tr> <tr> <td>Aberrant right subclavian artery</td> <td class=\"centered\">17.9 to 47.4</td> <td class=\"centered\">1.0 to 2.1</td> <td class=\"centered\">3.94</td> </tr> <tr> <td>Ventriculomegaly<sup>&#182;</sup></td> <td class=\"centered\">4.2 to 12.9</td> <td class=\"centered\">0.1 to 0.4</td> <td class=\"centered\">3.81</td> </tr> <tr> <td>Increased nuchal fold<sup>&#916;</sup></td> <td class=\"centered\">20.3 to 32.9</td> <td class=\"centered\">0.5 to 1.9</td> <td class=\"centered\">3.79</td> </tr> <tr> <td>Hyperechoic bowel<sup>&#9674;</sup></td> <td class=\"centered\">13.4 to 20.7</td> <td class=\"centered\">0.8 to 1.5</td> <td class=\"centered\">1.65</td> </tr> <tr> <td>Pyelectasis<sup>&#167;</sup></td> <td class=\"centered\">11.2 to 17.2</td> <td class=\"centered\">1.4 to 2.0</td> <td class=\"centered\">1.08</td> </tr> <tr> <td>Echogenic intracardiac focus</td> <td class=\"centered\">20.9 to 28.2</td> <td class=\"centered\">3.4 to 4.5</td> <td class=\"centered\">0.95</td> </tr> <tr> <td>Short humerus</td> <td class=\"centered\">17.1 to 47.9</td> <td class=\"centered\">2.8 to 7.4</td> <td class=\"centered\">0.78</td> </tr> <tr> <td>Short femur</td> <td class=\"centered\">19.3 to 38.1</td> <td class=\"centered\">4.7 to 8.8</td> <td class=\"centered\">0.61</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Results from meta-analysis of data pooled from 48 studies of low and high risk populations. Gestational age at ultrasound 14 to 24 weeks. Most studies involved women at increased risk.<br />The authors concluded that if a systematic ultrasound examination is performed by expert sonologists and all of these markers are absent, the risk of Down syndrome is the mother's a priori risk based on maternal serum screening multiplied by 0.13.</div><div class=\"graphic_footnotes\">* Derived by multiplying the positive likelihood ratio for the marker by the negative likelihood ratio for each of the other markers.<br />&para; Diameter of lateral cerebral ventricle &ge;10 mm.<br />&Delta; Thickness &ge;6 mm.<br /><span class=\"lozenge\">&loz;</span> Echogenicity the same as bone.<br />&sect; Anteroposterior diameter 3 to 5 mm.</div><div class=\"graphic_reference\">Data from: Agathokleous M, Chaveeva P, Poon LCY, et al. Meta-analysis of second trimester markers for trisomy 21. Ultrasound Obstet Gynecol 2013; 41:247.</div><div id=\"graphicVersion\">Graphic 82498 Version 6.0</div></div></div>"},"82499":{"type":"graphic_table","displayName":"Radiographic patterns in ILD II","title":"Helpful radiographic patterns in the differential diagnosis of interstitial lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Helpful radiographic patterns in the differential diagnosis of interstitial lung disease</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Associated with Kerley B lines</td></tr>\n\t\t\t\t\t\t<tr><td>Lymphangitic carcinomatosis</td></tr>\n\t\t\t\t\t\t<tr><td>Chronic left ventricular failure</td></tr>\n\t\t\t\t\t\t<tr><td>Mitral valve disease</td></tr>\n\t\t\t\t\t\t<tr><td>Lymphoma</td></tr>\n\t\t\t\t\t\t<tr><td>Lymphangioleiomyomatosis</td></tr>\n\t\t\t\t\t\t<tr><td>Amyloidosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Miliary pattern</td></tr>\n\t\t\t\t\t\t<tr><td>Sarcoidosis</td></tr>\n\t\t\t\t\t\t<tr><td>Silicosis</td></tr>\n\t\t\t\t\t\t<tr><td>Hypersensitivity pneumonitis</td></tr>\n\t\t\t\t\t\t<tr><td>Bronchiolitis obliterans</td></tr>\n\t\t\t\t\t\t<tr><td>Infectious granulomatous disease (tuberculosis, histoplasmosis, coccidioidomycosis)</td></tr>\n\t\t\t\t\t\t<tr><td>Metastatic malignant disease</td></tr>\n\t\t\t\t\t\t<tr><td>Renal cell carcinoma</td></tr>\n\t\t\t\t\t\t<tr><td>Adenocarcinoma of breast</td></tr>\n\t\t\t\t\t\t<tr><td>Malignant melanoma</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Fleeting or migratory infiltrates</td></tr>\n\t\t\t\t\t\t<tr><td>Bronchiolitis obliterans with organizing pneumonia (idiopathic or radiation-induced)</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td>Simple pulmonary eosinophilia (Loffler's syndrome)</td></tr>\n\t\t\t\t\t\t<tr><td>Hypersensitivity to drugs</td></tr>\n\t\t\t\t\t\t<tr><td>Parasitic infections</td></tr>\n\t\t\t\t\t\t<tr><td>Fungus-induced, especially allergic bronchopulmonary aspergillosis</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Subcutaneous calcinosis</td></tr>\n\t\t\t\t\t\t<tr><td>Scleroderma (CREST)</td></tr>\n\t\t\t\t\t\t<tr><td>Dermatopolymyositis</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n\n\n    \n\n    \n\n    \n\n    \n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 82499 Version 1.0</div></div></div>"},"82501":{"type":"graphic_picture","displayName":"Actinic lichen planus hand","title":"Actinic lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Actinic lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:364px;\" src=\"images/DERM/82501_Actinic_lichen_planus_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gray-brown plaques are present on the dorsal hand. Note the annular configuration of the largest lesion.</div><div class=\"graphic_reference\">Copyright © Shahbaz A Janjua, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 82501 Version 3.0</div></div></div>"},"82502":{"type":"graphic_diagnosticimage","displayName":"Post hemorrhagic hydrocephalus sequelae","title":"Post hemorrhagic hydrocephalus sequelae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Post hemorrhagic hydrocephalus sequelae</div><div class=\"cntnt\"><img style=\"width:297px; height:363px;\" src=\"images/PEDS/82502_Post_hemorrhagic_hydro2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T2 weighted magnetic resonance imaging (MRI) in a child with communicating hydrocephalus.</div><div class=\"graphic_reference\">Courtesy of Drs. Abilash Haridas and Tadanori Tomita.</div><div id=\"graphicVersion\">Graphic 82502 Version 2.0</div></div></div>"},"82503":{"type":"graphic_picture","displayName":"Single leg calf raise PI","title":"Single-leg calf raises","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Single-leg calf raises</div><div class=\"cntnt\"><img style=\"width:528px; height:370px;\" src=\"images/PI/82503_Single_leg_calf_raise_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stand behind a chair, holding onto the chair. Lift the \"good\" foot off the floor so that you are standing on the injured leg. Slowly rise up and stand on the ball of the foot and toes. Hold for 5 seconds then slowly roll down onto the entire foot. Rest as needed. Repeat 10 to 15 times (one set). Increase the difficulty of this exercise by rising higher, holding longer, or moving up and down more quickly. Perform a total of 3 sets.</div><div id=\"graphicVersion\">Graphic 82503 Version 4.0</div></div></div>"},"82504":{"type":"graphic_table","displayName":"ATPIII LDL goals","title":"ATP III LDL-cholesterol goals and cutpoints for therapeutic lifestyle changes and drug therapy in different risk categories","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ATP III LDL-cholesterol goals and cutpoints for therapeutic lifestyle changes and drug therapy in different risk categories</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk category</td> <td class=\"subtitle1\">LDL-cholesterol goal</td> <td class=\"subtitle1\">LDL-cholesterol level at which to initiate therapeutic lifestyle changes</td> <td class=\"subtitle1\">LDL-cholesterol level at which to consider drug therapy</td> </tr> <tr> <td>Coronary heart disease (CHD) or CHD risk equivalent (10-year risk &#62;20 percent)*</td> <td>&#60;100 mg/dL (2.58 mmol/L)</td> <td>&#8805;100 mg/dL (2.58 mmol/L)</td> <td>&#8805;130 mg/dL (3.36 mmol/L); drug optional at 100 to 129 mg/dL (2.58 to 3.33 mmol/L)<sup>&#182;</sup></td> </tr> <tr> <td>2 or more risk factors (10-year risk &#8804;20 percent)<sup>&#916;</sup></td> <td>&#8804;130 mg/dL (3.36 mmol/L)</td> <td>&#8805;130 mg/dL (3.36 mmol/L)</td> <td>10-year risk 10 to 20 percent: &#62;130 mg/dL (3.36 mmol/L) 10-year risk &#60;10 percent: &#8805;160 mg/dL (4.13 mmol/L)</td> </tr> <tr> <td>0 to 1 risk factor<sup>&#9674;</sup></td> <td>&#8804;160 mg/dL (4.13 mmol/L)</td> <td>&#8805;160 mg/dL (4.13 mmol/L)</td> <td>&#8805;190 mg/dL (4.91 mmol/L); LDL-cholesterol lowering drug optional at 160 to 189 mg/dL (4.13 to 4.88 mmol/L)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* CHD risk equivalents defined in text. 10-year risk defined by Framingham risk score (see text).<br />¶ Some authorities recommend use of LDL-cholesterol lowering drugs in this category if LDL-cholesterol &lt;100 mg/dL (2.58 mmol/L) cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-cholesterol (eg, nicotinic acid or fibrate). Clinical judgement may also call for deferring drug therapy in this subcategory.<br />Δ Risk factors that modify LDL-cholesterol goals include cigarette smoking; hypertension (BP 140/90 mmHg or on antihypertensive medication); low HDL-cholesterol (&lt;40 mg/dL [1.03 mmol/L]); family history of premature CHD (CHD in male first degree relative &lt;55 years or CHD in female first degree relative &lt;65 years); age (men 45 years; women 55 years). HDL-cholesterol 60 mg/dL (1.55 mmol/L) counts as a negative risk factor; its presence removes one risk factor from the total count. <br /><FONT class=lozenge>◊</FONT> Almost all people with 0 to 1 risk factor have a 10-year risk &lt;10 percent; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary.</div><div class=\"graphic_reference\">Adapted from Adult Treatment Panel III at http://www.nhlbi.nih.gov/.</div><div id=\"graphicVersion\">Graphic 82504 Version 5.0</div></div></div>"},"82505":{"type":"graphic_diagnosticimage","displayName":"Nondisplaced transverse fracture of little toe: Lateral view","title":"Nondisplaced transverse fracture of little toe: Lateral view","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Nondisplaced transverse fracture of little toe: Lateral view</div><div class=\"cntnt\"><img style=\"width:468px; height:300px;\" src=\"images/EM/82505_Trans_fx_5th_toe_lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note how difficult it is to identify the phalanx on the lateral view, let alone recognize that it is fractured and minimally displaced (arrow).</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 82505 Version 4.0</div></div></div>"},"82507":{"type":"graphic_figure","displayName":"Placement lateral sutures cone","title":"Placement of lateral sutures at cervicovaginal junction during cervical (uterine cervix) conization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Placement of lateral sutures at cervicovaginal junction during cervical (uterine cervix) conization</div><div class=\"cntnt\"><img style=\"width:368px; height:342px;\" src=\"images/OBGYN/82507_Placement_lateral_sutures_c.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 82507 Version 2.0</div></div></div>"},"82508":{"type":"graphic_table","displayName":"Radiation biodosimetry","title":"Radiation biodosimetry","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiation biodosimetry</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Dose (Gy)</td> <td class=\"subtitle1\">Vomiting (percent)</td> <td class=\"subtitle1\">Time to vomiting (hours)</td> <td class=\"subtitle1\">ALC day 1* </td> <td class=\"subtitle1\">Lymphocyte fall rate constant (k)<sup>&#182;</sup></td> <td class=\"subtitle1\">Lymphocyte dicentrics (per 1000)<sup>&#916;</sup></td> </tr> <tr> <td>0</td> <td>0</td> <td>-</td> <td>2450</td> <td>-</td> <td>1-2</td> </tr> <tr> <td>1</td> <td>19</td> <td>-</td> <td>2160</td> <td>0.126</td> <td>88</td> </tr> <tr> <td>2</td> <td>35</td> <td>4.6</td> <td>1900</td> <td>0.252</td> <td>234</td> </tr> <tr> <td>3</td> <td>54</td> <td>2.6</td> <td>1680</td> <td>0.378</td> <td>439</td> </tr> <tr> <td>4</td> <td>72</td> <td>1.7</td> <td>1480</td> <td>0.504</td> <td>703</td> </tr> <tr> <td>5</td> <td>86</td> <td>1.3</td> <td>1310</td> <td>0.63</td> <td>1000</td> </tr> <tr> <td>6</td> <td>94</td> <td>1</td> <td>1150</td> <td>0.756</td> <td>&nbsp;</td> </tr> <tr> <td>7</td> <td>98</td> <td>0.8</td> <td>1010</td> <td>0.881</td> <td>&nbsp;</td> </tr> <tr> <td>8</td> <td>99</td> <td>0.7</td> <td>890</td> <td>1.01</td> <td>&nbsp;</td> </tr> <tr> <td>9</td> <td>100</td> <td>0.6</td> <td>790</td> <td>1.13</td> <td>&nbsp;</td> </tr> <tr> <td>10</td> <td>100</td> <td>0.5</td> <td>700</td> <td>1.26</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Gy: absorbed whole body dose in Gray units.<br />* ALC day 1: absolute lymphocyte count per microL on day 1 after exposure.<br />¶ The lymphocyte fall rate constant is derived from a semilogarithmic plot of the absolute lymphocyte count (ALC) versus time in days, in the form of 2450 x e<SUP>–kt</SUP>. The time (in days) for the ALC to fall to one-half of its original value [half-time, T(1/2)] can be obtained from the following equation: T(1/2) = 0.693/k.<br />Δ Dicentric chromosomes are those containing two separate centromeres, caused by end-to-end recombination of two damaged chromosomes.</div><div class=\"graphic_reference\">Modified with permission from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Intern Med 2004; 140:1037. Copyright &copy; 2004 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 82508 Version 22.0</div></div></div>"},"82510":{"type":"graphic_table","displayName":"Standard skeletal survey","title":"The standard skeletal survey","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The standard skeletal survey</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Appendicular skeleton</td> </tr> <tr> <td class=\"indent1\">Humeri (AP)</td> </tr> <tr> <td class=\"indent1\">Forearms (AP)</td> </tr> <tr> <td class=\"indent1\">Hands (PA)</td> </tr> <tr> <td class=\"indent1\">Femurs (AP)</td> </tr> <tr> <td class=\"indent1\">Lower legs (AP)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Feet (AP)</td> </tr> <tr> <td class=\"subtitle1_single\">Axial skeleton</td> </tr> <tr> <td class=\"indent1\">Thorax (AP, lateral, right and left oblique views) to include the ribs, thoracic spine, and upper lumbar spine</td> </tr> <tr> <td class=\"indent1\">Ribs (oblique views)</td> </tr> <tr> <td class=\"indent1\">Abdomen (AP, to include the pelvis)</td> </tr> <tr> <td class=\"indent1\">Lumbosacral spine (lateral)</td> </tr> <tr> <td class=\"indent1\">Skull (frontal and lateral)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cervical spine (lateral [if not completely visualized on lateral skull])</td> </tr> <tr> <td class=\"subtitle1_single\">Technique</td> </tr> <tr> <td class=\"indent1\">High resolution</td> </tr> <tr> <td class=\"indent1\">High contrast</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AP: anteroposterior; PA: posteroanterior.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Section on Radiology; American Academy of Pediatrics. Diagnostic imaging of child abuse. Pediatrics 2009; 123:1430.</li>&#xD;&#xA;    <li>The American College of Radiology. ACR appropriateness criteria. Suspected physical abuse - child. available at the following <a href=\"https://acsearch.acr.org/docs/69443/Narrative/\" target=\"_blank\">link</a>.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 82510 Version 10.0</div></div></div>"},"82511":{"type":"graphic_diagnosticimage","displayName":"Bronchial atresia CT","title":"Bronchial atresia in adult with incidental left lower lobe nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchial atresia in adult with incidental left lower lobe nodule</div><div class=\"cntnt\"><img style=\"width:360px; height:208px;\" src=\"images/PULM/82511_Bronchial_atresia_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of lower chest shows a left lower lobe nodule with surrounding halo of hyperlucency. The nodule represents mucoid impaction in the posterobasal segment of the left lower lobe with air-trapping in the surrounding lung.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82511 Version 4.0</div></div></div>"},"82515":{"type":"graphic_picture","displayName":"Traction alopecia braids","title":"Traction alopecia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traction alopecia</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/82515_Traction_alopecia_braids.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of the frontal hairline is evident in this patient with traction alopecia. Traction alopecia may result from tightly braided hairstyles.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82515 Version 4.0</div></div></div>"},"82519":{"type":"graphic_figure","displayName":"Conventional pancreaticoduodenectomy","title":"Conventional pancreaticoduodenectomy (Whipple procedure)","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Conventional pancreaticoduodenectomy (Whipple procedure)</div><div class=\"cntnt\"><img style=\"width:540px; height:663px;\" src=\"images/SURG/82519_Standard_whipple.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82519 Version 2.0</div></div></div>"},"82520":{"type":"graphic_table","displayName":"Causes of cyanosis child","title":"Causes of cyanosis and conditions mimicking cyanosis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of cyanosis and conditions mimicking cyanosis in children</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Category\n   </td>\n   <td  class=\"subtitle1\">\n   Condition*\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Decreased inspired FiO2 (eg, smoke inhalation)\n   </td>\n   <td>Exposure to asphyxiating gas</td>\n   </tr>\n   <tr>\n   <td>Smoke inhalation</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"5\">\n   Upper airway obstruction\n   </td>\n   <td>Bacterial tracheitis</td>\n   </tr>\n   <tr>\n   <td>Croup</td>\n   </tr>\n   <tr>\n   <td>Epiglottitis</td>\n   </tr>\n   <tr>\n   <td>Foreign body aspiration</td>\n   </tr>\n   <tr>\n   <td>Traumatic disruption (laryngeal fracture, burn)</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"5\">\n   Impairment of chest wall or lung expansion\n   </td>\n   <td>External compression</td>\n   </tr>\n   <tr>\n   <td>Flail chest</td>\n   </tr>\n   <tr>\n   <td>Hemothorax</td>\n   </tr>\n   <tr>\n   <td>Open pneumothorax</td>\n   </tr>\n   <tr>\n   <td>Pneumothorax</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"7\">\n   Intrinsic lung disease\n   </td>\n   <td>Asthma</td>\n   </tr>\n   <tr>\n   <td>Bronchiolitis</td>\n   </tr>\n   <tr>\n   <td>Bronchopulmonary dysplasia</td>\n   </tr>\n   <tr>\n   <td>Cystic fibrosis</td>\n   </tr>\n   <tr>\n   <td>Empyema</td>\n   </tr>\n   <tr>\n   <td>Hyaline membrane disease</td>\n   </tr>\n   <tr>\n   <td>Pneumonia</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"4\">\n   Disordered control of breathing\n   </td>\n   <td>Coma</td>\n   </tr>\n   <tr>\n   <td>Cyanotic breath-holding spells</td>\n   </tr>\n   <tr>\n   <td>Seizures</td>\n   </tr>\n   <tr>\n   <td>Severe head trauma</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"9\">\n   Cyanotic congenital heart disease\n   </td>\n   <td>Atrioventricular canal defect</td>\n   </tr>\n   <tr>\n   <td>Epstein anomaly</td>\n   </tr>\n   <tr>\n   <td>Hypoplastic left heart syndrome</td>\n   </tr>\n   <tr>\n   <td>Pulmonary atresia</td>\n   </tr>\n   <tr>\n   <td>Pulmonic stenosis</td>\n   </tr>\n   <tr>\n   <td>Tetralogy of Fallot</td>\n   </tr>\n   <tr>\n   <td>Total anomalous pulmonary venous drainage</td>\n   </tr>\n   <tr>\n   <td>Transposition of the great vessels</td>\n   </tr>\n   <tr>\n   <td>Truncus arteriosus</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"5\">\n   Pulmonary vascular disorders\n   </td>\n   <td>PPHN</td>\n   </tr>\n   <tr>\n   <td>Pulmonary edema</td>\n   </tr>\n   <tr>\n   <td>Pulmonary embolism</td>\n   </tr>\n   <tr>\n   <td>Pulmonary hemorrhage</td>\n   </tr>\n   <tr>\n   <td>Pulmonary hypertension</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Hematologic\n   </td>\n   <td>Methemoglobinemia</td>\n   </tr>\n   <tr>\n   <td>Polycythemia</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Decreased peripheral perfusion\n   </td>\n   <td>Acrocyanosis</td>\n   </tr>\n   <tr>\n   <td>Cold exposure</td>\n   </tr>\n   <tr>\n   <td>Shock</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"4\">\n   Altered skin coloration\n   </td>\n   <td>Extensive tattoos</td>\n   </tr>\n   <tr>\n   <td>External skin exposure to blue dye</td>\n   </tr>\n   <tr>\n   <td>Large pigmentary lesions (eg, Mongolian spots)</td>\n   </tr>\n   <tr>\n   <td>Treatment with amiodarone, silver</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">8/19/2009--Requested permission (JD). 9/27/2009--Permission granted; figure to Terrence, agreement mailed back to Arnetta (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=10631&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Causes_of_cyanosis_child.htm</title></head></div><div class=\"graphic_footnotes\">PPHN: persistent pulmonary hypertension of the newborn; FiO2: fractional concentration of inspired oxygen.<br> * Examples of pediatric etiologies.</div><div class=\"graphic_reference\">Reproduced with permission from: Stack AM. Cyanosis. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82520 Version 11.0</div></div></div>"},"82521":{"type":"graphic_table","displayName":"EuroSCORE risk index","title":"EuroSCORE risk prediction algorithm for cardiac surgical mortality","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">EuroSCORE risk prediction algorithm for cardiac surgical mortality</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Predictor</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Risk points*</td> </tr> <tr> <td>Age</td> <td>Per 5 years or part thereof over 60 years</td> <td>1</td> </tr> <tr> <td>Sex</td> <td>Female</td> <td>1</td> </tr> <tr> <td>Chronic pulmonary disease</td> <td>Long-term use of bronchodilators or steroids for lung disease</td> <td>1</td> </tr> <tr> <td rowspan=\"4\">Extracardiac arteriopathy</td> <td>Any one or more of the following:</td> <td rowspan=\"4\">2</td> </tr> <tr> <td class=\"sublist1\">claudication</td> </tr> <tr> <td class=\"sublist1\">carotid occlusion or &#62;50% stenosis</td> </tr> <tr> <td class=\"sublist1\">previous or planned intervention on the abdominal aorta, limb arteries, or carotids</td> </tr> <tr> <td>Neurological dysfunction</td> <td>Disease severely affecting ambulation or day-to-day functioning</td> <td>2</td> </tr> <tr> <td>Previous cardiac surgery</td> <td>Requiring opening of the pericardium</td> <td>3</td> </tr> <tr> <td>Serum creatinine</td> <td>&#62;200 micromol/L (2.3 mg/dL) preoperatively</td> <td>2</td> </tr> <tr> <td>Active endocarditis</td> <td>Patient still under antibiotic treatment for endocarditis at the time of surgery</td> <td>3</td> </tr> <tr> <td rowspan=\"7\">Critical preoperative state</td> <td>Any one or more of the following:</td> <td rowspan=\"7\">3</td> </tr> <tr> <td class=\"sublist1\">ventricular tachycardia or fibrillation or aborted sudden death</td> </tr> <tr> <td class=\"sublist1\">preoperative cardiac massage</td> </tr> <tr> <td class=\"sublist1\">preoperative ventilation before arrival in the anesthetic room</td> </tr> <tr> <td class=\"sublist1\">preoperative inotropic support</td> </tr> <tr> <td class=\"sublist1\">intraaortic balloon counterpulsation</td> </tr> <tr> <td class=\"sublist1\">preoperative acute renal failure (anuria or oliguria &#60;10 mL/hour)</td> </tr> <tr> <td>Unstable angina</td> <td>Rest angina requiring IV nitrates until arrival in the anesthetic room</td> <td>2</td> </tr> <tr> <td rowspan=\"2\">LV dysfunction</td> <td>Moderate or LV ejection fraction 30 to 50%</td> <td>1</td> </tr> <tr> <td>Poor or LV ejection fraction &#60;30%</td> <td>3</td> </tr> <tr> <td>Recent myocardial infarct</td> <td>&#60;90 days</td> <td>2</td> </tr> <tr> <td>Pulmonary hypertension</td> <td>Systolic pulmonary artery pressure &#62;60 mmHg</td> <td>2</td> </tr> <tr> <td>Emergency operation</td> <td>Carried out on referral before the beginning of the next working day</td> <td>2</td> </tr> <tr> <td>Other than isolated CABG</td> <td>Major cardiac procedure other than or in addition to CABG </td> <td>2</td> </tr> <tr> <td>Surgery on thoracic aorta</td> <td>For disorder of ascending, arch or descending aorta</td> <td>3</td> </tr> <tr> <td>Postinfarct septal rupture</td> <td>&nbsp;</td> <td>4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; LV: left ventricle; CABG: coronary artery bypass grafting.<br> * To calculate the estimated perioperative mortality risk, the sum of the risk points is determined. Scores are stratified into low risk (0 to 2 points; estimated mortality 1.3 percent), medium risk (3 to 5 points; estimated mortality 2.9 percent) and high risk (≥6 points; estimated mortality 10.9 to 11.5 percent).</div><div class=\"graphic_reference\">Reproduced with permission from: Nashed SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16:9. Copyright © 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 82521 Version 4.0</div></div></div>"},"82522":{"type":"graphic_table","displayName":"Reflex examination score","title":"Reflex examination score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reflex examination score</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1\">Score</td>\n\t    <td class=\"subtitle1\">Description</td>\n\t  </tr>\n\t  <tr>\n\t    <td>0</td>\n\t    <td>Reflex absent</td>\n\t  </tr>\n\t  <tr>\n\t    <td>1</td>\n\t    <td>Reflex slight, less than normal (includes a trace response or a response brought out only by reinforcement)</td>\n\t  </tr>\n\t  <tr>\n\t    <td>2</td>\n\t    <td>Reflex in lower half of normal range</td>\n\t  </tr>\n\t  <tr>\n\t    <td>3</td>\n\t    <td>Reflex in upper half of normal range</td>\n\t  </tr>\n\t  <tr>\n\t    <td>4</td>\n\t    <td>Reflex enhanced, more than normal (includes clonus if present)</td>\n\t  </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">1/23/2010--Requested permission (JD). 2/1/2010--Permission granted; figure to Terrence (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=12936&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Reflex_exam_score.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Hallet M. NINDS myotatic reflex scale. Neurology 1993; 43:2723. Copyright © 1993 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82522 Version 12.0</div></div></div>"},"82523":{"type":"graphic_algorithm","displayName":"Dx pancreatic cancer algorithm","title":"Pancreatic cancer diagnosis algorithm","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Pancreatic cancer diagnosis algorithm</div><div class=\"cntnt\"><img style=\"width:714px; height:818px;\" src=\"images/GAST/82523_Dx_pancreatic_cancer_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; Mets: metastases; ERCP: endoscopic retrograde cholangiopancreatography; MRCP: magnetic resonance cholangiopancreatography; FNA: fine-needle aspiration; EUS: endoscopic ultrasound; MDCT: multidetector row computed tomography.<br />* If the clinical suspicion for malignancy is high, obtaining an EUS is reasonable to exclude a small pancreatic cancer.<br />¶ Based on symptomatology and the appearance of the mass or stricture.</div><div id=\"graphicVersion\">Graphic 82523 Version 6.0</div></div></div>"},"82526":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber carcinoid","title":"Carcinoid heart disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carcinoid heart disease</div><div class=\"cntnt\"><img style=\"width:252px; height:382px;\" src=\"images/CARD/82526_Apical_4_chamber_carcinoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber views in systole (panel A) and diastole (panel B) show thickened and shortened tricuspid valve leaflets (TVL) and enlargement of the right atrium (RA) and ventricle (RV). Characteristically, the diseased tricuspid leaflets stay in a nearly fixed and open position regardless of phase of the the cardiac cycle. Thus, they are both stenotic, because they fail to open, and insufficient, because they fail to close. The degree of insufficiency almost always greatly exceeds the degree of stenosis.</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium; MV: mitral valve.</div><div id=\"graphicVersion\">Graphic 82526 Version 2.0</div></div></div>"},"82528":{"type":"graphic_diagnosticimage","displayName":"Fused SPECT-CT of right inguinal sentinel node","title":"Fused SPECT-CT of right inguinal sentinel node","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fused SPECT-CT of right inguinal sentinel node</div><div class=\"cntnt\"><img style=\"width:435px; height:514px;\" src=\"images/ONC/82528_Fused_SPECT_ingu_sent_node.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Kevin Donohoe.</div><div id=\"graphicVersion\">Graphic 82528 Version 3.0</div></div></div>"},"82529":{"type":"graphic_picture","displayName":"Morphea and lichen sclerosus","title":"Morphea and lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Morphea and lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:432px; height:260px;\" src=\"images/DERM/82529_Morphea_lichen_sclerosus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sclerotic lesions of morphea with overlying hypopigmented, finely wrinkled skin are present.</div><div id=\"graphicVersion\">Graphic 82529 Version 1.0</div></div></div>"},"82531":{"type":"graphic_waveform","displayName":"Basic case 11 with answer","title":"Ectopic atrial rhythm","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Ectopic atrial rhythm</div><div class=\"cntnt\"><img style=\"width:540px; height:95px;\" src=\"images/CARD/82531_Basic_case_11_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rhythm strip in lead II showing ectopic atrial rhythm with inverted P waves which represent a low atrial focus with retrograde activation of the atrium.</div><div class=\"graphic_reference\">Courtesy of Ary L Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 82531 Version 2.0</div></div></div>"},"82533":{"type":"graphic_table","displayName":"Adverse effects of antipsychotic meds","title":"Selected adverse effects of antipsychotic medications for schizophrenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected adverse effects of antipsychotic medications for schizophrenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Weight gain/diabetes mellitus</td> <td class=\"subtitle1\">Hyper-cholesterolemia</td> <td class=\"subtitle1\">EPS/TD</td> <td class=\"subtitle1\">Prolactin elevation</td> <td class=\"subtitle1\">Sedation</td> <td class=\"subtitle1\">Anticholinergic side effects</td> <td class=\"subtitle1\">Orthostatic hypotension</td> <td class=\"subtitle1\">QTc prolongation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">First generation agents</td> </tr> <tr> <td class=\"indent1\">Chlorpromazine</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Fluphenazine</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">ND</td> </tr> <tr> <td class=\"indent1\">Haloperidol</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Loxapine</td> <td class=\"centered\">++</td> <td class=\"centered\">ND</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Perphenazine</td> <td class=\"centered\">++</td> <td class=\"centered\">ND</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">ND</td> </tr> <tr> <td class=\"indent1\">Pimozide</td> <td class=\"centered\">+</td> <td class=\"centered\">ND</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> </tr> <tr> <td class=\"indent1\">Thioridazine*</td> <td class=\"centered\">++</td> <td class=\"centered\">ND</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> <td class=\"centered\">++++</td> <td class=\"centered\">++++</td> <td class=\"centered\">+++</td> </tr> <tr> <td class=\"indent1\">Thiothixene</td> <td class=\"centered\">++</td> <td class=\"centered\">ND</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trifluoperazine</td> <td class=\"centered\">++</td> <td class=\"centered\">ND</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">ND</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Second generation agents</td> </tr> <tr> <td class=\"indent1\">Aripiprazole</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;/+</td> </tr> <tr> <td class=\"indent1\">Asenapine</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Brexpiprazole<sup><span style=\"font-size: 13px;\">&#182;</span></sup></td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;/+</td> </tr> <tr> <td class=\"indent1\">Cariprazine<sup><span style=\"font-size: 13px;\">&#182;</span></sup></td> <td class=\"centered\">&nbsp;+</td> <td class=\"centered\">&nbsp;&ndash;/+</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;/+&nbsp;</td> <td class=\"centered\">&ndash;/+&nbsp;</td> </tr> <tr> <td class=\"indent1\">Clozapine<sup>&#916;</sup></td> <td class=\"centered\">++++</td> <td class=\"centered\">++++</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Iloperidone</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> </tr> <tr> <td class=\"indent1\">Lurasidone</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;/+</td> </tr> <tr> <td class=\"indent1\">Olanzapine</td> <td class=\"centered\">++++</td> <td class=\"centered\">++++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Paliperidone</td> <td class=\"centered\">+++</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Pimavanserin</td> <td class=\"centered\">+</td> <td class=\"centered\">-</td> <td class=\"centered\">-/+</td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">++&nbsp;</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Quetiapine</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Risperidone</td> <td class=\"centered\">+++</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Ziprasidone</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Adverse effects may be dose dependent.</div><div class=\"graphic_footnotes\">EPS: extrapyramidal symptoms; TD: tardive dyskinesia; ND: no data.<br />* Thioridazine is also associated with dose-dependent retinitis pigmentosa. Refer to text.<br />¶ Based upon limited experience.<br />Δ&nbsp;Clozapine also causes granulocytopenia or agranulocytosis in approximately 1 percent of patients requiring regular blood cell count monitoring. Clozapine has been associated with excess risk of myocarditis and venous thromboembolic events including fatal pulmonary embolism. These issues are addressed in the UpToDate topic review of guidelines for prescribing clozapine section on adverse effects.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2017 Lexicomp, Inc. All Rights Reserved.</LI>&#xD;&#xA;<LI>The Medical Letter on Drugs and Therapeutics (April 2016); Some&nbsp;Relative Adverse Effects of Second-Generation&nbsp;Antipsychotics&nbsp;(table 3);&nbsp;Vol. 58 (1493):52. <A href=\"http://www.medicalletter.org/\" target=_blank>www.medicalletter.org</A>.</LI>&#xD;&#xA;<LI>Rummel-Kluge C, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123:225.</LI>&#xD;&#xA;<LI>Durán CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol 2013; 69:1485.</LI></OL></div><div id=\"graphicVersion\">Graphic 82533 Version 27.0</div></div></div>"},"82534":{"type":"graphic_figure","displayName":"Self-retaining retractor","title":"Self-retaining retractor","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Self-retaining retractor</div><div class=\"cntnt\"><img style=\"width:519px; height:486px;\" src=\"images/SURG/82534_Bilateral-Thompson-retractor.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82534 Version 2.0</div></div></div>"},"82536":{"type":"graphic_diagnosticimage","displayName":"Displaced oblique metatarsal shaft fracture","title":"Displaced oblique metatarsal shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Displaced oblique metatarsal shaft fracture</div><div class=\"cntnt\"><img style=\"width:301px; height:432px;\" src=\"images/RHEUM/82536_Displaced_oblique_mt_shaft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On this view, there is minimal displacement of the fracture in the fourth metatarsal shaft (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Eiff MP, Hatch RL Calmbach, W (Eds). Fracture Management for Primary Care, 2nd Edition, W.B. Saunders Company, Philadelphia 2002. Copyright © 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 82536 Version 3.0</div></div></div>"},"82537":{"type":"graphic_table","displayName":"Long-term outcome in RA","title":"Natural history and prognosis of rheumatoid arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Natural history and prognosis of rheumatoid arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>70 percent of joint erosions detectable by x-ray of hands and feet occur in the first two years of disease</td> </tr> <tr> <td>At 20 years, over 60 percent of patients with RA belong to functional class III (significantly impaired, self-caring, using aids, requiring joint replacements) or class IV (loss of independence requiring daily care)</td> </tr> <tr> <td class=\"sublist1_start\">Increased incidence of:</td> </tr> <tr> <td class=\"sublist1\">Infections</td> </tr> <tr> <td class=\"sublist1\">Cardiovascular disease</td> </tr> <tr> <td class=\"sublist1\">Lymphomas</td> </tr> <tr> <td class=\"sublist1_start\">Life expectancy of RA less than age/sex-matched control populations, especially in patients with one or more of the following:</td> </tr> <tr> <td class=\"sublist1\">Polyarticular disease</td> </tr> <tr> <td class=\"sublist1\">Systemic extraarticular disease</td> </tr> <tr> <td class=\"sublist1\">Persistent disease activity (high ESR, CRP)</td> </tr> <tr> <td class=\"sublist1\">Positive rheumatoid factor and circulating immune complex</td> </tr> <tr> <td class=\"sublist1\">HLA-DR&nbsp;beta chain \"shared epitope,\" especially if bialleic</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82537 Version 2.0</div></div></div>"},"82538":{"type":"graphic_figure","displayName":"Seasonal pattern MI","title":"Incidence of MI is lowest during the summer","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Incidence of MI is lowest during the summer</div><div class=\"cntnt\"><img style=\"width:481px; height:260px;\" src=\"images/CARD/82538_SeasonalpatternMI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Analysis of 259,891 patients hospitalized for an acute myocardial infarction (MI) demonstrates a gradual decline in the number of MIs during the spring, reaching a nadir in the summer, and an increase during the fall, reaching a maximum in the winter. Approximately 53 percent more infarctions occurred in the winter or spring compared&nbsp;with the summer.</div><div class=\"graphic_reference\">Data from Spencer, FA, Goldberg, RJ, Becker, RC, et al, and the Participants in the National Registry of Myocardial Infarction, J Am Coll Cardiol 1998; 31:1226.</div><div id=\"graphicVersion\">Graphic 82538 Version 2.0</div></div></div>"},"82539":{"type":"graphic_table","displayName":"Risk acalculous cholecystitis","title":"Risk factors for acute acalculous cholecystitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for acute acalculous cholecystitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Acute myelogenous leukemia</td> </tr> <tr> <td>Acquired immune deficiency syndrome</td> </tr> <tr> <td>Ampullary stenosis</td> </tr> <tr> <td>Bone marrow transplantation</td> </tr> <tr> <td>Burns</td> </tr> <tr> <td>Cardiopulmonary resuscitation</td> </tr> <tr> <td>Childbirth</td> </tr> <tr> <td>Choledochal cyst</td> </tr> <tr> <td>Cholesterol emboli</td> </tr> <tr> <td>Coronary heart disease</td> </tr> <tr> <td>Cystic duct obstruction by a percutaneous transhepatic catheter in the bile duct</td> </tr> <tr> <td>Diabetes mellitus</td> </tr> <tr> <td>End-stage renal disease</td> </tr> <tr> <td>Heart failure</td> </tr> <tr> <td>Hemobilia</td> </tr> <tr> <td>Immunosuppression</td> </tr> <tr> <td>Infections</td> </tr> <tr> <td>Major trauma</td> </tr> <tr> <td>Mechanical ventilation</td> </tr> <tr> <td>Medications (eg, opiates, sunitinib)</td> </tr> <tr> <td>Metastases to porta hepatis</td> </tr> <tr> <td>Multiple transfusions</td> </tr> <tr> <td>Nonbiliary surgery</td> </tr> <tr> <td>Sepsis/hypotension</td> </tr> <tr> <td>Total parenteral nutrition</td> </tr> <tr> <td>Vasculitis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82539 Version 3.0</div></div></div>"},"82540":{"type":"graphic_figure","displayName":"Major arteries and nerves of the anterior elbow region","title":"Major arteries and nerves of the anterior elbow region","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Major arteries and nerves of the anterior elbow region</div><div class=\"cntnt\"><img style=\"width:496px; height:495px;\" src=\"images/EM/82540_Anteriorviewrightelbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The brachial artery runs along the anteromedial aspect of the humerus. As the artery extends into the forearm, it splits into the radial and ulnar artery. The median nerve crosses the elbow joint with the brachial artery. The anterior interosseous nerve is the branch of the median nerve most commonly injured after supracondylar fractures in children. The radial nerve runs lateral to the humerus before crossing the elbow. The ulnar nerve crosses the elbow posterior to the medial epicondyle in the cubital tunnel.</div><div id=\"graphicVersion\">Graphic 82540 Version 5.0</div></div></div>"},"82542":{"type":"graphic_picture","displayName":"Erysipelas of the leg","title":"Erysipelas of the leg","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Erysipelas of the leg</div><div class=\"cntnt\"><img style=\"width:504px; height:381px;\" src=\"images/ID/82542_Erysipelas_of_leg_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erysipelas of the lower leg. The rash is intensely red, sharply demarcated, swollen, and indurated.</div><div class=\"graphic_reference\">Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82542 Version 3.0</div></div></div>"},"82544":{"type":"graphic_picture","displayName":"Alcoholic steatohepatitis and cirrhosis - low power","title":"Alcoholic steatohepatitis and cirrhosis in a 35-year-old woman (low power, Masson trichrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alcoholic steatohepatitis and cirrhosis in a 35-year-old woman (low power, Masson trichrome)</div><div class=\"cntnt\"><img style=\"width:432px; height:240px;\" src=\"images/GAST/82544_Alc_steatohep_cirrhosis_low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This section of the liver biopsy demonstrated more inflammation and scarring than what was seen&nbsp;in other&nbsp;sections from the same patient.</div><div class=\"graphic_reference\">Courtesy of Marshall M Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 82544 Version 2.0</div></div></div>"},"82546":{"type":"graphic_picture","displayName":"Serous cystadenoma Light II","title":"Pancreatic serous cystadenoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pancreatic serous cystadenoma</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/GAST/82546_Serous_cystadenoma_Light_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light microscopic appearance of a pancreatic serous cystadenoma (H&amp;E stain). Note cuboidal cells lining cystic spaces and amorphous stroma.</div><div class=\"graphic_reference\">Courtesy of Michael L Steer, MD.</div><div id=\"graphicVersion\">Graphic 82546 Version 2.0</div></div></div>"},"82547":{"type":"graphic_table","displayName":"Major congenital malformations","title":"Major congenital malformations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major congenital malformations</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Head and craniofacial structures</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">Skull</td>\n</tr>\n<tr>\n<td class=\"indent1\">Anencephaly</td>\n</tr>\n<tr>\n<td class=\"indent1\">Encephalocele (occipital, frontal)</td>\n</tr>\n<tr>\n<td class=\"indent1\">Holoprosencephaly</td>\n</tr>\n<tr>\n<td class=\"indent1\">Hydrocephaly</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">Eyes</td>\n</tr>\n<tr>\n<td class=\"indent1\">Microphthalmia</td>\n</tr>\n<tr>\n<td class=\"indent1\">Anophthalmia</td>\n</tr>\n<tr>\n<td class=\"indent1\">Colobomas (iris, retina)</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">Ears</td>\n</tr>\n<tr>\n<td class=\"indent1\">Severe microtia</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">Mouth and throat</td>\n</tr>\n<tr>\n<td class=\"indent1\">Cleft lip</td>\n</tr>\n<tr>\n<td class=\"indent1\">Cleft palate</td>\n</tr>\n<tr>\n<td class=\"indent1\">Severe micrognathia (Robin sequence)</td>\n</tr>\n<tr>\n<td class=\"indent1\">Macro or microglossia</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Neck</td>\n</tr>\n<tr>\n<td>Cystic hygroma</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Chest</td>\n</tr>\n<tr>\n<td>Pectus excavatum</td>\n</tr>\n<tr>\n<td>Absent or hypoplastic clavicles</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Back</td>\n</tr>\n<tr>\n<td>Meningomyelocele</td>\n</tr>\n<tr>\n<td>Spina bifida</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Abdomen</td>\n</tr>\n<tr>\n<td>Omphalocele</td>\n</tr>\n<tr>\n<td>Gastrochisis</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Genitalia</td>\n</tr>\n<tr>\n<td>Ambiguous genitalia</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Extremities</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">Arms</td>\n</tr>\n<tr>\n<td class=\"indent1\">Absent or limb deficiencies</td>\n</tr>\n<tr>\n<td class=\"subtitle2_single\">Hands and feet</td>\n</tr>\n<tr>\n<td class=\"indent1\">Polydactyly, complete syndactyly, polysyndactyly</td>\n</tr>\n<tr>\n<td class=\"indent1\">Absent digits</td>\n</tr>\n<tr>\n<td class=\"indent1\">Ectrodactyly</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Cardiovascular and great vessels</td>\n</tr>\n<tr>\n<td>Tetralogy of Fallot</td>\n</tr>\n<tr>\n<td>Truncus arteriosus</td>\n</tr>\n<tr>\n<td>Hypoplastic left heart</td>\n</tr>\n<tr>\n<td>Ventricular or atrial septal defect</td>\n</tr>\n<tr>\n<td>Transposition of the great vessels</td>\n</tr>\n<tr>\n<td>Interrupted aortic arch type B</td>\n</tr>\n<tr>\n<td>Total anomaly of pulmonary venous return</td>\n</tr>\n<tr>\n<td>Hypoplasia or coarctation of the aorta</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=53742&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Major_malformations.htm</title></head></div><div id=\"graphicVersion\">Graphic 82547 Version 2.0</div></div></div>"},"82548":{"type":"graphic_algorithm","displayName":"Epistaxis management algorithm","title":"Flow diagram for management of epistaxis in adults","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Flow diagram for management of epistaxis in adults</div><div class=\"cntnt\"><img style=\"width:484px; height:557px;\" src=\"images/EM/82548_Epistaxis_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ENT: ears, nose, and throat.</div><div id=\"graphicVersion\">Graphic 82548 Version 3.0</div></div></div>"},"82549":{"type":"graphic_figure","displayName":"Structure of the insulin receptor extra-cellular domain","title":"Structure of the insulin receptor extra-cellular domain","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Structure of the insulin receptor extra-cellular domain</div><div class=\"cntnt\"><img style=\"width:511px; height:519px;\" src=\"images/ENDO/82549_Structureinsulinrecepedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The receptor domains in all panels are colored as follows: L1 domain, magenta; cysteine rich domain, yellow; L2 domain, green; FnIII-1 domain, red; FnIII-2 domain, cyan; FnIII-3 domain, purple.<BR>(A) Domain structure of the receptor monomer: The extra-cellular receptor monomer is depicted in ribbon representation to show secondary structural elements. The Insert Domain which is not visualized in the crystal structure is designated by the locations of its N- and C-termini.<BR>(B) Receptor dimer: This illustrates the inverted V conformation. The monomer in front is shown in tube representation and that in the rear in surface representation. The position of the major inter α-cystine (Cys 524-Cys 524) is shown.<BR>(C) Insulin binding sites: Side view of dimer rotated 90 degrees counter-clockwise around the vertical axis from the view in B. Receptor monomers are shown in ribbon representation and the heavy black lines designate the approximate locations of the insulin binding sites. The cell membrane would be located at the bottom of each panel.</div><div class=\"graphic_reference\">Courtesy of Dr. Jonathan Whittaker, based on the coordinates of PDB structure 2DTG.</div><div id=\"graphicVersion\">Graphic 82549 Version 6.0</div></div></div>"},"82552":{"type":"graphic_diagnosticimage","displayName":"Intracardiac echocardiography mitral stenosis 1","title":"Intracardiac echocardiography mitral stenosis 1","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Intracardiac echocardiography mitral stenosis 1</div><div class=\"cntnt\"><img style=\"width:504px; height:180px;\" src=\"images/CARD/82552_ICE_mitral_stenosis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intracardiac ultrasound examination shows a stenotic mitral valve with some leaflet thickening and a hockey-stick appearance of the anterior mitral valve leaflet.</div><div id=\"graphicVersion\">Graphic 82552 Version 3.0</div></div></div>"},"82553":{"type":"graphic_diagnosticimage","displayName":"RB ILD CT II","title":"Respiratory bronchiolitis-associated interstitial lung disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Respiratory bronchiolitis-associated interstitial lung disease</div><div class=\"cntnt\"><img style=\"width:370px; height:287px;\" src=\"images/PULM/82553_RB_ILD_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution CT scan (1.5 mm thick section) in a 35-year-old woman with heavy smoking history and progressive dyspnea with exertion. Extensive ground-glass opacities are seen more clearly than on conventional CT scan (5 mm thick section).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 82553 Version 3.0</div></div></div>"},"82554":{"type":"graphic_picture","displayName":"Cytology pancreatic cancer","title":"Fine needle aspirate of pancreatic cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fine needle aspirate of pancreatic cancer</div><div class=\"cntnt\"><img style=\"width:288px; height:294px;\" src=\"images/GAST/82554_Cytology_pancreatic_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cluster of malignant cells is seen in this aspirate taken from a patient with a pancreatic mass.</div><div class=\"graphic_reference\">Courtesy of Michael L Steer, MD.</div><div id=\"graphicVersion\">Graphic 82554 Version 1.0</div></div></div>"},"82556":{"type":"graphic_figure","displayName":"ACIj equation","title":"Equation for calculation of alternans correlation index (ACI) at each time sample (ACIj)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Equation for calculation of alternans correlation index (ACI) at each time sample (ACIj)</div><div class=\"cntnt\"><img style=\"width:375px; height:135px;\" src=\"images/CARD/82556_ACIj_equation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82556 Version 1.0</div></div></div>"},"82558":{"type":"graphic_figure","displayName":"Regression of LV hypertrophy with antihypertensive therapy","title":"Regression of left ventricular hypertrophy with antihypertensive therapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Regression of left ventricular hypertrophy with antihypertensive therapy</div><div class=\"cntnt\"><img style=\"width:407px; height:287px;\" src=\"images/NEPH/82558_RegressionofLVHinHTN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of therapy with each of five antihypertensive drug classes on reduction in&nbsp;LV mass in patients with hypertension. These data represent a meta-analysis of 80 trials of over 4100 patients. The decrease in&nbsp;LV mass index, adjusted for the duration of therapy and diastolic pressure, was significantly higher with angiotensin II receptor blockers (13%), calcium channel blockers (11%), and&nbsp;ACE&nbsp;inhibitors (10%) compared with beta blockers (6%).</div><div class=\"graphic_footnotes\">LV: left ventricular; ACE: angiotensin-converting enzyme.</div><div class=\"graphic_reference\">Data from: Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41.</div><div id=\"graphicVersion\">Graphic 82558 Version 6.0</div></div></div>"},"82560":{"type":"graphic_waveform","displayName":"Atrial pacemaker tutorial","title":"Atrial  pacing","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial  pacing</div><div class=\"cntnt\"><img style=\"width:290px; height:125px;\" src=\"images/CARD/82560_Atrial_pacemaker_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A single pacemaker spike (marked by red lines) is followed by a P wave, normal PR interval, and normal QRS complex.</div><div id=\"graphicVersion\">Graphic 82560 Version 3.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"82561":{"type":"graphic_picture","displayName":"Macular erythema in toxic shock syndrome","title":"Toxic shock syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toxic shock syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/82561_Macular_erythema_tss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Macular erythema in toxic shock syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82561 Version 3.0</div></div></div>"},"82562":{"type":"graphic_diagnosticimage","displayName":"Small pericardial effusion I","title":"Pericardial effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial effusion</div><div class=\"cntnt\"><img style=\"width:371px; height:288px;\" src=\"images/CARD/82562_Small_pericardial_effusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the apical four-chamber view from a patient with a small pericardial effusion (pe), the pe is seen best behind and above the right atrium (RA), which is the most sensitive area for detecting small effusions. In larger pe, the RA collapses at this point, providing a highly sensitive, but minimally specific sign of cardiac tamponade.</div><div class=\"graphic_footnotes\">LV: left ventricle; RV: right ventricle; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 82562 Version 3.0</div></div></div>"},"82563":{"type":"graphic_diagnosticimage","displayName":"Roux stasis syndrome after gastric bypass","title":"Roux stasis syndrome after gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Roux stasis syndrome after gastric bypass</div><div class=\"cntnt\"><img style=\"width:432px; height:431px;\" src=\"images/SURG/82563_Roux_stasis_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Roux stasis syndrome with contrast held up in the Roux limb.</div><div id=\"graphicVersion\">Graphic 82563 Version 4.0</div></div></div>"},"82564":{"type":"graphic_figure","displayName":"Lymph nodes neck child PI","title":"Lymph nodes in a child's neck","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Lymph nodes in a child's neck</div><div class=\"cntnt\"><img style=\"width:512px; height:502px;\" src=\"images/PI/82564_Lymph-nodes-neck-child-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph nodes are pea-shaped organs. This drawing shows where the lymph nodes in a child’s neck are.</div><div id=\"graphicVersion\">Graphic 82564 Version 1.0</div></div></div>"},"82565":{"type":"graphic_diagnosticimage","displayName":"Breast MRI screening of BRCA carrier","title":"Breast MRI screening of BRCA carrier","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Breast MRI screening of BRCA carrier</div><div class=\"cntnt\"><img style=\"width:432px; height:232px;\" src=\"images/SURG/82565_Br_MRI_screen_BRCA_carrier.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast MRI is useful for screening women with genetic mutations that confer a very high risk for breast cancer. The figure depicts a breast MRI that was performed on a BRCA-1 gene carrier, revealing a focal circumscribed mass in left breast not visible on mammography (arrow). MR-guided core biopsy confirmed an invasive ductal carcinoma.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; BRCA: breast cancer susceptibility gene; MR: magnetic resonance.</div><div id=\"graphicVersion\">Graphic 82565 Version 4.0</div></div></div>"},"82567":{"type":"graphic_table","displayName":"Overview of selective serotonin reuptake inhibitor poisoning","title":"Overview of selective serotonin reuptake inhibitor (SSRI) poisoning","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of selective serotonin reuptake inhibitor (SSRI) poisoning</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\"><span style=\"color: #0000ff;\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</span></a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Overview</td> </tr> <tr> <td>SSRIs rarely cause significant toxicity in isolated ingestions</td> </tr> <tr> <td>Search for coingestants in any patient with significant symptoms</td> </tr> <tr> <td>Serotonin syndrome, seizure, and QTc prolongation are rare but dangerous complications</td> </tr> <tr> <td>Citalopram is the most toxic SSRI in overdose</td> </tr> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td>Ascertain the drugs ingested (including coingestants and formulations)</td> </tr> <tr> <td>Ascertain the amounts ingested and when the ingestion occurred</td> </tr> <tr> <td class=\"subtitle1_single\">Physical examination</td> </tr> <tr> <td>First, assess and secure airway, breathing, and circulation</td> </tr> <tr> <td>Examination usually unremarkable; infrequently drowsiness, tremor, and vomiting can occur</td> </tr> <tr> <td>Evaluate for serotonin syndrome: hyperthermia, diaphoresis, ocular clonus, hypertonia, tremor, lower extremity hyperreflexia, ankle clonus</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory evaluation</td> </tr> <tr> <td>Obtain the following: acetaminophen and salicylate serum concentrationss; serum ethanol concentration; electrocardiogram (ECG); serum bicarbonate; pregnancy test in women of childbearing age</td> </tr> <tr> <td>Obtain serial ECGs if QRS or QTc interval is prolonged on initial ECG; admit patient if conduction abnormalities persist; citalopram and escitalopram are most likely to cause prolonged intervals</td> </tr> <tr> <td>Obtain the following if severe serotonin syndrome is suspected: creatine kinase, urine myoglobin; serum creatinine; serum aminotransferases; coagulation studies (aPTT, PT, INR, platelet count, d-dimer); arterial blood gas</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Most SSRI ingestions cause minimal toxicity; supportive care is generally sufficient</td> </tr> <tr> <td>Secure airway, breathing, and circulation; intubate as clinically indicated</td> </tr> <tr> <td>Give one dose only of activated charcoal (1 g/kg; standard adult dose is 50 g) <strong>without</strong> additives</td> </tr> <tr> <td>Avoid additional serotonergic agents</td> </tr> <tr> <td>Treat seizures with benzodiazepines (eg, lorazepam 1 to 2 mg IV every five minutes as needed)</td> </tr> <tr> <td>Treat prolonged QRS interval with sodium bicarbonate: 1 to 2 meq/kg IV push; if QRS narrows with bicarbonate bolus, infuse bicarbonate: approximately 133 meq NaHCO3 in one liter D5W, at 250 mL/hour in adults, or twice maintenance fluid infusion rate in children</td> </tr> <tr> <td>Observe patients with prolonged QTc for development of torsades</td> </tr> <tr> <td>Treat torsades with magnesium sulfate (Mg): initial dose 2 g IV over two minutes; may repeat after 10 minutes; infusion may be needed</td> </tr> <tr> <td>For management of serotonin syndrome, see separate UpToDate topic</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82567 Version 9.0</div></div></div>"},"82568":{"type":"graphic_table","displayName":"Functional classificat HF","title":"Functional classification of patients with heart failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Functional classification of patients with heart failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Severity</td> <td class=\"subtitle1\">VO<sub>2</sub>max, mL/kg/min</td> <td class=\"subtitle1\">Anaerobic threshold, mL/kg/min</td> <td class=\"subtitle1\">Maximal cardiac index, L/min/m<sup>2</sup></td> </tr> <tr> <td>A</td> <td>None to mild</td> <td>&#62;20</td> <td>&#62;14</td> <td>&#62;8</td> </tr> <tr> <td>B</td> <td>Mild to moderate</td> <td>16-20</td> <td>11-14</td> <td>6-8</td> </tr> <tr> <td>C</td> <td>Moderate to severe</td> <td>10-15</td> <td>8-11</td> <td>4-6</td> </tr> <tr> <td>D</td> <td>Severe</td> <td>6-9</td> <td>5-8</td> <td>2-4</td> </tr> <tr> <td>E</td> <td>Very severe</td> <td>&#60;6</td> <td>3-4</td> <td>&#60;2</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Weber KT, Janicki JS. CardioPulmonary Exercise Testing. Physiologic Principles and Clinical Applications. WB Saunders, Philadelphia, 1986.</div><div id=\"graphicVersion\">Graphic 82568 Version 4.0</div></div></div>"},"82569":{"type":"graphic_picture","displayName":"Nodular lymphoid hyperplasia High II","title":"Nodular lymphoid hyperplasia in Sjögren's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular lymphoid hyperplasia in Sj&#246;gren's syndrome</div><div class=\"cntnt\"><img style=\"width:346px; height:227px;\" src=\"images/PULM/82569_Pseudolymphoma_High_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows a focus of small lymphocytes, which proved polyclonal by immunostaining.</div><div class=\"graphic_reference\">From: Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 82569 Version 3.0</div></div></div>"},"82571":{"type":"graphic_table","displayName":"Properties beta blockers","title":"Beta blocker properties","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Beta blocker properties</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Alpha blockade</td> <td class=\"subtitle1\">Beta-1 selectivity</td> <td class=\"subtitle1\">ISA</td> <td class=\"subtitle1\">MSA</td> <td class=\"subtitle1\">Lipophilicity</td> <td class=\"subtitle1\">Usual dose*</td> <td class=\"subtitle1\">Half life, hours<sup>&#182;</sup></td> <td class=\"subtitle1\">Elimination</td> </tr> <tr> <td>Acebutolol</td> <td>No</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Low</td> <td>100 to 400 mg twice per day</td> <td>3 to 4</td> <td> <p>Hepatic (primary)</p> Renal (secondary)</td> </tr> <tr> <td>Atenolol</td> <td>No</td> <td>Yes</td> <td>No</td> <td>No</td> <td>Low</td> <td>50 to 200 mg once daily</td> <td>6 to 9</td> <td>Renal</td> </tr> <tr> <td>Betaxolol</td> <td>No</td> <td>Yes</td> <td>No</td> <td>Yes</td> <td>Low</td> <td>10 to 20 mg once daily</td> <td>14 to 22</td> <td> <p>Hepatic (primary)</p> Renal (secondary)</td> </tr> <tr> <td>Bisoprolol</td> <td>No</td> <td>Yes</td> <td>No</td> <td>No</td> <td>Moderate</td> <td>2.5 to 20 mg once daily</td> <td>9 to 12</td> <td>Renal and hepatic</td> </tr> <tr> <td>Carteolol</td> <td>No</td> <td>No</td> <td>Yes</td> <td>No</td> <td>Low</td> <td>2.5 to 5 mg once daily</td> <td>6</td> <td>Renal</td> </tr> <tr> <td>Carvedilol</td> <td>Yes</td> <td>No</td> <td>No</td> <td>Yes</td> <td>High</td> <td>3.125 to 25 mg twice per day</td> <td>7 to 10</td> <td> <p>Biliary (primary)</p> Hepatic (secondary)</td> </tr> <tr> <td>Esmolol</td> <td>No</td> <td>Yes</td> <td>No</td> <td>No</td> <td>Low</td> <td>IV only 250 to 500 micrograms/kg over one minute then 25 to 50 micrograms/kg per minute as IV infusion; titrate incrementally up to maximum of 300 microgram/kg per minute<sup>&#916;</sup></td> <td>9 minutes</td> <td>Blood esterases</td> </tr> <tr> <td>Labetalol</td> <td>Yes</td> <td>No</td> <td>Yes (Beta<sub>2</sub>)</td> <td>Low</td> <td>Moderate</td> <td> <p>IV 20 mg<sup>&#916;</sup></p> Orally 100-400 mg two or three times per day</td> <td>3 to 4</td> <td>Hepatic</td> </tr> <tr> <td>Metoprolol tartrate</td> <td>No</td> <td>Yes</td> <td>No</td> <td>Low</td> <td>Moderate</td> <td> <p>IV 1.25 to 5 mg<sup>&#916;</sup></p> Orally 25 to 100 mg two or three times per day</td> <td>3 to 4<br /> (7 to 9 hours in poor metabolizers)</td> <td>Hepatic via CYP2D6 (polymorphic)</td> </tr> <tr> <td>Metoprolol succinate (extended release)</td> <td>No</td> <td>Yes</td> <td>No</td> <td>Low</td> <td>Moderate</td> <td>Orally 50 to 400 mg once daily</td> <td>Apparent half-life prolonged by continuous osmotic release over ~20 hours</td> <td>Hepatic via CYP2D6 (polymorphic)<br /> </td> </tr> <tr> <td>Nadolol</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>Low</td> <td>40 to 160 mg once daily</td> <td>20 to 24</td> <td>Renal</td> </tr> <tr> <td>Nebivolol</td> <td>No</td> <td>Yes</td> <td>No</td> <td>No</td> <td>High</td> <td>5 to 40 mg once daily</td> <td>10 to 12<br /> (19 to 32 poor metabolizers)</td> <td>Hepatic</td> </tr> <tr> <td>Oxprenolol<sup>&#9674;</sup></td> <td>No</td> <td>No</td> <td>Yes</td> <td>Yes</td> <td>Moderate</td> <td>40 to 80 mg three times per day</td> <td>1.5</td> <td>Hepatic</td> </tr> <tr> <td>Penbutolol</td> <td>No</td> <td>No</td> <td>Yes</td> <td>No</td> <td>High</td> <td>10 to 40 mg once daily</td> <td>5</td> <td>Hepatic</td> </tr> <tr> <td>Pindolol</td> <td>No</td> <td>No</td> <td>Yes</td> <td>Low</td> <td>Moderate</td> <td>5 to 30 mg twice per day</td> <td>3 to 4</td> <td> <p>Hepatic (primary)</p> Renal (secondary)</td> </tr> <tr> <td>Propranolol</td> <td>No</td> <td>No</td> <td>No</td> <td>Yes</td> <td>High</td> <td> <p>IV 1 to 5 mg<sup>&#916;</sup></p> Orally 10 to 80 mg two to four times daily</td> <td>3 to 4</td> <td>Hepatic</td> </tr> <tr> <td>Sotalol<sup>&#167;</sup></td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>Low</td> <td>80 to 160 mg twice per day</td> <td>12</td> <td>Renal</td> </tr> <tr> <td>Timolol</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>Moderate</td> <td>10 to 30 mg twice per day</td> <td>4 to 5</td> <td> <p>Hepatic (primary)</p> Renal (secondary)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ISA: intrinsic sympathomimetic activity; MSA: membrane stabilizing activity; IV: intravenous.<br />* Range of usual, oral, anti-hypertensive dose, unless \"IV\" noted.<br />&para; Duration of hypotensive effect, in general, is longer than may be predicted by serum half-life.<br />&Delta; Usual initial IV dose. Subsequent dosing generally needed. See drug monograph for detail.<br /><span class=\"lozenge\">&loz;</span> Not available in US.<br />&sect; Sotalol has independent class III antiarrhythmic activity.</div><div class=\"graphic_reference\">Prepared with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Frishman WH, Alwarshetty M. &beta;-Adrenergic blockers in systemic hypertension pharmacokinetic considerations related to current guidelines. Clin Pharmacokinet 2002; 41:505.</li>&#xD;&#xA;    <li>Brubacher JR. &beta;-Adrenergic Antagonists. In: Goldfrank's Toxicologic Emergencies, 9th ed, Nelson LS (Ed), McGraw-Hill, New York 2010.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 82571 Version 9.0</div></div></div>"},"82572":{"type":"graphic_table","displayName":"Beta blocker poisoning - Rapid overview","title":"Beta blocker poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Beta blocker poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical and laboratory features</td> </tr> <tr> <td>Prominent features include hypotension and bradycardia</td> </tr> <tr> <td>Electrocardiogram can show PR prolongation or any bradydysrhythmia</td> </tr> <tr> <td>Beta-blockers with membrane-stabilizing activity may cause QRS prolongation</td> </tr> <tr> <td>Mild hyperkalemia and hypoglycemia may also be present</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td>Diagnosis depends on history and clinical presentation</td> </tr> <tr> <td>Assays for beta-blockers are not routinely available</td> </tr> <tr> <td>Toxicologic differential diagnosis for unexplained bradycardia includes beta blockers, calcium channel blockers, digoxin, and cholinergic agents</td> </tr> <tr> <td class=\"subtitle1_single\">Management</td> </tr> <tr> <td>Stabilize airway, breathing, and circulation</td> </tr> <tr> <td>Give boluses of isotonic IV fluids: give atropine 1 mg IV (up to 3 doses) for initial treatment of hypotension and bradycardia</td> </tr> <tr> <td> <p>For severe poisoning (eg, profound hypotension), give following treatments simultaneously (dosing given below): IV glucagon, IV calcium salts, vasopressor, IV high-dose insulin (with glucose), and IV lipid emulsion therapy.</p> For mild symptoms, give treatments in succession, but only if prior treatment is ineffective.</td> </tr> <tr> <td>Gastrointestinal decontamination: single dose activated charcoal; consider whole bowel irrigation if an extended-release preparation has been ingested</td> </tr> <tr> <td>Glucagon: give 5 mg IV bolus, if IV fluids and atropine ineffective; may be repeated if the initial bolus has no effect</td> </tr> <tr> <td>Calcium chloride (via central venous access) 10 to 20 mL of 10 percent solution <strong>OR</strong> calcium gluconate IV 30 to 60 mL of 10 percent solution</td> </tr> <tr> <td>Vasopressors (eg, epinephrine) can be used for hypotension</td> </tr> <tr> <td class=\"sublist1_start\">High-dose insulin and glucose:</td> </tr> <tr> <td class=\"sublist1\">Bolus of 1 unit/kg IV of regular, short-acting insulin, followed by</td> </tr> <tr> <td class=\"sublist1\">Continuous infusion of 0.5 units/kg per hour IV; titrate infusion upwards until hypotension corrected or dose reaches 2 units/kg per hour</td> </tr> <tr> <td>Intravenous lipid emulsion (20 percent solution): give 1.5 mL/kg over 2 minutes, followed by 1.5 mL/kg infusion over 60 minutes</td> </tr> <tr> <td>Other potential treatments include: sodium bicarbonate (eg, prolonged QRS), magnesium (ventricular dysrhythmia), intraaortic balloon pump, temporary transvenous pacing, and hemodialysis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82572 Version 15.0</div></div></div>"},"82573":{"type":"graphic_figure","displayName":"Amiodarone in EMIAT","title":"Effect of amiodarone after MI in EMIAT","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Effect of amiodarone after MI in EMIAT</div><div class=\"cntnt\"><img style=\"width:482px; height:501px;\" src=\"images/CARD/82573_Amiodarone_in_EMIAT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of amiodarone in 1486 postmyocardial patients who were randomized to amiodarone or placebo. When analyzed by baseline ejection fraction, amiodarone had no effect on all-cause mortality (top panel), but reduced the incidence of arrhythmic death or resuscitated cardiac arrest (bottom panel). The benefit was greatest in patients with an EF &#8804;30 percent (dashed lines).</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Data from Julian, DG, Camm, AJ, Frangin, G, et al. Lancet 1997; 349:667.</div><div id=\"graphicVersion\">Graphic 82573 Version 1.0</div></div></div>"},"82574":{"type":"graphic_table","displayName":"Characteristics of chromosomal breakage syndromes","title":"Characteristics of chromosomal breakage syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of chromosomal breakage syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Immunodeficiency</td> <td class=\"subtitle1\">Cancer predisposition</td> </tr> <tr> <td>Ataxia-telangiectasia</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Ataxia-telangiectasia like disorder</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Bloom syndrome</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Nijmegen breakage syndrome</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Fanconi's anemia</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">+</td> </tr> <tr> <td>Immunodeficiency/centrometric instability/facial anomalies syndrome</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Cockaynes syndromes</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Trichothiodystrophy</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Xeroderma pigmentosa</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> <tr> <td>DNA ligase I deficiency</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>PMS2 deficiency</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>DNA recombinase repair defects (DNA-PKcs, Artemis, DNA ligase 4, Cernunnos/XLF)</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DNA: deoxyribonucleic acid; PMS2: postmeiotic segregation increased, S. cerevisiae, 2; DNA-PKcs: protein kinase, DNA-activated, catalytic subunit; XLF: x-ray repair, complementing defective, in Chinese hampster, 4 (XRCC4)-like factor.</div><div class=\"graphic_reference\">Courtesy of Howard M Lederman, MD.</div><div id=\"graphicVersion\">Graphic 82574 Version 9.0</div></div></div>"},"82575":{"type":"graphic_picture","displayName":"Bronchoalveolar lavage in PAP","title":"Bronchoalveolar lavage in alveolar proteinosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoalveolar lavage in alveolar proteinosis</div><div class=\"cntnt\"><img style=\"width:224px; height:314px;\" src=\"images/PULM/82575_Bronchoalveolar_lavage_in_P.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">First two liters of proteinaceous material lavaged, as it appears after sedimentation. Three layers can be visualized: an upper foamy layer, a clear white middle layer, and a thick layer of dense proteinaceous material at the bottom. Lavages are repeated until the return fluid is clear.</div><div class=\"graphic_reference\">From Keller, CA, Frost, A, Cagle, PT, Abraham, JL, Chest 1995; 108:277.</div><div id=\"graphicVersion\">Graphic 82575 Version 2.0</div></div></div>"},"82576":{"type":"graphic_diagnosticimage","displayName":"Empyema due to Staphylococcus aureus","title":"Empyema due to <EM>Staphylococcus aureus</EM>","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Empyema due to <EM>Staphylococcus aureus</EM></div><div class=\"cntnt\"><img style=\"width:463px; height:448px;\" src=\"images/ID/82576_EmpyemadueStaphaureus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior (A) and lateral (B) chest radiographs show large loculated right pleural effusion (arrows). Cross-sectional (C) contrast-enhanced multidetector computed tomography (CT) image and sagittal reformation (D) demonstrate the extent of the loculated effusion, pleural thickening, and enhancement (arrows). The patient was a 44-year-old man and an intravenous drug user. He had no radiologic evidence of the septic embolism.</div><div class=\"graphic_reference\">Reproduced with permission from: Müller NL, Franquet T, Lee KS, Silva CIS. Bacterial pneumonia. In: Imaging of pulmonary infections, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82576 Version 12.0</div></div></div>"},"82578":{"type":"graphic_diagnosticimage","displayName":"Retained surgical sponge on plain abdominal film","title":"Retained surgical sponge on plain abdominal film","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retained surgical sponge on plain abdominal film</div><div class=\"cntnt\"><img style=\"width:398px; height:576px;\" src=\"images/SURG/82578_Gossypiboma_plain_abd_film.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior view of an enema study in a 28-year-old woman. Area of stricture involving the descending colon (thick arrow) is caused by extrinsic compression from a retained surgical sponge (ie, gossypiboma). Note the soft-tissue mass with gas bubbles next to stricture (thin arrows).</div><div class=\"graphic_reference\">From: Manzella A, Filho PB, Albuquerque E, et al. Imaging of gossypibomas: Pictorial review. AJR Am J Roentgenol 2009; 193:S94. Reprinted with permission from the American Journal of Roentgenology. Copyright © 2009 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 82578 Version 10.0</div></div></div>"},"82579":{"type":"graphic_figure","displayName":"Collateral circulation between external and internal carotid","title":"Collateral circulation between external and internal carotid arteries","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Collateral circulation between external and internal carotid arteries</div><div class=\"cntnt\"><img style=\"width:541px; height:613px;\" src=\"images/SURG/82579_Collateral-circulation-between-external-internal-carotid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The facial, maxillary, and occipital branches of the external carotid artery can supply collateral blood flow to the intracerebral internal carotid artery branches when the extracerebral internal carotid artery is occluded.<br />Although the Circle of Willis is the more important source of intracerebral collateral flow from the contralateral internal carotid or vertebral arteries, external carotid collateral flow becomes more significant when multiple cervical vessels (carotid, vertebral) are occluded or in those patients with an incomplete Circle of Willis.</div><div id=\"graphicVersion\">Graphic 82579 Version 4.0</div></div></div>"},"82580":{"type":"graphic_table","displayName":"Cancer deaths in women 2012","title":"Estimated cancer deaths for United States women in 2012","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated cancer deaths for United States women in 2012</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Site </td> <td class=\"subtitle1\">Number of deaths </td> <td class=\"subtitle1\">Percent of cancer deaths </td> </tr> <tr> <td>Lung</td> <td>72,590</td> <td>26 percent</td> </tr> <tr> <td>Breast</td> <td>39,510</td> <td>14 percent</td> </tr> <tr> <td>Colon and rectum</td> <td>25,220</td> <td>9&nbsp;percent</td> </tr> <tr> <td>Leukemia and lymphomas</td> <td>19,180</td> <td>7 percent</td> </tr> <tr> <td>Ovary</td> <td>15,500</td> <td>6 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Siegel R, et al. CA-Cancer Journal for Clinicians 2012; 62:10.</div><div id=\"graphicVersion\">Graphic 82580 Version 5.0</div></div></div>"},"82581":{"type":"graphic_diagnosticimage","displayName":"Posterior fossa epidural hematoma","title":"Posterior fossa epidural hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior fossa epidural hematoma</div><div class=\"cntnt\"><img style=\"width:289px; height:352px;\" src=\"images/EM/82581_Posterior_fossa_EDH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rapid deterioration in previously awake patients with this type of injury is a major concern.</div><div id=\"graphicVersion\">Graphic 82581 Version 3.0</div></div></div>"},"82582":{"type":"graphic_diagnosticimage","displayName":"PTC cholangiocarcinoma","title":"Cholangiocarcinoma demonstrated by percutaneous transhepatic cholangiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholangiocarcinoma demonstrated by percutaneous transhepatic cholangiography</div><div class=\"cntnt\"><img style=\"width:299px; height:432px;\" src=\"images/GAST/82582_PTC_cholangiocarcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percutaneous transhepatic cholangiogram demonstrates dilated intrahepatic bile ducts (small arrows) due to an eccentric cholangiocarcinoma of the common bile duct. The mass appears as a filling defect (large arrow) below the dilated ducts.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 82582 Version 3.0</div></div></div>"},"82583":{"type":"graphic_table","displayName":"Physical findings ETOH abuse","title":"Physical findings in alcohol abuse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical findings in alcohol abuse</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Abdominal wall collaterals (caput medusa)</td>\n</tr>\n<tr>\n<td>Ascites</td>\n</tr>\n<tr>\n<td>Cutaneous telangiectasias</td>\n</tr>\n<tr>\n<td>Digital clubbing</td>\n</tr>\n<tr>\n<td>Disheveled appearance</td>\n</tr>\n<tr>\n<td>Dupuytren's contractures</td>\n</tr>\n<tr>\n<td>Gynecomastia</td>\n</tr>\n<tr>\n<td>Jaundice</td>\n</tr>\n<tr>\n<td>Malnutrition</td>\n</tr>\n<tr>\n<td>Palmar erythema</td>\n</tr>\n<tr>\n<td>Peripheral neuropathy</td>\n</tr>\n<tr>\n<td>Splenomegaly</td>\n</tr>\n<tr>\n<td>Testicular atrophy</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 82583 Version 1.0</div></div></div>"},"82584":{"type":"graphic_table","displayName":"Cyst malformations","title":"Malformative disorders associated with renal cyst formation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Malformative disorders associated with renal cyst formation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t<tbody>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1\">Syndrome</td>\n\n\t\t\t\t<td class=\"subtitle1\">Main extrarenal manifestations</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Ehlers-Danlos</td>\n\n\t\t\t\t<td>Joint hyperextensibility, increased stretchability of skin</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Elejalde</td>\n\n\t\t\t\t<td>Acrocephalopolydactylous dysplasia</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Ellis-van Creveld</td>\n\n\t\t\t\t<td>Chondroectodermal dysplasia</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Geominne</td>\n\n\t\t\t\t<td>Torticollis, multiple keloids, cryptorchidism</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Goldston</td>\n\n\t\t\t\t<td>Dandy-Walker malformation, cerebellar malformations</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Ivemark</td>\n\n\t\t\t\t<td>Spleen agenesis, cyanotic heart disease, gut malrotation</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Jeune</td>\n\n\t\t\t\t<td>Asphyxiating thoracic dystrophy, short limb dwarfism, hypoplastic iliac wings</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Laurence-Moon-Bardet-Biedl</td>\n\n\t\t\t\t<td>Mental retardation, obesity, polydactyly, retinopathy</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Meckel-Gruber</td>\n\n\t\t\t\t<td>Posterior encephalocoele, cleft palate, polydactyly</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Melnick-Fraser</td>\n\n\t\t\t\t<td>Branchial fistulas, preauricular pits, hearing loss</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Papillon-Leage-Psaume</td>\n\n\t\t\t\t<td>Oral frenula, cleft tongue, digital malformations</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Passarge</td>\n\n\t\t\t\t<td>Hypotonia, abnormal ears, hepatomegaly</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Roberts</td>\n\n\t\t\t\t<td>Tetraphocomelia, cleft lip, genital hypertrophy</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Trisomy 13 (Patau)</td>\n\n\t\t\t\t<td>Microcephaly, cleft lip, digital anomalies, mental retardation</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Trisomy 18 (Edwards)</td>\n\n\t\t\t\t<td>Overlapping fingers, foot deformities, muscular hypertonicity, neonatal hepatitis</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Trisomy 21 (Down)</td>\n\n\t\t\t\t<td>Brachycephaly, epicanthal folds, hypotonia, congenital heart disease</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Zellweger</td>\n\n\t\t\t\t<td>Brain malformations, craniofacial dysmorphism, limb deformities, metabolic defect</td>\n\t\t\t</tr>\n\t\t</tbody>\n\t</table></div><div class=\"graphic_lgnd\">Extrarenal manifestations of the major malformative syndromes associated with renal cyst formation.</div><div id=\"graphicVersion\">Graphic 82584 Version 1.0</div></div></div>"},"82585":{"type":"graphic_figure","displayName":"Imaging magnet","title":"Schematic diagram of imaging magnet","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Schematic diagram of imaging magnet</div><div class=\"cntnt\"><img style=\"width:496px; height:287px;\" src=\"images/PULM/82585_Imaging_magnet.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large hollow cylinder contains windings of superconducting wire bathed in cryogen (coolant). Additional shim windings provide small magnetic field corrections. Three sets of nonsuperconducting gradient coils provide spatial localization of spins. A radiofrequency transmit/receive coil provides the RF excitation for each MR sequence and collects the signals used to create an image. Control electronics are located outside the room containing the magnet. The part of the patient being imaged is moved to the center of the magnet by the transport table.</div><div class=\"graphic_footnotes\"><br>* Liquid helium/nitrogen.</div><div id=\"graphicVersion\">Graphic 82585 Version 1.0</div></div></div>"},"82586":{"type":"graphic_figure","displayName":"Cytokines which perpetuate RA","title":"Cytokine networks in the perpetuation of rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cytokine networks in the perpetuation of rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:409px; height:233px;\" src=\"images/RHEUM/82586_Cytokines_which_perpetuate.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cytokine networks responsible for the perpetuation of rheumatoid arthritis are primarily based upon the interactions between macrophages and fibroblasts.</div><div id=\"graphicVersion\">Graphic 82586 Version 1.0</div></div></div>"},"82587":{"type":"graphic_picture","displayName":"Stent fracture","title":"Stent fracture","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Stent fracture</div><div class=\"cntnt\"><img style=\"width:517px; height:273px;\" src=\"images/SURG/82587_Stent_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subclavian to vertebral anatomy may create unique mechanical forces that make stent fracture more likely than other parts of the body.</div><div id=\"graphicVersion\">Graphic 82587 Version 1.0</div></div></div>"},"82588":{"type":"graphic_diagnosticimage","displayName":"Lymphoma bone MRI 2","title":"Primary lymphoma of bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary lymphoma of bone</div><div class=\"cntnt\"><img style=\"width:377px; height:362px;\" src=\"images/HEME/82588_Lymphoma_bone_MRI_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This MRI image of the right knee demonstrates a metadiaphyseal lesion of the proximal tibia without extensive cortical destruction (arrows). The bone lesion was associated with a soft tissue component that was not well-visualized on this image.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Courtesy of Heather Pacholke, MD.</div><div id=\"graphicVersion\">Graphic 82588 Version 3.0</div></div></div>"},"82589":{"type":"graphic_table","displayName":"First events MI angina","title":"Proportion of first coronary events as myocardial infarction and angina pectoris Framingham study subjects ages 35 to 94","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proportion of first coronary events as myocardial infarction and angina pectoris Framingham study subjects ages 35 to 94</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">Age</td>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Percent\nas myocardial infarction</td>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Percent\nas angina</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">Men</td>\n\n      <td class=\"subtitle2\">Women</td>\n\n      <td class=\"subtitle2\">Men</td>\n\n      <td class=\"subtitle2\">Women</td>\n\n    </tr>\n\n    <tr>\n\n      <td>35 to 54</td>\n\n      <td>52.1</td>\n\n      <td>31.9</td>\n\n      <td>32.2</td>\n\n      <td>57.1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>55 to 64</td>\n\n      <td>46.1</td>\n\n      <td>27.5</td>\n\n      <td>39.7</td>\n\n      <td>59.2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>65 to 74</td>\n\n      <td>56.6</td>\n\n      <td>36.8</td>\n\n      <td>28.9</td>\n\n      <td>49.8</td>\n\n    </tr>\n\n    <tr>\n\n      <td>75 to 94</td>\n\n      <td>60.2</td>\n\n      <td>57.0</td>\n\n      <td>21.1</td>\n\n      <td>29.1</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">44-year follow-up of cohort and 20-year follow-up of offspring.</div><div id=\"graphicVersion\">Graphic 82589 Version 1.0</div></div></div>"},"82590":{"type":"graphic_picture","displayName":"Radical vulvectomy3","title":"Radical vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radical vulvectomy</div><div class=\"cntnt\"><img style=\"width:325px; height:504px;\" src=\"images/OBGYN/82590_Radical_vulvectomy3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Kelly forcep has been passed in the midline to split the crura of the clitoris.</div><div class=\"graphic_reference\">Courtesy of C. William Helm, MD.</div><div id=\"graphicVersion\">Graphic 82590 Version 2.0</div></div></div>"},"82592":{"type":"graphic_picture","displayName":"Endoscopic view of the hypopharynx","title":"Endoscopic view of the hypopharynx","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of the hypopharynx</div><div class=\"cntnt\"><img style=\"width:521px; height:465px;\" src=\"images/GAST/82592_Endoscopic_view_hypopharynx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypopharynx as seen during esophagogastroduodenoscopy.</div><div id=\"graphicVersion\">Graphic 82592 Version 1.0</div></div></div>"},"82595":{"type":"graphic_picture","displayName":"Finger buddy taping PI","title":"Finger buddy taping","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Finger buddy taping</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/PI/82595_Finger_buddy_taping_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Finger buddy taping involves taping an injured finger to the finger next to it.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 82595 Version 2.0</div></div></div>"},"82597":{"type":"graphic_figure","displayName":"Hemoglobin and viscosity","title":"Relationship between hemoglobin concentration and whole blood viscosity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relationship between hemoglobin concentration and whole blood viscosity</div><div class=\"cntnt\"><img style=\"width:406px; height:435px;\" src=\"images/HEME/82597_Hemoglobin_and_viscosity.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Experimental relative viscosities of hemoglobin solutions at various concentrations; the temperature is 37&#176;C.</div><div class=\"graphic_reference\">Data from Cokelet, GR, Meiselman, HJ, Science 1968; 162:275.</div><div id=\"graphicVersion\">Graphic 82597 Version 2.0</div></div></div>"},"82598":{"type":"graphic_figure","displayName":"Benefit of LTOT in NOTT","title":"Survival benefit of continuous long-term oxygen therapy in COPD","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Survival benefit of continuous long-term oxygen therapy in COPD</div><div class=\"cntnt\"><img style=\"width:478px; height:226px;\" src=\"images/PULM/82598_Benefit_of_LTOT_in_NOTT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Nocturnal Oxygen Therapy Trial randomly assigned 203 patients with chronic obstructive pulmonary disease complicated by hypoxemia to treatment with nearly continuous oxygen therapy (red line) or nocturnal oxygen alone (blue line). Continuous oxygen therapy was associated with a significant survival benefit (p = 0.01).</div><div class=\"graphic_reference\">Redrawn from Nocturnal Oxygen Trial Therapy Group, Ann Intern Med 1980; 93:391.</div><div id=\"graphicVersion\">Graphic 82598 Version 1.0</div></div></div>"},"82599":{"type":"graphic_diagnosticimage","displayName":"Pulmonary plethora PA","title":"Graves' disease with high output failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graves' disease with high output failure</div><div class=\"cntnt\"><img style=\"width:351px; height:295px;\" src=\"images/PULM/82599_Pulmonary_plethora_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows pulmonary plethora with equalization of blood flow, due to recruitment of upper lobe vessels in the process of hyperperfusion with balanced flow. The periphery of the lung in the outer 2 cm is well perfused with clearly visible vessels.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82599 Version 3.0</div></div></div>"},"82600":{"type":"graphic_picture","displayName":"Pes cavus (high arch) foot","title":"Pes cavus (high arch) foot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pes cavus (high arch) foot</div><div class=\"cntnt\"><img style=\"width:354px; height:547px;\" src=\"images/SM/82600_Pes_cavus_high_arch_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with a high arch (pes cavus), as shown in these photographs, may be at higher risk for a number of conditions, including patellofemoral pain syndrome and a fixed plantar-flexed first ray of the foot.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 82600 Version 4.0</div></div></div>"},"82602":{"type":"graphic_table","displayName":"Medications associated with fever","title":"Medications associated with fever","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications associated with fever</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Antimicrobials</td>\n</tr>\n<tr>\n<td>Penicillins</td>\n</tr>\n<tr>\n<td>Cephalosporins</td>\n</tr>\n<tr>\n<td>Fluoroquinolones</td>\n</tr>\n<tr>\n<td>Vancomycin</td>\n</tr>\n<tr>\n<td>Sulfonamides</td>\n</tr>\n<tr>\n<td>Nitrofurantoin</td>\n</tr>\n<tr>\n<td>Rifampin</td>\n</tr>\n<tr>\n<td>Amphotericin B</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Cardiovascular medications</td>\n</tr>\n<tr>\n<td>Thiazide diuretics</td>\n</tr>\n<tr>\n<td>Furosemide</td>\n</tr>\n<tr>\n<td>Spironolactone</td>\n</tr>\n<tr>\n<td>Hydralazine</td>\n</tr>\n<tr>\n<td>Quinidine</td>\n</tr>\n<tr>\n<td>Procainamide</td>\n</tr>\n<tr>\n<td>Alpha methyldopa</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Anticonvulsants</td>\n</tr>\n<tr>\n<td>Phenytoin</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Other</td>\n</tr>\n<tr>\n<td>Heparin (especially unfractionated)</td>\n</tr>\n<tr>\n<td>Salicylates</td>\n</tr>\n<tr>\n<td>Nonsteroidal antiinflammatory drugs</td>\n</tr>\n<tr>\n<td>Allopurinol</td>\n</tr>\n<tr>\n<td>Immunoglobulins</td>\n</tr>\n<tr>\n<td>Iodides</td>\n</tr>\n<tr>\n<td>Propylthiouracil</td>\n</tr>\n<tr>\n<td>Hydroxyurea</td>\n</tr>\n<tr>\n<td>Mycophenolate mofetil</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 82602 Version 2.0</div></div></div>"},"82603":{"type":"graphic_figure","displayName":"RA RV pressure junct rhythm","title":"Pressure waveform changes with a junctional rhythm","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Pressure waveform changes with a junctional rhythm</div><div class=\"cntnt\"><img style=\"width:486px; height:206px;\" src=\"images/CARD/82603_RA_RV_pressure_junct_rhythm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The initial rhythm in panel A is junctional and the P waves are superimposed on the QRS complex, resulting in simultaneous atrial and ventricular contraction and giant &quot;v&quot; waves on the right atrial (RA) pressure tracing due to atrial contraction against the closed tricuspid valve. With resumption of sinus rhythm, the RA pressure becomes normal with an &quot;a&quot; wave that is taller than the &quot;v&quot; wave. There is also a change in the right ventricular pressure waveform. The initial rhythm in panel B is junctional and the RV pressure is 38 mmHg. With resumption of sinus rhythm (end of panel B) and the restoration of atrial contribution to RV filling, the RV pressure increases to 50 mmHg.</div><div class=\"graphic_reference\">Courtesy of Morton Kern, MD.</div><div id=\"graphicVersion\">Graphic 82603 Version 1.0</div></div></div>"},"82604":{"type":"graphic_figure","displayName":"Typical sleep time in children by age group","title":"Average sleep time for children","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Average sleep time for children</div><div class=\"cntnt\"><img style=\"width:496px; height:492px;\" src=\"images/PEDS/82604_Avg_sleep_children_4.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean sleep time of 493 healthy Swiss children enrolled in the Zurich Longitudinal Studies, based on parent report.<SUP>[1]</SUP> Error bars represent ±2 standard deviations (which includes 97% of the population). The dashed red lines represent the lower and upper limit of recommended sleep time for each age group, established by the American Academy of Sleep Medicine (AASM)<SUP>[2]</SUP> and endorsed by the American Academy of Pediatrics (AAP).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Iglowstein I, Jenni OG, Molinari L, Largo RH. Sleep duration from infancy to adolescence: Reference values and generational trends. Pediatrics 2003; 111:302.</LI>&#xD;&#xA;<LI>Paruthi S, Brooks LJ, D'Ambrosio C, et al. Recommended Amount of Sleep for Pediatric Populations: A Consensus Statement of the American Academy of Sleep Medicine. J Clin Sleep Med 2016; 12:785.​</LI></OL></div><div id=\"graphicVersion\">Graphic 82604 Version 3.0</div></div></div>"},"82606":{"type":"graphic_figure","displayName":"Resec urethral diverticulum","title":"Diverticular resection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diverticular resection</div><div class=\"cntnt\"><img style=\"width:433px; height:576px;\" src=\"images/OBGYN/82606_Resec_urethral_diverticulum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Incision and development of periurethral fascial planes. The incision in the fascia should be over the central diameter of the diverticular lesion. B) Dissection (circumferential) of the diverticular sac to the urethral ostium. The dissection plane between the sac and the urethra may be poorly defined in the presence of substantial peridiverticular inflammation. C) Running closure of the urethral defect over a small caliber (14 Fr) urethral catheter. Avoid excessive tension or compromise of the lumen. D) Vaginal closure after periurethral reapproximation.</div><div class=\"graphic_reference\">Reproduced with permission from: Dmochowski, D. Surgery for vesicovaginal fistula, urethrovaginal fistula, and urethral diverticulum. In: Campbell's urology, 8th ed, Walsh, PC (Ed), Saunders, Philadelphia, PA 2002. p. 1213. Copyright ©2002 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 82606 Version 2.0</div></div></div>"},"82608":{"type":"graphic_figure","displayName":"Intermediate case 19 answer","title":"Sick sinus syndrome and atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Sick sinus syndrome and atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:540px; height:112px;\" src=\"images/CARD/82608_Intermediate_case_19_answer_ED.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rhythm strip showing sick sinus syndrome. The initial part of the tracing reveals coarse fibrillation with a slow ventricular response in the absence of drugs that slow AV nodal conduction. The atrial fibrillation breaks and is followed by a sinus escape beat with a long escape inverval of nearly four seconds and then another escape beat at a similar interval (not shown).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 82608 Version 2.0</div></div></div>"},"82609":{"type":"graphic_figure","displayName":"FTT components","title":"Components of failure to thrive in elderly adults","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Components of failure to thrive in elderly adults</div><div class=\"cntnt\"><img style=\"width:520px; height:440px;\" src=\"images/PC/82609_FTT_components.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82609 Version 3.0</div></div></div>"},"82610":{"type":"graphic_diagnosticimage","displayName":"Congenital emphysema CT","title":"Congenital lobar emphysema, left upper lobe in adolescent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital lobar emphysema, left upper lobe in adolescent</div><div class=\"cntnt\"><img style=\"width:360px; height:220px;\" src=\"images/PULM/82610_Congenital_emphysema_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan demonstrates a hyperexpanded, oligemic left upper lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 82610 Version 2.0</div></div></div>"},"82612":{"type":"graphic_picture","displayName":"Cutaneous neurofibroma","title":"Cutaneous neurofibroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous neurofibroma</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/82612_Cutaneous_neurofibroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous neurofibromas are soft, flesh-colored papules or nodules. This patient had a solitary lesion unassociated with neurofibromatosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82612 Version 3.0</div></div></div>"},"82613":{"type":"graphic_picture","displayName":"Multiple neurofibromas","title":"Multiple neurofibromas in an adult patient with neurofibromatosis type 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple neurofibromas in an adult patient with neurofibromatosis type 1</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/82613_Multiple_neurofibromas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple papules and nodules consistent with neurofibromas are present on the trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82613 Version 4.0</div></div></div>"},"82615":{"type":"graphic_picture","displayName":"Venous lake lip","title":"Venous lake","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Venous lake</div><div class=\"cntnt\"><img style=\"width:384px; height:308px;\" src=\"images/DERM/82615_Venous_lake_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A compressible blue papule is present on the central lower lip.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82615 Version 2.0</div></div></div>"},"82616":{"type":"graphic_table","displayName":"Subdural hematoma children - Rapid overview","title":"Subdural hematoma in children: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Subdural hematoma in children: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td>Evaluate for SDH in victims of major head trauma with impaired consciousness or abnormal neurologic examination at any time after injury</td> </tr> <tr> <td>Suspect inflicted head injury (Shaken baby syndrome) in infants &#8804;2 years of age with SDH and no plausible mechanism for head injury</td> </tr> <tr> <td>Physical findings of SDH: irritability, vomiting, bulging anterior fontanelle, increased head circumference, pallor, lethargy, coma, or seizures</td> </tr> <tr> <td>Findings of child abuse: retinal hemorrhages, skeletal or skull fractures with SDH (refer to UpToDate topics on child abuse)</td> </tr> <tr> <td>Findings of cerebral herniation: lateralizing signs such as a fixed, dilated pupil and contralateral hemiparesis</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td>Determine GCS, identify pupillary abnormalities and lateralizing motor findings</td> </tr> <tr> <td>Initial laboratory evaluation: complete blood count with platelets, PT, PTT, INR, bleeding time (if available), and type and cross</td> </tr> <tr> <td>Obtain emergency brain imaging (eg, CT or fast MRI)</td> </tr> <tr> <td>Lumbar puncture is <strong>contraindicated</strong></td> </tr> <tr> <td>Obtain neurosurgical consultation for all patients with GCS &#8804;12 or in patients with identified SDH</td> </tr> <tr> <td>Make report of suspected child abuse, as indicated by physical findings, to the appropriate government agency according to local requirements and consult a child abuse team, if available</td> </tr> <tr> <td>Ensure funduscopic examination by an ophthalmologist and perform skeletal survey in all children with suspected child abuse once clinically stabile</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"sublist1_start\">Manage patient according to principles of advanced trauma life support*:</td> </tr> <tr> <td class=\"sublist1\">Immobilize cervical spine</td> </tr> <tr> <td class=\"sublist1\">Treat hypoxemia</td> </tr> <tr> <td class=\"sublist1\">Assess airway, breathing, circulation, and disability and initiate supportive care</td> </tr> <tr> <td class=\"sublist1\">Endotracheally intubate children with GCS &#8804;8 or rapidly worsening mental status</td> </tr> <tr> <td class=\"sublist1\">If impending herniation, provide hyperosmolar therapy (3 percent saline or mannitol, refer to UpToDate topics on the management of increased ICP in children)</td> </tr> <tr> <td>Ensure definitive management by a neurosurgeon with pediatric expertise</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SDH: subdural hematoma; PT: prothrombin time; PTT: partial thromboplastin time; INR: international normalized ratio; CT: computed tomography; MRI: magnetic resonance imaging; GCS: Glasgow Coma Score; ICP: Intracranial pressure.<br />* Refer to UpToDate topics on trauma management in children.</div><div id=\"graphicVersion\">Graphic 82616 Version 6.0</div></div></div>"},"82617":{"type":"graphic_figure","displayName":"Childhood immunization schedule 0 through 6 years","title":"Recommended immunization schedule for children age 0 through 6 years - United States, 2018 (for those who fall behind or start late, refer to UpToDate content related to the catch-up schedule)","html":"<div class=\"graphic\"><div style=\"width: 1252px\" class=\"figure\"><div class=\"ttl\">Recommended immunization schedule for children age 0 through 6 years - United States, 2018 (for those who fall behind or start late, refer to UpToDate content related to the catch-up schedule)</div><div class=\"cntnt\"><img style=\"width:1232px; height:575px;\" src=\"images/PEDS/82617_Childhdimmnztnschd06yrs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schedule includes recommendations in effect as of January 1, 2018 and is approved by the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists. &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Consult relevant <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/index.html\" target=_blank>ACIP statements</A> for detailed recommendations.</LI>&#xD;&#xA;<LI>When a vaccine is not administered at the recommended age, administer at a subsequent visit.</LI>&#xD;&#xA;<LI>Use combination vaccines instead of separate injections when appropriate.</LI>&#xD;&#xA;<LI>Report clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) online at <A href=\"https://vaers.hhs.gov/\" target=_blank>https://vaers.hhs.gov</A> or by telephone, 800-822-7967.</LI>&#xD;&#xA;<LI>Report suspected cases of vaccine-preventable diseases to your state or local health department.</LI>&#xD;&#xA;<LI>For information about precautions and contraindications, refer to <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html\" target=_blank>https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html</A>.</LI></UL></div><div class=\"graphic_footnotes\">* <STRONG>Hepatitis B (HepB) vaccine</STRONG><br /><EM>(Minimum age: Birth)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>Birth dose</STRONG> (monovalent HepB vaccine only): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Mother is hepatitis B surface antigen (HBsAg)-negative: One dose within 24 hours of birth for medically stable infants ≥2 kg. Infants &lt;2 kg: Administer One dose at chronologic age one month or hospital discharge.</LI>&#xD;&#xA;<LI>Mother is HBsAg-positive: Give HepB vaccine and 0.5 mL of hepatitis B immune globulin ([HBIG] at separate anatomic sites) within 12 hours of birth, regardless of birth weight. Test for HBsAg and anti-HBs at age 9 through 12 months. If HepB series is delayed, test one to two months after final dose.</LI>&#xD;&#xA;<LI>Mother's HBsAg status is unknown: Give HepB vaccine within 12 hours of birth, regardless of birth weight. For infants &lt;2 kg, give 0.5 mL of HBIG in addition to HepB vaccine within 12 hours of birth. Determine mother's HBsAg status as soon as possible. If mother is HBsAg-positive, give 0.5 mL of HBIG to infants ≥2 kg as soon as possible, but no later than seven days of age.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Routine series:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>A complete series is three doses at 0, 1 through 2, and 6 through 18 months (monovalent HepB vaccine should be used for doses given before age six weeks).</LI>&#xD;&#xA;<LI>Infants who did not receive a birth dose should begin the series as soon as feasible. Refer to UpToDate content related to the catch-up schedule.</LI>&#xD;&#xA;<LI>Administration of four doses is permitted when a combination vaccine containing HepB is used after the birth dose.</LI>&#xD;&#xA;<LI>Minimum age for the final (third or fourth) dose: 24 weeks.</LI>&#xD;&#xA;<LI>Minimal intervals: Dose one to dose two: Four weeks; dose two to dose three: Eight weeks; dose one to dose three: 16 weeks (when four doses are given, substitute \"dose four\" for \"dose three\" in these calculations).</LI></UL></LI></UL>¶ <STRONG>Rotavirus (RV) vaccines</STRONG><br /><EM>(Minimum age: Six weeks)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>RV1 (Rotarix): Two-dose series at two and four months.</LI>&#xD;&#xA;<LI>RV5 (RotaTeq): Three-dose series at two, four, and six months.</LI>&#xD;&#xA;<LI>If any dose in the series is either RV5 or unknown, default to three-dose series.</LI></UL>Δ <STRONG>Diphtheria and tetanus toxoids, and acellular pertussis (DTaP) vaccine</STRONG><br /><EM>(Minimum age: Six weeks. Exception: DTaP-inactivated poliovirus [Kinrix, Quadracel]: Four years.)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Five-dose series at 2, 4, 6, and 15 through 18 months, and 4 through 6 years. &#xD;&#xA;<UL>&#xD;&#xA;<LI>Prospectively: A fourth dose may be given as early as age 12 months if at least six months have elapsed since the third dose.</LI>&#xD;&#xA;<LI>Retrospectively: A fourth dose that was inadvertently given as early as 12 months may be counted if at least four months have elapsed since the third dose.</LI></UL></LI></UL><FONT class=lozenge>◊</FONT> <STRONG><EM>Haemophilus influenzae</EM> type b (Hib) conjugate vaccine</STRONG><br /><EM>(Minimum age: Six weeks)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>ActHIB, Hiberix, or Pentacel: Four-dose series at 2, 4, 6, and 12 through 15 months.</LI>&#xD;&#xA;<LI>PedvaxHIB: Three-dose series at 2, 4, and 12 through 15 months.</LI>&#xD;&#xA;<LI><STRONG>Special situations or high-risk conditions:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Refer to UpToDate content related to Hib vaccination and immunization in the specific high-risk group and the <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html\" target=_blank>ACIP recommendations</A>. Special situations and high-risk groups include chemotherapy or radiation treatment, hematopoietic stem cell transplant, anatomic or functional asplenia (including sickle cell disease), elective splenectomy, human immunodeficiency virus (HIV) infection, immunoglobulin deficiency, and early complement component deficiency.</LI></UL></LI></UL>§ <STRONG>Pneumococcal conjugate vaccine (PCV13)</STRONG><br /><EM>(Minimum age: Six weeks)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Four-dose series at 2, 4, 6, and 12 through 15 months.</LI></UL>¥ <STRONG>Pneumococcal polysaccharide vaccine (PPSV23)</STRONG><br /><EM>(Minimum age: Two years)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>High-risk conditions:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Refer to UpToDate content related to pneumococcal vaccines in children and immunization in the specific high-risk condition and the <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html\" target=_blank>ACIP recommendations</A>. High-risk conditions include chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma treated with high-dose, oral, corticosteroids); diabetes mellitus; cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiency; HIV infection; chronic renal failure; nephrotic syndrome; malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and other diseases associated with treatment with immunosuppressive drugs or radiation therapy; solid organ transplantation; and chronic liver disease.</LI></UL></LI></UL>‡ <STRONG>Inactivated poliovirus vaccine (IPV)</STRONG><br /><EM>(Minimum age: Six weeks)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Four-dose series at ages 2, 4, and 6 through 18 months, and 4 through 6 years. Administer the final dose on or after the fourth birthday and at least six months after the previous dose.</LI></UL>† <STRONG>Influenza vaccines</STRONG><br /><EM>(Minimum age: Six months for inactivated influenza vaccine [IIV])</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer an age-appropriate formulation and dose of influenza vaccine annually: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Children six months through eight years who did not receive at least two doses of influenza vaccine before July 1, 2017 should receive two doses separated by at least four weeks.</LI></UL></LI>&#xD;&#xA;<LI>Live attenuated influenza vaccine is not recommended for the 2017-2018 season.</LI>&#xD;&#xA;<LI>For additional guidance, refer to the 2017-2018 ACIP influenza vaccine recommendations, available at <A href=\"https://www.cdc.gov/mmwr/volumes/66/rr/rr6602a1.htm\" target=_blank>MMWR Recomm Rep 2017; 66:1</A>.</LI></UL>** <STRONG>Measles, mumps, and rubella (MMR) vaccine</STRONG><br /><EM>(Minimum age: 12 months for routine vaccination)</EM> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Two-dose series at 12 through 15 months and 4 through 6 years.</LI>&#xD;&#xA;<LI>The second dose may be given as early as four weeks after the first dose.</LI>&#xD;&#xA;<LI><STRONG>International travel:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Infants 6 through 11 months: One dose before departure. Revaccinate with two doses at 12 through 15 months (12 months for children in high-risk areas) and second dose as early as four weeks later.</LI>&#xD;&#xA;<LI>Unvaccinated children 12 months and older: Two doses at least four weeks apart before departure.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Mumps outbreak:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Children ≥12 months who previously received ≤2 doses of mumps-containing vaccine and are identified by public health authorities to be at increased risk during a mumps outbreak should receive a dose of mumps virus-containing vaccine.</LI></UL></LI></UL>¶¶ <STRONG>Varicella (VAR) vaccine</STRONG><br /><EM>(Minimum age: 12 months)</EM> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Two-dose series: 12 through 15 months and 4 through 6 years.</LI>&#xD;&#xA;<LI>The second dose may be given as early as three months after the first dose (a dose given after a four-week interval may be counted).</LI></UL>ΔΔ <STRONG>Hepatitis A (HepA) vaccine</STRONG><br /><EM>(Minimum age: 12 months)</EM> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Two doses, separated by 6 to 18 months, between the first and second birthdays (a series begun before the second birthday should be completed even if the child turns two before the second dose is given).</LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> Previously unvaccinated persons who should be vaccinated: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Persons traveling to or working in countries with high or intermediate endemicity.</LI>&#xD;&#xA;<LI>Persons with clotting-factor disorders.</LI>&#xD;&#xA;<LI>Persons with chronic liver disease.</LI>&#xD;&#xA;<LI>Persons who anticipate close, personal contact (eg, household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity (administer the first dose as soon as the adoption is planned–ideally at least two weeks before the adoptee's arrival.</LI></UL></LI></UL><FONT class=double_lozenge>◊◊</FONT> <STRONG>Serogroups A, C, W, Y meningococcal (MenACWY) vaccines</STRONG><br /><EM>(Minimum age: Two months for MenACWY-CRM [Menveo], nine months for MenACWY-D [Menactra])</EM> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI><STRONG>High-risk conditions and other persons at increased risk of meningococcal disease:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Refer to UpToDate content related to meningococcal vaccines and immunization in the specific high-risk group and the <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html\" target=_blank>ACIP recommendations</A>. High-risk conditions include anatomic or functional asplenia, sickle cell disease, HIV infection, persistent complement component deficiency (including eculizumab use), travel to or residence in countries where meningococcal disease is hyperendemic or epidemic (including countries in the African meningitis belt or during the Hajj), or exposure to an outbreak attributable to a vaccine serogroup.</LI></UL></LI></UL></div><div class=\"graphic_reference\">Adapted from: Centers for Disease Control and Prevention. Immunization schedules. Available at: <A href=\"https://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html\" target=_blank>www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html</A> (Accessed on February 14, 2018).</div><div id=\"graphicVersion\">Graphic 82617 Version 30.0</div></div></div>"},"82618":{"type":"graphic_table","displayName":"Reversible cause incontinence A","title":"Identification of reversible conditions that cause or contribute to urinary incontinence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Identification of reversible conditions that cause or contribute to urinary incontinence</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Condition</td> </tr> <tr> <td class=\"subtitle2_single\">Affecting the lower urinary tract</td> </tr> <tr> <td class=\"indent1\">Urinary tract infection (symptomatic with frequency, urgency, dysuria, etc)</td> </tr> <tr> <td class=\"indent1\">Atrophic vaginitis/urethritis</td> </tr> <tr> <td class=\"indent1\">Pregnancy/vaginal delivery/episiotomy</td> </tr> <tr> <td class=\"indent1\">Stool impaction</td> </tr> <tr> <td class=\"subtitle2_single\">Increased urine production</td> </tr> <tr> <td class=\"indent1\">Metabolic (hyperglycemia, chronic hypercalcemia)</td> </tr> <tr> <td class=\"indent1\">Excess fluid intake</td> </tr> <tr> <td class=\"subtitle2_single\">Impaired ability or willingness to reach a toilet</td> </tr> <tr> <td class=\"indent1\">Delirium</td> </tr> <tr> <td class=\"indent1\">Chronic illness, injury or restraint that interferes with mobility</td> </tr> <tr> <td class=\"indent1\">Psychological</td> </tr> <tr> <td class=\"subtitle2_single\">Nocturia</td> </tr> <tr> <td class=\"indent1\">Nocturnal polyuria</td> </tr> <tr> <td class=\"indent1\">Sleep disturbance</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82618 Version 5.0</div></div></div>"},"82619":{"type":"graphic_figure","displayName":"Reconstruction with a DIEP flap PI","title":"Reconstruction with a DIEP flap","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Reconstruction with a DIEP flap</div><div class=\"cntnt\"><img style=\"width:534px; height:698px;\" src=\"images/PI/82619_Reconstruct_DIEP_flap_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Women who have reconstruction with a DIEP flap have a flap of tissue taken from their belly and attached to their chest. This surgery is different than the TRAM flap surgery, because the flap is made up of skin and fat, <STRONG>not </STRONG>muscle. DIEP stands for \"deep inferior epigastric perforator.\"</div><div id=\"graphicVersion\">Graphic 82619 Version 3.0</div></div></div>"},"82620":{"type":"graphic_picture","displayName":"Acne excoriee","title":"Acne excoriée","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Acne excori&eacute;e</div><div class=\"cntnt\"><img style=\"width:464px; height:532px;\" src=\"images/DERM/82620_Acne_excoriee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small excoriated lesions on the face of a 30-year-old woman who cleared completely after treatment with fluoxetine, a selective serotonin reuptake inhibitor.</div><div id=\"graphicVersion\">Graphic 82620 Version 2.0</div></div></div>"},"82621":{"type":"graphic_diagnosticimage","displayName":"VSD with prolapsed RCC of aortic valve still frame","title":"VSD with prolapsed RCC of aortic valve still frame","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">VSD with prolapsed RCC of aortic valve still frame</div><div class=\"cntnt\"><img style=\"width:560px; height:425px;\" src=\"images/CARD/82621_VSD_prolapsed_RCC_aortic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this parasternal long axis still frame, the right coronary cusp of the aortic valve (*) is seen prolapsing across the VSD. The arrow denotes the small residual defect, the remainder closed by the prolapsed cusp.</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; AO: aorta; MV: mitral valve; LA: left atrium; arrow: VSD.<br> * Denotes right coronary cusp of the aortic valve.</div><div id=\"graphicVersion\">Graphic 82621 Version 4.0</div></div></div>"},"82622":{"type":"graphic_figure","displayName":"Partial bicornuate uterus","title":"Uterus bicornuate: partial","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterus bicornuate: partial</div><div class=\"cntnt\"><img style=\"width:350px; height:204px;\" src=\"images/OBGYN/82622_Partialbicornuateuterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82622 Version 14.0</div></div></div>"},"82624":{"type":"graphic_figure","displayName":"Shave biopsy technique","title":"Shave biopsy technique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shave biopsy technique</div><div class=\"cntnt\"><img style=\"width:450px; height:597px;\" src=\"images/PC/82624_Shave_biopsy_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The shave biopsy can be facilitated by raising the lesion with a wheal of injected anesthetic. When performing a superficial shave biopsy, a number 15 blade on a scalpel is held tangential to the skin surface. The lesion is then removed with a smooth sweeping stroke of the blade going just under and across the lesion.</div><div id=\"graphicVersion\">Graphic 82624 Version 4.0</div></div></div>"},"82625":{"type":"graphic_picture","displayName":"ERCP biliary leak post LT","title":"Bile leak following liver transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bile leak following liver transplantation</div><div class=\"cntnt\"><img style=\"width:360px; height:449px;\" src=\"images/GAST/82625_ERCP_biliary_leak_post_LT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a classic ERCP for a biliary leak in a patient after a liver transplant. The arrow is pointing to the area of extravasation of contrast from the biliary tree.</div><div class=\"graphic_reference\">Courtesy of Karen Krok, MD and Paul J Thuluvath, MBBS, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 82625 Version 2.0</div></div></div>"},"82626":{"type":"graphic_figure","displayName":"Microwave endometrial ablation","title":"Microwave endometrial ablation","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Microwave endometrial ablation</div><div class=\"cntnt\"><img style=\"width:547px; height:212px;\" src=\"images/OBGYN/82626_Microsulis_endometrial_abla.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bradley, LD. Microsulis Endometrial Ablation (MEA): Versatility to treat more patients. OBG Management 2005. Copyright &#169; 2005 Dowden Health Media.</div><div id=\"graphicVersion\">Graphic 82626 Version 2.0</div></div></div>"},"82627":{"type":"graphic_diagnosticimage","displayName":"Invasive aspergillosis CT","title":"Invasive aspergillosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Invasive aspergillosis</div><div class=\"cntnt\"><img style=\"width:338px; height:234px;\" src=\"images/PULM/82627_Invasive_aspergillosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan of an immunosuppressed patient with fever, hypoxemia, and a nonresolving pneumonia. Invasive aspergillosis was ultimately diagnosed.</div><div class=\"graphic_reference\">Courtesy of Alan Fein, MD.</div><div id=\"graphicVersion\">Graphic 82627 Version 2.0</div></div></div>"},"82631":{"type":"graphic_figure","displayName":"UDCA and survival in PBC","title":"Ursodeoxycholic acid slows disease progression in primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Ursodeoxycholic acid slows disease progression in primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:475px; height:254px;\" src=\"images/GAST/82631_UDCA_and_survival_in_PBC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of ursodeoxycholic acid (UDCA) on progression to liver transplantation or death in primary biliary cholangitis. Patients were randomized to UDCA (dashed line) or placebo (solid line) for the first 24 months and then all patients were treated with UDCA for the next 24 months. The relative risk for liver transplantation or death was 0.32 in patients treated with UDCA throughout the study.</div><div class=\"graphic_reference\">Data from: Poupon RE, Poupon R, Balkau B, and the UDCA-PBC Study Group, N Engl J Med 1994; 330:1342.</div><div id=\"graphicVersion\">Graphic 82631 Version 4.0</div></div></div>"},"82632":{"type":"graphic_diagnosticimage","displayName":"Saber sheath CXR","title":"Saber sheath trachea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saber sheath trachea</div><div class=\"cntnt\"><img style=\"width:308px; height:588px;\" src=\"images/PULM/82632_Saber_sheath_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal chest radiograph from a patient with a typical saber sheath trachea (A) demonstrates severe intrathoracic coronal narrowing (arrows). Marked intrathoracic sagittal widening is apparent on the lateral view (arrowheads).</div><div id=\"graphicVersion\">Graphic 82632 Version 4.0</div></div></div>"},"82633":{"type":"graphic_algorithm","displayName":"Mucocutaneous bleeding children","title":"Diagnostic approach to a child with mucocutaneous bleeding (purpuric disorders) based on platelet count and platelet appearance on peripheral smear*","html":"<div class=\"graphic\"><div style=\"width: 653px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to a child with mucocutaneous bleeding (purpuric disorders) based on platelet count and platelet appearance on peripheral smear*</div><div class=\"cntnt\"><img style=\"width:633px; height:289px;\" src=\"images/HEME/82633_Mcctns_bld_chld.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ITP: immune thrombocytopenia (previously known as idiopathic thrombocytopenic purpura); vWD: von Willebrand disease.<br />​* Mucocutaneous bleeding in children is characteristic of disorders that cause abnormal platelet number and/or function. However, mucocutaneous bleeding can also occur in patients with abnormal coagulation (eg, hemophilia, disseminated intravascular coagulation). The diagnostic approach presented here represents a simplified approach based solely on platelet count and the appearance of the platelets on peripheral smear. In many cases, additional evaluation is warranted. Refer to UpToDate topic on the evaluation of bleeding symptoms in children for additional details.</div><div id=\"graphicVersion\">Graphic 82633 Version 6.0</div></div></div>"},"82634":{"type":"graphic_figure","displayName":"Vaccine schedule for healthy adults","title":"Recommended immunization schedule for adults aged 19 years or older by age group - United States, 2018","html":"<div class=\"graphic\"><div style=\"width: 721px\" class=\"figure\"><div class=\"ttl\">Recommended immunization schedule for adults aged 19 years or older by age group - United States, 2018</div><div class=\"cntnt\"><img style=\"width:701px; height:652px;\" src=\"images/ID/82634_Vaxschedhealthadult2018.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* <STRONG>Influenza vaccines</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer one dose of age-appropriate inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV) annually.</LI>&#xD;&#xA;<LI>NOTE: Live attenuated influenza vaccine (LAIV) is not recommended for the 2017 to 2018 influenza season. A list of currently available influenza vaccines is available at <A href=\"https://www.cdc.gov/flu/protect/vaccine/vaccines.htm\" target=_blank>www.cdc.gov/flu/protect/vaccine/vaccines.htm</A>.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer age-appropriate IIV or RIV to: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Pregnant women.</LI>&#xD;&#xA;<LI>Adults with hives-only egg allergy.</LI>&#xD;&#xA;<LI>Adults with egg allergy other than hives (eg, angioedema or respiratory distress): Administer IIV or RIV in a medical setting under supervision of a health care provider who can recognize and manage severe allergic conditions.</LI></UL></LI></UL></LI></UL>¶ <STRONG>Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/tdap-td.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/tdap-td.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer to adults who previously did not receive a dose of Tdap as an adult or child (routinely recommended at age 11 to 12 years) one dose of Tdap, followed by a dose of Td booster every 10 years.</LI>&#xD;&#xA;<LI>Information on the use of Tdap or Td as tetanus prophylaxis in wound management is available at <A href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5517a1.htm\" target=_blank>www.cdc.gov/mmwr/preview/mmwrhtml/rr5517a1.htm</A>.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Pregnant women: Administer one dose of Tdap during each pregnancy, preferably in the early part of gestational weeks 27 to 36.</LI></UL></LI></UL>Δ <STRONG>Measles, mumps, and rubella (MMR) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer one dose of MMR vaccine to adults with no evidence of immunity to measles, mumps, or rubella.</LI>&#xD;&#xA;<LI>Evidence of immunity is: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Born before 1957 (except for health care personnel, refer below).</LI>&#xD;&#xA;<LI>Documentation of receipt of MMR.</LI>&#xD;&#xA;<LI>Laboratory evidence of immunity or disease.</LI></UL></LI>&#xD;&#xA;<LI>Documentation of a health care provider-diagnosed disease without laboratory confirmation is not considered evidence of immunity.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Pregnant women and nonpregnant women of childbearing age with no evidence of immunity to rubella: Administer one dose of MMR (if pregnant, administer MMR after pregnancy and before discharge from health care facility).</LI>&#xD;&#xA;<LI>HIV infection and CD4 cell count ≥200 cells/mcL for at least six months and no evidence of immunity to measles, mumps, or rubella: Administer two doses of MMR at least 28 days apart.</LI>&#xD;&#xA;<LI>Students in postsecondary educational institutions, international travelers, and household contacts of immunocompromised persons: Administer two doses of MMR at least 28 days apart (or one dose of MMR if previously administered one dose of MMR).</LI>&#xD;&#xA;<LI>Health care personnel born in 1957 or later with no evidence of immunity: Administer two doses of MMR at least 28 days apart for measles or mumps, or one dose of MMR for rubella (if born before 1957, consider MMR vaccination).</LI>&#xD;&#xA;<LI>Adults who previously received ≤2 doses of mumps-containing vaccine and are identified by public health authority to be at increased risk for mumps in an outbreak: Administer one dose of MMR.</LI>&#xD;&#xA;<LI>MMR is contraindicated for pregnant women and adults with severe immunodeficiency.</LI></UL></LI></UL><FONT class=lozenge>◊</FONT> <STRONG>Varicella (VAR) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/varicella.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/varicella.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer to adults without evidence of immunity to varicella two doses of VAR vaccine four to eight weeks apart if previously received no VAR-containing vaccine (if previously received one dose of VAR-containing vaccine, administer one dose of VAR vaccine at least four weeks after the first dose).</LI>&#xD;&#xA;<LI>Evidence of immunity to varicella is: &#xD;&#xA;<UL>&#xD;&#xA;<LI>United States-born before 1980 (except for pregnant women and health care personnel, refer below).</LI>&#xD;&#xA;<LI>Documentation of receipt of two doses of VAR vaccine or VAR-containing vaccine at least four weeks apart.</LI>&#xD;&#xA;<LI>Diagnosis or verification of history of varicella or herpes zoster by a health care provider.</LI>&#xD;&#xA;<LI>Laboratory evidence of immunity or disease.</LI></UL></LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer two doses of VAR vaccine four to eight weeks apart if previously received no VAR-containing vaccine (if previously received one dose of VAR-containing vaccine, administer one dose of VAR vaccine at least four weeks after the first dose) to: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Pregnant women without evidence of immunity: Administer the first of the two doses or the second dose after pregnancy and before discharge from health care facility.</LI>&#xD;&#xA;<LI>Health care personnel without evidence of immunity.</LI></UL></LI>&#xD;&#xA;<LI>Adults with HIV infection and CD4 cell count ≥200 cells/mcL: May administer, based on individual clinical decision, two doses of VAR vaccine three months apart.</LI>&#xD;&#xA;<LI>VAR vaccine is contraindicated for pregnant women and adults with severe immunodeficiency.</LI></UL></LI></UL>§ <STRONG>Zoster vaccines</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/shingles.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/shingles.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer two doses of recombinant zoster vaccine (RZV) two to six months apart to adults aged 50 years or older regardless of past episode of herpes zoster or receipt of zoster vaccine, live (ZVL).</LI>&#xD;&#xA;<LI>Administer two doses of RZV two to six months apart to adults who previously received ZVL at least two months after ZVL.</LI>&#xD;&#xA;<LI>For adults aged 60 years or older, administer either RZV or ZVL (RZV is preferred).</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>ZVL is contraindicated for pregnant women and adults with severe immunodeficiency.</LI></UL></LI></UL>¥ <STRONG>Human papillomavirus (HPV) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer HPV vaccine to females through age 26 years and males through age 21 years (males aged 22 through 26 years may be vaccinated based on individual clinical decision).</LI>&#xD;&#xA;<LI>The number of doses of HPV vaccine to be administered depends on age at initial HPV vaccination: &#xD;&#xA;<UL>&#xD;&#xA;<LI>No previous dose of HPV vaccine: Administer three-dose series at 0, 1 to 2, and 6 months (minimum intervals: 4 weeks between doses 1 and 2, 12 weeks between doses 2 and 3, and 5 months between doses 1 and 3; repeat doses if given too soon).</LI>&#xD;&#xA;<LI>Aged 9 to 14 years at HPV vaccine series initiation and received one dose or two doses less than five months apart: Administer one dose.</LI>&#xD;&#xA;<LI>Aged 9 to 14 years at HPV vaccine series initiation and received two doses at least five months apart: No additional dose is needed.</LI></UL></LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Adults with immunocompromising conditions (including HIV infection) through age 26 years: Administer three-dose series at zero, one to two, and six months.</LI>&#xD;&#xA;<LI>Adult females and males through age 26 years with immunocompromising conditions (described below), including those with HIV infection, should receive a three-dose series of HPV vaccine at zero, one to two, and six months.</LI>&#xD;&#xA;<LI>Men who have sex with men (MSM) through age 26 years: Administer two- or three-dose series depending on age at initial vaccination (refer above); if no history of HPV vaccine, administer three-dose series at zero, one to two, and six months.</LI>&#xD;&#xA;<LI>Pregnant women through age 26 years: HPV vaccination is not recommended during pregnancy, but there is no evidence that the vaccine is harmful and no intervention needed for women who inadvertently receive HPV vaccine while pregnant; delay remaining doses until after pregnancy; pregnancy testing is not needed before vaccination.</LI></UL></LI></UL>‡ <STRONG>Pneumococcal vaccines</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer to immunocompetent adults aged 65 years or older one dose of 13-valent pneumococcal conjugate vaccine (PCV13), if not previously administered, followed by one dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) at least one year after PCV13; if PPSV23 was previously administered but not PCV13, administer PCV13 at least one year after PPSV23.</LI>&#xD;&#xA;<LI>When both PCV13 and PPSV23 are indicated, administer PCV13 first (PCV13 and PPSV23 should not be administered during the same visit); additional information on vaccine timing is available at <A href=\"https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf\" target=_blank>www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf</A>.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer to adults aged 19 through 64 years with the following chronic conditions one dose of PPSV23 (at age 65 years or older, administer one dose of PCV13, if not previously received, and another dose of PPSV23 at least one year after PCV13 and at least five years after PPSV23): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Chronic heart disease (excluding hypertension).</LI>&#xD;&#xA;<LI>Chronic lung disease.</LI>&#xD;&#xA;<LI>Chronic liver disease.</LI>&#xD;&#xA;<LI>Alcoholism.</LI>&#xD;&#xA;<LI>Diabetes mellitus.</LI>&#xD;&#xA;<LI>Cigarette smoking.</LI></UL></LI>&#xD;&#xA;<LI>Administer to adults aged 19 years or older with the following indications one dose of PCV13 followed by one dose of PPSV23 at least eight weeks after PCV13, and a second dose of PPSV23 at least five years after the first dose of PPSV23 (if the most recent dose of PPSV23 was administered before age 65 years, at age 65 years or older, administer another dose of PPSV23 at least five years after the last dose of PPSV23): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Immunodeficiency disorders (including B- and T-lymphocyte deficiency, complement deficiencies, and phagocytic disorders).</LI>&#xD;&#xA;<LI>HIV infection.</LI>&#xD;&#xA;<LI>Anatomical or functional asplenia (including sickle cell disease and other hemoglobinopathies).</LI>&#xD;&#xA;<LI>Chronic renal failure and nephrotic syndrome.</LI></UL></LI>&#xD;&#xA;<LI>Administer to adults aged 19 years or older with the following indications one dose of PCV13 followed by one dose of PPSV23 at least eight weeks after PCV13 (if the dose of PPSV23 was administered before age 65 years, at age 65 years or older, administer another dose of PPSV23 at least five years after the last dose of PPSV23): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Cerebrospinal fluid leak.</LI>&#xD;&#xA;<LI>Cochlear implant.</LI></UL></LI></UL></LI></UL>† <STRONG>Hepatitis A (HepA) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepa.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepa.html</A> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer to adults who have a specific risk (refer below), or lack a risk factor but want protection, two-dose series of single-antigen HepA vaccine (Havrix at 0 and 6 to 12 months or Vaqta at 0 and 6 to 18 months; minimum interval: 6 months) or a three-dose series of combined hepatitis A and hepatitis B (HepA-HepB) vaccine at 0, 1, and 6 months; minimum intervals: 4 weeks between first and second doses, 5 months between second and third doses.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer HepA vaccine or HepA-HepB vaccine to adults with the following indications: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Travel to or work in countries with high or intermediate HepA endemicity.</LI>&#xD;&#xA;<LI>MSM.</LI>&#xD;&#xA;<LI>Injection or noninjection drug use.</LI>&#xD;&#xA;<LI>Work with HepA virus in a research laboratory or with nonhuman primates infected with HepA virus.</LI>&#xD;&#xA;<LI>Clotting factor disorders.</LI>&#xD;&#xA;<LI>Chronic liver disease.</LI>&#xD;&#xA;<LI>Close, personal contact with an international adoptee (eg, household or regular babysitting) during the first 60 days after arrival in the United States from a country with high or intermediate endemicity (administer the first dose as soon as the adoption is planned).</LI>&#xD;&#xA;<LI>Healthy adults through age 40 years who have recently been exposed to HepA virus; adults older than age 40 years may receive HepA vaccine or HepA-HepB vaccine if HepA immunoglobulin cannot be obtained.</LI></UL></LI>&#xD;&#xA;<LI>Adults who travel in countries with high or intermediate levels of endemic HepA infection or anticipate close personal contact with an international adoptee (eg, reside in the same household or regularly babysit) from a country with high or intermediate level of endemic HepA infection within the first 60 days of arrival in the United States should receive a HepA series.</LI></UL></LI></UL>** <STRONG>Hepatitis B (HepB) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html</A> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI><STRONG>General information:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer to adults who have a specific risk (refer below), or lack a risk factor but want protection, three-dose series of single-antigen HepB vaccine or combined HepA-HepB vaccine at zero, one, and six months (minimum intervals: Four weeks between doses 1 and 2 for HepB vaccine and HepA-HepB vaccine; between doses 2 and 3, eight weeks for HepB vaccine and five months for HepA-HepB vaccine).</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer HepB vaccine or HepA-HepB vaccine to adults with the following indications: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Chronic liver disease (eg, hepatitis C infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal).</LI>&#xD;&#xA;<LI>HIV infection.</LI>&#xD;&#xA;<LI>Percutaneous or mucosal risk of exposure to blood (eg, household contacts of hepatitis B surface antigen [HBsAg]-positive persons; adults younger than age 60 years with diabetes mellitus or aged 60 years or older with diabetes mellitus based on individual clinical decision; adults in predialysis care or receiving hemodialysis or peritoneal dialysis; recent or current injection drug users; health care and public safety workers at risk for exposure to blood or blood-contaminated body fluids).</LI>&#xD;&#xA;<LI>Sexual exposure risk (eg, sex partners of HBsAg-positive persons; sexually active persons not in a mutually monogamous relationship; persons seeking evaluation or treatment for a sexually transmitted infection; and MSM).</LI>&#xD;&#xA;<LI>Receive care in settings where a high proportion of adults have risks for HepB infection (eg, facilities providing sexually transmitted disease treatment, drug-abuse treatment and prevention services, hemodialysis and end-stage renal disease programs, institutions for developmentally disabled persons, health care settings targeting services to injection drug users or MSM, HIV testing and treatment facilities, and correctional facilities).</LI>&#xD;&#xA;<LI>Travel to countries with high or intermediate HepB endemicity.</LI></UL></LI></UL></LI></UL>¶¶ <STRONG>Meningococcal vaccines</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html</A> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI><STRONG>Special populations: Serogroups A, C, W, and Y meningococcal vaccine (MenACWY)</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer two doses of MenACWY at least eight weeks apart and revaccinate with one dose of MenACWY every five years, if the risk remains, to adults with the following indications: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Anatomical or functional asplenia (including sickle cell disease and other hemoglobinopathies).</LI>&#xD;&#xA;<LI>HIV infection.</LI>&#xD;&#xA;<LI>Persistent complement component deficiency.</LI>&#xD;&#xA;<LI>Eculizumab use.</LI></UL></LI>&#xD;&#xA;<LI>Administer one dose of MenACWY and revaccinate with one dose of MenACWY every five years, if the risk remains, to adults with the following indications: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Travel to or live in countries where meningococcal disease is hyperendemic or epidemic, including countries in the African meningitis belt or during the Hajj.</LI>&#xD;&#xA;<LI>At risk from a meningococcal disease outbreak attributed to serogroup A, C, W, or Y.</LI>&#xD;&#xA;<LI>Microbiologists routinely exposed to <EM>Neisseria meningitidis</EM>.</LI>&#xD;&#xA;<LI>Military recruits.</LI>&#xD;&#xA;<LI>First-year college students who live in residential housing (if they did not receive MenACWY at age 16 years or older).</LI></UL></LI></UL></LI>&#xD;&#xA;<LI><STRONG>General Information: Serogroup B meningococcal vaccine (MenB)</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>May administer, based on individual clinical decision, to young adults and adolescents aged 16 to 23 years (preferred age is 16 to 18 years) who are not at increased risk two-dose series of MenB-4C (Bexsero) at least one month apart or two-dose series of MenB-FHbp (Trumenba) at least six months apart.</LI>&#xD;&#xA;<LI>MenB-4C and MenB-FHbp are not interchangeable.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations: MenB</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer two-dose series of MenB-4C at least one month apart or three-dose series of MenB-FHbp at zero, one to two, and six months to adults with the following indications: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Anatomical or functional asplenia (including sickle cell disease).</LI>&#xD;&#xA;<LI>Persistent complement component deficiency.</LI>&#xD;&#xA;<LI>Eculizumab use.</LI>&#xD;&#xA;<LI>At risk from a meningococcal disease outbreak attributed to serogroup B.</LI>&#xD;&#xA;<LI>Microbiologists routinely exposed to <EM>N. meningitidis</EM>.</LI></UL></LI></UL></LI></UL>ΔΔ <STRONG><EM>Haemophilus influenzae</EM> type b (Hib) vaccine</STRONG><br /><A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html</A> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer Hib vaccine to adults with the following indications: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Anatomical or functional asplenia (including sickle cell disease) or undergoing elective splenectomy: Administer one dose if not previously vaccinated (preferably at least 14 days before elective splenectomy).</LI>&#xD;&#xA;<LI>Hematopoietic stem cell transplant (HSCT): Administer three-dose series with doses 4 weeks apart starting 6 to 12 months after successful transplant regardless of Hib vaccination history.</LI></UL></LI></UL></LI></UL></div><div class=\"graphic_reference\">Reproduced from: Advisory Committee on Immunization Practices (ACIP). Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2018. Available at: <A href=\"http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf\" target=_blank>http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf</A> (Accessed on February 9, 2018).</div><div id=\"graphicVersion\">Graphic 82634 Version 26.0</div></div></div>"},"82635":{"type":"graphic_table","displayName":"Func out women rad cystect","title":"Functional outcomes in women undergoing radical cystectomy and orthotopic reconstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Functional outcomes in women undergoing radical cystectomy and orthotopic reconstruction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author, year</td> <td class=\"subtitle1\">Number of women</td> <td class=\"subtitle1\">Median follow-up, months</td> <td class=\"subtitle1\">Daytime continence rate, percentage</td> <td class=\"subtitle1\">Nighttime continence rate, percentage</td> <td class=\"subtitle1\">Catheterization required, percentage</td> </tr> <tr> <td>Ali-el-Dein B; 1999</td> <td>60</td> <td>20</td> <td>93</td> <td>84</td> <td>14</td> </tr> <tr> <td>Arai Y; 1999</td> <td>12</td> <td>33</td> <td>83</td> <td>50</td> <td>33</td> </tr> <tr> <td>Hautmann R; 2000</td> <td>42</td> <td>NR</td> <td>86*</td> <td>NR</td> <td>47</td> </tr> <tr> <td>Stenzl A; 2001</td> <td>102</td> <td>24</td> <td>82</td> <td>72</td> <td>12</td> </tr> <tr> <td>Stein J; 2002</td> <td>88</td> <td>30</td> <td>75-78*<sup>&#182;</sup></td> <td>NR</td> <td>44-58<sup>​&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NR: not reported.<br />* Percentage of patients reporting continence both during the day and at night.<br />¶ Range based on chart review and patient questionnaire.</div><div id=\"graphicVersion\">Graphic 82635 Version 4.0</div></div></div>"},"82636":{"type":"graphic_table","displayName":"Health belief model","title":"Key components of the health belief model","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key components of the health belief model</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Threat</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Perceived susceptility to an ill-health condition (or\nacceptance of diagnosis)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Perceived seriousness of condition</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Outcome expectations</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Perceived benefits of specified action</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Perceived barriers to taking that action</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Efficacy expectations</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Conviction about one's ability to carry out the\nrecommended action (self-efficacy)</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Adapted from Rosenstock, IM. In: Health Behavior and Health Education, Glanz, K, et al. (Eds), Jossey-Bass, San Francisco, 1990.</div><div id=\"graphicVersion\">Graphic 82636 Version 1.0</div></div></div>"},"82638":{"type":"graphic_table","displayName":"Features of photoaged skin","title":"Features of photoaged skin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of photoaged skin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical</td> <td class=\"subtitle1\">Histologic</td> </tr> <tr> <td>Dryness (roughness)</td> <td>Increased compaction of stratum corneum, increased thickness of granular cell layer, reduced epidermal thickness, reduced epidermal mucin content</td> </tr> <tr> <td>Actinic keratoses</td> <td>Nuclear atypia, loss of orderly, progressive keratinocyte maturation; irregular epidermal hyperplasia and/or hypoplasia; occasional dermal inflammation</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Irregular pigmentation</td> </tr> <tr> <td class=\"sublist1\">Freckling</td> <td class=\"sublist_other\">Reduced or increased number of hypertrophic, strongly DOPA-positive melanocytes</td> </tr> <tr> <td class=\"sublist1\">Lentigines</td> <td class=\"sublist_other\">Elongation of epidermal rete ridges; increases in number and melanization of melanocytes</td> </tr> <tr> <td class=\"sublist1\">Guttate hypomelanosis</td> <td class=\"sublist_other\">Reduced number of atypical melanocytes</td> </tr> <tr> <td class=\"sublist1\">Diffuse irreversible hyperpigmentation (bronzing)</td> <td class=\"sublist_other\">Increased number of DOPA-positive melanocytes and increased melanin content per unit area and increased number of dermal melanophages</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Wrinkling</td> </tr> <tr> <td class=\"sublist1\">Fine surface lines</td> <td class=\"sublist_other\">None detected</td> </tr> <tr> <td class=\"sublist1\">Deep furrows</td> <td class=\"sublist_other\">Contraction of septae in the subcutaneous fat</td> </tr> <tr> <td>Stellate pseudoscars</td> <td>Absence of epidermal pigmentation, altered fragmented dermal collagen</td> </tr> <tr> <td>Elastosis (fine nodularity and/or coarseness)</td> <td>Nodular aggregations of fibrous to amorphous material in the papillary dermis</td> </tr> <tr> <td>Inelasticity</td> <td>Elastotic dermis</td> </tr> <tr> <td>Telangiectasia</td> <td>Ectatic vessels often with atrophic walls</td> </tr> <tr> <td>Venous lakes</td> <td>Ectatic vessels often with atrophic walls</td> </tr> <tr> <td>Purpura (easy bruising)</td> <td>Extravasated erythrocytes and increased perivascular inflammation</td> </tr> <tr> <td>Comedones (maladie de Favre et Racouchot)</td> <td>Ectasia of the pilosebaceous follicular orifice</td> </tr> <tr> <td>Sebaceous hyperplasia</td> <td>Concentric hyperplasia of sebaceous glands</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Yaar M, Gilchrest BA. Aging of skin. In: Fitzpatrick's Dermatology in General Medicine, 7th ed. Wolff K, Goldsmith L, Katz S, et al (Eds), McGraw-Hill Medical 2008. Copyright &copy; 2008 The McGraw-Hill Companies, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 82638 Version 5.0</div></div></div>"},"82640":{"type":"graphic_figure","displayName":"Shenton line","title":"Shenton line","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shenton line</div><div class=\"cntnt\"><img style=\"width:447px; height:596px;\" src=\"images/PEDS/82640_Shenton_line.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shenton line as seen in an&nbsp;anteroposterior diagram of the hips. Shenton line is drawn from the medial border of the femoral neck to the superior border of the obturator foramen. In the normal right hip, it is a continuous contour, whereas in the hip with DDH (the left hip), it is disrupted.</div><div class=\"graphic_footnotes\">DDH: developmental dysplasia of the hip.</div><div id=\"graphicVersion\">Graphic 82640 Version 4.0</div></div></div>"},"82641":{"type":"graphic_picture","displayName":"Gingival hyperplasia","title":"Gingival hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gingival hyperplasia</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/82641_Gingival_hyperplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82641 Version 3.0</div></div></div>"},"82643":{"type":"graphic_figure","displayName":"Rotational stretch exercise","title":"Rotational stretching exercise for congenital muscular torticollis with a tight right sternocleidomastoid muscle","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Rotational stretching exercise for congenital muscular torticollis with a tight right sternocleidomastoid muscle</div><div class=\"cntnt\"><img style=\"width:501px; height:536px;\" src=\"images/PEDS/82643_Rotational-stretch-exercise-new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the child in the supine or sitting position, place one hand on the shoulder of the unaffected side (the infant's left side). Use the other hand to gently rotate the infant's chin so that it touches the tip of the shoulder of the affected side (right). This maneuver should be performed without applying pressure to the child's neck with the palm of the hand.</div><div id=\"graphicVersion\">Graphic 82643 Version 3.0</div></div></div>"},"82644":{"type":"graphic_figure","displayName":"Standard cricothyrotomy step two","title":"Standard cricothyrotomy step two","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard cricothyrotomy step two</div><div class=\"cntnt\"><img style=\"width:372px; height:322px;\" src=\"images/EM/82644_Cric_standard_step_two.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><FONT class=red color=black><FONT color=black>Make a midline vertical skin incision, 3-5 cm in length.</FONT></FONT></div><div class=\"graphic_reference\">Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &#169;2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 82644 Version 2.0</div></div></div>"},"82645":{"type":"graphic_figure","displayName":"Methimazole dose response","title":"Methimazole dose in hyperthyroidism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Methimazole dose in hyperthyroidism</div><div class=\"cntnt\"><img style=\"width:340px; height:252px;\" src=\"images/ENDO/82645_Methimazole_dose_response.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The proportion of patients with hyperthyroidism who became euthyroid at two different doses of MMI. The euthyroid state was defined as normalization of the serum T4 and T3 concentrations. Both doses were equally effective; similar results (not shown) were achieved with 10 mg given three times daily.</div><div class=\"graphic_footnotes\">MMI: methimazole; T4: thyroxine; T3: triiodothyronine.</div><div class=\"graphic_reference\">Data from: Shiroozu A, Okamura K, Ikenoue H, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab 1986; 63:125.</div><div id=\"graphicVersion\">Graphic 82645 Version 3.0</div></div></div>"},"82648":{"type":"graphic_figure","displayName":"Lyme vector map","title":"Lyme disease vector map","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Lyme disease vector map</div><div class=\"cntnt\"><img style=\"width:537px; height:308px;\" src=\"images/ID/82648_Lyme_vector_map.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The geographical distribution of the Ixodes tick vectors of the spirochetes that cause Lyme disease.</div><div class=\"graphic_reference\">Redrawn with permission from: Eisen L, Lane RS. Vectors of Borrelia burgdorferi sensu lato. In: Lyme Borreliosis Biology, Epidemiology and Control, Gray JS, Kahl O, Lane RS, et al (Eds), CABI Publishing, Wallingford, Oxon, UK 2002. p. 91. Copyright ©2002 CAB International, Wallingford, UK.</div><div id=\"graphicVersion\">Graphic 82648 Version 4.0</div></div></div>"},"82649":{"type":"graphic_figure","displayName":"Na handling in nephrosis","title":"Increased collecting tubule sodium reabsorption in nephrotic syndrome","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Increased collecting tubule sodium reabsorption in nephrotic syndrome</div><div class=\"cntnt\"><img style=\"width:503px; height:217px;\" src=\"images/NEPH/82649_Na_handling_in_nephrosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Micropuncture studies (in which samples are taken via micropipettes from different nephron segments) of sodium handling in unilateral nephrotic syndrome in the rat. Although less sodium is filtered in the nephrotic kidney, less is reabsorbed so that the quantity of sodium remaining in the tubular lumen at the end of the distal tubule is the same in the two kidneys. Thus, sodium reabsorption must be increased in the collecting tubules to account for the two-thirds reduction in total sodium excretion in the nephrotic kidney when compared to the normal kidney.</div><div class=\"graphic_reference\">Data from Ichikawa, I, Rennke, HG, Hoyer, JR, et al, J Clin Invest 1983; 71:91.</div><div id=\"graphicVersion\">Graphic 82649 Version 1.0</div></div></div>"},"82650":{"type":"graphic_picture","displayName":"TM retraction","title":"Retractions of the tympanic membrane","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retractions of the tympanic membrane</div><div class=\"cntnt\"><img style=\"width:324px; height:390px;\" src=\"images/PEDS/82650_TM_retraction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retractions of the tympanic membrane located in the regions of the pars flaccida (P), pars tensa (T), and incudostapedial joint (I).</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 82650 Version 2.0</div></div></div>"},"82651":{"type":"graphic_table","displayName":"Sliding scale 1","title":"Sliding scale 1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sliding scale 1</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Blood glucose, mg/dL</td> <td class=\"subtitle1\">Lispro insulin, units</td> </tr> <tr> <td>&#60;80</td> <td>0</td> </tr> <tr> <td>80 to 139</td> <td>2</td> </tr> <tr> <td>140 to 179</td> <td>4</td> </tr> <tr> <td>180 to 219</td> <td>6</td> </tr> <tr> <td>&#62;220</td> <td>10</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82651 Version 2.0</div></div></div>"},"82652":{"type":"graphic_picture","displayName":"Ocular cicatricial pemphigoid immunoperoxidase","title":"Ocular cicatricial pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ocular cicatricial pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/82652_Ocul_cicatricial_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunohistochemistry avidin-biotin-complex immunoperoxidase technique showing the deposition of IgG at the epithelial basement membrane (note the thin line of brown at the BMZ).</div><div id=\"graphicVersion\">Graphic 82652 Version 1.0</div></div></div>"},"82657":{"type":"graphic_diagnosticimage","displayName":"Toe osteo","title":"Osteomyelitis of the toe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis of the toe</div><div class=\"cntnt\"><img style=\"width:360px; height:366px;\" src=\"images/ID/82657_Toe_osteo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph of the foot demonstrates air in the soft tissues about the 5th toe (black arrowheads). Cortical destruction of the 5th metatarsal head is also seen (white arrow). Irregular contour of the overlying skin represents associated soft tissue ulceration (asterisk).</div><div class=\"graphic_reference\">Courtesy of Perry Horwich, MD.</div><div id=\"graphicVersion\">Graphic 82657 Version 2.0</div></div></div>"},"82658":{"type":"graphic_table","displayName":"Antifungal treatments PI","title":"Examples of topical antifungal agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of topical antifungal agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug </td> <td class=\"subtitle1\">How supplied </td> </tr> <tr> <td>Terbinafine (Lamisil)*</td> <td>Cream, gel</td> </tr> <tr> <td>Clotrimazole (Lotrimin)*</td> <td>Cream, lotion, solution</td> </tr> <tr> <td>Econazole (Spectazole)</td> <td>Cream</td> </tr> <tr> <td>Sulconazole (Exelderm)</td> <td>Cream, solution</td> </tr> <tr> <td>Oxiconazole (Oxistat)</td> <td>Cream, lotion</td> </tr> <tr> <td>Naftifine (Naftin)</td> <td>Cream, gel</td> </tr> <tr> <td>Ciclopirox (Loprox)</td> <td>Cream, lotion, liquid</td> </tr> <tr> <td>Ketoconazole (Nizoral)</td> <td>Cream</td> </tr> <tr> <td>Sertaconazole (Ertaczo)</td> <td>Cream</td> </tr> <tr> <td>Miconazole (Monistat)*</td> <td>Cream</td> </tr> <tr> <td>Tolnaftate (Tinactin)*</td> <td>Cream, gel, powder, spray, liquid</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Available without a prescription.</div><div id=\"graphicVersion\">Graphic 82658 Version 3.0</div></div></div>"},"82662":{"type":"graphic_picture","displayName":"OCT system","title":"Commercially available intracoronary Fourier domain OCT system (Lightlab Imaging Inc, Westford, MA)","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Commercially available intracoronary Fourier domain OCT system (Lightlab Imaging Inc, Westford, MA)</div><div class=\"cntnt\"><img style=\"width:583px; height:371px;\" src=\"images/CARD/82662_OCT_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) OCT system consisting in (1) console containing the light source, a computer and imaging display screen and (2) the automated pullback device allowing for pullback speeds up to 20 mm/sec.<br> (B) OCT imaging catheter (Dragonfly&#8482;, Lightlab Imaging Inc, Westford, MA, USA).<br> (C) Magnification of the distal OCT catheter tip. The OCT imaging catheter is introduced into the coronary artery using a conventional guide wire in short monorail technique. The short monorail catheter segment is indicated by (1) the radiopaque distal catheter tip marker and (2) a more proximal radiopaque marker; (3) the imaging core is located approx 15 mm proximal to the distal tip marker and moderately radiopaque. During pullback, the imaging core is withdrawn within the transparent catheter sheath, while the OCT imaging catheter itself is stationary within the artery.</div><div class=\"graphic_reference\">Courtesy of Dr. Evelyn Regar, Thoraxcenter.</div><div id=\"graphicVersion\">Graphic 82662 Version 3.0</div></div></div>"},"82663":{"type":"graphic_algorithm","displayName":"BAT algorithm","title":"Blunt abdominal trauma ED management","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Blunt abdominal trauma ED management</div><div class=\"cntnt\"><img style=\"width:599px; height:536px;\" src=\"images/EM/82663_BAT_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Abd CT: abdominal CT scan; DPT: diagnostic peritoneal tap; LAP: laparotomy; NOM: nonoperative management; US: ultrasound.</div><div id=\"graphicVersion\">Graphic 82663 Version 2.0</div></div></div>"},"82664":{"type":"graphic_figure","displayName":"Retinopathy and A1C","title":"Relation between diabetic retinopathy and glycemic control","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relation between diabetic retinopathy and glycemic control</div><div class=\"cntnt\"><img style=\"width:314px; height:281px;\" src=\"images/ENDO/82664_Retinopathy_and_HbA1c.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Risk of sustained progression of retinopathy in patients with type 1 diabetes according to the mean glycated hemoglobin values at six-month intervals (solid line). Better glycemic control was associated with a lesser rate of progressive retinopathy. The dashed lines represent the 95 percent confidence intervals.</div><div class=\"graphic_reference\">Data from: The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.</div><div id=\"graphicVersion\">Graphic 82664 Version 4.0</div></div></div>"},"82669":{"type":"graphic_diagnosticimage","displayName":"CT pneumomediastinum","title":"CT scan of pneumomediastinum","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">CT scan of pneumomediastinum</div><div class=\"cntnt\"><img style=\"width:460px; height:407px;\" src=\"images/EM/82669_CT_pneumo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This axial CT of the chest with lung windows demonstrates extensive pneuomediastinum (arrow) in the patient whose plain radiographs appear in the accompanying graphic.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Pierre J Sasson, MD.</div><div id=\"graphicVersion\">Graphic 82669 Version 4.0</div></div></div>"},"82670":{"type":"graphic_picture","displayName":"Squamous cell carcinoma of the distal esophagus Endosc","title":"Endoscopic appearance of a squamous cell carcinoma of the distal esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic appearance of a squamous cell carcinoma of the distal esophagus</div><div class=\"cntnt\"><img style=\"width:252px; height:208px;\" src=\"images/GAST/82670_Squamous_cell_CA_esoph_Endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the distal esophagus showing an infiltrating and ulcerated circumferential lesion.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud MD.</div><div id=\"graphicVersion\">Graphic 82670 Version 3.0</div></div></div>"},"82671":{"type":"graphic_picture","displayName":"Pruritic papular eruption","title":"Pruritic papular eruption, anterior trunk and arm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pruritic papular eruption, anterior trunk and arm</div><div class=\"cntnt\"><img style=\"width:252px; height:432px;\" src=\"images/DERM/82671_Pruriticpapulareruption.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pruritic papular eruption is an intensely pruritic skin rash seen commonly in people infected with HIV in Sub-Saharan Africa.</div><div class=\"graphic_reference\">Reproduced with permission from: Resneck JS, Van Beek M, Furmanski L, et al. Etiology of pruritic papular eruption with HIV Infection in Uganda. JAMA 2004; 292:2614. Copyright © 2004 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 82671 Version 17.0</div></div></div>"},"82673":{"type":"graphic_table","displayName":"Criteria DI","title":"Laboratory features of diabetes insipidus in a potential pediatric organ donor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory features of diabetes insipidus in a potential pediatric organ donor</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>Serum sodium &#62;150 mmol/L</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Serum osmolality &#62;305 mOsm/L</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Low urinary sodium &#60;20 mmol/L</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Dilute urine 50 to 150 mOsm/L</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Urine output &#62;4 ml/kg/hr</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Exclude diuresis - (eg, caused by diuretics, mannitol, or hypertonic saline)</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 82673 Version 2.0</div></div></div>"},"82674":{"type":"graphic_table","displayName":"PHQ","title":"Patient health questionnaire® (PHQ)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient health questionnaire&#174; (PHQ)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_single\" colspan=\"5\">This questionnaire is an important part of providing you with the best health care possible. Your answers will help in understanding problems that you may have. Please answer every question to the best of your ability unless you are requested to skip over a question. </td> </tr> <tr> <td class=\"subtitle1_single\">Name: </td> <td class=\"subtitle1_single\">Age: </td> <td class=\"subtitle1_single\" colspan=\"2\">Sex: [&nbsp;] Female [&nbsp;] Male </td> <td class=\"subtitle1_single\">Date: </td> </tr> <tr> <td class=\"subtitle2_left\">1. During the last 4 weeks, how much have you been bothered by any of the following problems? </td> <td class=\"subtitle2_left\" colspan=\"2\">Not bothered at all </td> <td class=\"subtitle2_left\">Bothered a little </td> <td class=\"subtitle2_left\">Bothered a lot </td> </tr> <tr> <td class=\"indent2\">a. Stomach pain </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">b. Back pain </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">c. Pain in your arms, legs, or joints (knees, hips, etc.) </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">d. Menstrual cramps or other problems with your periods </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">e. Pain or problems during sexual intercourse </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">f. Headaches </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">g. Chest pain </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">h. Dizziness </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">i. Fainting spells </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">j. Feeling your heart pound or race </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">k. Shortness of breath </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">l. Constipation, loose bowels, or diarrhea </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">m. Nausea, gas, or indigestion </td> <td colspan=\"2\">[&nbsp;] </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\">2. Over the last two weeks, how often have you been bothered by any of the following problems? </td> <td class=\"subtitle2_left\">Not at all </td> <td class=\"subtitle2_left\">Several days </td> <td class=\"subtitle2_left\">More than half the days </td> <td class=\"subtitle2_left\">Nearly every day </td> </tr> <tr> <td class=\"indent2\">a. Little interest or pleasure in doing things </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">b. Feeling down, depressed, or hopeless </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">c. Trouble falling or staying asleep, or sleeping too much </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">d. Feeling tired or having little energy </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">e. Poor appetite or overeating </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">f. Feeling bad about yourself, or that you are a failure, or have let yourself or your family down </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">g. Trouble concentrating on things, such as reading the newspaper or watching television </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">h. Moving or speaking so slowly that other people could have noticed? Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\">i. Thoughts that you would be better off dead or of hurting yourself in some way </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td colspan=\"5\">FOR OFFICE CODING: Som Dis if at least three of #1a-m are \"a lot\" and lack an adequate biol explanation. Maj Dep Syn if answers to #2a or b and five or more of #2a-i are at least \"More than half the days\" (count #2i if present at all). Other Dep Syn if #2a or b and two, three, or four of #2a-i are at least \"More than half the days\" (count #2i if present at all). </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">3. Questions about anxiety </td> <td class=\"subtitle2_left\">No </td> <td class=\"subtitle2_left\">Yes </td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">a. In the last 4 weeks, have you had an anxiety attack - suddenly feeling fear or panic? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle3_single\" colspan=\"5\">If you checked \"No\", go to question #5 </td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">b. Has this ever happened before? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">c. Do some of these attacks come suddenly out of the blue - that is, in situations where you don't expect to be nervous or uncomfortable? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">d. Do these attacks bother you a lot or are you worried about having another attack? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">4. Think about your last bad anxiety attack </td> <td class=\"subtitle2_left\">No </td> <td class=\"subtitle2_left\">Yes </td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">a. Were you short of breath? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">b. Did your heart race, pound, or skip? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">c. Did you have chest pain or pressure? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">d. Did you sweat? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">e. Did you feel as if you were choking? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">f. Did you have hot flashes or chills? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">g. Did you have nausea or an upset stomach, or the feeling that you were going to have diarrhea? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">h. Did you feel dizzy, unsteady, or faint? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">i. Did you have tingling or numbness in parts of your body? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">j. Did you tremble or shake? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">k. Were you afraid you were dying? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">5. Over the last 4 weeks, how often have you been bothered by any of the following problems? </td> <td class=\"subtitle2_left\">Not at all </td> <td class=\"subtitle2_left\">Several days </td> <td class=\"subtitle2_left\">More than half the days </td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">a. Feeling nervous, anxious, on edge, or worrying a lot about different things </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle3_single\" colspan=\"5\">If you checked \"Not at all\", go to question #6 </td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">b. Feeling restless so that it is hard to sit still </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">c. Getting tired very easily </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">d. Muscle tension, aches, or soreness </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">e. Trouble falling asleep or staying asleep </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">f. Trouble concentrating on things, such as reading a book, watching TV </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">g. Becoming easily annoyed or irritable </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td colspan=\"5\">FOR OFFICE CODING: Pan Syn if all of #3a-d are 'YES' and four or more of #4a-k are 'YES'. Other Anx Syn if #5a and answers to three or more of #5b-g are \"More than half the days\". </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">6. Questions about eating </td> <td class=\"subtitle2_left\">No </td> <td class=\"subtitle2_left\">Yes </td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">a. Do you often feel that you can't control what or how much you eat? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">b. Do you often eat, within any 2-hour period, what most people would regard as an unusually large amount of food? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle3_single\" colspan=\"5\">If you checked \"NO\" to either #6a or #6b, go to question #9 </td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">c. Has this been as often, on average, as twice a week for the last 3 months? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">7. In the last 3 months have you often done any of the following in order to avoid gaining weight? </td> <td class=\"subtitle2_left\">No </td> <td class=\"subtitle2_left\">Yes </td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">a. Made yourself vomit? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">b. Took more than twice the recommended dose of laxatives? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">c. Fasted - not eaten anything at all for at least 24 hours? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">d. Exercised for more than an hour specifically to avoid gaining weight after binge eating? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">8. If you checked \"Yes\" to any of these ways of avoiding gaining weight, were any as often, on average, as twice a week? </td> <td class=\"subtitle2_left\">No [&nbsp;] </td> <td class=\"subtitle2_left\">Yes [&nbsp;] </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">9. Do you ever drink alcohol (including beer or wine)? </td> <td class=\"subtitle2_left\">No [&nbsp;] </td> <td class=\"subtitle2_left\">Yes [&nbsp;] </td> </tr> <tr> <td class=\"subtitle3_single\" colspan=\"5\">If you checked \"No\", go to question #11 </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">10. Have any of the following happened to you more than once in the last 6 months? </td> <td class=\"subtitle2_left\">No </td> <td class=\"subtitle2_left\">Yes </td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">a. You drank alcohol even though a doctor suggested that you stop drinking because of a problem with your health </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">b. You drank alcohol, were high from alcohol, or hung over while you were working, going to school, or taking care of children or other responsibilities </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">c. You missed or were late for work, school, or other activities because you were drinking or hung over </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">d. You had a problem getting along with other people while you were drinking </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">e. You drove a car after having several drinks or after drinking too much </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\">11. If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people? </td> <td class=\"subtitle2_left\">Not difficult at all [&nbsp;] </td> <td class=\"subtitle2_left\">Somewhat difficult [&nbsp;] </td> <td class=\"subtitle2_left\">Very difficult [&nbsp;] </td> <td class=\"subtitle2_left\">Extremely difficult [&nbsp;] </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td colspan=\"5\">FOR OFFICE CODING: Bul Ner if #6a,b, and -c and #8 are all 'YES'; Bin Eat Dis the same but #8 either 'NO' or left blank. Alc Abu if any of #10a-e is 'YES'. </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">12. During the last 4 weeks, how much have you been bothered by any of the following problems? </td> <td class=\"subtitle2_left\">Not bothered at all </td> <td class=\"subtitle2_left\">Bothered a little </td> <td class=\"subtitle2_left\">Bothered a lot </td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">a. Worrying about your health </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">b. Your weight or how you look </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">c. Little or no sexual desire or pleasure during sex </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">d. Difficulties with husband/wife, partner/lover or boyfriend/girlfriend </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">e. The stress of taking care of children, parents or other family members </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">f. Stress at work or outside of the home or at school </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">g. Financial problems or worries </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">h. Having no one to turn to when you have a problem </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">i. Something bad that happened recently </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">j. Thinking or dreaming about something terrible that happened to you in the past - like your house being destroyed, a severe accident, being hit or assaulted, or being forced to commit a sexual act </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">13. In the last year, have you been hit, slapped, kicked or otherwise physically hurt by someone, or has anyone forced you to have an unwanted sexual act? </td> <td class=\"subtitle2_left\">No [&nbsp;] </td> <td class=\"subtitle2_left\">Yes [&nbsp;] </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\"> <p>14. What is the most stressful thing in your life right now?</p> <p>____________________________________________________________________________________________________________________</p> <p>____________________________________________________________________________________________________________________</p> <p>____________________________________________________________________________________________________________________</p> <p>____________________________________________________________________________________________________________________</p> </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">15. Are you taking any medicine for anxiety, depression or stress? </td> <td class=\"subtitle2_left\">No [&nbsp;] </td> <td class=\"subtitle2_left\">Yes [&nbsp;] </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">16. FOR WOMEN ONLY: Questions about menstruation, pregnancy and childbirth </td> </tr> <tr> <td class=\"indent2\" colspan=\"5\">a. Which best describes your menstrual periods? </td> </tr> <tr> <td class=\"indent3\" colspan=\"5\">___ Periods are unchanged </td> </tr> <tr> <td class=\"indent3\" colspan=\"5\">___ No periods because pregnant or recently gave birth </td> </tr> <tr> <td class=\"indent3\" colspan=\"5\">___ Periods have become irregular or changed in frequency, duration or amount </td> </tr> <tr> <td class=\"indent3\" colspan=\"5\">___ No periods for at least a year </td> </tr> <tr> <td class=\"indent3\" colspan=\"5\">___ Having periods because taking hormone replacement (estrogen) therapy or oral contraceptive </td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\" colspan=\"3\">b. During the week before your period starts, do you have a serious problem with your mood - like depression, anxiety, irritability, anger or mood swings? </td> <td class=\"subtitle2_left\">No </td> <td class=\"subtitle2_left\">Yes </td> </tr> <tr> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent3\" colspan=\"3\">- IF Yes: Do these problems go away by the end of your period? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">c. Have you given birth within the last 6 months? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">d. Have you had a miscarriage within the last 6 months? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">e. Are you having difficulty getting pregnant? </td> <td>[&nbsp;]</td> <td>[&nbsp;]</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">&nbsp; </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"5\">(DO NOT DISTRIBUTE THIS PAGE TO THE PATIENT) </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"5\">Quick guide to the patient health questionnaire </td> </tr> <tr> <td colspan=\"5\"><strong>Purpose.</strong> The Patient Health Questionnaire (PHQ) is designed to facilitate the recognition and diagnosis of the most common mental disorders in primary care patients. For patients with a depressive disorder, a PHQ Depression Severity Index score can be calculated and repeated over time to monitor change. </td> </tr> <tr> <td colspan=\"5\"><strong>Who should take the phq.</strong> Ideally, the PHQ should be used with all new patients, all patients who have not completed the questionnaire in the last year, and all patients suspected of having a mental disorder. </td> </tr> <tr> <td colspan=\"5\"><strong>Making a diagnosis.</strong> Since the questionnaire relies on patient self-report, definitive diagnoses must be verified by the clinician, taking into account how well the patient understood the questions in the questionnaire, as well as other relevant information from the patient, his or her family or other sources. </td> </tr> <tr> <td colspan=\"5\"><strong>Interpreting the PHQ.</strong> To facilitate interpretation of patient responses, all clinically significant responses are found in the column farthest to the right. (The only exception is for suicidal ideation when diagnosing a depressive syndrome.) In addition, the diagnoses of Major Depressive Disorder (rather than Syndrome) and Other Depressive Disorder requires ruling out normal bereavement (mild symptoms, duration less than 2 months), a history of a manic episode (Bipolar Disorder) and a physical disorder, medication or other drug as the biological cause of the depressive symptoms. Similarly, the diagnoses of Panic Disorder and Other Anxiety Disorder require ruling out a physical disorder, medication or other drug as the biological cause of the anxiety symptoms. Criteria for diagnostic judgments for summarizing responses are located at different points, beginning with \"FOR OFFICE CODING\", in small type. The names of the categories are abbreviated, eg, Major Depressive Syndrome is Maj Dep Syn. </td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"5\"><strong>Page 1</strong> </td> </tr> <tr> <td class=\"sublist3\" colspan=\"5\">Somatoform Disorder if at least 3 of #1a-m bother the patient \"a lot\" and lack an adequate biological explanation. </td> </tr> <tr> <td class=\"sublist3\" colspan=\"5\">Major Depressive Syndrome if #2a or b and 5 or more of #2a-i are at least \"more than half the days\" (count #2i if present at all). </td> </tr> <tr> <td class=\"sublist3\" colspan=\"5\">Other Depressive Syndrome if #2a or b and 2, 3 or 4 of #2a-i are at least \"more than half the days\" (count #2i if present at all). </td> </tr> <tr> <td class=\"sublist3\" colspan=\"5\"><strong>Note:</strong> the diagnoses of Major Depressive Disorder and Other Depressive Disorder requires ruling out normal <strong>bereavement (mild symptoms, duration less than 2 months)</strong>, a history of a <strong>manic</strong> episode (Bipolar Disorder) and a <strong>physical disorder, medication or other drug</strong> as the biological cause of the depressive symptoms. </td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"5\"><strong>Page 2</strong> </td> </tr> <tr> <td class=\"sublist3\" colspan=\"5\">Panic Syndrome if #3a-d are all 'Yes' and 4 or more of #4a-k are 'Yes'. </td> </tr> <tr> <td class=\"sublist3\" colspan=\"5\">Other Anxiety Syndrome if #5a and answers to 3 or more of #5b-g are \"more than half the days\". </td> </tr> <tr> <td class=\"sublist3\" colspan=\"5\"><strong>Note:</strong> The diagnoses of Panic Disorder and Other Anxiety Disorder require ruling out a <strong>physical disorder, medication or other drug</strong> as the biological cause of the anxiety symptoms. </td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"5\"><strong>Page 3</strong> </td> </tr> <tr> <td class=\"sublist3\" colspan=\"5\">Bulimia Nervosa if #6a,b, and c and #8 are 'Yes'; Binge Eating Disorder the same but #8 is either 'NO' or left blank. </td> </tr> <tr> <td class=\"sublist3\" colspan=\"5\">Alcohol abuse if any of #10a-e are 'Yes'. </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\"><strong>Additional clinical considerations.</strong> After making a provisional diagnosis with the PHQ, there are additional clinical considerations that may affect decisions about management and treatment: </td> </tr> <tr> <td class=\"sublist1\" colspan=\"5\"><em>Have current symptoms been triggered by psychosocial <strong>stressor(s)</strong>?</em> </td> </tr> <tr> <td class=\"sublist1\" colspan=\"5\"><em>What is the <strong>duration</strong> of the current disturbance and has the patient received any <strong>treatment</strong> for it?</em> </td> </tr> <tr> <td class=\"sublist1\" colspan=\"5\"><em>To what extent are the patient's symptoms <strong>impairing</strong> his or her usual work and activities?</em> </td> </tr> <tr> <td class=\"sublist1\" colspan=\"5\"><em>Is there a <strong>history</strong> of similar episodes, and were they <strong>treated</strong>?</em> </td> </tr> <tr> <td class=\"sublist1\" colspan=\"5\"><em>Is there a <strong>family history</strong> of similar conditions?</em> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Copyright &#169; Pfizer Inc. All rights reserved. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 82674 Version 3.0</div></div></div>"},"82676":{"type":"graphic_algorithm","displayName":"Algorithm shoulder pain","title":"Shoulder pain algorithm","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Shoulder pain algorithm</div><div class=\"cntnt\"><img style=\"width:483px; height:588px;\" src=\"images/EM/82676_Algorithm_shoulder_pain.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AC: acromioclavicular; DL: dislocation; Fx: fracture; GH: glenohumeral; SL: subluxation.</div><div id=\"graphicVersion\">Graphic 82676 Version 2.0</div></div></div>"},"82677":{"type":"graphic_table","displayName":"Signs of meningeal irritation","title":"Signs of meningeal irritation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs of meningeal irritation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Signs of meningeal irritation</td> <td class=\"subtitle1\">Maneuver</td> <td class=\"subtitle1\">Positive test</td> </tr> <tr> <td>Kernig sign</td> <td>Place patient supine with hip flexed at 90 degrees. Attempt to extend the leg at the knee.</td> <td>The test is positive when there is resistance to extension at the knee to &#62;135 degrees or pain in the lower back or posterior thigh.</td> </tr> <tr> <td>Brudzinski sign</td> <td>Place patient in the supine position and passively flex the head toward the chest.</td> <td>The test is positive when there is flexion of the knees and hips of the patient.</td> </tr> <tr> <td>Jolt accentuation of headache</td> <td>Patient rotates his/her head horizontally two to three times per second.</td> <td>The test is positive if the patient reports exacerbation of his/her headache with this maneuver.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82677 Version 4.0</div></div></div>"},"82678":{"type":"graphic_picture","displayName":"Invasive urothelial carcino","title":"Invasive urothelial carcinoma (UC)","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Invasive urothelial carcinoma (UC)</div><div class=\"cntnt\"><img style=\"width:592px; height:166px;\" src=\"images/ONC/82678_Invasive_urothelial_carcino.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: Photograph of a surgically resected urinary bladder opened anteriorly to show urothelial carcinoma involving the mucosa that surrounds the orifices of the ureters. B: Cross-section of urinary bladder wall demonstrating transmural diffuse growth of urothelial carcinoma. The tumor invades the perivesical adipose tissue. C: Microscopic appearance of invasive urothelial carcinoma (20x).</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 82678 Version 1.0</div></div></div>"},"82679":{"type":"graphic_table","displayName":"UAI RAD NV trials","title":"Randomized trials for upper abdomen irradiation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Randomized trials for upper abdomen irradiation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Reference</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Radiotherapy</td> <td class=\"subtitle1\">Antiemetic</td> <td class=\"subtitle1\">Complete response (percent)</td> <td class=\"subtitle1\">Results</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Priestman<sup>1</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">82</td> <td class=\"divider_bottom\" rowspan=\"2\">8-10 Gy single fraction</td> <td>OND (8 mg x 3/day PO for 5 days)</td> <td>97</td> <td class=\"divider_bottom\" rowspan=\"2\">OND better than MCP</td> </tr> <tr class=\"divider_bottom\"> <td>MCP (10 mg x 3/day PO for 5 days)</td> <td>46</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Priestman<sup>2</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">135</td> <td class=\"divider_bottom\" rowspan=\"2\">1.8 Gy/day for at least 5 fractions</td> <td>OND (8 mg x 3/day PO)</td> <td>61</td> <td class=\"divider_bottom\" rowspan=\"2\">OND better than MCP for vomiting</td> </tr> <tr class=\"divider_bottom\"> <td>MCP (10 mg x 3/day PO)</td> <td>35</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Bey<sup>3</sup></td> <td class=\"divider_bottom\" rowspan=\"4\">50</td> <td class=\"divider_bottom\" rowspan=\"4\">At least 6 Gy single fraction</td> <td>DOL (0.3 mg/kg IV)</td> <td>100*</td> <td class=\"divider_bottom\" rowspan=\"4\">DOL better than placebo</td> </tr> <tr> <td>DOL (0.6 mg/kg IV)</td> <td>93*</td> </tr> <tr> <td>DOL (1.2 mg/kg IV)</td> <td>83*</td> </tr> <tr class=\"divider_bottom\"> <td>Placebo</td> <td>54*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Franzen<sup>4</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">111</td> <td class=\"divider_bottom\" rowspan=\"2\">At least 1.7 Gy/day for &#8805;10 fractions</td> <td>OND (8 mg x 2/day PO)</td> <td>67</td> <td class=\"divider_bottom\" rowspan=\"2\">OND better than placebo</td> </tr> <tr class=\"divider_bottom\"> <td>Placebo</td> <td>45</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Aass<sup>5</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">23</td> <td class=\"divider_bottom\" rowspan=\"2\">2 Gy/day to 30 Gy in 15 fractions</td> <td>TRO (5 mg/day PO)</td> <td>91</td> <td class=\"divider_bottom\" rowspan=\"2\">TRO better than MCP</td> </tr> <tr class=\"divider_bottom\"> <td>MCP (10 mg x 3/day PO)</td> <td>50</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Lanciano<sup>6</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">260</td> <td>10-30 fractions</td> <td>GRAN (2 mg/day)</td> <td>57.5</td> <td class=\"divider_bottom\" rowspan=\"2\">GRAN better than placebo</td> </tr> <tr class=\"divider_bottom\"> <td>(1.8-3 Gy/fraction)</td> <td>Placebo</td> <td>42</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Kirkbride<sup>7</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">154</td> <td class=\"divider_bottom\" rowspan=\"2\">At least 5 fractions to minimum total dose of 20 Gy</td> <td>DEX (2 mg x 3/day PO for 5-7 days)</td> <td>70</td> <td class=\"divider_bottom\" rowspan=\"2\">DEX better than placebo</td> </tr> <tr class=\"divider_bottom\"> <td>Placebo</td> <td>49</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Wong<sup>8</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">211</td> <td class=\"divider_bottom\" rowspan=\"2\">&#8805;15 fractions to the upper abdomen to a dose of 20 or more Gy</td> <td>OND (8 mg BID for 5 days) + placebo for 5 days</td> <td> <p>71<sup>&#182;</sup></p> 12<sup>&#916;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">OND + DEX better than OND alone</td> </tr> <tr class=\"divider_bottom\"> <td>OND (8 mg BID) + DEX (4 mg for 5 days)</td> <td> <p>78<sup>&#182;</sup></p> 23<sup>&#916;</sup></td> </tr> <tr> <td rowspan=\"2\">Mystakidou<sup>9</sup></td> <td rowspan=\"2\">288</td> <td rowspan=\"2\">Fractionated radiotherapy of moderate or high emetogenic potential</td> <td>TRO 5 mg daily starting 1 day before radiotherapy until 7 days after end of radiotherapy</td> <td rowspan=\"2\">Incidence of vomiting was 2.19 times higher in rescue arm</td> <td rowspan=\"2\">Prophylactic TRO better than rescue TRO</td> </tr> <tr> <td>TRO 5 mg on an as needed basis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OND: ondansetron; PO: orally; MCP: metoclopramide; DOL: dolasetron; IV: intravenously; TRO: tropisetron; DEX: dexamethasone; BID: twice a day.<br />* Complete plus major response.<br />¶ Primary endpoint: CR day 1-5.<br />Δ Secondary endpoint: CR day 1-15.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Priestman TJ, Roberts JT, Lucraft H, et al. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol (R Coll Radiol) 1990; 2:71.</LI>&#xD;&#xA;<LI>Priestman TJ, Roberts JT, Upadhyaya BK. A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol (R Coll Radiol) 1993; 5:358.</LI>&#xD;&#xA;<LI>Bey P, Wilkinson PM, Resbeut M, et al. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer 1996; 4:378.</LI>&#xD;&#xA;<LI>Franzen L, Nyman J, Hagberg H, et al. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 1996; 7:587.</LI>&#xD;&#xA;<LI>Aass N, Håtun DE, Thoresen M, Fosså SD. Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. Radiother Oncol 1997; 45:125.</LI>&#xD;&#xA;<LI>Lanciano R, Sherman DM, Michalski J, et al. The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest 2001; 19:763.</LI>&#xD;&#xA;<LI>Kirkbride P, Bezjak A, Pater J, et al. Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol 2000; 18:1960.</LI>&#xD;&#xA;<LI>Wong RK, Paul N, Ding K, et al. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 2006; 24:3458.</LI>&#xD;&#xA;<LI>Mystakidou K, Katsouda E, Linou A, et al. Prophylactic tropisetron versus rescue tropisetron in fractionated radiotherapy to moderate or high emetogenic areas: a prospective randomized open label study in cancer patients. Med Oncol 2006; 23:251.</LI></OL></div><div id=\"graphicVersion\">Graphic 82679 Version 3.0</div></div></div>"},"82681":{"type":"graphic_figure","displayName":"Classification of simple acetabular fractures","title":"Letournel and Judet classification of simple acetabulum fractures","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Letournel and Judet classification of simple acetabulum fractures</div><div class=\"cntnt\"><img style=\"width:525px; height:472px;\" src=\"images/EM/82681_Acetab_simple_fx_scheme.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Posterior wall. B) Posterior column. C) Anterior wall. D) Anterior column. E) Transverse.</div><div class=\"graphic_reference\">Reproduced with permission from: Matta, JM. Surgical Treatment of Acetabular Fractures. In: Skeletal Trauma: Basic Science, Management, and Reconstruction, Browner, BD, Jupiter, JB, Levine, AM, Trafton, PG (Eds), Saunders, Philadelphia 2003. p. 1110. Illustrations used with permission of Elsevier Inc. All rights reserved. Copyright &#169;2003 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 82681 Version 2.0</div></div></div>"},"82682":{"type":"graphic_table","displayName":"Specimen collection methods IV","title":"Microbiology specimen handling and collection - IV","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Microbiology specimen handling and collection - IV</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Specimen</td> <td class=\"subtitle1\">Method</td> <td class=\"subtitle1\">Volume</td> <td class=\"subtitle1\">Storage temperature*</td> <td class=\"subtitle1\">Comments</td> <td class=\"subtitle1\">Refer to UpToDate topic review</td> </tr> <tr> <td class=\"subtitle2_left\">Tissue or abscess fluid (pus)</td> <td>Transport in sterile container. Keep moist; add sterile (non-bacteriostatic saline) if necessary.</td> <td>As much tissue or pus as possible</td> <td>25&ordm;C</td> <td>Tissue itself and abscess contents (pus) provide much better yield than swabs</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Urine</td> </tr> <tr> <td class=\"indent1\">Clean catch or straight catheter</td> <td>Midstream urine in sterile wide-mouth container</td> <td>&#8805;1 mL for routine culture (&#62;20 mL for fungal or mycobacterial culture)</td> <td>4&ordm;C</td> <td>Always send urinalysis as well</td> <td>Urine sampling and culture in the diagnosis of urinary tract infection</td> </tr> <tr> <td class=\"indent1\">Indwelling catheter</td> <td>Disinfect specimen port with alcohol, remove 5 to 10 mL of urine with needle and syringe and transfer into sterile container</td> <td>&#8805;1 mL for routine culture (&#62;20 mL for fungal or mycobacterial culture)</td> <td>4&ordm;C</td> <td>Always send urinalysis as well</td> <td>Urine sampling and culture in the diagnosis of urinary tract infection</td> </tr> <tr> <td class=\"indent1\">Suprapubic aspirate</td> <td>Sterile container</td> <td>&#8805;1 mL for routine culture (&#62;20 mL for fungal or mycobacterial culture)</td> <td>4&ordm;C</td> <td>Always send urinalysis as well</td> <td>Urine sampling and culture in the diagnosis of urinary tract infection</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* If immediate processing is not possible.</div><div id=\"graphicVersion\">Graphic 82682 Version 3.0</div></div></div>"},"82684":{"type":"graphic_figure","displayName":"Posterior rectopexy with mesh sling","title":"Posterior rectopexy with mesh sling","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Posterior rectopexy with mesh sling</div><div class=\"cntnt\"><img style=\"width:493px; height:603px;\" src=\"images/SURG/82684_Posterior-rectopexy-with-mesh-sling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the mobilization of the rectum anteriorly and posteriorly. The&nbsp;mesh sling is attached to the presacral fascia, wrapped anterior onto the anterior surface of the rectum, and attached to the seromuscular layer. This procedure can be performed laparoscopically or open.</div><div id=\"graphicVersion\">Graphic 82684 Version 4.0</div></div></div>"},"82685":{"type":"graphic_figure","displayName":"BNP levels etiology dyspnea","title":"Plasma BNP in the diagnosis of dyspnea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma BNP in the diagnosis of dyspnea</div><div class=\"cntnt\"><img style=\"width:426px; height:331px;\" src=\"images/CARD/82685_BNP_levels_etiology_dyspnea.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are the plasma B-type natriuretic peptide (BNP) concentrations in patients presenting with acute dyspnea who are diagnosed noncardiac causes without or with a history of left ventricular (LV) dysfunction, or heart failure (HF). Patients with a diagnosis of HF have significantly higher median values of plasma BNP compared to those without heart failure (675 versus 110 pg/mL). The boxes show the interquarile ranges, and the I bars represent the highest and lowest values.</div><div class=\"graphic_reference\">Data from Maisel AS, Krishnaswamy P, Nowak RM, et al. N Engl J Med 2002; 347:161.</div><div id=\"graphicVersion\">Graphic 82685 Version 2.0</div></div></div>"},"82687":{"type":"graphic_table","displayName":"Immunization resources","title":"Online resources regarding vaccines and vaccine safety","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Online resources regarding vaccines and vaccine safety</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organization/URL</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Professional organizations/societies</td> </tr> <tr> <td class=\"indent1\"> <p>American Academy of Family Physicians</p> <p><a href=\"http://www.familydoctor.org/\" target=\"_blank\">www.familydoctor.org</a> (search on \"vaccines\")</p> </td> <td>Patient information on childhood vaccines (what they are and why children need them)</td> </tr> <tr> <td class=\"indent1\"> <p>American Academy of Pediatrics Childhood Immunization Support Program</p> <p><a href=\"http://www.aap.org/immunization\" target=\"_blank\">www.aap.org/immunization</a></p> </td> <td> <p>Compilation of resources for families and providers, including Q&#38;A for families and information on vaccine-preventable illnesses, vaccine ingredients, vaccine safety, and the immunization schedule</p> <p>Provides information for clinicians on how to communicate with parents about immunization, including responses for common reasons for parental refusal to vaccinate</p> </td> </tr> <tr> <td class=\"indent1\"> <p>Canadian Pediatric Society</p> <p><a href=\"http://www.caringforkids.cps.ca/\" target=\"_blank\">www.caringforkids.cps.ca/</a></p> </td> <td>Provides a parent's guide to immunization information on the internet</td> </tr> <tr> <td class=\"indent1\"> <p>Infectious Diseases Society of America (IDSA)</p> <p><a href=\"http://www.idsociety.org/\" target=\"_blank\">www.idsociety.org</a></p> </td> <td>Provides lists of resources, IDSA position statements, and policy statements</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Academic institutions</td> </tr> <tr> <td class=\"indent1\"> <p>Center for Vaccine Awareness and Research, Texas Children's Hospital</p> <p><a href=\"http://www.texaschildrens.org/departments/center-vaccine-awareness-and-research-cvar\" spellcheck=\"true\" target=\"_blank\">www.texaschildrens.org/departments/center-vaccine-awareness-and-research-cvar</a></p> </td> <td>Provides valuable information regarding vaccination. Includes links to resources, including a book that profiles families devastated by vaccine-preventable illness (for purchase)</td> </tr> <tr> <td class=\"indent1\"> <p>Institute for Vaccine Safety, Johns Hopkins University</p> <p><a href=\"http://www.vaccinesafety.edu/\" target=\"_blank\">www.vaccinesafety.edu</a></p> </td> <td>Provides an independent assessment of vaccines and vaccine safety to guide decision makers and educate physicians, the public, and the media about the safety of vaccines</td> </tr> <tr> <td class=\"indent1\"> <p>The Nemours Foundation KidsHealth</p> <p><a href=\"http://kidshealth.org/teen/your_body/health_basics/immunizations.html\" spellcheck=\"true\" target=\"_blank\">kidshealth.org/teen/your_body/health_basics/immunizations.html</a></p> </td> <td>Vaccine information targeted to adolescents</td> </tr> <tr> <td class=\"indent1\"> <p>The Vaccine Education Center at the Children's Hospital of Philadelphia</p> <p><a href=\"http://www.vaccine.chop.edu/\" target=\"_blank\">www.vaccine.chop.edu</a></p> </td> <td>Provides reliable information about vaccines to parents and health care professionals</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Public health/advocacy groups</td> </tr> <tr> <td class=\"indent1\"> <p>Allied Vaccine Group</p> <p><a href=\"http://www.vaccine.org/\" target=\"_blank\">www.vaccine.org</a></p> </td> <td>Links to web sites dedicated to presenting valid scientific information about vaccines</td> </tr> <tr> <td class=\"indent1\"> <p>Program for Appropriate Technology in Health (PATH) Vaccine Resource Library</p> <p><a href=\"http://www.path.org/vaccineresources/\" target=\"_blank\">www.path.org/vaccineresources/</a></p> </td> <td>Offers a variety of high-quality, scientifically accurate documents and links to information about vaccine-preventable diseases and vaccines</td> </tr> <tr> <td class=\"indent1\"> <p>Every Child by Two</p> <p><a href=\"http://www.ecbt.org/\" target=\"_blank\">www.ecbt.org</a></p> </td> <td>Seeks to raise parental awareness of the need for timely infant immunizations</td> </tr> <tr> <td class=\"indent1\"> <p>Health on the Net Foundation</p> <p><a href=\"http://www.hon.ch/\" target=\"_blank\">www.hon.ch</a></p> </td> <td>Nonprofit, nongovernmental organization that promotes and guides the deployment of useful and reliable online health information</td> </tr> <tr> <td class=\"indent1\"> <p>Immunization Action Coalition (IAC)</p> <p><a href=\"http://www.immunize.org/\" target=\"_blank\">www.immunize.org</a> (search on \"immunization safety\")</p> </td> <td>The IAC creates and distributes educational materials and facilitates communication about the safety, efficacy, and use of vaccines</td> </tr> <tr> <td class=\"indent1\"> <p>National Academy of Medicine (formerly Institute of Medicine, IOM) National Academies Press</p> <p><a href=\"http://www.nap.edu/\" target=\"_blank\">www.nap.edu</a></p> </td> <td>An independent organization of medical and health professionals that works to address critical issues in health, medicine, and related policy. Provides access to the IOM immunization safety reviews (eg, vaccines and autism, multiple immunizations and immune dysfunction, etc).</td> </tr> <tr> <td class=\"indent1\"> <p>National Alliance for Hispanic Health</p> <p><a href=\"http://www.hispanichealth.org/\" target=\"_blank\">www.hispanichealth.org</a></p> </td> <td>Advocacy and research forum focused on Hispanic health and well-being. Provides links to information about vaccine-preventable disease and other health issues.</td> </tr> <tr> <td class=\"indent1\"> <p>National Foundation for Infectious Diseases</p> <p><a href=\"http://www.nfid.org/\" target=\"_blank\">www.nfid.org</a></p> </td> <td>Nonprofit organization dedicated to educating the public and health care professionals about the causes, treatment, and prevention of infectious diseases</td> </tr> <tr> <td class=\"indent1\"> <p>National Meningitis Association</p> <p><a href=\"http://www.nmaus.org/\" target=\"_blank\">www.nmaus.org</a></p> </td> <td>Nonprofit organization founded by parents whose children have died or have permanent disability from meningococcal disease. Includes links to educational materials, including a video featuring the stories of meningococcal disease survivors and families affected by the disease.</td> </tr> <tr> <td class=\"indent1\"> <p>The Vaccine Page</p> <p><a href=\"http://www.vaccines.org/\" target=\"_blank\">www.vaccines.org</a></p> </td> <td>Provides access to news about vaccines and annotated database of vaccine resources on the internet; the vaccine page does not control the content of the news links and encourages readers to validate the news items through reputable resources (eg, the Allied Vaccine Group)</td> </tr> <tr> <td class=\"indent1\"> <p>World Health Organization</p> <p><a href=\"http://www.who.int/topics/vaccines/en/\" target=\"_blank\">www.who.int/topics/vaccines/en/</a></p> </td> <td>Provides links to information about immunization</td> </tr> <tr> <td class=\"indent1\"> <p>Vaccine Information You Need</p> <a href=\"http://www.vaccineinformation.org/\" target=\"_blank\">www.vaccineinformation.org</a></td> <td>Provides information about vaccines and the diseases they prevent, including a video library</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Parent/family groups</td> </tr> <tr> <td class=\"indent1\"> <p>Families Fighting Flu</p> <p><a href=\"http://www.familiesfightingflu.org/\" target=\"_blank\">www.familiesfightingflu.org</a></p> </td> <td>Nonprofit corporation dedicated to educating people about the severity of influenza and the importance of vaccinating children against the flu</td> </tr> <tr> <td class=\"indent1\"> <p>Parents of Kids with Infectious Diseases</p> <p><a href=\"http://www.pkids.org/immunizations.php\" target=\"_blank\">www.pkids.org/immunizations.php</a></p> </td> <td>Provides links to information about vaccines and vaccine safety</td> </tr> <tr> <td class=\"indent1\"> <p>Meningitis Angels</p> <p><a href=\"http://www.meningitis-angels.org/\" target=\"_blank\">www.meningitis-angels.org</a></p> </td> <td>Provides education about bacterial meningitis and prevention of bacterial meningitis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Government agencies</td> </tr> <tr> <td class=\"indent1\"> <p>United States Centers for Disease Control and Prevention</p> <p><a href=\"http://www.cdc.gov/vaccines\" target=\"_blank\">www.cdc.gov/vaccines</a></p> </td> <td>Provides information and links about vaccines and vaccine-preventable diseases</td> </tr> <tr> <td class=\"indent1\"> <p>US Food and Drug Administration</p> <p><a href=\"http://www.fda.gov/cber/vaccines.htm\" target=\"_blank\">www.fda.gov/cber/vaccines.htm</a></p> </td> <td>Provides information about vaccines licensed in the United States and information about vaccine safety, including consumer updates</td> </tr> <tr> <td class=\"indent1\">&nbsp;National Institute of Allergy and Infectious Diseases</td> <td>Provides information about understanding vaccines, community immunity, and vaccine research</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\"> <p>Baby 411</p> <p><a href=\"http://www.windsorpeak.com/baby411/\" target=\"_blank\">www.windsorpeak.com/baby411/</a></p> </td> <td>Link to free excerpt on vaccines</td> </tr> <tr> <td class=\"subtitle2_left\">Books</td> <td class=\"subtitle2_left\">Publisher</td> </tr> <tr> <td class=\"indent1\"><em>Immunizations and Infectious Diseases: An Informed Parent's Guide</em> by Fisher MC</td> <td>American Academy of Pediatrics, Elk Grove Village, IL 2005</td> </tr> <tr> <td class=\"indent1\"><em>Vaccinating Your Child: Questions and Answers for the Concerned Parent</em> by Humiston SG, Good C</td> <td>Peachtree Publishers, Atlanta 2000</td> </tr> <tr> <td class=\"indent1\"><em>Do Vaccines Cause That? A guide for Evaluating Vaccine Safety Concerns</em> by Myers MG, Pineda D</td> <td>Immunizations for Public Health 2008</td> </tr> <tr> <td class=\"indent1\"><em>Vaccines: What Every Parent Should Know</em> by Offit PA, Bell LM</td> <td>IDG Books, New York 1999</td> </tr> <tr> <td class=\"indent1\"><em>Autism's False Prophets: Bad science, risky medicine, and the search for a cure</em> by Offit PA</td> <td>Columbia University Press, New York 2008</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Resources for optimizing communications with parent about immunizations. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed,&nbsp;Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.12.</LI>&#xD;&#xA;<LI>Pickering LK, Baker CJ, Freed GL, et al. Immunization programs for infants, children, adolescents, and adults: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:817.</LI></OL></div><div id=\"graphicVersion\">Graphic 82687 Version 13.0</div></div></div>"},"82688":{"type":"graphic_table","displayName":"Immunization for travel","title":"Some immunizations for travel","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some immunizations for travel</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccines</td> <td class=\"subtitle1\">Adult dose</td> <td class=\"subtitle1\">Pediatric age/dose</td> <td class=\"subtitle1\">Standard primary schedule</td> <td class=\"subtitle1\">Duration of protection</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Hepatitis A</td> </tr> <tr> <td class=\"indent1\">Havrix</td> <td>1 mL IM (1440 EU)</td> <td>1 to 18 years: 0.5 mL IM (720 EU).</td> <td>0 and 6 to 12 months.</td> <td class=\"divider_bottom\" rowspan=\"2\">Probably lifelong after completion of primary series.*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vaqta</td> <td>1 mL IM (50 units)</td> <td>1 to 18 years: 0.5 mL IM (25 units).</td> <td>0 and 6 to 18 months.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Hepatitis B</td> </tr> <tr> <td class=\"indent1\">Engerix-B</td> <td>1 mL IM (20 mcg)</td> <td>Birth to 19 years: 0.5 mL IM (10 mcg).</td> <td>0, 1, and 6 months.<sup>&#182;</sup><sup>&#916;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">Probably lifelong after completion of primary series.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Recombivax-HB</td> <td>1 mL IM (10 mcg)</td> <td>Birth to 19 years: 0.5 mL IM (5 mcg).</td> <td>0, 1, and 6 months.<sup>&#916;</sup><sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Hepatitis A/B</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Twinrix</td> <td>1 mL IM (720 EU/20 mcg)</td> <td>Not approved for &#60;18 years.</td> <td>0, 1, and 6 months (alternative: 0, 7, and 21 to 30 days).</td> <td>Booster recommended at 12 months with accelerated schedule; otherwise, probably lifelong after completion of primary series.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Japanese encephalitis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ixiaro</td> <td>0.5 mL IM/dose; a total of two doses given on days 0 and 28</td> <td> <p>2 months to &#60;3 years: 0.25 mL IM/dose; a total of two doses given on days 0 and 28.</p> &#8805;3 years: Same as adult dose.</td> <td>0, 28 days.<sup>&#167;</sup></td> <td>A single booster &#62;1 year after completion of primary series if ongoing risk.<sup>&#165;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Meningococcal</td> </tr> <tr> <td class=\"indent1\">Menveo</td> <td>0.5 mL IM (10 mcg serogroup A, 5 mcg serogroup C, Y, W135)</td> <td>&#8805;2 years: 0.5 mL IM (10 mcg serogroup A, 5 mcg serogroup C, Y, W135).</td> <td>&#8805;2 to 55 years: Single dose.<sup>&#135;</sup></td> <td>Repeat every 5 years<sup>&#134;</sup> if ongoing risk.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Menactra</td> <td>0.5 mL IM (4 mcg of each antigen)</td> <td>&#8805;9 months: 0.5 mL IM 4 mcg of each antigen.</td> <td> <p>9 to 23 months: 0, 3 months.</p> &#8805;2 to 55 years: Single dose.</td> <td>Repeat every 5 years<sup>&#134;</sup> if ongoing risk.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Rabies</td> </tr> <tr> <td class=\"indent1\">Imovax</td> <td>1 mL IM (&#8805;2.5 international units of rabies antigen)</td> <td>Birth: 1 mL IM (&#8805;2.5 international units of rabies antigen).</td> <td>0, 7, and 21 or 28 days.**</td> <td class=\"divider_bottom\" rowspan=\"2\">Routine boosters not necessary; for those engaging in frequent high-risk activities (cavers, veterinarians, laboratory workers), serologic testing is recommended every 2 years with booster doses if low levels.<sup>&#182;&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">RabAvert</td> <td>1 mL IM (&#8805;2.5 international units of rabies antigen)</td> <td>Birth: 1 mL IM (&#8805;2.5 international units of rabies antigen).</td> <td>0, 7, and 21 or 28 days.**</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Typhoid</td> </tr> <tr> <td class=\"indent1\">Vivotif</td> <td>1 cap PO (contains 2 to 6 &times; 10** viable colony-forming units of <em>S</em>. Typhi Ty21a)</td> <td>&#8805;6 years: 1 cap PO (contains 2 to 6 &times; 10** viable colony-forming units of <em>S</em>. Typhi Ty21a).</td> <td>1 cap every other day &times; 4 doses.</td> <td>Repeat every 5 years if ongoing risk.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Typhim Vi</td> <td>0.5 mL IM (25 mcg)</td> <td>&#8805;2 years: 0.5 mL IM (25 mcg).</td> <td>Single dose.</td> <td>Repeat every 2 years (3 years in Canada) if ongoing risk.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Yellow fever</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">YF-Vax</td> <td>0.5 mL SC (4.74 log<sup>&#182;&#182;</sup> plaque forming units of 17D204 attenuated YF virus)</td> <td>&#8805;9 months: 0.5 mL SC (4.74 log<sup>&#182;&#182;</sup> plaque forming units of 17D204 attenuated YF virus).</td> <td>Single dose.</td> <td>Booster dose every 10 years if ongoing risk.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Cholera</td> </tr> <tr> <td class=\"indent1\">Vaxchora</td> <td>100 mL PO (lyophilized <em>V. cholerae</em> CVD 103-HgR)</td> <td>Not approved for &#60;18 years.</td> <td>Single dose.</td> <td>No specific recommendation; consider booster every 6 months if at continued risk.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscular; SC: subcutaneous; PO: by mouth.<br />* Protection likely lasts at least 12 months after a single dose.<br />¶ An alternate schedule is three doses given at 0, 1, and 2 months, followed by a fourth dose at 12 months.<br />Δ An accelerated schedule of 0, 7, and 14 days followed by a booster dose at 6 months has been used but is not FDA-approved.<br /><FONT class=lozenge>◊</FONT> An alternate schedule for adolescents 11 to 15 years old is 0 and 4 to 6 months.<br />§ For adults aged 18 to 65, an accelerated schedule of JE-VC with doses administered on days 0 and 7 is licensed in Europe; this off-label regimen is supported by relevant CDC experts.<SUP>[1]</SUP><br />¥ Adults previously vaccinated with JE Vax should receive a primary series of Ixiaro.<SUP>[2]</SUP><br />‡ For children 2 to 5 years old at continued high risk, a second dose may be administered two months after the first.<br />† Repeat after 3 years for children vaccinated at &lt;7 years of age. Considerable published data indicates that protection significantly wanes after 3 years; travelers to the meningitis belt should consider a booster after 3 years due to the high risk of infection compared to risk at home.<SUP>[3]</SUP><br />** Regimen for pre-exposure prophylaxis. If a previously vaccinated traveler is exposed to a potentially rabid animal, postexposure prophylaxis with 2 additional vaccine doses separated by 3 days should be initiated as soon as possible.<br />¶¶ Minimal acceptable antibody level is complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Hills SL, Rabe IB, Fischer M. Japanese encephalitis. In: CDC Health Information for International Travel 2018. <a href=\"https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/japanese-encephalitis\" target=\"_blank\">https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/japanese-encephalitis</a> (Accessed on July 7, 2017).</li>&#xD;&#xA;    <li>Centers for Disease Control and Prevention (CDC). Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: Advisory committee on immunization practices, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:661.</li>&#xD;&#xA;    <li>Cohn AC, MacNeil JR, Harrison LH. Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine. Pediatrics 2017; pii: e20162193.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reprinted with special permission from: Treatment Guidelines from The Medical Letter, June 2012; Vol. 10 (118):45. <a href=\"http://www.medicalletter.org/\" target=\"_blank\">www.medicalletter.org</a>.</div><div id=\"graphicVersion\">Graphic 82688 Version 11.0</div></div></div>"},"82690":{"type":"graphic_table","displayName":"Assessment of COPD","title":"Multidimensional assessment of COPD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Multidimensional assessment of COPD</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"3\">GOLD: Severity of airflow limitation (based on postbronchodilator FEV<sub>1</sub>)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2\">Stage</td> <td class=\"subtitle2\">Severity</td> <td class=\"subtitle2\">FEV<sub>1</sub> (percent predicted)</td> </tr> <tr> <td colspan=\"3\"><strong>In patients with FEV<sub>1</sub>/FVC &#60;0.7:</strong>*</td> </tr> <tr> <td class=\"indent1\">GOLD 1</td> <td class=\"centered\">Mild</td> <td class=\"centered\">&#8805;80</td> </tr> <tr> <td class=\"indent1\">GOLD 2</td> <td class=\"centered\">Moderate</td> <td class=\"centered\">50 to 79</td> </tr> <tr> <td class=\"indent1\">GOLD 3</td> <td class=\"centered\">Severe</td> <td class=\"centered\">30 to 49</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">GOLD 4</td> <td class=\"centered\">Very severe</td> <td class=\"centered\">&#60;30</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\" colspan=\"3\">&nbsp;</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"3\">GOLD: Assessment of symptoms and risk of exacerbations</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2\" rowspan=\"2\">Exacerbations/hospitalizations</td> <td class=\"subtitle2\" colspan=\"2\">Symptom assessment</td> </tr> <tr> <td class=\"subtitle3\">mMRC<sup>&#182;</sup> 0 to 1; CAT &#60;10<sup>&#916;</sup></td> <td class=\"subtitle3\">mMRC &#8805;2; CAT &#8805;10</td> </tr> <tr> <td>0 or 1 exacerbations without hospitalization</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> </tr> <tr> <td>&#8805;2 exacerbations or &#8805;1 hospitalization</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; FEV<SUB>1</SUB>: forced expiratory volume in one second; FVC: forced vital capacity; CAT: COPD Assessment Test; mMRC: modified Medical Research Council (mMRC) dyspnea scale.<br />* The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (www.goldgopd.org) prefer the threshold of &lt;0.7 to the alternative of the fifth percentile LLN for FEV<SUB>1</SUB>/FVC.<br />¶ mMRC dyspnea scale: Refer to UpToDate graphic.<br />Δ http://www.catestonline.org.</div><div class=\"graphic_reference\">From the Global Strategy for the Diagnosis, Management and Prevention of COPD 2017, &copy; Global Initiative for Chronic Obstructive Lung Disease (GOLD), <a href=\"http://www.goldcopd.org/\" target=\"_blank\">www.goldcopd.org</a>. Adapted with permission.</div><div id=\"graphicVersion\">Graphic 82690 Version 9.0</div></div></div>"},"82691":{"type":"graphic_figure","displayName":"Clavicle fracture displacement","title":"Clavicle fracture displacement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clavicle fracture displacement</div><div class=\"cntnt\"><img style=\"width:418px; height:363px;\" src=\"images/EM/82691_Clav_fx_inf_displace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This diagram depicts the mechanisms typically involved in the displacement of a clavicle fracture, which is caused by the upward pull of the sternocleidomastoid muscle and the downward pull of the weight of the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: Eiff MP, Hatch RL, Calmbach W (Eds). Fracture Management for Primary Care, 2nd Edition, W.B. Saunders Company, Philadelphia 2002. Illustration used with permission of Elsevier Inc. All right reserved. Copyright &copy; 2002 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 82691 Version 4.0</div></div></div>"},"82693":{"type":"graphic_picture","displayName":"Tuberculoid leprosy","title":"Tuberculoid leprosy (TT/PB)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculoid leprosy (TT/PB)</div><div class=\"cntnt\"><img style=\"width:427px; height:290px;\" src=\"images/ID/82693_Tuberculoid_leprosy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tuberculoid lesion with a raised, well-defined margin.</div><div class=\"graphic_reference\">Courtesy of James L Krahenbuhl, Phd and Robert R Jacobson, MD, PhD.</div><div id=\"graphicVersion\">Graphic 82693 Version 2.0</div></div></div>"},"82694":{"type":"graphic_diagnosticimage","displayName":"MRI pediatric MS","title":"MRI pediatric multiple sclerosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">MRI pediatric multiple sclerosis</div><div class=\"cntnt\"><img style=\"width:504px; height:247px;\" src=\"images/NEURO/82694_MRI_pediatric_MS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Axial FLAIR MRI demonstrating periventricular well-demarcated lesions. B) Axial T1 from the same patient demonstrating a black hole in the right centrum semiovale.</div><div class=\"graphic_footnotes\">FLAIR: fluid-attenuated inversion recovery; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 82694 Version 2.0</div></div></div>"},"82700":{"type":"graphic_table","displayName":"Causes of acute dyspnea","title":"Causes of acute dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Cardiovascular system</td>\n</tr>\n\n<tr>\n<td>Acute myocardial ischemia</td>\n</tr>\n\n<tr>\n<td>Heart failure</td>\n</tr>\n\n<tr>\n<td>Cardiac tamponade</td>\n</tr>\n\n<tr>\n<td class=\"subtitle1_single\">Respiratory system</td>\n</tr>\n\n<tr>\n<td>Bronchospasm</td>\n</tr>\n\n<tr>\n<td>Pulmonary embolism</td>\n</tr>\n\n<tr>\n<td>Pneumothorax</td>\n</tr>\n\n<tr>\n<td>Pulmonary infection - bronchitis, pneumonia</td>\n</tr>\n\n<tr>\n<td>Upper airway obstruction - aspiration, anaphylaxis</td>\n</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 82700 Version 1.0</div></div></div>"},"82701":{"type":"graphic_diagnosticimage","displayName":"Classic DWI-PWI mismatch","title":"Classic pattern of DWI-PWI mismatch","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Classic pattern of DWI-PWI mismatch</div><div class=\"cntnt\"><img style=\"width:545px; height:452px;\" src=\"images/NEURO/82701_Classic_DWI_PWI_mismatch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative case with classic pattern of mismatch.<br />(A) Diffusion weighted-image (DWI).<br />(B) DWI abnormal lesion (shown in red) and hypoperfusion lesion (shown in green) superimposed on DWI.<br />(C) DWI abnormal lesion and hypoperfusion lesion with brain image (DWI) removed.</div><div class=\"graphic_footnotes\">PWI: perfusion-weighted image.</div><div class=\"graphic_reference\">Reproduced with permission from: Ogata T, Nagakane Y, Christensen S, et al. A topographic study of the evolution of the MR DWI/PWI mismatch pattern and its clinical impact: a study by the EPITHET and DEFUSE Investigators. Stroke 2011; 42:1596. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82701 Version 5.0</div></div></div>"},"82702":{"type":"graphic_diagnosticimage","displayName":"Gastric bezoar abdominal radiograph","title":"Gastric bezoar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric bezoar</div><div class=\"cntnt\"><img style=\"width:216px; height:267px;\" src=\"images/GAST/82702_Gastric_bezoar_KUB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This abdominal&nbsp;radiograph shows a distended stomach with an air-fluid level outlining a large gastric bezoar (arrows).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 82702 Version 4.0</div></div></div>"},"82703":{"type":"graphic_diagnosticimage","displayName":"Spontaneous pneumomediastinum in a young child","title":"Spontaneous pneumomediastinum in a young child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spontaneous pneumomediastinum in a young child</div><div class=\"cntnt\"><img style=\"width:396px; height:348px;\" src=\"images/PEDS/82703_SPM_AP_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows gas outlining inner surface of mediastinal pleura and aortlc arch (white arrows). This radiograph also demonstrates the \"spinnaker sign\", in which the thymic lobes are seen deviating upwards and outwards (arrowheads), a radiographic sign of pneumomediastinum that is seen only in infants and young children.</div><div class=\"graphic_reference\">Courtesy of Ibrahim Janahi&nbsp;and Ammar Saadoon.</div><div id=\"graphicVersion\">Graphic 82703 Version 5.0</div></div></div>"},"82704":{"type":"graphic_figure","displayName":"Diffuse esophageal spasm HREPT and manometry","title":"High-resolution esophageal pressure topography and conventional manometry in a patient with diffuse esophageal spasm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High-resolution esophageal pressure topography and conventional manometry in a patient with diffuse esophageal spasm</div><div class=\"cntnt\"><img style=\"width:362px; height:545px;\" src=\"images/GAST/82704_Diffuse_esoph_spasm_HREPT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-resolution esophageal pressure topography (panel A) and standard manometry (panel B) from a patient with diffuse esophageal spasm. High-resolution esophageal pressure topography reveals simultaneous contractions in the distal esophagus (orange and red bars to the right of the thick arrow) with normal relaxation of the lower esophageal sphincter (thin arrow). There is abnormal bolus transit shown by impedance recording at the top of both panel A and panel B. Notice the subsequent normally progressing peristaltic wave (to the right of the thin arrow). The corresponding findings on conventional manometry are seen in the tracing on the right.</div><div id=\"graphicVersion\">Graphic 82704 Version 3.0</div></div></div>"},"82705":{"type":"graphic_picture","displayName":"Facial allergic contact dermatitis","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/82705_Facial_aller_contact_derma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute allergic contact dermatitis is severely pruritic. Skin often weeps.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82705 Version 4.0</div></div></div>"},"82708":{"type":"graphic_picture","displayName":"Advanced tennis forehand grip","title":"Advanced tennis forehand grip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advanced tennis forehand grip</div><div class=\"cntnt\"><img style=\"width:396px; height:309px;\" src=\"images/EM/82708_Tenniswgrip.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Jayanthi N, Subbarao JV. Racket sports injuries. In: Sports Medicine and Rehabilitation: A Sports Specific Approach. Buschbacher R, Prahlow N, Dave SJ (eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82708 Version 13.0</div></div></div>"},"82709":{"type":"graphic_figure","displayName":"Pratt cervical dilators","title":"Pratt cervical dilators (uterine cervix)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pratt cervical dilators (uterine cervix)</div><div class=\"cntnt\"><img style=\"width:412px; height:233px;\" src=\"images/OBGYN/82709_Pratt_cervical_dilators.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82709 Version 3.0</div></div></div>"},"82710":{"type":"graphic_picture","displayName":"Frozen knees in NSF","title":"Picture showing large joint involvement of patient with nephrogenic system fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Picture showing large joint involvement of patient with nephrogenic system fibrosis</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/NEPH/82710_Frozen_knees_in_NSF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with nephrogenic systemic fibrosis can have involvement of large joints. The knees pictured here are in a permanently flexed position, making walking and standing impossible. In addition, there is brownish mottling of the skin.</div><div class=\"graphic_reference\">With permission from: Shawn E Cowper, MD.</div><div id=\"graphicVersion\">Graphic 82710 Version 3.0</div></div></div>"},"82711":{"type":"graphic_table","displayName":"WHO IGCTs","title":"World Health Organization classification of intracranial germ cell tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization classification of intracranial germ cell tumors</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Germinomas\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   <strong>Nongerminomatous germ cell tumors</strong>\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Embryonal carcinoma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Yolk sac tumor</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Choriocarcinoma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Teratoma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td class=\"indent1\">Bening teratomas</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td class=\"indent2\">Immature*</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td class=\"indent2\">Mature</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td class=\"indent1\">Teratoma with malignant transformation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Mixed germ cell tumors</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Media_Notes msdt:dt=\"string\">3/9/2009--Requested permission (JD). 6/8/2009--Permission granted; figures to Terrence (JD). 5/15/2010--Renewal requested (JD). 6/16/2010--Renewal granted (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48709&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>WHO_IGCTs.htm</title></head></div><div class=\"graphic_footnotes\">* May contain rare malignant germ cell elements.</div><div class=\"graphic_reference\">Reproduced with permission from: Louis DN, Ohgaki H, Wiesterl O, et al. World Health Organization Classification of Tumours of the Central Nervous System, 3rd Edition, IARC Press, Lyon, 2007. Copyright © 2007 IARC Press.</div><div id=\"graphicVersion\">Graphic 82711 Version 9.0</div></div></div>"},"82712":{"type":"graphic_figure","displayName":"Cervical block","title":"Cervical block anesthesia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical block anesthesia</div><div class=\"cntnt\"><img style=\"width:298px; height:590px;\" src=\"images/SURG/82712_Cervical_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) A superficial cervical block is administered posterior and deep to the sternocleidomastoid muscle (1). B) Local infiltration is also performed along the anterior border of the sternocleidomastoid muscle (2), and a local field block (3) is performed.</div><div class=\"graphic_reference\">Reproduced with permission from: Udelsman R. Unilateral neck exploration under local or regional anesthesia. In: Minimally Invasive Endocrine Surgery, Gagner M, Inabnet W (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 82712 Version 7.0</div></div></div>"},"82715":{"type":"graphic_figure","displayName":"Respiratory chain","title":"The mitochondrial respiratory chain","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">The mitochondrial respiratory chain</div><div class=\"cntnt\"><img style=\"width:542px; height:345px;\" src=\"images/NEURO/82715_Respiratory-chain-edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the subunits of the respiratory chain encoded by nuclear DNA (nDNA) in orange and the subunits encoded by mitochondrial DNA (mtDNA) in yellow. As electrons (e-) flow along the electron-transport chain, protons (H+) are pumped from the matrix to the intermembrane space through complexes I, III, and IV and then back into the matrix through complex V, to produce ATP. Coenzyme Q (CoQ) and cytochrome c (Cyt c) are electron-transfer carriers.</div><div id=\"graphicVersion\">Graphic 82715 Version 6.0</div></div></div>"},"82716":{"type":"graphic_table","displayName":"Dosing schedules for fire ant immunotherapy","title":"Dosing schedules for fire ant immunotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing schedules for fire ant immunotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Schedule 1</td> <td class=\"subtitle1\" colspan=\"3\">Schedule 2</td> </tr> <tr> <td class=\"subtitle2\">Dose number</td> <td class=\"subtitle2\">Concentration (weight/volume)</td> <td class=\"subtitle2\">Volume</td> <td class=\"subtitle2\">Dose number</td> <td class=\"subtitle2\">Concentration (weight/volume)</td> <td class=\"subtitle2\">Volume</td> </tr> <tr> <td>1</td> <td>1:100,000</td> <td>0.05 mL</td> <td>1</td> <td>1:100,000</td> <td>0.05 mL</td> </tr> <tr> <td>2</td> <td>1:100,000</td> <td>0.10 mL</td> <td>2</td> <td>1:100,000</td> <td>0.15 mL</td> </tr> <tr> <td>3</td> <td>1:100,000</td> <td>0.20 mL</td> <td>3</td> <td>1:100,000</td> <td>0.25 mL</td> </tr> <tr> <td>4</td> <td>1:100,000</td> <td>0.30 mL</td> <td>4</td> <td>1:100,000</td> <td>0.50 mL</td> </tr> <tr> <td>5</td> <td>1:100,000</td> <td>0.40 mL</td> <td>5</td> <td>1:10,000</td> <td>0.05 mL</td> </tr> <tr> <td>6</td> <td>1:100,000</td> <td>0.50 mL</td> <td>6</td> <td>1:10,000</td> <td>0.10 mL</td> </tr> <tr> <td>7</td> <td>1:10,000</td> <td>0.05 mL</td> <td>7</td> <td>1:10,000</td> <td>0.20 mL</td> </tr> <tr> <td>8</td> <td>1:10,000</td> <td>0.10 mL</td> <td>8</td> <td>1:10,000</td> <td>0.30 mL</td> </tr> <tr> <td>9</td> <td>1:10,000</td> <td>0.20 mL</td> <td>9</td> <td>1:10,000</td> <td>0.40 mL</td> </tr> <tr> <td>10</td> <td>1:10,000</td> <td>0.30 mL</td> <td>10</td> <td>1:10,000</td> <td>0.50 mL</td> </tr> <tr> <td>11</td> <td>1:10,000</td> <td>0.40 mL</td> <td>11</td> <td>1:1000</td> <td>0.05 mL</td> </tr> <tr> <td>12</td> <td>1:10,000</td> <td>0.50 mL</td> <td>12</td> <td>1:1000</td> <td>0.10 mL</td> </tr> <tr> <td>13</td> <td>1:1000</td> <td>0.05 mL</td> <td>13</td> <td>1:1000</td> <td>0.20 mL</td> </tr> <tr> <td>14</td> <td>1:1000</td> <td>0.10 mL</td> <td>14</td> <td>1:1000</td> <td>0.30 mL</td> </tr> <tr> <td>15</td> <td>1:1000</td> <td>0.20 mL</td> <td>15</td> <td>1:1000</td> <td>0.40 mL</td> </tr> <tr> <td>16</td> <td>1:1000</td> <td>0.30 mL</td> <td>16</td> <td>1:1000</td> <td>0.50 mL</td> </tr> <tr> <td>17</td> <td>1:1000</td> <td>0.40 mL</td> <td>17</td> <td>1:100</td> <td>0.05 mL</td> </tr> <tr> <td>18</td> <td>1:1000</td> <td>0.50 mL</td> <td>18</td> <td>1:100</td> <td>0.07 mL</td> </tr> <tr> <td>19</td> <td>1:100</td> <td>0.05 mL</td> <td>19</td> <td>1:100</td> <td>0.10 mL</td> </tr> <tr> <td>20</td> <td>1:100</td> <td>0.10 mL</td> <td>20</td> <td>1:100</td> <td>0.15 mL</td> </tr> <tr> <td>21</td> <td>1:100</td> <td>0.15 mL</td> <td>21</td> <td>1:100</td> <td>0.20 mL</td> </tr> <tr> <td>22</td> <td>1:100</td> <td>0.20 mL</td> <td>22</td> <td>1:100</td> <td>0.25 mL</td> </tr> <tr> <td>23</td> <td>1:100</td> <td>0.25 mL</td> <td>23</td> <td>1:100</td> <td>0.30 mL</td> </tr> <tr> <td>24</td> <td>1:100</td> <td>0.30 mL</td> <td>24</td> <td>1:100</td> <td>0.40 mL</td> </tr> <tr> <td>25</td> <td>1:100</td> <td>0.35 mL</td> <td>25</td> <td>1:100</td> <td>0.50 mL</td> </tr> <tr> <td>26</td> <td>1:100</td> <td>0.40 mL</td> <td rowspan=\"3\" colspan=\"3\">&nbsp;</td> </tr> <tr> <td>27</td> <td>1:100</td> <td>0.45 mL</td> </tr> <tr> <td>28</td> <td>1:100</td> <td>0.50 mL</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Moffitt JE, Golden DB, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol 2004; 114:869. Copyright © 2004 The American Academy of Allergy, Asthma, and Immunology.</div><div id=\"graphicVersion\">Graphic 82716 Version 5.0</div></div></div>"},"82717":{"type":"graphic_diagnosticimage","displayName":"Gastric erosion after gastric banding - Case 2","title":"Case 2: Gastric erosion after gastric banding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Case 2: Gastric erosion after gastric banding</div><div class=\"cntnt\"><img style=\"width:429px; height:432px;\" src=\"images/SURG/82717_Gastric_erosion_case_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast on esophagram empties around the band and not through the central channel in this partially intragastric eroded band.</div><div id=\"graphicVersion\">Graphic 82717 Version 5.0</div></div></div>"},"82718":{"type":"graphic_table","displayName":"Cross-reactivity between penicillins and cephalosporins","title":"Cross-reactivity between penicillins and cephalosporins with identical side chains","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cross-reactivity between penicillins and cephalosporins with identical side chains</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Selective allergy to</td> <td class=\"subtitle1\">Cephalosporin with identical side chain</td> <td class=\"subtitle1\">Reaction rate (%)</td> </tr> <tr> <td>Audicana (1994)<sup>[1]</sup></td> <td class=\"centered\">Ampicillin</td> <td class=\"centered\">Cephalexin</td> <td class=\"centered\">1 of 10 (10)</td> </tr> <tr> <td>Sastre (1996)<sup>[2]</sup></td> <td class=\"centered\">Amoxicillin</td> <td class=\"centered\">Cefadroxil</td> <td class=\"centered\">2 of 16 (12)</td> </tr> <tr class=\"divider_bottom\"> <td>Miranda (1996)<sup>[3]</sup></td> <td class=\"centered\">Amoxicillin</td> <td class=\"centered\">Cefadroxil</td> <td class=\"centered\">8 of 21 (38)</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> <td class=\"centered\"><strong>11 of 47 (23)</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Summary of patients proven to be selectively allergic to amoxicillin or ampicillin challenged with cephalosporins that contain identical R1 side chains.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Audicana M, Bernaola G, Urrutia I, et al. Allergic reactions to betalactams: studies in a group of patients allergic to penicillin and evaluation of cross-reactivity with cephalosporin. Allergy 1994; 49:108.</li>&#xD;&#xA;    <li>Sastre J, Quijano LD, Novalbos A, et al. Clinical cross-reactivity between amoxicillin and cephadroxil in patients allergic to amoxicillin and with good tolerance of penicillin. Allergy 1996; 51:383.</li>&#xD;&#xA;    <li>Miranda A, Blanca M, Vega JM, et al. Cross-reactivity between a penicillin and a cephalosporin with the same side chain. J Allergy Clin Immunol 1996; 98:671.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 82718 Version 9.0</div></div></div>"},"82722":{"type":"graphic_picture","displayName":"Blebitis","title":"Blebitis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Blebitis</div><div class=\"cntnt\"><img style=\"width:468px; height:306px;\" src=\"images/ID/82722_Blebitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is a 32-year-old man with glaucoma who suffered minor trauma to the eye two days prior. He now complains of pain, redness, and discharge from the eye.</div><div class=\"graphic_reference\">Reproduced with permission from: Lawrence B Stack, MD. Copyright © Lawrence B Stack, MD.</div><div id=\"graphicVersion\">Graphic 82722 Version 2.0</div></div></div>"},"82725":{"type":"graphic_diagnosticimage","displayName":"Right arch compression CXR","title":"Type II right aortic arch with aberrant left subclavian artery compressing the trachea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Type II right aortic arch with aberrant left subclavian artery compressing the trachea</div><div class=\"cntnt\"><img style=\"width:308px; height:450px;\" src=\"images/PULM/82725_Right_arch_compression_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a woman treated for asthma for many years prior to diagnosis.</div><div id=\"graphicVersion\">Graphic 82725 Version 2.0</div></div></div>"},"82727":{"type":"graphic_diagnosticimage","displayName":"Postov endo","title":"Postovulatory endometrium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postovulatory endometrium</div><div class=\"cntnt\"><img style=\"width:385px; height:262px;\" src=\"images/ENDO/82727_Postov_endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasonography of the uterus - the bright appearance of the postovulatory endometrium.</div><div class=\"graphic_reference\">Courtesy of Judith Adams, DMU.</div><div id=\"graphicVersion\">Graphic 82727 Version 2.0</div></div></div>"},"82729":{"type":"graphic_figure","displayName":"Duration symptoms TIA","title":"Temporal behavior of symptoms in patients with transient ischemic attack (TIA)","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Temporal behavior of symptoms in patients with transient ischemic attack (TIA)</div><div class=\"cntnt\"><img style=\"width:522px; height:451px;\" src=\"images/NEURO/82729_Duration_symptoms_TIA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The probability density function curve of symptom duration for transient symptoms associated with infarction (TSI) indicates the absence of continuity within the first 24 hours. The probability density function is the probability that the variable takes a value in a given interval and is equal to 1 over its entire range of values. The area under curve is almost equal to 1 at around 200 minutes. Also note that the curves for TIA with or without infarction overlap (p = 0.82). The distribution of duration of symptoms as seen here suggests that symptom duration is not a reliable feature to be used for predicting whether a transient neurological spell is associated with infarction. </div><div class=\"graphic_footnotes\">DWI: diffusion-weighted magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Ay, H, Koroshetz, WJ, Benner, T, et al. Transient ischemic attack with infarction: a unique syndrome. Ann Neurol 2005; 57:679. Copyright &#169; 2005 John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 82729 Version 1.0</div></div></div>"},"82731":{"type":"graphic_figure","displayName":"JSGE classification of early endoluminal cancers","title":"Japanese Society for Gastroenterological Endoscopy classification of early endoluminal cancers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Japanese Society for Gastroenterological Endoscopy classification of early endoluminal cancers</div><div class=\"cntnt\"><img style=\"width:304px; height:409px;\" src=\"images/GAST/82731_Macros_type_prim_tumor_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is also known as the Borrmann Pathologic Classification of Gastric Cancer.</div><div class=\"graphic_reference\">Reproduced from: Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, 2nd English Edition. Gastric Cancer 1998; 1:10, with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 82731 Version 7.0</div></div></div>"},"82732":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound image of allantoic cyst and patent urachus","title":"Prenatal ultrasound image of allantoic cyst and patent urachus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of allantoic cyst and patent urachus</div><div class=\"cntnt\"><img style=\"width:432px; height:412px;\" src=\"images/OBGYN/82732_US_allantoic_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the clear communication between the bladder (B) and the cyst (C).</div><div id=\"graphicVersion\">Graphic 82732 Version 3.0</div></div></div>"},"82733":{"type":"graphic_picture","displayName":"Esoph endoscopic removal","title":"Esophagitis dissecans superficialis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophagitis dissecans superficialis</div><div class=\"cntnt\"><img style=\"width:425px; height:242px;\" src=\"images/GAST/82733_Esoph_endoscopic_removal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross specimen of an esophageal cast in a patient with esophagitis dissecans superficialis after endoscopic removal.</div><div class=\"graphic_reference\">Courtesy of S. Ian Gan, MD, and Daniel Wild, MD.</div><div id=\"graphicVersion\">Graphic 82733 Version 2.0</div></div></div>"},"82734":{"type":"graphic_figure","displayName":"IVUS transducers","title":"Intracoronary ultrasound transducer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intracoronary ultrasound transducer</div><div class=\"cntnt\"><img style=\"width:344px; height:287px;\" src=\"images/CARD/82734_IVUS_transducers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are two types of intracoronary ultrasound transducers: phased array or solid state (left)&nbsp;and mechanical (right). The solid state transducer has multiple fixed transducer elements at the tip of the catheter while the mechanical transducer utilizes a single transducer that rotates rapidly to visualize 360&#186;.</div><div class=\"graphic_reference\">Reprinted by permission from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995; 2:68; illustration by Nadine B Sokol.</div><div id=\"graphicVersion\">Graphic 82734 Version 2.0</div></div></div>"},"82736":{"type":"graphic_diagnosticimage","displayName":"Syphilitic aortic aneurysm","title":"Chest x-ray of tertiary cardiovascular syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest x-ray of tertiary cardiovascular syphilis</div><div class=\"cntnt\"><img style=\"width:284px; height:360px;\" src=\"images/ID/82736_Syphilitic_aortic_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The characteristic lesion is a fusiform aneurysm of the thoracic aorta which almost always involving the ascending arch.</div><div class=\"graphic_reference\">Courtesy of Charles Hicks, MD.</div><div id=\"graphicVersion\">Graphic 82736 Version 2.0</div></div></div>"},"82739":{"type":"graphic_waveform","displayName":"ECG acute inferior and right ventricular myocardial infarction","title":"ECG of acute inferior and right ventricular myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">ECG of acute inferior and right ventricular myocardial infarction</div><div class=\"cntnt\"><img style=\"width:478px; height:295px;\" src=\"images/CARD/82739_Right_ventricular_MI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram shows Q waves and prominent doming ST segment elevation in II, III, and aVF, findings which are characteristic of an acute inferior myocardial infarction. ST elevation in the right precordial leads - V4R, V5R, and V6R - indicates right ventricular involvement as well (arrows). The ST depressions in leads I and aVL represent reciprocal changes.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 82739 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"82741":{"type":"graphic_figure","displayName":"Atheroma v cardiac allograft vasculopathy","title":"Atherosclerosis versus cardiac allograft vasculopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atherosclerosis versus cardiac allograft vasculopathy</div><div class=\"cntnt\"><img style=\"width:420px; height:315px;\" src=\"images/CARD/82741_Atheroscl_v_TPL_vasculopath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the anatomic differences between coronary nontransplant atherosclerosis and cardiac allograft vasculopathy.</div><div class=\"graphic_reference\">Redrawn from Arbustini E, Roberts WC. Am J Cardiol 1996; 78:814.</div><div id=\"graphicVersion\">Graphic 82741 Version 3.0</div></div></div>"},"82742":{"type":"graphic_table","displayName":"Low-potassium diet PI","title":"Sample low-potassium diet","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample low-potassium diet</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">Calories</td> <td class=\"subtitle1\">Sodium content, mg</td> <td class=\"subtitle1\">Potassium content, mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Breakfast</td> </tr> <tr> <td class=\"indent1\">English muffin, white</td> <td>129</td> <td>242</td> <td>62</td> </tr> <tr> <td class=\"indent1\">Low-calorie margarine, 2 teaspoons</td> <td>58</td> <td>65</td> <td>4</td> </tr> <tr> <td class=\"indent1\">Puffed corn cereal (non-sweetened), 1.5 cups</td> <td>135</td> <td>247</td> <td>45</td> </tr> <tr> <td class=\"indent1\">Eggs, 2 medium fresh</td> <td>126</td> <td>123</td> <td>118</td> </tr> <tr> <td class=\"indent1\">Coffee, 1.25 cups</td> <td>3</td> <td>6</td> <td>145</td> </tr> <tr> <td class=\"indent1\">Artificial sweetener (Splenda, any amount)</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Non-dairy, fat-free coffee creamer, 1 ounce</td> <td>20</td> <td>3</td> <td>0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snack</td> </tr> <tr> <td class=\"indent1\">Cheddar cheese (reduced fat), 1 ounce</td> <td>49</td> <td>270</td> <td>19</td> </tr> <tr> <td class=\"indent1\">Apple, 1 medium</td> <td>72</td> <td>1</td> <td>148</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Lunch</td> </tr> <tr> <td class=\"indent1\">White bread, 2 slices</td> <td>108</td> <td>234</td> <td>44</td> </tr> <tr> <td class=\"indent1\">Turkey breast, 3 ounces</td> <td>119</td> <td>189</td> <td>236</td> </tr> <tr> <td class=\"indent1\">Mayonnaise (low fat), 1 tablespoon</td> <td>25</td> <td>140</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Cheddar cheese (reduced fat), 1 ounce</td> <td>49</td> <td>270</td> <td>19</td> </tr> <tr> <td class=\"indent1\">Egg, hard boiled</td> <td>78</td> <td>62</td> <td>63</td> </tr> <tr> <td class=\"indent1\">Lettuce (iceberg; shredded), 1 cup</td> <td>8</td> <td>6</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Cucumber, peeled, 1/2 medium</td> <td>12</td> <td>2</td> <td>137</td> </tr> <tr> <td class=\"indent1\">Water chestnuts, canned &#38; drained, 5 pieces</td> <td>17</td> <td>5</td> <td>54</td> </tr> <tr> <td class=\"indent1\">Salad dressing (Italian, low fat), 1 tablespoon</td> <td>27</td> <td>192</td> <td>4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snack</td> </tr> <tr> <td class=\"indent1\">Clementine, 1</td> <td>35</td> <td>1</td> <td>131</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Dinner</td> </tr> <tr> <td class=\"indent1\">Chicken breast (skin removed, baked with breadcrumb coating and no fat), 4 ounces</td> <td>221</td> <td>87</td> <td>287</td> </tr> <tr> <td class=\"indent1\">Green beans, cooked, no salt added, 1 cup</td> <td>60</td> <td>46</td> <td>184</td> </tr> <tr> <td class=\"indent1\">Margarine, low fat, 1 teaspoon</td> <td>29</td> <td>33</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Rice, white, cooked in unsalted water, 1 cup after cooking</td> <td>234</td> <td>3</td> <td>89</td> </tr> <tr> <td class=\"indent1\">Olive oil,&nbsp;2 teaspoons</td> <td>40</td> <td>0</td> <td>0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snack</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oatmeal cookies (reduced fat), 2 small</td> <td>56</td> <td>58</td> <td>22</td> </tr> <tr> <td><strong>TOTALS</strong></td> <td><strong>1710</strong></td> <td><strong>2285</strong></td> <td><strong>1895</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This sample diet is calorically adequate for people of smaller stature and activity levels. People who are active or larger may require additional nutrients and calories. This diet contains less than 7% of calories from saturated fat, which meets the American Heart Association (AHA) guidelines for that nutrient.</div><div id=\"graphicVersion\">Graphic 82742 Version 7.0</div></div></div>"},"82749":{"type":"graphic_picture","displayName":"Postpolypectomy bleeding","title":"Delayed postpolypectomy bleeding in the colon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Delayed postpolypectomy bleeding in the colon</div><div class=\"cntnt\"><img style=\"width:346px; height:304px;\" src=\"images/GAST/82749_Postpolypectomy_bleeding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Brisk bleeding in the ascending colon one week following polypectomy. (B) Bleeding has diminished following submucosal epinephrine injection. (C) Bleeding has completely stopped following heater probe application - note the heater probe &quot;footprint.&quot;</div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD. A2 A1</div><div id=\"graphicVersion\">Graphic 82749 Version 2.0</div></div></div>"},"82750":{"type":"graphic_table","displayName":"Tests of autonomic function","title":"Commonly performed tests of autonomic function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly performed tests of autonomic function</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Principle</td> <td class=\"subtitle1\">Nerves assessed</td> </tr> <tr> <td>Sweat test</td> <td>Heat stimulates thermoregulatory center</td> <td>Central sympathetic adrenergic and peripheral sympathetic cholinergic</td> </tr> <tr> <td>BP lying, standing</td> <td>Postural BP control by adrenergic nerves</td> <td>Sympathetic adrenergic</td> </tr> <tr> <td>RR interval with deep breathing</td> <td>Vagal reflux bradycardia</td> <td>Cardiac vagus</td> </tr> <tr> <td>Plasma pancreatic polypeptide response to modified sham feeding</td> <td>Sham feeding stimulates vagal center and efferents </td> <td>Efferent vagus to abdomen</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82750 Version 2.0</div></div></div>"},"82751":{"type":"graphic_table","displayName":"Fetal testing for thalassemia","title":"Results of fetal DNA testing for thalassemia major syndromes, June 1974 - December 1989","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of fetal DNA testing for thalassemia major syndromes, June 1974 - December 1989</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Parameter</td>\n\n      <td class=\"subtitle1\">Number of cases</td>\n\n      <td class=\"subtitle1\">Percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Total cases at risk for thalassemia</td>\n\n      <td>4300</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Affected cases</td>\n\n      <td>1074</td>\n\n      <td>25.0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pregnancies continued</td>\n\n      <td>29</td>\n\n      <td>2.7</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fetal losses</td>\n\n      <td>-</td>\n\n      <td>1.2*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diagnostic errors</td>\n\n      <td>-</td>\n\n      <td>0.5*</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Data from 6300 cases tested for either thalassemia or sickle cell disease.</div><div class=\"graphic_reference\">Reproduced with permission from:&nbsp;Beris P, Darbellay R, Extermann P. Prevention of beta-thalassemia major and Hb Bart's hydrops fetalis syndrome. Semin Hematol 1995; 32:244.</div><div id=\"graphicVersion\">Graphic 82751 Version 5.0</div></div></div>"},"82754":{"type":"graphic_picture","displayName":"Quad sets PI","title":"Quad sets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Quad sets</div><div class=\"cntnt\"><img style=\"width:432px; height:355px;\" src=\"images/PI/82754_Quad_sets_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sit on the floor with the legs extended in front of the body. Place the hands behind the affected knee. Keep the leg straight and contract the quadriceps muscle (just above the knee), which should cause the knee cap to move towards the body. Hold for a count of 10 seconds. Release and rest as needed. Repeat 10 to 15 times (one set). Perform a total of 3 sets.</div><div id=\"graphicVersion\">Graphic 82754 Version 3.0</div></div></div>"},"82757":{"type":"graphic_picture","displayName":"Scarlet fever rash: Trunk and extremities","title":"Scarlet fever rash: Trunk and extremities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scarlet fever rash: Trunk and extremities</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/ID/82757_SFRtrunkextremities.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rash of scarlet fever is a diffuse erythema that blanches with pressure, with numerous small (1 to 2 mm) papular elevations, giving a \"sandpaper\" quality to the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82757 Version 4.0</div></div></div>"},"82758":{"type":"graphic_picture","displayName":"Scarlet fever rash - sandpaper papules","title":"Scarlet fever rash - 'sandpaper' papules","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scarlet fever rash - 'sandpaper' papules</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/82758_SFR_sandpaper_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rash of scarlet fever is a diffuse erythema that blanches with pressure, with numerous small (1 to 2 mm) papular elevations, giving a \"sandpaper\" quality to the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82758 Version 4.0</div></div></div>"},"82759":{"type":"graphic_picture","displayName":"Cutaneous bacillary angiomatosis above eyebrow","title":"Cutaneous lesion of bacillary angiomatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cutaneous lesion of bacillary angiomatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/82759_Cutan_BA_eyebrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82759 Version 4.0</div></div></div>"},"82760":{"type":"graphic_picture","displayName":"Cutaneous bacillary angiomatosis","title":"Cutaneous lesion of bacillary angiomatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cutaneous lesion of bacillary angiomatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/82760_Cutaneous_BA_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82760 Version 4.0</div></div></div>"},"82761":{"type":"graphic_picture","displayName":"Ulcerative lesion secondary to bacillary angiomatosis","title":"Ulcerative lesion secondary to bacillary angiomatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ulcerative lesion secondary to bacillary angiomatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/82761_Ulcer_second_BA.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82761 Version 3.0</div></div></div>"},"82762":{"type":"graphic_picture","displayName":"Lymphomatoid papulosis arm","title":"Lymphomatoid papulosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lymphomatoid papulosis</div><div class=\"cntnt\"><img style=\"width:504px; height:320px;\" src=\"images/DERM/82762_Lymphom_papul_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin lesions in various states of development and regression.</div><div id=\"graphicVersion\">Graphic 82762 Version 1.0</div></div></div>"},"82763":{"type":"graphic_picture","displayName":"Lymphomatoid papulosis histology","title":"Histopathology of lymphomatoid papulosis","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Histopathology of lymphomatoid papulosis</div><div class=\"cntnt\"><img style=\"width:505px; height:341px;\" src=\"images/DERM/82763_Lymphom_pap_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Early perivascular lesion.<br />(B) Neutrophils within and around blood vessels are characteristic.<br />(C) Mature wedge-shaped lesion.<br />(D) Advanced ulcerated lesion.<br />Early lesions have a perivascular lymphoid infiltrate. Mature lesions have a wedge-shaped appearance. The most common type A lesions have large Reed-Sternberg-like cells and frequent mitoses in an inflammatory background. Type B lesions resemble mycosis fungoides (MF) and may be a papular variant of MF. Type C lesions demonstrate a relatively monotonous population of large CD30+ cells with few inflammatory cells.</div><div class=\"graphic_reference\">Panel C reproduced from: Kadin ME. Primary cutaneous CD30-positive t-cell lymphoproliferative disorders. In: Hematopathology, Jaffe ES, Harris NL, Vardiman JW, et al. (Eds), Philadelphia, Elsevier 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 82763 Version 3.0</div></div></div>"},"82764":{"type":"graphic_picture","displayName":"Lymphomatoid papulosis histo 2","title":"Wedge-shaped infiltrate of lymphomatoid papulosis","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Wedge-shaped infiltrate of lymphomatoid papulosis</div><div class=\"cntnt\"><img style=\"width:513px; height:195px;\" src=\"images/DERM/82764_Lympho_pap_hist_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CD30 immunostaining.</div><div id=\"graphicVersion\">Graphic 82764 Version 2.0</div></div></div>"},"82766":{"type":"graphic_picture","displayName":"Mumps PI","title":"A child with mumps","html":"<div class=\"graphic\"><div style=\"width: 828px\" class=\"figure\"><div class=\"ttl\">A child with mumps</div><div class=\"cntnt\"><img style=\"width:808px; height:482px;\" src=\"images/PI/82766_Mumps_pi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mumps is an infection that causes the glands in front of the ears and&nbsp;below the jaw to swell.</div><div class=\"graphic_reference\">Reprinted with permission from Salivary Gland Disorders, June 1, 2014, Vol 89, No 11, American Family Physician Copyright &copy; 2014 American Academy of Family physicians. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 82766 Version 2.0</div></div></div>"},"82767":{"type":"graphic_picture","displayName":"Paronychia PI","title":"Paronychia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paronychia</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/PI/82767_Paronychia_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paronychia is a skin infection that causes a painful, red, swollen area around a fingernail or toenail. Some people also get pus-filled blisters, as shown in this photo.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82767 Version 4.0</div></div></div>"},"82769":{"type":"graphic_picture","displayName":"Kissing bug on hand","title":"Kissing bug (Triatoma) on hand","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Kissing bug (Triatoma) on hand</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ALLRG/82769_Kissing_bug_on_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Photo copyright 2008 by Jerome Goddard, PhD.</div><div id=\"graphicVersion\">Graphic 82769 Version 2.0</div></div></div>"},"82771":{"type":"graphic_picture","displayName":"Primary syphilis oral","title":"Primary syphilis of the oral cavity","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Primary syphilis of the oral cavity</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/82771_Primary_syphilis_oral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary syphilis manifesting as a painless tongue ulcer with indurated raised borders and clean base.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82771 Version 3.0</div></div></div>"},"82772":{"type":"graphic_table","displayName":"CP symptoms PI","title":"Cerebral palsy symptoms at different ages","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cerebral palsy symptoms at different ages</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">The symptoms of cerebral palsy change as babies grow older. Possible symptoms from birth to age 2 are listed below.</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_single\">A baby younger than 6 months might:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Have&nbsp;trouble holding up his or her head when picked up</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Have a stiff or floppy body</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Stretch his or her back and neck away when being held. (Your baby might seem to be pushing away from you.)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Cross or stiffen his or her legs when picked up</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_single\">A baby older than 6 months might:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Have&nbsp;trouble controlling his or her neck</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Reach with only 1 hand and keep the other hand in a fist</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_single\">A baby older than 10 months might:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Crawl by pushing off with 1 hand and leg while dragging the other hand and leg</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Not sit by him or herself</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_single\">A child older than 1 year might:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Not crawl</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Not be able to stand up when holding onto something</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_single\">A child older than 2 years might:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Not be able to walk</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Not be able to push a toy with wheels</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 82772 Version 1.0</div></div></div>"},"82774":{"type":"graphic_picture","displayName":"Cryocrit","title":"Cryocrit analysis of cryoglobulin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryocrit analysis of cryoglobulin</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/RHEUM/82774_Cryocrit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cryocrit in a Wintrobe tube from a patient with a monoclonal gammopathy. One cryocrit was 25 percent and the other 35 percent. The patient's serum was refrigerated at 4&#176;C for 72 hours and was then centrifuged to determine the proportion forming a cryoprecipitate.</div><div class=\"graphic_reference\">Courtesy of Peter H Schur, MD.</div><div id=\"graphicVersion\">Graphic 82774 Version 2.0</div></div></div>"},"82775":{"type":"graphic_figure","displayName":"Uveitis PI","title":"Uveitis","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Uveitis</div><div class=\"cntnt\"><img style=\"width:602px; height:320px;\" src=\"images/PI/82775_Uveitis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Uveitis is inflammation of the uvea, which includes the iris, the ciliary body, and the choroid layer.</div><div id=\"graphicVersion\">Graphic 82775 Version 2.0</div></div></div>"},"82776":{"type":"graphic_table","displayName":"Guidelines for optimizing heat acclimatization","title":"Guidelines for optimizing heat acclimatization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for optimizing heat acclimatization</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td colspan=\"2\">Acclimatization should be performed gradually over 10-14 consecutive days</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td rowspan=\"4\">Environment</td>\r\n            <td>Reflects the environment that will be encountered during goal activity</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Warm or hot (WBGT &#62;26&#176;C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Relative humidity reflects the humidity that will be encountered</td>\r\n        </tr>\r\n        <tr>\r\n            <td>If necessary environmental conditions not present, add clothing or exercise during hottest/most humid part of the day</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td rowspan=\"4\">Exercise session</td>\r\n            <td>Duration: &#62;60 minutes</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Type: aerobic</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Intensity: moderate intensity (should progress from 60-80 percent age-predicted maximum heart rate)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Frequency: one session per day (may progress to two sessions per day alternating with a single session day)</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td rowspan=\"3\">Hydration</td>\r\n            <td>Urine specific gravity: &#60;1.020 </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Urine osmolality: &#60;700</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Urine color: &#60;3 (using 8 color scale)</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td rowspan=\"7\">Safety</td>\r\n            <td>Monitor temperature with rectal or gastrointestinal thermistor (&#60;40&#176;C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Monitor athlete for signs&nbsp;and symptoms of heat illness</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Monitor heart rate for increased intensity (&#62;80 percent age-predicted maximum)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Avoid interval training at race speeds (may be&nbsp;performed separately in a cooler environment)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Calculate sweat rate: pre-exercise nude body mass (kg)&nbsp;- post-exercise nude body mass (kg) + fluid ingested (L) per exercise time (hour) = sweat rate (L/hour)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Keep athlete well hydrated before and during exercise (&#60;2 percent dehydrated)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Training intensity should correspond with fitness level</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;  <li>Daanen HAM, Jonkman AG, Layden JD, et al. Optimising the acquisition and rentention of heat acclimation. Int J Sports Med 2011; 32:822-828.</li>&#xD;&#xA;  <li>Cheung SS. Heat Stress. Advanced Environmental Exercise Physiology. Champaign, IL:Human Kinetics; 2010.</li>&#xD;&#xA;  <li>Kuennen M, Gillum T, Dokladny K, et al. Thermotolerance and heat acclimation may share a common mechanism in humans. Am J Physiol Regul Integr Comp Physiol 2011; 301: R524-R533.</li>&#xD;&#xA;  <li>Armstrong LE, Maresh CM, Castellani JW, et al. Urineary indices of hydration status. Int J Sport Nutr 1992; 4:265.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 82776 Version 3.0</div></div></div>"},"82777":{"type":"graphic_figure","displayName":"Wet Bulb Globe Temperature Chart","title":"Wet Bulb Globe Temperature Chart","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Wet Bulb Globe Temperature Chart</div><div class=\"cntnt\"><img style=\"width:614px; height:351px;\" src=\"images/EM/82777_Wet_Bulb_Globe_Temp.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Thermal Comfort Observations. Australian Government Bureau of Meteorology. Available at:&nbsp;<A style=\"FONT-STYLE: italic\" href=\"http://www.bom.gov.au/info/thermal_stress/\" target=_blank>http://www.bom.gov.au/info/thermal_stress/</A> (Accessed 6 March 2012).</div><div id=\"graphicVersion\">Graphic 82777 Version 1.0</div></div></div>"},"82778":{"type":"graphic_table","displayName":"Sample heat acclimatization program for American football","title":"Sample heat acclimatization program for American football<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample heat acclimatization program for American football<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Modification</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">Practices 1-5</td>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Practices 6-14</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2\">Days 1-2</td>\r\n            <td class=\"subtitle2\">Days 3-5</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Number of practices permitted per day</td>\r\n            <td>1</td>\r\n            <td>1</td>\r\n            <td>2 (only every other day)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Equipment</td>\r\n            <td>Helmets only</td>\r\n            <td>Helmets &#38; shoulder pads</td>\r\n            <td>Full equipment</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Maximum duration of practice session</td>\r\n            <td>3 hours</td>\r\n            <td>3 hours</td>\r\n            <td>3 hours (maximum of 5 hours total on double session days)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Permitted walk through time (in addition to regular practice session)</td>\r\n            <td colspan=\"2\">1 hour (must be separated from regular practice by 3 hours)</td>\r\n            <td>1 hour (must be separated from regular practice by 3 hours)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Contact</td>\r\n            <td>No contact</td>\r\n            <td>Contact only with blocking sleds/dummies</td>\r\n            <td>Full contact drills</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_lgnd\">NOTE: Warm-up, stretching, cool-down, conditioning, and weight-room activities are all included as part of practice time.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Preseason Heat-Acclimatization Guidelines for Secondary School Athletics.&nbsp;Journal of Athletic Training 2009; 44:332.</LI></OL></div><div id=\"graphicVersion\">Graphic 82778 Version 3.0</div></div></div>"},"82781":{"type":"graphic_picture","displayName":"Dyshidrotic eczema mild 2","title":"Dyshidrotic eczema of the hands","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic eczema of the hands</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/82781_Dyshidroticeczemahands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep-seated, tiny vesicles on the palm of a patient with mild dyshidrotic eczema.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82781 Version 5.0</div></div></div>"},"82782":{"type":"graphic_picture","displayName":"Dyshidrotic eczema foot 2","title":"Dyshidrotic foot eczema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic foot eczema</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/82782_Dyshidroticeczemafoot2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Desquamation following vesicle&nbsp;desiccation in a patient with plantar dyshidrotic eczema.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" style=\"font-style: italic;\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82782 Version 7.0</div></div></div>"},"82783":{"type":"graphic_picture","displayName":"Dyshidrotic eczema fingers","title":"Dyshidrotic hand eczema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic hand eczema</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/82783_Dyshidrotic_eczema_fingers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tense, deep-seated vesicles&nbsp;and bullae involving the dorsal aspect of fingers in a patient with palmoplantar dyshidrotic eczema.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82783 Version 4.0</div></div></div>"},"82784":{"type":"graphic_picture","displayName":"Dyshidrotic eczema nail dystrophy","title":"Dyshidrotic hand eczema with associated nail dystrophy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic hand eczema with associated nail dystrophy</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/82784_Dyshidr_eczema_nail_dystrop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red and scaling patches with crusts and fissures are characteristic of chronic dyshidrotic eczema. Note the nail dystrophy secondary to involvement of the nail matrix.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82784 Version 4.0</div></div></div>"},"82787":{"type":"graphic_picture","displayName":"Tinea pedis bullous","title":"Bullous tinea pedis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous tinea pedis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/82787_Tinea_pedis_bullous.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles and bullae on the plantar skin of a patient with acute tinea pedis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82787 Version 4.0</div></div></div>"},"82789":{"type":"graphic_figure","displayName":"Lymphomatoid papulosis age distribution","title":"Lymphomatoid papulosis: Distribution by age and sex at presentation","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Lymphomatoid papulosis: Distribution by age and sex at presentation</div><div class=\"cntnt\"><img style=\"width:578px; height:352px;\" src=\"images/DERM/82789_Lymphomat_papulos_age_distr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This series of 111 cases of lymphomatoid papulosis shows a bimodal distribution by age and sex at presentation: 60 percent of male patients and only 25 percent of female patients were &lt;18 years old at the time of diagnosis (p&lt;0.001).</div><div class=\"graphic_reference\">Reproduced with permission from: Clara Curiel-Lewandrowski, MD.</div><div id=\"graphicVersion\">Graphic 82789 Version 1.0</div></div></div>"},"82790":{"type":"graphic_diagnosticimage","displayName":"CT imaging thyroglossal duct cyst","title":"CT imaging thyroglossal duct cyst","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">CT imaging thyroglossal duct cyst</div><div class=\"cntnt\"><img style=\"width:517px; height:323px;\" src=\"images/SURG/82790_CT_im_thyro_d_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These CT scan images show a thyroglossal duct cyst in the (A) axial view and (B) sagittal view. The arrows indicate the cyst.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Massachusetts Eye and Eary Infirmary, Radiology Department.</div><div id=\"graphicVersion\">Graphic 82790 Version 2.0</div></div></div>"},"82791":{"type":"graphic_figure","displayName":"Clavicle PI","title":"Clavicle (collarbone)","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Clavicle (collarbone)</div><div class=\"cntnt\"><img style=\"width:533px; height:603px;\" src=\"images/PI/82791_Clavicle-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the location of the clavicle, also called the collarbone.</div><div id=\"graphicVersion\">Graphic 82791 Version 2.0</div></div></div>"},"82792":{"type":"graphic_figure","displayName":"Congenital hernia of the diaphragm PI","title":"Congenital hernia of the diaphragm","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Congenital hernia of the diaphragm</div><div class=\"cntnt\"><img style=\"width:485px; height:627px;\" src=\"images/PI/82792_Diaphragmatic-hernia-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The baby in picture A is a normal newborn baby. The baby in picture B has a congenital hernia of the diaphragm. In this condition, the diaphragm (the layer of muscle that separates the organs in the chest from the organs in the belly) has a hole in it. Because of this, organs in the belly move through the hole into the chest.</div><div id=\"graphicVersion\">Graphic 82792 Version 2.0</div></div></div>"},"82793":{"type":"graphic_figure","displayName":"Hip PI","title":"Hip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hip</div><div class=\"cntnt\"><img style=\"width:400px; height:596px;\" src=\"images/PI/82793_Hip-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the location of the pelvis, hip joint, and femur (thigh bone).</div><div id=\"graphicVersion\">Graphic 82793 Version 2.0</div></div></div>"},"82794":{"type":"graphic_figure","displayName":"Rib PI","title":"Rib bones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rib bones</div><div class=\"cntnt\"><img style=\"width:375px; height:357px;\" src=\"images/PI/82794_Rib_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the location of the ribs.</div><div id=\"graphicVersion\">Graphic 82794 Version 1.0</div></div></div>"},"82795":{"type":"graphic_figure","displayName":"Tibia PI","title":"Tibia (shinbone)","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Tibia (shinbone)</div><div class=\"cntnt\"><img style=\"width:469px; height:645px;\" src=\"images/PI/82795_Tibia-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the location of the tibia, or shinbone.</div><div id=\"graphicVersion\">Graphic 82795 Version 1.0</div></div></div>"},"82797":{"type":"graphic_table","displayName":"Stillbirth support PI","title":"Support groups for stillbirth ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Support groups for stillbirth </div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Group</td>\r\n            <td class=\"subtitle1\">Toll free number</td>\r\n            <td class=\"subtitle1\">Web address</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Compassionate Friends</td>\r\n            <td>877-969-0010</td>\r\n            <td><a href=\"http://www.compassionatefriends.org/\" target=\"_blank\">www.compassionatefriends.org</a></td>\r\n        </tr>\r\n        <tr>\r\n            <td>M.I.S.S. Foundation</td>\r\n            <td>888-455-6477</td>\r\n            <td><a href=\"http://www.misschildren.org/\" target=\"_blank\">www.misschildren.org</a></td>\r\n        </tr>\r\n        <tr>\r\n            <td>Wisconsin Stillbirth Services Program</td>\r\n            <td>877-216-8535</td>\r\n            <td><a href=\"http://www2.marshfieldclinic.org/wissp/\" target=\"_blank\">www2.marshfieldclinic.org/wissp/</a></td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 82797 Version 1.0</div></div></div>"},"82803":{"type":"graphic_picture","displayName":"ACE inhibitor-induced angioedema","title":"ACE inhibitor-induced angioedema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">ACE inhibitor-induced angioedema</div><div class=\"cntnt\"><img style=\"width:504px; height:408px;\" src=\"images/ALLRG/82803_ACE_inhibit_induc_angio.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme.</div><div class=\"graphic_reference\">From: Grant NN, Deeb ZE, Chia SH. Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema. Otolaryngol Head Neck Surg 2007; 137:931. Copyright &copy; 2007. Reprinted by permission of SAGE Publications.</div><div id=\"graphicVersion\">Graphic 82803 Version 4.0</div></div></div>"},"82804":{"type":"graphic_algorithm","displayName":"Types of bradykinin-mediated angioedema","title":"Types of bradykinin-mediated angioedema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Types of bradykinin-mediated angioedema</div><div class=\"cntnt\"><img style=\"width:450px; height:184px;\" src=\"images/ALLRG/82804_Type_bradykinin_med_angio.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Differential diagnosis of bradykinin-mediated angioedema.</div><div class=\"graphic_footnotes\">HAE: hereditary angioedema; ACE: angiotensin-converting enzyme.</div><div class=\"graphic_reference\">Reproduced from: Vasekar M, Craig TJ. ACE inhibitor-induced angioedema. Curr Allergy Asthma Rep 2012; 12:72. Copyright &copy; 2012; with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 82804 Version 6.0</div></div></div>"},"82805":{"type":"graphic_algorithm","displayName":"Mechanisms of drugs for angioedema","title":"Drug therapy for angioedema: Mechanisms of action","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Drug therapy for angioedema: Mechanisms of action</div><div class=\"cntnt\"><img style=\"width:456px; height:380px;\" src=\"images/ALLRG/82805_Mechanisms_drugs_angioedema.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The renin-angiotensin (AT)-bradykinin (BK) system and sites of drug action.<br /><strong>Bold</strong> text: drugs.<br /><em>Italicized</em> text: enzymes.</div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; BK: bradykinin;&nbsp;ARB: angiotensin II receptor blocker.</div><div class=\"graphic_reference\">Reproduced with permission from: Hurst M, Empson M. Oral angioedema secondary to ACE inhibitors, a frequently overlooked association: case report and review. N Z Med J 2006; 119:U1930. Copyright &copy; 2006 New Zealand Medical Association.</div><div id=\"graphicVersion\">Graphic 82805 Version 5.0</div></div></div>"},"82806":{"type":"graphic_diagnosticimage","displayName":"Ultrasound urethral diverticulum","title":"Transvaginal sonography of a urethral diverticlum","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Transvaginal sonography of a urethral diverticlum</div><div class=\"cntnt\"><img style=\"width:501px; height:344px;\" src=\"images/OBGYN/82806_Ultras_urethral_divert_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal sonographic image shows the cystic space of a diverticulum (white arrow) immediately adjacent to a thick-walled urethra (yellow arrow).</div><div class=\"graphic_reference\">Dr. Deborah Levine</div><div id=\"graphicVersion\">Graphic 82806 Version 1.0</div></div></div>"},"82811":{"type":"graphic_picture","displayName":"Positioning for puncture of radiocarpal joint","title":"Positioning for ultrasound-guided puncture of radiocarpal joint","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Positioning for ultrasound-guided puncture of radiocarpal joint</div><div class=\"cntnt\"><img style=\"width:500px; height:353px;\" src=\"images/RHEUM/82811_Posit_punct_radio_joint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Puncture of the dorsal radiocarpal joint under direct&nbsp;ultrasound guidance.</div><div class=\"graphic_reference\">Reproduced with permission from: George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 82811 Version 1.0</div></div></div>"},"82814":{"type":"graphic_diagnosticimage","displayName":"Magnetic resonance imaging arthrogram of acetabular labral tear","title":"Magnetic resonance imaging arthrogram of acetabular labral tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging arthrogram of acetabular labral tear</div><div class=\"cntnt\"><img style=\"width:403px; height:504px;\" src=\"images/RADIOL/82814_MRI_Acetabul_labral_tears_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acetabular labral tear. Magnetic resonance arthrogram coronal image of the right hip shows linear hyperintense signal within the acetabular labrum (arrow) indicating a tear.</div><div class=\"graphic_reference\">Courtesy of Cecilia M Jude, MD, and Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 82814 Version 3.0</div></div></div>"},"82815":{"type":"graphic_figure","displayName":"Exercise intensity and duration and reduction in mortality","title":"Exercise intensity and duration and reduction in mortality","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Exercise intensity and duration and reduction in mortality</div><div class=\"cntnt\"><img style=\"width:586px; height:343px;\" src=\"images/NEPH/82815_Exercintendurredmort.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Wen CP, Wai JPM, Tsai MK, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: A prospective cohort study. Lancet 2011; 378:1244. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 82815 Version 2.0</div></div></div>"},"82817":{"type":"graphic_diagnosticimage","displayName":"MRI of synovial chondromatosis of the hip","title":"MRI of synovial chondromatosis of the hip","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">MRI of synovial chondromatosis of the hip</div><div class=\"cntnt\"><img style=\"width:496px; height:449px;\" src=\"images/RADIOL/82817_MRI_synovial_chondrom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Synovial chondromatosis of the hip. Pelvic MR coronal inversion recovery&nbsp;image&nbsp;shows multiple low-signal, intraarticular loose bodies in the right hip joint (arrows), consistent with synovial chondromatosis.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Cecilia M Jude, MD, and Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 82817 Version 3.0</div></div></div>"},"82823":{"type":"graphic_table","displayName":"Chemo regimens relapsed or refractory AML","title":"Chemotherapy regimens for relapsed or refractory acute myeloid leukemia (AML) in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapy regimens for relapsed or refractory acute myeloid leukemia (AML) in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Common side effects</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Cytarabine plus daunorubicin</td> <td>Common nonhematologic side effects seen in the majority of patients include stomatitis (mostly mild), alopecia, nausea and vomiting (10 percent severe), and diarrhea (mostly mild). Daunorubicin can be associated with an infusion reaction and cardiac arrhythmias; a flu-like syndrome and rash due to cytarabine may be seen during induction.</td> <td>Re-induction with cytarabine plus daunorubicin will produce a complete remission in approximately 50 percent of patients with a first remission <strong>lasting longer than</strong> one year<sup>[1]</sup>.</td> </tr> <tr class=\"divider_top\"> <td>High-dose cytarabine (HiDAC)</td> <td>The most common nonhematologic toxicities are nausea and vomiting, abnormal liver chemistries, diarrhea, conjunctivitis, rash, and cerebellar dysfunction. Toxicity is high in most patients over the age of 60 years.</td> <td>HiDAC may be effective in 35 to 40 percent of patients resistant to conventional dose cytarabine regimens<sup>[2]</sup>.</td> </tr> <tr class=\"divider_top\"> <td>High-dose cytarabine plus mitoxantrone (HAM)</td> <td>In addition to the side effects described for HiDAC above, nonhematologic toxicities include stomatitis, infections, and neutropenic fever. Infrequent transient, mild cardiac failure and tachyarrhythmias have also been reported.</td> <td>If an anthracycline (eg, daunorubicin) was not used during initial induction, the combination of HiDAC plus the synthetic anthracycline analogue, mitoxantrone, may produce higher response rates than HiDAC alone<sup>[3]</sup>.</td> </tr> <tr class=\"divider_top\"> <td>High-dose cytarabine plus etoposide</td> <td>In addition to the side effects described for HiDAC above, nonhematologic toxicities include hepatic toxicity, peripheral neuropathy, and anaphylactic-like reaction.</td> <td>HiDAC plus etoposide results in similar response rates as HiDAC alone with a nonsignificant trend towards longer remission duration<sup>[4]</sup>.</td> </tr> <tr class=\"divider_top\"> <td>Mitoxantrone plus etoposide</td> <td>Nonhematologic toxicities include stomatitis, nausea, infections, and neutropenic fever. Infrequent transient, mild cardiac failure and tachyarrhythmias have also been reported.</td> <td>Mitoxantrone and etoposide given together for five days is a commonly used regimen to treat refractory or relapsed AML and has demonstrated complete response rates of approximately 40 percent<sup>[5]</sup>.</td> </tr> <tr class=\"divider_top\"> <td>Mitoxantrone, etoposide, cytarabine (MEC)</td> <td>Side effects are similar to those described for mitoxantrone plus etoposide above, but also include hepatic dysfunction. </td> <td>MEC demonstrates a trend towards higher complete response rates for patients &#60;60 years old and those with unfavorable risk cytogenetics when compared with mitoxantrone plus etoposide alone<sup>[6]</sup>.</td> </tr> <tr class=\"divider_top\"> <td>Gemtuzumab ozogamicin (GO)&nbsp;as a single agent or plus&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">cytarabine and mitoxantrone</span></td> <td>Serious adverse reactions to GO include fatal anaphylaxis, hemorrhage, teratogenicity, and hepatic injury including sinusoidal obstruction syndrome (also known as hepatic veno-occlusive disease), plus side effects similar to mitoxantrone plus cytarabine, above.</td> <td>GO&nbsp;as a single agent or in combination with mitoxantrone plus cytarabine&nbsp;can achieve complete remission in up to 25 to 35 percent<sup>[7]</sup>.</td> </tr> <tr class=\"divider_top\"> <td>Fludarabine, cytarabine, plus G-CSF (FLAG)</td> <td>Studies including older adults have reported mild nonhematologic toxicity, most commonly with mucositis.</td> <td>FLAG has reported complete remission rates of 45 to 55 percent in patients with primary refractory or relapsing AML<sup>[8]</sup>.</td> </tr> <tr class=\"divider_top\"> <td>Cladribine, cytarabine, G-CSF (CLAG)</td> <td>Nonhematologic toxicity is generally mild to moderate (grade I/II) and includes fever/infection, mucositis, nausea and vomiting, diarrhea, and alopecia.</td> <td>CLAG results in a complete remission in approximately 50 percent of patients, with a median duration of response of 16 weeks<sup>[9]</sup>.</td> </tr> <tr class=\"divider_top\"> <td>Cyclophosphamide plus high-dose etoposide</td> <td>The most common non-hematologic toxicities include fever/infection, mucositis, hepatic toxicity, and hemorrhagic cystitis.</td> <td>Approximately 42 percent of patients with resistant AML will achieve a complete remission<sup>[10]</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients with resistant or relapsed AML should be encouraged to enroll on a clinical trial. While a number of chemotherapy regimens have been used for patients with resistant or relapsed disease, none results in acceptable long term remission rates. Many of these combinations are dose-intensive and cannot easily be applied in older patients. Since these regimens have not been directly compared, a choice is primarily based upon clinical experience and patient co-morbidities. A selection of these regimens is described above. Although response rates are presented for some of these regimens, an individual's chance of responding to a particular regimen is influenced not only by prior exposure to chemotherapy but also by other patient- and leukemia-associated factors. In theory, the preferred regimen to treat relapsed AML would exclude agents at dose levels which the patient has been exposed to recently.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>J Clin Oncol 2005; 23:1969.</LI>&#xD;&#xA;<LI>J Clin Oncol 1985; 3:992.</LI>&#xD;&#xA;<LI>Leuk Res 1999; 23:787.</LI>&#xD;&#xA;<LI>Leukemia 1994; 8:1847.</LI>&#xD;&#xA;<LI>J Clin Oncol 1988; 6:213.</LI>&#xD;&#xA;<LI>Leuk Res 2012; 36:394.</LI>&#xD;&#xA;<LI>Leukemia 2017; 31:1855.</LI>&#xD;&#xA;<LI>Br J Haematol 2001; 112:127.</LI>&#xD;&#xA;<LI>Leuk Lymphoma 2000; 39:121.</LI>&#xD;&#xA;<LI>Blood 1990; 76:473.</LI></OL></div><div id=\"graphicVersion\">Graphic 82823 Version 2.0</div></div></div>"},"82827":{"type":"graphic_table","displayName":"Diagnostic criteria for cutaneous and systemic mastocytosis","title":"Diagnostic criteria for cutaneous and systemic mastocytosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for cutaneous and systemic mastocytosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cutaneous mastocytosis (CM)</td> </tr> <tr> <td>Skin lesions demonstrating the typical clinical findings of urticaria pigmentosa/maculopapular cutaneous mastocytosis, diffuse cutaneous mastocytosis or solitary mastocytoma, and typical histologic infiltrates of mast cells in a multifocal or diffuse pattern in an adequate skin biopsy. In addition, a diagnostic prerequisite for the diagnosis of CM is the absence of features/criteria sufficient to establish the diagnosis of SM.</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic mastocytosis (SM)</td> </tr> <tr> <td><strong>The diagnosis of SM can be made when the major criterion and one minor criterion or at least three minor criteria are present.</strong></td> </tr> <tr> <td class=\"subtitle1_single\">Major criterion:</td> </tr> <tr> <td>Multifocal, dense infiltrates of mast cells (&#8805;15 mast cells in aggregates) detected in sections of bone marrow and/or other extracutaneous organ(s).</td> </tr> <tr> <td class=\"subtitle1_single\">Minor criteria:</td> </tr> <tr> <td> <ol> <li>In biopsy sections of bone marrow or other extracutaneous organs, &#62;25% of the mast cells in the infiltrate are spindle-shaped or have atypical morphology or, of all mast cells in bone marrow aspirate smears, &#62;25% are immature or atypical. </li> <li>Detection of an activating point mutation at codon 816 of <em>KIT</em> in bone marrow, blood, or another extracutaneous organ. </li> <li>Mast cells in bone marrow, blood, or other extracutaneous organs express CD2 and/or CD25 in addition to normal mast cell markers. </li> <li>Serum total tryptase persistently exceeds 20 ng/mL (unless there is an associated clonal myeloid disorder, in which case this parameter is not valid). </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Horny HP, Metcalfe DD, Bennet JM, et al. Mastocytosis. In: WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, Swerdlow SH, Camp E, Harris NL, et al (Eds), IARC, Lyon 2008. Copyright © 2008.</div><div id=\"graphicVersion\">Graphic 82827 Version 8.0</div></div></div>"},"82828":{"type":"graphic_table","displayName":"Diagnostic criteria of subtypes of systemic mastocytosis","title":"Diagnostic criteria of subtypes (variant forms) of systemic mastocytosis (SM) ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria of subtypes (variant forms) of systemic mastocytosis (SM) </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Indolent systemic mastocytosis (ISM)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"> <ul> <li>SM diagnostic criteria; no \"C\" findings </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Smoldering systemic mastocytosis (SSM)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"> <ul> <li>SM diagnostic criteria plus&nbsp;two or more \"B\" findings; no \"C\" findings </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Aggressive systemic mastocytosis (ASM)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"> <ul> <li>SM diagnostic criteria plus \"C\" findings; no features of mast cell leukemia </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Mast cell leukemia (MCL)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"> <ul> <li>SM diagnostic criteria plus features of MCL </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"> <ul> <li>SM diagnostic criteria <span style=\"color: black;\">plus clonal hematologic nonmast cell lineage disorder </span>(eg, MDS, MPN, AML, lymphoma, other) </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">SM diagnostic criteria:</td> <td class=\"subtitle1\">\"B\" findings:</td> <td class=\"subtitle1\">\"C\" findings:</td> <td class=\"subtitle1\">Features of MCL:</td> </tr> <tr> <td> <p>Major criterion plus one minor criterion OR three minor criteria.</p> <strong>Major criterion:</strong> <ol> <li>Multifocal, dense infiltrates of mast cells (&#8805;15 mast cells in aggregates) detected in sections of bone marrow and/or other extracutaneous organ(s). </li> </ol> <strong>Minor criterion:</strong> <ol> <li>In biopsy sections of bone marrow or other extracutaneous organs, &#62;25% of the mast cells in the infiltrate are spindle-shaped or have atypical morphology, or of all mast cells in bone marrow aspirate smears, &#62;25% are immature or atypical. </li> <li>Detection of an activating point mutation at codon 816 of KIT in bone marrow, blood, or another extracutaneous organ. </li> <li>Mast cells in bone marrow, blood, or other extracutaneous organs express CD2 and/or CD25 in addition to normal mast cell markers. </li> <li>Serum total tryptase persistently exceeds 20 mg/mL (unless there is an associated clonal myeloid disorder, in which case this parameter is not valid). </li> </ol> </td> <td> <ol class=\"numbers_to_nine\"> <li>Bone marrow biopsy showing &#62;30% infiltration by mast cells (focal, dense aggregates) and/or serum total tryptase level &#62;200 mg/mL. </li> <li>Signs of dysplasia or myeloproliferation, in nonmast cell lineage(s), but insufficient criteria for definitive diagnosis of a hematopoietic neoplasm (SM-AHN), with normal or only slightly abnormal blood counts. </li> <li>Hepatomegaly without impairment of liver function, and/or palpable splenomegaly without hypersplenism, and/or lymphadenopathy on palpation or imaging. </li> </ol> </td> <td> <ol class=\"numbers_to_nine\"> <li>Bone marrow dysfunction manifested by one or more cytopenia (ANC &#60;1 &times; 10<sup>9</sup>/L, Hb &#60;10 g/dL, or platelets &#60;100 &times; 10<sup>9</sup>/L), but no obvious nonmast cell hematopoietic malignancy. </li> <li>Palpable hepatomegaly with impairment of liver function, ascites, and/or portal hypertension. </li> <li>Skeletal involvement with large osteolytic lesions and/or pathologic fractures. </li> <li>Palpable splenomegaly with hypersplenism. </li> <li>Malabsorption with weight loss due to gastrointestinal mast cell infiltrates. </li> </ol> </td> <td>Bone marrow biopsy shows a diffuse infiltration, usually compact, by atypical, immature mast cells. Bone marrow aspirate smears show &#8805;20% mast cells.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Solid mast cell tumors (mast cell sarcoma and extracutaneous mastocytoma) are not forms of SM.</div><div class=\"graphic_footnotes\">MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; AML: acute myelogenous leukemia; KIT: the receptor for stem cell factor; ANC: absolute neutrophil count.</div><div class=\"graphic_reference\">Modified with permission from: Horny HP, Metcalfe DD, Bennet JM, et al. Mastocytosis. In: WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, Swerdlow SH, Campo E, Harris NL, et al (Eds), IARC: Lyon, 2008. Copyright © 2008.<br />Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Arber DA, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</LI></OL></div><div id=\"graphicVersion\">Graphic 82828 Version 22.0</div></div></div>"},"82831":{"type":"graphic_figure","displayName":"Clinical criteria for diagnosis of anaphylaxis","title":"Clinical criteria for diagnosis of anaphylaxis","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Clinical criteria for diagnosis of anaphylaxis</div><div class=\"cntnt\"><img style=\"width:632px; height:688px;\" src=\"images/ALLRG/82831_Clincritdiaganaphylaxis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical criteria for the diagnosis of anaphylaxis: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>The clinical criteria pictured are based upon Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: Summary report: Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. J Allergy Clin Immunol 2006; 117:391. </LI>&#xD;&#xA;<LI>Anaphylaxis with involvement of only one body organ system and anaphylaxis in infants and young children are described in Simons FER, Ardusso LRF, Bilo MB, et al. World Allergy Organization guidelines for the assessment and management of anaphylaxis. J Allergy Clin Immunol 2011; 127:587.</LI></UL></div><div class=\"graphic_footnotes\">BP: blood pressure.<br />* For example, immunologic but immunoglobulin E (IgE)-independent or nonimmunologic (direct mast cell activation).<br />¶ For example, after an insect sting, reduced BP might be the only manifestation of anaphylaxis or after allergen immunotherapy, generalized hives might be the only initial manifestation of anaphylaxis.<br />Δ Low systolic BP for children is defined as less than 70 mmHg from&nbsp;1 month to&nbsp;1 year, less than (70 mmHg + [2 × age]) from 1 to 10 years, and less than 90 mmHg from 11 to 17 years. Normal heart rate ranges from 80 to 140 beats/minute at age&nbsp;1 to&nbsp;2 years, from 80 to 120 beats/minute at age&nbsp;3 years, and from 70 to 115 beats/minute after age&nbsp;3 years. In infants and children, respiratory compromise is more likely than hypotension or shock, and shock is more likely to be manifested initially by tachycardia than by hypotension.</div><div class=\"graphic_reference\">Reproduced with permission from: Simons FER, Ardusso LRF, Beatrice Bilo M, et al. World Allergy Organization guidelines for the assessment and management of anaphylaxis. WAO Journal 2011; 4:13. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82831 Version 12.0</div></div></div>"},"82835":{"type":"graphic_table","displayName":"Neurologic gait disorders in elderly patients","title":"Neurologic gait disorders in elderly patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neurologic gait disorders in elderly patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Cause</td>\r\n            <td class=\"subtitle1\">Characteristics of gait</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Upper motor neuron weakness</td>\r\n            <td>The toes do not adequately clear the ground because the hip flexors are weak, and the toes scuff with each step. The strategy of circumduction at the hip helps with toe clearance.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Lower motor neuron weakness</td>\r\n            <td>With lower motor neuron foot drop, the gait is high stepping because the hip flexors are strong and compensate for the weakness to allow foot clearance.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Myopathic weakness</td>\r\n            <td>Waddling gait and abnormal pelvic tilt with each step because of limb girdle weakness.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Spasticity</td>\r\n            <td>Gait is narrow-based; the toes turn in and scrape on the floor with each step, producing a scuffing sound and wearing of the tips of the soles.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Deafferentation</td>\r\n            <td>Classically, gait is high stepping and stamping, and may be slightly wide-based. Stride length is normal or a little reduced. The gait deteriorates markedly in the dark.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Extrapyramidal</td>\r\n            <td>Narrow-based gait&nbsp;with reduced stride length; the feet barely clear the floor. Posture is stooped&nbsp;and&nbsp;arm swing reduced&nbsp;when walking. The forward center of gravity causes increasingly faster, short steps (hurrying or \"festinating\"). Turning is by small steps rather than pivoting.&nbsp;Additional manifestations may include gait initiation difficulty, start hesitation, freezing, and retropulsion.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cerebellar ataxia</td>\r\n            <td>The gait may appear to be stumbling, lurching, staggering, reeling, drunken,&nbsp;or slow, with reduced step length and a&nbsp;wide base. Associated features can include other signs of ataxia, including scanning and slow speech, finger-nose and heel-shin dysmetria, and dyssynergia.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Vestibular dysfunction</td>\r\n            <td>Deviation on walking to the side of the affected ear. The gait varies from an occasional stumble to frank veering. The legs are slightly spread, and stride length is slightly reduced. Stamping on the spot with eyes closed demonstrates veering (Unterberger test). Often associated with nystagmus.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Frontal lobe dysfunction</td>\r\n            <td>\r\n            <ul>\r\n                <li>Cautious gait, a consequence of compensatory adjustments in response to real or perceived disequilibrium </li>\r\n                <li>Isolated gait ignition failure, characterized by difficulty initiating or maintaining locomotion </li>\r\n                <li>Frontal disequilibrium, characterized by inappropriate or counterproductive postural and locomotion responses </li>\r\n                <li>Frontal gait disorder, characterized by variable base (narrow to wide), short shuffling steps, disequilibrium, and start and turn hesitation </li>\r\n            </ul>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Orthostatic myoclonus</td>\r\n            <td>Leg jerking occurs while upright. The locomotion problem is variable, with either gait \"apraxia\" or gait initiation difficulty noted in approximately one-half of the patients.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Psychogenic</td>\r\n            <td>Walking is bizarre and does not conform to any of the usual patterns. There may be excessive slowness and stiffness, or maintenance of postural control on a narrow base with flailing arms and excessive trunk sway.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Confusional state</td>\r\n            <td>Asterixis of the lower limbs may throw the patient to the floor. Inattention to task may lead to gait ataxia.</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 82835 Version 1.0</div></div></div>"},"82836":{"type":"graphic_picture","displayName":"Bullous pemphigoid IIF","title":"Serum IgG basement membrane zone antibodies localizing to the epidermal side of split skin substrate in bullous pemphigoid by indirect immunofluorescence microscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Serum IgG basement membrane zone antibodies localizing to the epidermal side of split skin substrate in bullous pemphigoid by indirect immunofluorescence microscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/82836_Bull_pemph_IIF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear IgG antibody staining on the epidermal side of basement membrane zone-split skin substrate characteristic of bullous pemphigoid. This pattern also is referred to as staining the roof of the blister.</div><div class=\"graphic_reference\">Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.</div><div id=\"graphicVersion\">Graphic 82836 Version 6.0</div></div></div>"},"82837":{"type":"graphic_picture","displayName":"Pemphigus vulgaris DIF","title":"Pemphigus vulgaris direct immunofluorescence","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pemphigus vulgaris direct immunofluorescence</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/82837_Pemph_vulg_DIF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An intercellular pattern of IgG antibody binding is evident on direct immunofluorescence in this specimen from a patient with pemphigus vulgaris.</div><div class=\"graphic_reference\">Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.</div><div id=\"graphicVersion\">Graphic 82837 Version 2.0</div></div></div>"},"82838":{"type":"graphic_picture","displayName":"Pemphigus foliaceus DIF","title":"Pemphigus foliaceus direct immunofluorescence","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pemphigus foliaceus direct immunofluorescence</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/82838_Pemph_foli_DIF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intercellular antibody binding is evident within the upper epidermis in this direct immunofluorescence specimen from a patient with pemphigus foliaceus.</div><div class=\"graphic_reference\">Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.</div><div id=\"graphicVersion\">Graphic 82838 Version 2.0</div></div></div>"},"82839":{"type":"graphic_picture","displayName":"Pemphigus vulgaris IIF","title":"Pemphigus vulgaris indirect immunofluorescence","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pemphigus vulgaris indirect immunofluorescence</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/82839_Pemph_vulg_IIF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pemphigus vulgaris. Indirect immunofluorescence performed on monkey esophagus demonstrates intercellular IgG antibody deposition.</div><div class=\"graphic_reference\">Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.</div><div id=\"graphicVersion\">Graphic 82839 Version 2.0</div></div></div>"},"82840":{"type":"graphic_picture","displayName":"Varicella histopathology","title":"Varicella","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Varicella</div><div class=\"cntnt\"><img style=\"width:504px; height:339px;\" src=\"images/DERM/82840_Varicella_histopath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photomicrograph of the skin from a patient with varicella shows an intraepidermal vesicle. Multinucleated giant cells and nuclear inclusions are present.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82840 Version 1.0</div></div></div>"},"82841":{"type":"graphic_picture","displayName":"Allergic contact dermatitis histopathology","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:332px;\" src=\"images/DERM/82841_Aller_con_derma_hist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epidermal spongiosis and spongiotic vesicles are present in this biopsy taken from a patient with poison ivy. Infiltrating lymphocytes are apparent in the epidermis.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82841 Version 1.0</div></div></div>"},"82842":{"type":"graphic_picture","displayName":"Palmoplantar pustulosis old lesions","title":"Palmoplantar pustulosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Palmoplantar pustulosis</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/82842_Palmoplant_pust_old_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In palmoplantar pustulosis, pustules become old over several days, become brown in color and dry, and desquamate.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82842 Version 3.0</div></div></div>"},"82843":{"type":"graphic_picture","displayName":"Palmoplantar pustulosis hands","title":"Palmoplantar pustulosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Palmoplantar pustulosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/82843_Palmoplantar_pustulos_hands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep-seated pustules with surrounding erythema and scale involving the entire palmar surface of this patient with&nbsp;palmoplantar pustulosis. Older lesions typically appear dusky red-brown in color with crusting.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82843 Version 5.0</div></div></div>"},"82849":{"type":"graphic_picture","displayName":"Cutaneous schistosomiasis swimmers itch","title":"Cutaneous schistosomiasis (swimmer's itch)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cutaneous schistosomiasis (swimmer's itch)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/82849_Cutan_schisto_swimmers_itch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Swimmer's itch consists of erythematous pruritic papules after exposure to water contaminated by cercariae of bird schistosomes carried by intermediate snail hosts.</div><div class=\"graphic_reference\">Reproduced with permission from <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82849 Version 3.0</div></div></div>"},"82851":{"type":"graphic_picture","displayName":"Stonefish","title":"Stonefish","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Stonefish</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/82851_Stonefish.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The stonefish is found in the Indian and Pacific Oceans and has 13 spines along the back. Envenomation is very painful. Treatment consists of hot water immersion, oral or parenteral analgesia, and local wound care. Stonefish antivenom is available for patients whose pain does not resolve with initial therapy.</div><div class=\"graphic_reference\">Photo courtesy of Sean Mack. Reproduced with permission under the Creative Commons Attribution. Available from: http://en.wikipedia.org/wiki/Synanceia.</div><div id=\"graphicVersion\">Graphic 82851 Version 1.0</div></div></div>"},"82852":{"type":"graphic_picture","displayName":"Scorpionfish","title":"Scorpionfish","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scorpionfish</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/82852_Scorpionfish.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82852 Version 3.0</div></div></div>"},"82853":{"type":"graphic_picture","displayName":"Lionfish","title":"Lionfish","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Lionfish</div><div class=\"cntnt\"><img style=\"width:460px; height:382px;\" src=\"images/EM/82853_Lionfish.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lionfish is found widely in tropical and temperate oceans. They are frequently kept as pets in home aquariums. Envenomation is painful. Treatment consists of hot water immersion and local wound care.</div><div class=\"graphic_reference\">Photo reproduced with permission from: James W Fatherree, M. Sc. From: Fatherree JW. Lionfish envenomations and the aquarist. Reefkeeping. Available at: <a href=\"http://www.reefkeeping.com/issues/2002-11/jf/feature/index.php\" target=\"_blank\">http://www.reefkeeping.com/issues/2002-11/jf/feature/index.php</a>.</div><div id=\"graphicVersion\">Graphic 82853 Version 1.0</div></div></div>"},"82858":{"type":"graphic_picture","displayName":"Wrist anatomic snuffbox location","title":"Location of the wrist anatomic snuffbox","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Location of the wrist anatomic snuffbox</div><div class=\"cntnt\"><img style=\"width:504px; height:380px;\" src=\"images/EM/82858_Anatom_snuff_location.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anatomic snuffbox is located proximal to the base of the thumb between the extensor pollicis longus tendon medially and extensor pollicis brevis and abductor pollicis longus tendons laterally. A fracture of the scaphoid waist often manifests as tenderness in this region.</div><div class=\"graphic_reference\">Courtesy of Kevin Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 82858 Version 2.0</div></div></div>"},"82859":{"type":"graphic_picture","displayName":"Palpation of scaphoid in anatomic snuffbox","title":"Palpation of the scaphoid in anatomic snuffbox","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the scaphoid in anatomic snuffbox</div><div class=\"cntnt\"><img style=\"width:403px; height:504px;\" src=\"images/EM/82859_Palp_scaph_snuff.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A good method for evaluating the body of the scaphoid is to gently bring the patient&#8217;s wrist into ulnar deviation and slight volar flexion, and then, palpate the anatomic snuffbox. The snuffbox lies&nbsp;between the extensor pollicis longus tendon medially and extensor pollicis brevis and abductor pollicis longus tendons laterally.</div><div class=\"graphic_reference\">Courtesy of Kevin Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 82859 Version 1.0</div></div></div>"},"82862":{"type":"graphic_table","displayName":"Suggested equipment for temporal artery biopsy","title":"Suggested equipment for temporal artery biopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested equipment for temporal artery biopsy</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td><strong>&nbsp;Site selection</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Hand-held Doppler</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Water soluble gel</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Marking pen</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;<strong>Site preparation</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Electric hair clipper</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Skin preparation solution</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Lidocaine cream 4%</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Lidocaine 1% with 1:200,000 epinephrine</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Bupivacaine 0.5% with 1:200,000 epinephrine</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;1:1 mixture of Lidocaine 1% with 1:200,000 epinephrine/Bupivicaine 1% with 1:200,000 epinephrine</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;10 mL syringe</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;18 gauge needle to draw up medications</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;27 or 30 gauge 1-1/4 inch needle for injection</td>\r\n        </tr>\r\n        <tr>\r\n            <td><span class=\"subtitle1_single\"><strong>Drapes and sponges</strong></span></td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Sterile Mayo stand cover</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Sterile towels, drape with central opening</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;4 x 4 sterile gauze sponges</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong>&nbsp;Instruments</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Scalpel holder</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Scalpel blade (no. 15) x 2</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Adson-Brown forceps</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Skin hooks</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Self-retaining retractor (eg, Alm, Heiss)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Tenotomy scissors</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Metzenbaum scissors</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Needle holder</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Hemostat clamps (curved or straight) x 2</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Hand-held cautery (battery powered) </td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Frazier suction tip, suction tubing</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;<strong>Specimen collection</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Ruler</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Sterile specimen cup with formalin</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;<strong>Skin closure and dressing</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;3-0 or 4-0 silk ties to ligate the artery</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;4-0 or 5-0 absorable suture for skin closure</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Tincture of benzoin</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Skin closure strips 1/4 inch</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Nonadherent absorbant dressing (eg, Telfa)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;Transparent film dressing (eg, Tegaderm)</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 82862 Version 1.0</div></div></div>"},"82863":{"type":"graphic_picture","displayName":"Typical hypergranular APL peripheral smear","title":"Peripheral smear from a patient with the typical hypergranular type of acute promyelocytic leukemia (APL)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Peripheral smear from a patient with the typical hypergranular type of acute promyelocytic leukemia (APL)</div><div class=\"cntnt\"><img style=\"width:504px; height:494px;\" src=\"images/HEME/82863_Typ_hypergran_APL_prph_smr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The white cell count in this type of APL is usually low with only a few circulating malignant promyelocytes. The abnormal promyelocytes frequently have bi-lobed or dumbbell shaped nuclei with granular cytoplasm. They can be difficult to recognize due to their scarcity, but when seen they should immediately raise the possibility of APL.</div><div id=\"graphicVersion\">Graphic 82863 Version 1.0</div></div></div>"},"82864":{"type":"graphic_picture","displayName":"APL bone marrow aspirate I","title":"Bone marrow aspirate smear from a patient with acute promyelocytic leukemia (APL)","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Bone marrow aspirate smear from a patient with acute promyelocytic leukemia (APL)</div><div class=\"cntnt\"><img style=\"width:540px; height:316px;\" src=\"images/HEME/82864_APL_bone_marrow_aspirate_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most of the cells are abnormal promyelocytes with folded, bi-lobed, dumbbell or reniform-shaped nuclei with abundant granular cytoplasm. Sometimes the granules can obscure the details of the nucleus.</div><div id=\"graphicVersion\">Graphic 82864 Version 1.0</div></div></div>"},"82865":{"type":"graphic_picture","displayName":"APL bone marrow aspirate II","title":"Bone marrow aspirate from a patient with acute promyelocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bone marrow aspirate from a patient with acute promyelocytic leukemia</div><div class=\"cntnt\"><img style=\"width:504px; height:427px;\" src=\"images/HEME/82865_APL_bone_marrow_aspirate_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with acute promyelocytic leukemia (APL; formerly described in the French-American-British [FAB] classification as the M3 variant of acute myeloid leukemia). The cytoplasm of these promyelocytes contains densely-packed bright pink, reddish-blue or dark purple granules. Note the cell on the bottom left with a single Auer rod. (Wright-Giemsa stain) </div><div id=\"graphicVersion\">Graphic 82865 Version 2.0</div></div></div>"},"82866":{"type":"graphic_picture","displayName":"APL bone marrow aspirate III","title":"Bone marrow aspirate from a patient with acute promyelocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Bone marrow aspirate from a patient with acute promyelocytic leukemia</div><div class=\"cntnt\"><img style=\"width:540px; height:351px;\" src=\"images/HEME/82866_APL_bone_marrow_aspirat_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with acute promyelocytic leukemia (APL). Note that some of the abnormal promyelocytes have abundant Auer rods filling the cytoplasm. </div><div id=\"graphicVersion\">Graphic 82866 Version 2.0</div></div></div>"},"82867":{"type":"graphic_picture","displayName":"Microgranular APL variant peripheral smear","title":"Peripheral smear from a patient with the microgranular (or hypogranular) variant of acute promyelocytic leukemia (APL)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Peripheral smear from a patient with the microgranular (or hypogranular) variant of acute promyelocytic leukemia (APL)</div><div class=\"cntnt\"><img style=\"width:504px; height:404px;\" src=\"images/HEME/82867_Microgr_APL_var_perip_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The white blood cell count in the microgranular (or hypogranular)&nbsp;type of APL is usually elevated, and the cells are identified by their bi-lobed, dumbbell-shaped, or reniform nuclei. The cells have no recognizable granules, but granules are in fact present and can be seen by electron microscopy. Despite the sub-light microscopic nature of the granules, the cells are still strongly positive for the myeloperoxidase reaction.</div><div id=\"graphicVersion\">Graphic 82867 Version 1.0</div></div></div>"},"82868":{"type":"graphic_picture","displayName":"PML monoclonal antibody staining","title":"Promyelocytic leukemia (PML) monoclonal antibody staining in acute promyelocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Promyelocytic leukemia (PML) monoclonal antibody staining in acute promyelocytic leukemia</div><div class=\"cntnt\"><img style=\"width:582px; height:291px;\" src=\"images/HEME/82868_PML_monocl_antibod_staining.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal staining.<BR>(B) Acute promyelocytic leukemia demonstrates a microspeckled pattern with PML monoclonal antibody staining.</div><div id=\"graphicVersion\">Graphic 82868 Version 1.0</div></div></div>"},"82870":{"type":"graphic_table","displayName":"Potential historical findings in children with AKI","title":"Potential historical findings in children with acute kidney injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential historical findings in children with acute kidney injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History of fluid loss</td> </tr> <tr> <td> <ul> <li>Diarrhea, vomiting </li> <li>Burns </li> <li>Surgery </li> <li>Shock </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Exposure to nephrotoxic agents</td> </tr> <tr> <td> <ul> <li>Nonsteroidal antiinflammatory drugs </li> <li>Aminoglycosides </li> <li>Contrast agents </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Factors associated with glomerular diseases</td> </tr> <tr> <td> <ul> <li>Streptococcal infection: Poststreptococcal glomerulonephritis </li> <li>Bloody diarrhea: Hemolytic uremic syndrome </li> <li>Joint symptoms, rash, or purpura: Henoch-Sch&#246;nlein purpura </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Signs of obstruction</td> </tr> <tr> <td> <ul> <li>Complete anuria </li> <li>Poor urinary stream </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82870 Version 2.0</div></div></div>"},"82871":{"type":"graphic_table","displayName":"Physical findings in pediatric acute kidney injury","title":"Physical findings in pediatric acute kidney injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical findings in pediatric acute kidney injury</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Signs of intravascular volume depletion</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <ul>\r\n                <li>Tachycardia </li>\r\n                <li>Delayed capillary refill </li>\r\n                <li>Low blood pressure </li>\r\n                <li>Weak peripheral pulses </li>\r\n                <li>Dry mucous membranes </li>\r\n            </ul>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Signs of fluid overload</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <ul>\r\n                <li>Edema </li>\r\n                <li>Hypertension </li>\r\n                <li>Heart failure </li>\r\n                <li>Pulmonary edema </li>\r\n            </ul>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Renal disease due to systemic causes</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <ul>\r\n                <li>Rash: Henoch-Sch&#246;nlein purpura, acute presentation of systemic lupus erythematous, interstitial nephritis due to drug reaction </li>\r\n                <li>Joint findings (tenderness or swelling): Henoch-Sch&#246;nlein purpura, acute presentation of systemic lupus erythematous </li>\r\n            </ul>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Palpably enlarged kidneys</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <ul>\r\n                <li>Polycystic/multicystic kidney disease </li>\r\n                <li>Renal vein thrombosis </li>\r\n            </ul>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Signs of obstruction</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <ul>\r\n                <li>Poor urinary stream </li>\r\n                <li>Palpably enlarged bladder </li>\r\n                <li>Therapeutic catheterization </li>\r\n            </ul>\r\n            </td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 82871 Version 1.0</div></div></div>"},"82872":{"type":"graphic_table","displayName":"Urinary indices for prerenal AKI versus ATN","title":"Urinary indices differentiating prerenal acute kidney injury (AKI) from acute tubular necrosis (intrinsic AKI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urinary indices differentiating prerenal acute kidney injury (AKI) from acute tubular necrosis (intrinsic AKI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Measurement</td> <td class=\"subtitle1\">Prerenal AKI</td> <td class=\"subtitle1\">Intrinsic AKI</td> </tr> <tr> <td>Urine specific gravity</td> <td>&#62;1.020</td> <td>&#60;1.010</td> </tr> <tr> <td>Urine/plasma creatinine</td> <td>&#62;40</td> <td>&#60;20</td> </tr> <tr> <td>Urine Na (mEq/L)</td> <td>&#60;20</td> <td>&#62;40</td> </tr> <tr> <td>FENa</td> <td>&#60;1 percent</td> <td>&#62;2 percent</td> </tr> <tr> <td>FEUrea</td> <td>&#60;35 percent</td> <td>&#62;50 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Na: sodium; FENa: fractional excretion of sodium; FEUrea: fractional excretion of urea.</div><div id=\"graphicVersion\">Graphic 82872 Version 3.0</div></div></div>"},"82873":{"type":"graphic_table","displayName":"Features of AKI versus CKD in children","title":"Clinical features differentiating acute kidney injury from chronic kidney disease in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features differentiating acute kidney injury from chronic kidney disease in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Finding</td>\r\n            <td class=\"subtitle1\">Acute kidney injury (AKI)</td>\r\n            <td class=\"subtitle1\">Chronic kidney disease</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Serum BUN and Cr</td>\r\n            <td>Progressive rise in BUN and Cr</td>\r\n            <td>Stable elevated BUN and Cr</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Historical clues</td>\r\n            <td>Positive history for AKI etiology (eg, recent streptococcal infection: poststreptococcal glomerulonephritis) </td>\r\n            <td>History of chronic hypertension</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Growth</td>\r\n            <td>Normal growth</td>\r\n            <td>Impaired growth</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Bone status</td>\r\n            <td>Normal bones</td>\r\n            <td>Evidence of renal osteodystrophy: History of fractures, abnormal tibial torsion</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Urine sediment</td>\r\n            <td>No broad urinary casts</td>\r\n            <td>Broad waxy urinary casts</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hematocrit</td>\r\n            <td>Anemia usually mild</td>\r\n            <td>Anemia usually severe</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Renal ultrasound</td>\r\n            <td>Normal or enlarged kidney size</td>\r\n            <td>Small shrunken kidneys</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">BUN: blood urea nitrogen, Cr: creatinine</div><div id=\"graphicVersion\">Graphic 82873 Version 1.0</div></div></div>"},"82874":{"type":"graphic_table","displayName":"Treatment of hyperkalemia in children","title":"Treatment of hyperkalemia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of hyperkalemia in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Onset of action</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Stabilization of cardiac myocardial membrane in setting of hyperkalemia-associated abnormal ECG or arrhythmia*</td> </tr> <tr> <td class=\"indent1\">Calcium gluconate, 10 percent<sup>&#182;</sup></td> <td> <p>0.5 to 1 mL/kg IV over 5 to 15 min (50 to 100 mg/kg calcium gluconate, maxiumum dose 3 grams)</p> Repeat after 10 minutes, if needed</td> <td>Immediate</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Movement of extracellular potassium into the cells*</td> </tr> <tr> <td class=\"indent1\">Glucose and insulin</td> <td> <p>IV administration of glucose 0.5 g/kg (equal to 2 mL/kg of a 25 percent dextrose solution)</p> IV administration of insulin 0.1 units/kg over 30 min</td> <td>30 minutes</td> </tr> <tr> <td class=\"indent1\">Inhaled beta-agonists (albuterol)</td> <td>0.1 to 0.3 mg/kg</td> <td>30 minutes</td> </tr> <tr> <td class=\"indent1\">Sodium bicarbonate<sup>&#916;</sup></td> <td>IV administration of 1 mEq/kg over 10 min (maximum dose of 50 mEq per hour)</td> <td>15 minutes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Removal of potassium</td> </tr> <tr> <td class=\"indent1\">Sodium polystyrene sulfonate</td> <td>1 g/kg PO or PR with sorbitol</td> <td>1 to 2 hours</td> </tr> <tr> <td class=\"indent1\">Furosemide</td> <td>IV administration of 1 to 2 mg/kg with replacement of fluid loss</td> <td>1 to 2 hours</td> </tr> <tr> <td class=\"indent1\">Hemodialysis</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous administration; PO: oral administration; PR: rectal administration; ECG: electrocardiogram.<br />* These measures do not remove potassium and additional interventions may be required to lower overall potassium levels.<br />&#182; Calcium should be administered in a larger vein or central line preferably (irritant), and sodium bicarbonate should not be introduced into the line because of potential precipitation. Continuous ECG monitoring should be performed during administration.<br />&Delta; Administration of sodium bicarbonate may have a minimal effect.</div><div id=\"graphicVersion\">Graphic 82874 Version 3.0</div></div></div>"},"82875":{"type":"graphic_figure","displayName":"Course of the superficial temporal artery","title":"Course of the superficial temporal artery","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Course of the superficial temporal artery</div><div class=\"cntnt\"><img style=\"width:531px; height:471px;\" src=\"images/SURG/82875_Course_of_the_superficial_temporal_artery.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82875 Version 2.0</div></div></div>"},"82876":{"type":"graphic_figure","displayName":"Superfical temporal artery","title":"Superfical temporal artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superfical temporal artery</div><div class=\"cntnt\"><img style=\"width:430px; height:579px;\" src=\"images/SURG/82876_Superficial-temporal-artery.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 82876 Version 1.0</div></div></div>"},"82877":{"type":"graphic_figure","displayName":"Temporal artery biopsy technique","title":"Temporal artery biopsy technique","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Temporal artery biopsy technique</div><div class=\"cntnt\"><img style=\"width:522px; height:616px;\" src=\"images/SURG/82877_Temporal-artery-biopsy-technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The incision is made overlying the temporal artery. The dissection is carried through the subcutaneous fat parallel to the vessel with care not to injure the vessel, and a self-retaining retractor placed. Dividing the overlying temporoparietal fascia exposes the superficial temporal artery. The vessel is ligated proximally and distally, and the intervening segment removed. Hemostasis is achieved using electrocautery or additional sutures.</div><div id=\"graphicVersion\">Graphic 82877 Version 2.0</div></div></div>"},"82878":{"type":"graphic_movie","displayName":"Apley scratch tests for shoulder motion","title":"Apley scratch tests for shoulder motion","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Apley scratch tests for shoulder motion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82878_Apleyscratchtestsvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:283px;\" src=\"images/EM/82878_Apleyscratchtestimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Apley “scratch” tests can provide an easy and reproducible way to assess shoulder motion. However, they should be performed as an adjunct to standard range of motion tests as they do not adequately assess all shoulder movements.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82878 Version 1.0</div></div></div>"},"82879":{"type":"graphic_movie","displayName":"Passive Painful Arc Neer Test","title":"Passive Painful Arc (Neer) Test","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Passive Painful Arc (Neer) Test</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82879_PasspainfularcNeervideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:287px;\" src=\"images/EM/82879_PasspainfularcNeerimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The passive painful arc maneuver&nbsp;is used to assess the degree of shoulder impingement. It is performed by passively flexing the glenohumeral joint, while simultaneously preventing the patient from shrugging their shoulder.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82879 Version 1.0</div></div></div>"},"82880":{"type":"graphic_movie","displayName":"Drop arm test","title":"Drop arm test","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Drop arm test</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82880_Droparmtestvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:342px;\" src=\"images/EM/82880_Droparmtestimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The drop arm test assesses the ability of the patient to lower his or her arms from a fully abducted position. A positive test occurs when the patient is unable to lower the affected arm with the same smooth coordinated motion as the unaffected arm.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82880 Version 1.0</div></div></div>"},"82881":{"type":"graphic_picture","displayName":"Atopic dermatitis hand","title":"Atopic hand dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Atopic hand dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/82881_Atopic_dermatitis_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atopic hand dermatitis typically involves the dorsum of hands. Diffuse erythema, scaling, and excoriations can be seen in this image.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82881 Version 3.0</div></div></div>"},"82882":{"type":"graphic_movie","displayName":"External rotation testing of shoulder","title":"External rotation testing of the shoulder","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">External rotation testing of the shoulder</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82882_Extrottestshouldvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:298px;\" src=\"images/EM/82882_Extrottestshouldimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isometric testing of the infraspinatus tendon is used to assess the strength and integrity of the tendon, as well as to elicit pain indicative of injury. This test can be performed by having the patient attempt to externally rotate their adducted arm while the clinician resists the movement with their hand</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82882 Version 1.0</div></div></div>"},"82883":{"type":"graphic_movie","displayName":"Sulcus sign for glenohumeral instability","title":"Sulcus sign for glenohumeral instability","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Sulcus sign for glenohumeral instability</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82883_Sulcsigngleninstabvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:301px;\" src=\"images/EM/82883_Sulcsigngleninstabimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sulcus sign maneuver evaluates the looseness of the glenohumeral joint. Clinicians should note that downward movement of the humeral head is influenced by the tone and bulk of the deltoid, the tone and thickness of the supraspinatus muscle and tendon, and the structure and integrity of the glenohumeral capsule. Therefore, it is important to compare shoulders.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82883 Version 2.0</div></div></div>"},"82884":{"type":"graphic_movie","displayName":"Apprehension relocation release tests for shoulder","title":"Apprehension, relocation, and release tests for the shoulder","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Apprehension, relocation, and release tests for the shoulder</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82884_Apprehreloreltestsvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:284px;\" src=\"images/EM/82884_Apprehreloreltestimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These tests work in combination and are most easily performed with the patient supine. For the apprehension test, the symptomatic arm is placed in the throwing position (shoulder abducted and externally rotated). Next, the clinician braces the posterior shoulder with one hand while using the other hand to push back on the wrist with steady pressure, thereby increasing the abduction and external rotation of the shoulder. Any sensation of impending dislocation at any time constitutes a positive test. The relocation immediately follows the apprehension test and is performed by simply reversing the forces being exerted by the examiner. Forced abduction and external rotation are stopped, and the clinician moves the hand that was bracing the posterior shoulder to the anterior shoulder. The examiner then pushes the humerus posteriorly. The resolution of either pain or the sensation of impending dislocation on the part of the patient represents a positive test. The release test is performed at the end of the relocation test when the clinician abruptly stops pushing the humerus posteriorly. Any sensation of impending dislocation on the part of the patient constitutes a positive test.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82884 Version 2.0</div></div></div>"},"82885":{"type":"graphic_movie","displayName":"Crank test for SLAP lesion","title":"Crank test for SLAP lesion","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Crank test for SLAP lesion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82885_Cranktestvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/82885_Cranktestimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the crank test, the patient abducts their arm 160 degrees while keeping the arm in the plane of the scapula. The elbow is flexed 90 degrees. The examiner then applies an axial load to the humerus with one hand while rotating the arm internally and externally with the other. Pain, a clicking sensation during the maneuver, or reproduction of symptoms similar to those experienced at work or sport indicates a positive test.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82885 Version 1.0</div></div></div>"},"82886":{"type":"graphic_movie","displayName":"Kim biceps load test one for SLAP lesion","title":"Biceps load (Kim) test one for SLAP lesion","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Biceps load (Kim) test one for SLAP lesion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82886_Bicepsloadtestonevideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:282px;\" src=\"images/EM/82886_Bicepsloadtestoneimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first biceps load test is intended to detect SLAP injuries in patients with chronic shoulder dislocation. The test is performed with the patient supine and the examiner seated alongside holding the patient's wrist and elbow. The patient's arm is positioned with the shoulder abducted 90 degrees to the side, the elbow flexed 90 degrees, and the arm fully supinated. The examiner then steadily rotates the shoulder externally in a manner similar to the apprehension test. Rotation is stopped when the patient feels as if the shoulder will dislocate. The patient then flexes the elbow while the examiner resists. The test is positive if the last maneuver provokes pain or continued apprehension about dislocation.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82886 Version 2.0</div></div></div>"},"82887":{"type":"graphic_movie","displayName":"Kim biceps load test two for SLAP lesion","title":"Biceps load (Kim) test two for SLAP lesion","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Biceps load (Kim) test two for SLAP lesion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82887_Bicepsloadtesttwovideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:281px;\" src=\"images/EM/82887_Bicepsloadtesttwoimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The positioning for the second biceps load test is identical to the first. However, in the second test, the shoulder is abducted 120 degrees before the shoulder is maximally externally rotated, again with the elbow flexed to 90 degrees and the arm supinated. The patient is then asked to flex the elbow while the examiner resists. The test is positive if pain develops when the patient flexes their elbow or increases when the examiner applies resistance.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82887 Version 2.0</div></div></div>"},"82888":{"type":"graphic_movie","displayName":"Pain provocation test for SLAP lesion","title":"Pain provocation test for SLAP lesion","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Pain provocation test for SLAP lesion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82888_Painprovocationvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:309px;\" src=\"images/EM/82888_Painprovocationimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the pain provocation test, the patient sits with the examiner standing behind them. The examiner holds the patient’s wrist with their ipsilateral hand while the contralateral hand gently braces the patient’s shoulder. The shoulder is abducted to 90 to 100 degrees directly to the side with the elbow flexed 90 degrees. The arm is then maximally externally rotated and while maintaining this position the arm is then maximally pronated and supinated. The test is positive if maximal pronation elicits or worsens pain.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82888 Version 1.0</div></div></div>"},"82890":{"type":"graphic_movie","displayName":"Compression rotation test for SLAP lesion","title":"Compression-rotation test for SLAP lesion","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Compression-rotation test for SLAP lesion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82890_Compressionrotationvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:282px;\" src=\"images/EM/82890_Compressionrotationimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform&nbsp;the compression-rotation test, the patient lays supine with their shoulder abducted 90 degrees directly to the side and their elbow flexed at 90 degrees. The examiner pushes the humerus into the glenoid by applying an axial load and then rotates the humerus internally and externally. A positive test produces a catching, popping, or snapping sensation.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82890 Version 1.0</div></div></div>"},"82892":{"type":"graphic_movie","displayName":"Modified dynamic labral shear test","title":"Modified dynamic labral shear test","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Modified dynamic labral shear test</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82892_Moddynlabralshearvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:323px;\" src=\"images/EM/82892_Moddynlabralshearimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The modified dynamic labral shear test is performed with the patient standing, their shoulder abducted to 120 degrees, arm kept in the scapular plane, elbow flexed to 90 degrees, and their shoulder externally rotated until they feel tightness in the shoulder. The examiner then pushes the proximal humerus anteriorly, thereby providing a shear force to the glenohumeral joint, while lowering the arm from 120 degrees to 60 degrees of abduction using the other hand. External rotation is maintained throughout. A positive test elicits pain or a painful clicking or catching sensation at the posterior joint line when the arm is abducted between 120 degrees and 90 degrees.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82892 Version 1.0</div></div></div>"},"82895":{"type":"graphic_table","displayName":"Etiology of post-herniorrhaphy neuralgia","title":"Etiology of post-herniorrhaphy neuralgia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of post-herniorrhaphy neuralgia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nerve</td> <td class=\"subtitle1\">Root</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Innervation</td> </tr> <tr> <td rowspan=\"3\">Ilioinguinal</td> <td rowspan=\"3\">T12, L1</td> <td rowspan=\"3\">Accompanies spermatic cord</td> <td>Proximal and medial thigh</td> </tr> <tr> <td>Mons pubis and labium majorum</td> </tr> <tr> <td>Root of penis and upper scrotum</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Iliohypogastric</td> <td class=\"sublist_other_start\" rowspan=\"3\">T12, L1</td> <td class=\"sublist_other_start\" colspan=\"2\">Divides into two branches:</td> </tr> <tr> <td class=\"sublist1\">Anterior cutaneous branch</td> <td class=\"sublist_other\">Passes between the aponeurosis and internal oblique; accompanies spermatic cord</td> <td class=\"sublist_other\">Skin of hypogastric region</td> </tr> <tr> <td class=\"sublist1\">Lateral cutaneous branch</td> <td class=\"sublist_other\">Pierces the internal and external oblique above the iliac crest</td> <td class=\"sublist_other\">Skin of the gluteal region</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Genitofemoral</td> <td class=\"sublist_other_start\" rowspan=\"3\">L1, L2</td> <td class=\"sublist_other_start\" colspan=\"2\">Divides into two branches:</td> </tr> <tr> <td class=\"sublist1\">Genital branch</td> <td class=\"sublist_other\">Through internal ring, joins spermatic cord</td> <td class=\"sublist_other\">Mons and labia/scrotum</td> </tr> <tr> <td class=\"sublist1\">Femoral branch</td> <td class=\"sublist_other\">With external illiac artery</td> <td class=\"sublist_other\">Anterior lateral thigh</td> </tr> <tr class=\"divider_top\"> <td>Lateral femoral cutaneous</td> <td>L2, L3</td> <td>Beneath inguinal ligament</td> <td>Anterior lateral thigh</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Femoral nerve</td> <td rowspan=\"2\">L2, L3</td> <td rowspan=\"2\">Beneath inguinal ligament</td> <td>Primarily motor nerve to quadriceps femoris</td> </tr> <tr> <td>Sensory branch anterior thigh</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82895 Version 1.0</div></div></div>"},"82896":{"type":"graphic_movie","displayName":"Speeds test for biceps tendon","title":"Speeds test for biceps tendon","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Speeds test for biceps tendon</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82896_Speedstestbicepsvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:308px;\" src=\"images/EM/82896_Speedstestbicepsimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Speeds test is used to detect pathology of the biceps tendon. It is performed with&nbsp;the patient's arm extended in full supination with the shoulder flexed. In this position the patient is asked to elevate the arm against a resisted isometric force applied by the examiner. A test that elicits pain in the anterior shoulder is considered positive.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82896 Version 1.0</div></div></div>"},"82897":{"type":"graphic_movie","displayName":"Yergasons test for biceps tendon","title":"Yergasons test for biceps tendon","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Yergasons test for biceps tendon</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82897_Yergasonstestbicepsvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:288px;\" src=\"images/EM/82897_Yergasonstestbicepsimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yergasons test is used to assess the biceps tendon. It&nbsp;is performed with the patient's arm pronated and flexed at the elbow to 90 degrees. The patient then attempts to supinate the arm against a resisted isometric force applied by the examiner. Pain localized to the long biceps tendon marks a positive test.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82897 Version 1.0</div></div></div>"},"82898":{"type":"graphic_movie","displayName":"Biceps tendon palpation technique","title":"Technique for biceps tendon palpation","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Technique for biceps tendon palpation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/82898_Bicepstendpalptechvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:295px;\" src=\"images/EM/82898_Bicepstendpalptechimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To&nbsp;palpate the biceps tendon,&nbsp;identify the greater tubercle of the humerus and then move your fingers slightly medially into the bicipital groove. The shoulder can then be externally and internally rotated while feeling the biceps tendon roll under&nbsp;your fingers. At this point, extending and flexing the elbow allows for appreciation of tendon movement, and crepitus if present.&nbsp;</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 82898 Version 1.0</div></div></div>"},"82900":{"type":"graphic_picture","displayName":"Moisture chambers PI","title":"Moisture chambers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Moisture chambers</div><div class=\"cntnt\"><img style=\"width:432px; height:304px;\" src=\"images/PI/82900_Moisture_chambers_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Moisture chambers like these attach to a pair of&nbsp;eyeglasses. They help trap moisture and can help&nbsp;relieve the symptoms of dry eye.</div><div id=\"graphicVersion\">Graphic 82900 Version 1.0</div></div></div>"},"82910":{"type":"graphic_picture","displayName":"Lymphocyte-rich type HL","title":"Hodgkin lymphoma, lymphocyte-rich type","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Hodgkin lymphoma, lymphocyte-rich type</div><div class=\"cntnt\"><img style=\"width:540px; height:364px;\" src=\"images/HEME/82910_LymphocyterichtypeHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Few Reed-Sternberg cells or variants within a mass of lymphocytes. Hematoxylin, phloxine, and saffron stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Hodgkin lymphoma: Classical. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82910 Version 6.0</div></div></div>"},"82911":{"type":"graphic_picture","displayName":"Nodular lymphocyte-predominant HL","title":"Nodular lymphocyte-predominant Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nodular lymphocyte-predominant Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/HEME/82911_NodularlymphpredomHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large multilobated L&amp;H cells can be seen in this field. Most of the L&amp;H cells in this case had distinct or prominent eosinophilic nucleoli, unlike classic \"popcorn\" cells. Hematoxylin and eosin stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Hodgkin lymphoma: Nodular lymphocyte predominant. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82911 Version 7.0</div></div></div>"},"82917":{"type":"graphic_figure","displayName":"Loa loa life cycle","title":"<EM>Loa loa</EM> life cycle","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\"><EM>Loa loa</EM> life cycle</div><div class=\"cntnt\"><img style=\"width:525px; height:432px;\" src=\"images/ID/82917_Loa_loa_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vector for <EM>Loa loa</EM> filariasis are flies from two species of the genus <EM>Chrysops</EM>, <EM>C. silacea</EM> and <EM>C. dimidiata</EM>. During a blood meal, an infected fly (genus <EM>Chrysops</EM>, day-biting flies) introduces third-stage filarial larvae onto the skin of the human host, where they penetrate into the bite wound <STRONG>(1)</STRONG>. The larvae develop into adults that commonly reside in subcutaneous tissue <STRONG>(2)</STRONG>. The female worms measure 40 to 70 mm in length and 0.5 mm in diameter, while the males measure 30 to 34 mm in length and 0.35 to 0.43 mm in diameter. Adults produce microfilariae measuring 250 to 300 mcm by 6 to 8 mcm, which are sheathed and have diurnal periodicity. Microfilariae have been recovered from spinal fluids, urine, and sputum. During the day, they are found in peripheral blood, but, during the noncirculation phase, they are found in the lungs <STRONG>(3)</STRONG>. The fly ingests microfilariae during a blood meal <STRONG>(4)</STRONG>. After ingestion, the microfilariae lose their sheaths and migrate from the fly's midgut through the hemocoel to the thoracic muscles of the arthropod <STRONG>(5)</STRONG>. There the microfilariae develop into first-stage larvae <STRONG>(6)</STRONG> and subsequently into third-stage infective larvae <STRONG>(7)</STRONG>. The third-stage infective larvae migrate to the fly's proboscis <STRONG>(8)</STRONG> and can infect another human when the fly takes a blood meal <STRONG>(1)</STRONG>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Loiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/loiasis/\">http://www.cdc.gov/dpdx/loiasis/</A>.</div><div id=\"graphicVersion\">Graphic 82917 Version 4.0</div></div></div>"},"82918":{"type":"graphic_picture","displayName":"Loa loa eye worm","title":"<EM>Loa loa</EM> eye worm","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\"><EM>Loa loa</EM> eye worm</div><div class=\"cntnt\"><img style=\"width:493px; height:333px;\" src=\"images/ID/82918_Loa_loa_eye_worm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagnosis of loiasis can be established by identifying a migrating adult worm in the subcutaneous tissue or conjunctiva.</div><div class=\"graphic_reference\">Reproduced with permission from: LWW's Organism Central, Koneman EW, Sutton DA, Fothergill AW (Eds), Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82918 Version 3.0</div></div></div>"},"82919":{"type":"graphic_picture","displayName":"Loa loa blood smear","title":"<EM>Loa loa </EM>blood smear","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\"><EM>Loa loa </EM>blood smear</div><div class=\"cntnt\"><img style=\"width:584px; height:201px;\" src=\"images/ID/82919_Loa_loa_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Microfilaria of <EM>L. loa</EM> in a thin blood smear, stained with Giemsa.<br />(B) Microfilaria of <EM>L. loa</EM> in a thick blood smear from a patient from Cameroon, stained with Giemsa. Note the nuclei extending to the tip of the tail to the left of the image.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Loiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/loiasis/index.html\">http://www.cdc.gov/dpdx/loiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 82919 Version 4.0</div></div></div>"},"82920":{"type":"graphic_figure","displayName":"M perstans lifecycle","title":"Mansonella perstans lifecycle","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Mansonella perstans lifecycle</div><div class=\"cntnt\"><img style=\"width:537px; height:452px;\" src=\"images/ID/82920_Mansonella_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a blood meal, an infected midge (genus <EM>Culicoides</EM>) introduces third-stage filarial larvae onto the skin of the human host, where they penetrate into the bite wound <STRONG>(1)</STRONG>. They develop into adults that reside in body cavities, most commonly the peritoneal cavity or pleural cavity, but less frequently in the pericardium <STRONG>(2)</STRONG>. The size range for female worms is 70 to 80 mm in length and 120 mcm in diameter, and the males measure approximately 45 mm by 60 mcm. Adults produce unsheathed and subperiodic microfilariae, measuring 200 by 4.5 mcm, which reach the blood stream <STRONG>(3)</STRONG>. A midge ingests microfilariae during a blood meal <STRONG>(4)</STRONG>. After ingestion, the microfilariae migrate from the midge's midgut through the hemocoel to the thoracic muscles of the arthropod <STRONG>(5)</STRONG>. There the microfilariae develop into first-stage larvae <STRONG>(6)</STRONG> and subsequently into third-stage infective larvae <STRONG>(7)</STRONG>. The third-stage infective larvae migrate to the midge's proboscis <STRONG>(8)</STRONG> and can infect another human when the midge takes a blood meal <STRONG>(1)</STRONG>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Mansonellosis. Available at: <A href=\"http://www.cdc.gov/dpdx/mansonellosis/index.html\">http://www.cdc.gov/dpdx/mansonellosis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 82920 Version 6.0</div></div></div>"},"82922":{"type":"graphic_waveform","displayName":"J point","title":"J point","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">J point</div><div class=\"cntnt\"><img style=\"width:514px; height:394px;\" src=\"images/CARD/82922_J_point.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The J point is the junction between the end of the QRS and the beginning of the ST segment.</div><div id=\"graphicVersion\">Graphic 82922 Version 2.0</div></div></div>"},"82924":{"type":"graphic_table","displayName":"Types of inborn errors of metabolism","title":"Types of inborn errors of metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of inborn errors of metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Disorders of intermediary metabolism</td> </tr> <tr> <td>Amino acid metabolism and transport</td> </tr> <tr> <td>Fatty acid oxidation and ketogenesis</td> </tr> <tr> <td>Carbohydrate metabolism and transport</td> </tr> <tr> <td>Vitamin related (cobalamin, folate)</td> </tr> <tr> <td>Peptide metabolism</td> </tr> <tr> <td>Mineral metabolism</td> </tr> <tr> <td>Mitochondrial energy metabolism</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of biosynthesis and breakdown of complex molecules</td> </tr> <tr> <td>Purine and pyrimidine metabolism</td> </tr> <tr> <td>Lysosomal storage</td> </tr> <tr> <td>Peroxisomes</td> </tr> <tr> <td>Isoprenoid and sterol metabolism</td> </tr> <tr> <td>Bile acid and heme metabolism</td> </tr> <tr> <td>Glycosylation</td> </tr> <tr> <td>Lipoprotein metabolism</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of neurotransmitter metabolism</td> </tr> <tr> <td>Glycine and serine metabolism</td> </tr> <tr> <td>Pterin and biogenic amine metabolism</td> </tr> <tr> <td>Gamma-aminobutyrate metabolism</td> </tr> <tr> <td>Other (eg, pyridoxine-dependent or folinic acid-dependent seizures, sulfite oxidase deficiency)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Hoffman GF, Nyhan WL, Zschocke J, et al. Inherited metabolic diseases, Lippincott Williams &amp; Wilkins, Philadelphia 2002.</div><div id=\"graphicVersion\">Graphic 82924 Version 2.0</div></div></div>"},"82925":{"type":"graphic_picture","displayName":"DLBCL immunoblast variant","title":"Immunoblast variant of diffuse large B-cell lymphoma in a lymph node biopsy","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Immunoblast variant of diffuse large B-cell lymphoma in a lymph node biopsy</div><div class=\"cntnt\"><img style=\"width:502px; height:375px;\" src=\"images/HEME/82925_DLBCLimmunoblastvariant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tumor cells show large vesicular nuclei with single prominent nucleolus and moderate amount of cytoplasm. Hematoxylin and eosin, 100x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application, case 32 diffuse large B-cell lymphoma. In: Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82925 Version 6.0</div></div></div>"},"82926":{"type":"graphic_picture","displayName":"DLBCL centroblast variant","title":"Centroblast variant of diffuse large B-cell lymphoma in a lymph node biopsy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Centroblast variant of diffuse large B-cell lymphoma in a lymph node biopsy</div><div class=\"cntnt\"><img style=\"width:504px; height:318px;\" src=\"images/HEME/82926_DLBCLcentroblastvariant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tumor cells show large round or oval nuclei with multiple membrane-bound nucleoli (arrow) and scanty cytoplasm. Hematoxylin and eosin, 100x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application, case 32 diffuse large B-cell lymphoma. In: Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82926 Version 6.0</div></div></div>"},"82928":{"type":"graphic_table","displayName":"Vibrio cases by species in the US, 2014","title":"Numbers of <EM>Vibrio</EM> infections by species and complications in the United States in 2014*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Numbers of <EM>Vibrio</EM> infections by species and complications in the United States in 2014*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Hospitalizations (%)</td> <td class=\"subtitle1\">Deaths (%)</td> </tr> <tr> <td><em>V. parahaemolyticus</em></td> <td class=\"centered\">605</td> <td class=\"centered\">15</td> <td class=\"centered\">1</td> </tr> <tr> <td><em>V. vulnificus</em></td> <td class=\"centered\">124</td> <td class=\"centered\">79</td> <td class=\"centered\">18</td> </tr> <tr> <td><em>V. cholerae</em> (non-toxigenic)&#182;</td> <td class=\"centered\">80</td> <td class=\"centered\">46</td> <td class=\"centered\">5</td> </tr> <tr> <td><em>V. alginolyticus</em></td> <td class=\"centered\">239</td> <td class=\"centered\">14</td> <td class=\"centered\">0</td> </tr> <tr> <td><em>V. fluvialis</em></td> <td class=\"centered\">71</td> <td class=\"centered\">37</td> <td class=\"centered\">2</td> </tr> <tr> <td><em>V. mimcus</em></td> <td class=\"centered\">31</td> <td class=\"centered\">57</td> <td class=\"centered\">3</td> </tr> <tr> <td><em>G. hollisae</em></td> <td class=\"centered\">10</td> <td class=\"centered\">40</td> <td class=\"centered\">0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* <EM>Vibrio </EM>species with 10 or more reported cases.&nbsp;<br />¶ Includes non-toxigenic <EM>V. cholerae</EM> non-O1, non-O139 (78 cases) and O1 (2 cases).</div><div class=\"graphic_reference\">Data from: Cholera and Other Vibrio Illness (COVIS) Annual Summary, 2014. Centers for Disease Control and Prevention. Available at: <a href=\"https://www.cdc.gov/vibrio/surveillance.html\" target=\"_blank\">https://www.cdc.gov/vibrio/surveillance.html</a> (Accessed on May 4, 2017).</div><div id=\"graphicVersion\">Graphic 82928 Version 6.0</div></div></div>"},"82929":{"type":"graphic_figure","displayName":"Prevalence of atrial fibrillation by sex and age","title":"Prevalence of atrial fibrillation by sex and age","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Prevalence of atrial fibrillation by sex and age</div><div class=\"cntnt\"><img style=\"width:575px; height:377px;\" src=\"images/CARD/82929_Prev_atrial_fibrill_sex_age.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lifetime risk for developing atrial fibrillation (AF) from the Framingham Heart Study. Men and women without AF at 40 years of age were determined to have a 26 and 23 percent likelihood of developing incident AF by 80 years of age.</div><div class=\"graphic_reference\">Reproduced with permission from: Magnani JW, Rienstra M, Lin H, et al. Atrial fibrillation: Current knowledge and future directions in epidemiology and genomics. Circulation 2011; 124:1982. Copyright &copy; Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82929 Version 4.0</div></div></div>"},"82930":{"type":"graphic_picture","displayName":"Cryptococcus lung histopathology","title":"<EM>Cryptococcus</EM> pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\"><EM>Cryptococcus</EM> pneumonitis</div><div class=\"cntnt\"><img style=\"width:582px; height:331px;\" src=\"images/ID/82930_Cryptococcuslunghistopath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Photomicrograph of a biopsy specimen shows interstitial pneumonitis. Alveolar airspaces are filled with numerous macrophages containing small, cyst-like spaces (arrows).<BR>(B) Magnified view shows the spaces to contain clusters of oval to round yeasts that have mucicarmine positive capsules (arrows). The patient was a 61-year-old man.</div><div class=\"graphic_reference\">Reproduced with permission from: Müller NL, Fraser RS, Soo Lee K, Johkoh T. Pulmonary Infection. In: Diseases of the Lung: Radiologic and Pathologic Correlations. Lippincott Williams &amp; Wilkins, Philadelphia 2003.&nbsp;Copyright © 2003 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82930 Version 7.0</div></div></div>"},"82933":{"type":"graphic_figure","displayName":"STRAW staging system for reproductive aging women","title":"The Stages of Reproductive Aging Workshop +10 staging system for reproductive aging in women","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">The Stages of Reproductive Aging Workshop +10 staging system for reproductive aging in women</div><div class=\"cntnt\"><img style=\"width:720px; height:496px;\" src=\"images/ENDO/82933_STRAW_stage_age_W.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FMP: final menstrual period; FSH: follicle-stimulating hormone; AMH: anti-müllerian hormone; Arrow: elevated.<br />* Blood draw on cycle days 2 to 5.<br />¶ Approximate expected level based on assays using current international pituitary standard.</div><div class=\"graphic_reference\">Reproduced with permission from: Harlow SD, Gass M, Hall JE, et al. Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging. J Clin Endocrinol Metab 2012. Copyright &copy; 2012 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 82933 Version 6.0</div></div></div>"},"82935":{"type":"graphic_figure","displayName":"Pregnancy terms PI","title":"Pregnancy terms","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Pregnancy terms</div><div class=\"cntnt\"><img style=\"width:540px; height:626px;\" src=\"images/PI/82935_Pregnancy_terms_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows a baby inside the mother's uterus (womb) late in pregnancy.</div><div id=\"graphicVersion\">Graphic 82935 Version 4.0</div></div></div>"},"82936":{"type":"graphic_figure","displayName":"Amplatzer plug","title":"Amplatzer plug","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amplatzer plug</div><div class=\"cntnt\"><img style=\"width:416px; height:583px;\" src=\"images/CARD/82936_Amplatzer_plug.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Amplatzer cardiac plug.<br />(B) Amplatzer cardiac plug in anatomical position.</div><div class=\"graphic_reference\">Reproduced from: Jain AK, Gallagher S. Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism: NICE guidance. Heart 2011; 97:762, with permission from BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 82936 Version 4.0</div></div></div>"},"82937":{"type":"graphic_diagnosticimage","displayName":"MRI urethral diverticulum1","title":"Magnetic resonance image of female urethral diverticulum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of female urethral diverticulum</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/OBGYN/82937_MRI_ureth_divert_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2 axial contrast enhanced&nbsp;magnetic resonance&nbsp;image shows a diverticulum (arrows) wrapped around the urethra.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 82937 Version 2.0</div></div></div>"},"82938":{"type":"graphic_diagnosticimage","displayName":"MRI urethral diverticulum2","title":"Magnetic resonance image of female urethral diverticulum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of female urethral diverticulum</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/OBGYN/82938_MRI_ureth_divert_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2 coronal contrast enhanced magnetic resonance&nbsp;image shows a diverticulum (arrow) wrapped around the urethra.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 82938 Version 2.0</div></div></div>"},"82939":{"type":"graphic_diagnosticimage","displayName":"MRI urethral diverticulum3","title":"Magnetic resonance image of female urethral diverticulum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of female urethral diverticulum</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/OBGYN/82939_MRI_ureth_divertic_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T1 axial contrast enhanced&nbsp;magnetic resonance&nbsp;image shows a diverticulum (arrows) wrapped around the urethra.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 82939 Version 2.0</div></div></div>"},"82950":{"type":"graphic_figure","displayName":"Looping during colonoscopy","title":"Looping during colonoscopy","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Looping during colonoscopy</div><div class=\"cntnt\"><img style=\"width:534px; height:364px;\" src=\"images/GAST/82950_Looping-during-colonoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;(on left) Shows a \"gamma\" loop in the transverse colon.<BR>(B) (on right) Shows an \"alpha\" loop in the sigmoid colon.</div><div id=\"graphicVersion\">Graphic 82950 Version 2.0</div></div></div>"},"82951":{"type":"graphic_table","displayName":"United States recommendations for cervical cancer screening","title":"Cervical cancer screening recommendations from United States professional organizations*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cervical cancer screening recommendations from United States professional organizations*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Organization</td> <td class=\"subtitle1\" rowspan=\"2\">Age to initiate</td> <td class=\"subtitle1\" rowspan=\"2\">Age to discontinue</td> <td class=\"subtitle1\" colspan=\"2\">Recommended screening test and frequency</td> <td class=\"subtitle1\" rowspan=\"2\">Post-hysterectomy for benign disease</td> <td class=\"subtitle1\" rowspan=\"2\">HPV vaccination</td> </tr> <tr> <td class=\"subtitle2\">Age 21 to 29</td> <td class=\"subtitle2\">Age &#8805;30</td> </tr> <tr> <td rowspan=\"2\">ACS/ASCCP/ASCP (2012)</td> <td rowspan=\"2\">21<sup>&#182;</sup></td> <td rowspan=\"2\">65<sup>&#916;</sup></td> <td rowspan=\"2\"> <p>Pap&nbsp;test&nbsp;every three years (preferred) </p> <p>&nbsp;</p> </td> <td>Co-testing&nbsp;(pap test and HPV testing)&nbsp;every five years (preferred)</td> <td rowspan=\"2\">Not indicated<sup>&#9674;</sup></td> <td rowspan=\"2\">Same recommendations as unvaccinated women</td> </tr> <tr> <td>Pap&nbsp;test every three years </td> </tr> <tr> <td>ASCCP/SGO (2015 interim guidelines) </td> <td>&nbsp;21</td> <td>&nbsp;N/A</td> <td>Can consider primary HPV testing every three years for women&nbsp;age&nbsp;&#8805;25&nbsp;</td> <td>Can consider primary HPV testing every three years</td> <td>&nbsp;N/A</td> <td>N/A</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">USPSTF (2012)</td> <td rowspan=\"2\">21</td> <td rowspan=\"2\">65<sup>&#167;</sup></td> <td rowspan=\"2\">Pap&nbsp;test&nbsp;every three years</td> <td>Pap&nbsp;test&nbsp;every three years</td> <td rowspan=\"2\">Not indicated<sup>&#135;</sup></td> <td rowspan=\"2\">Same recommendations as unvaccinated women</td> </tr> <tr> <td>Alternative: Co-testing&nbsp;(pap test and HPV testing)&nbsp;every five years<sup>&#165;</sup></td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">ACOG (2016)</td> <td rowspan=\"3\">21</td> <td rowspan=\"3\">65<sup>&#134;</sup></td> <td>Pap&nbsp;test&nbsp;every three years</td> <td>Co-testing (pap test and HPV&nbsp;testing)&nbsp;every five years (preferred)</td> <td rowspan=\"3\">Not indicated**</td> <td rowspan=\"3\">Same recommendations as unvaccinated women</td> </tr> <tr> <td rowspan=\"2\">Can consider primary HPV testing every three years for women&nbsp;age&nbsp;&#8805;25&nbsp;</td> <td>Pap&nbsp;test&nbsp;every three years</td> </tr> <tr> <td>Can consider primary HPV testing every three years for women&nbsp;age&nbsp;&#8805;25&nbsp;</td> </tr> <tr> <td rowspan=\"2\">&nbsp;ACP (2015)</td> <td rowspan=\"2\">&nbsp;21</td> <td rowspan=\"2\">65<sup>&#167;</sup></td> <td rowspan=\"2\">Pap test every three years</td> <td>Pap&nbsp;test&nbsp;every three years</td> <td rowspan=\"2\">Not indicated<sup><span style=\"font-size: 13px;\">&#135;</span></sup></td> <td rowspan=\"2\">&nbsp;N/A</td> </tr> <tr> <td>Alternative: Co-testing&nbsp;(pap test and HPV testing)&nbsp;every five years<sup><span style=\"font-size: 13px;\">&#165;</span></sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPV: human papillomavirus; ACS: American Cancer Society; ASCCP: American Society for <SPAN style=\"COLOR: black\">Colposcopy and Cervical Pathology; ASCP: American Society for Clinical Pathology; SGO: Society of Gynecologic Oncology; USPSTF</SPAN>: United States Preventive Services Task Force; ACOG: American College of Obstetricians and Gynecologists; ACP: American College of Physicians; <FONT color=black>DES:</FONT><FONT color=black> diethylstilbestrol; HIV: human immunodeficiency virus; CIN: cervical intraepithelial neoplasia.</FONT><br />* These guidelines are intended for the general population and are not intended for women who have a history of cervical cancer, high-grade cervical precancers, DES in utero exposure, or who are immunocompromised, as with HIV infection.<br />¶&nbsp;Regardless of the age of sexual initiation or other risk factors.<br />Δ For women with evidence of adequate negative prior screening (three consecutive negative cytology results or two consecutive negative co-tests with the previous 10 years, with the most recent test within the previous 5 years) and no history of CIN 2 or greater within the last 20 years. Screening should not be resumed for any reason, even if a woman has a new sexual partner.<br /><FONT class=lozenge>◊</FONT> For women who have had a benign hysterectomy with removal of the cervix who do not have a history of CIN 2, CIN 3 in the past 20 years, or a history of cervical cancer ever. Evidence of adequate negative prior screening not required.<br />§ For women with evidence of adequate negative prior screening, specified as three consecutive negative cytology results or two consecutive negative co-tests within the previous 10 years, with the most recent test within the previous 5 years.<br />¥ For women who want to lengthen the screening interval.<br />‡ For women who have had a benign hysterectomy with removal of the cervix who do not have a history of CIN 2 or higher.<br />† For women with no history of CIN 2 or higher with evidence of prior adequate screening (three or more negative cytology test results in a row or two consecutive negative co-tests in the past 10 years, with the most recent within the past 5 years).<br />** For women who have had a benign hysterectomy with removal of the cervix who do not have a history of CIN 2, CIN 3, or cervical cancer. Women in whom a negative history cannot be documented should continue to be screened.</div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62:147.</LI>&#xD;&#xA;<LI>Moyer VA. Screening for cervical cancer: United States Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156:880.</LI>&#xD;&#xA;<LI>Cervical cytology screening. ACOG Practice Bulletin No. 157. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016; 127:e1</LI>&#xD;&#xA;<LI>Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. Gynecol Oncol 2015; 136:178.&nbsp;<A href=\"http://dx.doi.org/10.1016/j.ygyno.2014.12.022\">http://dx.doi.org/10.1016/j.ygyno.2014.12.022</A></LI>&#xD;&#xA;<LI>Sawaya GF, Kulasingam S, Denberg TD, et al. Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2015; 162:851.</LI></OL></div><div id=\"graphicVersion\">Graphic 82951 Version 15.0</div></div></div>"},"82953":{"type":"graphic_figure","displayName":"Newborn appearance PI","title":"Normal newborn appearance","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Normal newborn appearance</div><div class=\"cntnt\"><img style=\"width:538px; height:362px;\" src=\"images/PI/82953_Newborn-appearance-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows some of the features that are common in healthy newborns.</div><div id=\"graphicVersion\">Graphic 82953 Version 1.0</div></div></div>"},"82955":{"type":"graphic_table","displayName":"Parental deployment resources","title":"Resources for military families affected by parental deployment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for military families affected by parental deployment</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p><strong>American Academy of Pediatrics</strong></p> <p><a href=\"http://www.healthychildren.org/English/family-life/work-play/Pages/Caring-for-Military-Children-Video.aspx\" target=\"_blank\">www.healthychildren.org/English/family-life/work-play/Pages/Caring-for-Military-Children-Video.aspx</a></p> <p>Provides resources for military families and professionals caring for military families</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Military Child Education Coalition</strong></p> <p><a href=\"http://www.militarychild.org/\" target=\"_blank\">www.militarychild.org</a></p> <p>Nonprofit organization that increases awareness of and implements programs to meet the challenges facing military children</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Military One Source</strong></p> <p><a href=\"http://www.militaryonesource.mil/\" spellcheck=\"true\" target=\"_blank\">www.militaryonesource.mil</a></p> <p>(telephone: 1-800-342-9647)</p> <p>Provides a range of services to active duty and reserve members and their families (including help with child care, personal finances, relocation information, etc)</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>National Guard Family Program</strong></p> <p><a href=\"http://www.jointservicessupport.org/FP/Default.aspx\" spellcheck=\"true\" target=\"_blank\">www.jointservicessupport.org/FP/Default.aspx</a></p> <p>Provides links to resources for National Guard families living away from military installations</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>National Military Family Association Operation Purple Program</strong></p> <p><a href=\"http://www.militaryfamily.org/kids-operation-purple/camps/\" spellcheck=\"true\" target=\"_blank\">www.militaryfamily.org/kids-operation-purple/camps</a></p> <p>Provides free summer camps for children and adolescents experiencing parental deployment</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Sesame Street Workshop: Talk, listen, connect</strong></p> <p><a href=\"http://www.sesameworkshop.org/what-we-do/our-initiatives/military-families/\" spellcheck=\"true\" target=\"_blank\">www.sesameworkshop.org/what-we-do/our-initiatives/military-families/</a></p> <p>English and Spanish multimedia outreach program to support military families with young children experiencing deployments, combat-related injury, or death</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Tragedy Assistance Program for Survivors</strong></p> <p><a href=\"http://www.taps.org/\" target=\"_blank\">www.taps.org</a></p> <p>Provides assistance for families who are grieving the death of a military service member</p> </td> </tr> <tr> <td> <p><strong>Zero to Three Coming Together Around Military Families</strong></p> <p><a href=\"http://www.zerotothree.org/about-us/funded-projects/military-families\" target=\"_blank\">www.zerotothree.org/about-us/funded-projects/military-families</a></p> <p>Aims at strengthening the resilience of young children and families who are experiencing deployment</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 82955 Version 4.0</div></div></div>"},"82956":{"type":"graphic_table","displayName":"Characteristics of military youth","title":"Characteristics of military youth during military deployment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of military youth during military deployment</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">During deployment, military youth:</td> </tr> <tr> <td>Demonstrate significant resiliency and adaptive responses in dealing with the challenges of military deployment</td> </tr> <tr> <td>Demonstrate great maturity as they take on more responsibilities at home</td> </tr> <tr> <td>Are aware of the dangers associated with deployment and ways in which their lives are changed as a result of parental deployment</td> </tr> <tr> <td>Feel as if they serve and sacrifice for their country and incorporate this concept positively into their sense of identity</td> </tr> <tr> <td>Report that deployment changes daily routines, requiring sacrifice of extracurricular activities or programs because of transportation issues or financial limitations</td> </tr> <tr> <td>Report behavior changes such as decreasing school performance and symptoms consistent with depression</td> </tr> <tr> <td>Tend to feel isolated with respect to their family deployment situation</td> </tr> <tr> <td>Demonstrate enhanced resiliency when they feel well connected and supported</td> </tr> <tr> <td>Are wary of the type of support offered by others and quick to detect instances of insincerity</td> </tr> <tr> <td>Have a great deal of access to their deployed family member through email or phone contact</td> </tr> <tr> <td>Feel the media do not report war-related events accurately</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics in Review, Vol. 30, Pages e42-e48, Copyright © 2009 by the AAP.</div><div id=\"graphicVersion\">Graphic 82956 Version 10.0</div></div></div>"},"82960":{"type":"graphic_figure","displayName":"Urinary tract adult PI","title":"Urinary tract in adults","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Urinary tract in adults</div><div class=\"cntnt\"><img style=\"width:508px; height:335px;\" src=\"images/PSYCH/82960_urinary_tract_adult_pi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures show the organs of the urinary tract in a woman and a man. Urine is made in the kidneys, and then flows down the ureters to the bladder. In a person with vesicoureteral reflux, some urine flows backwards from the bladder towards the kidneys through the ureter.</div><div id=\"graphicVersion\">Graphic 82960 Version 1.0</div></div></div>"},"82965":{"type":"graphic_table","displayName":"Causes of hydrocephalus in infants and children","title":"Common causes of hydrocephalus in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of hydrocephalus in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Communicating hydrocephalus</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Permanent impaired absorption:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Primary congenital hydrocephalus </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist2\">Malformed brain</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist2\">Developmental/genetic association</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Secondary prenatal hydrocephalus </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist2\">Posthemorrhagic</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist2\">Postinfectious</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Secondary postnatal hydrocephalus</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist2\">Prematurity-related</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist2\">Posthemorrhagic</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist2\">Postinfectious</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist2\">Venous congestion: craniosynostosis, achondroplasia</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist2\">Venous thrombosis: superior vena cava obstruction after cardiac surgery</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Increased secretion: Choroid plexus papilloma/carcinoma</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Communicating hydrocephalus, with an obstructive component</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Tumors</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Intraventricular hemorrhage resulting in a clot at aqueduct or fibrosis of aqueduct (acute phase)*</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Intraventricular hemorrhage resulting in intracranial cysts (acute phase)*</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Infection resulting in intracranial cysts</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Meningitis/encephalitis resulting in secondary obstruction*</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Chiari 2 malformation</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Dandy Walker malformation</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Holoprosencephaly: lobar, semilobar, alobar</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Encephalocele</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Lissencephaly</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hydranencephaly</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Obstructive hydrocephalus, with a transient minor communicating component</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Same as group 2, subacute or late phase (at least several months from primary insult: infection, bleed)*</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Large arachnoid cysts</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Chromosomal abnormalities, syndromic, genetic:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">X-linked hydrocephalus (mostly aqueductal stenosis)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Osteogenesis imperfecta</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Craniofacial syndromic disorders</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Part of metabolic inherited disease:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Hurler's disease (MPS T1)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Achondroplasia</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Obstructive hydrocephalus (pure)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Intracranial cysts with no evidence of bleed at diagnosis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Triventricular hydrocephalus due to radiologically apparent aqueductal stenosis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Membranous obstruction of aqueduct</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Asymmetrical hydrocephalus, due to atresia of the foramen of Monro</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Obstruction of fourth ventricle outlets</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">* In these disorders, the communicating component is initially prominent, but tends to decrease over time, so that the obstructive component predominates in the later phases.</div><div class=\"graphic_reference\">Reproduced from: Beni-Adani L, Biani N, Ben-Sirah L, Constantini S. The occurrence of obstructive vs absorptive hydrocephalus in newborns and infants: relevance to treatment choices. Childs Nerv Syst 2006; 22:1543; with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 82965 Version 4.0</div></div></div>"},"82968":{"type":"graphic_picture","displayName":"Atrophie blanche on foot","title":"Atrophie blanche","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Atrophie blanche</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/82968_Atrophie_blanche_on_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrophic, white, stellate scars consistent with atrophie blanche are present on the lower extremity in this patient with livedoid vasculitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82968 Version 4.0</div></div></div>"},"82969":{"type":"graphic_picture","displayName":"Atrophie blanche skin changes","title":"Atrophie blanche","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Atrophie blanche</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/82969_Atroph_blan_skin_change.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrophic, white, stellate scars consistent with atrophie blanche are present on the lower extremity in this patient with livedoid vasculitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82969 Version 4.0</div></div></div>"},"82970":{"type":"graphic_algorithm","displayName":"Emotional cycle of deployment","title":"Emotional cycle of deployment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Emotional cycle of deployment</div><div class=\"cntnt\"><img style=\"width:282px; height:679px;\" src=\"images/PEDS/82970_Emot_cycle_deploy.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from Logan KV. The emotional cycle of deployment. Available at: <A href=\"http://www.usni.org/magazines/proceedings/1987-02/emotional-cycle-deployment\" target=_blank>www.usni.org/magazines/proceedings/1987-02/emotional-cycle-deployment</A> Accessed on March 15, 2012.</div><div id=\"graphicVersion\">Graphic 82970 Version 4.0</div></div></div>"},"82973":{"type":"graphic_table","displayName":"Drug therapy for treatment of histoplasmosis infections in HIV","title":"Drug therapy for treatment and chronic maintenance therapy of AIDS-associated histoplasma capsulatum infections in adults and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug therapy for treatment and chronic maintenance therapy of AIDS-associated histoplasma capsulatum infections in adults and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Preferred therapy, duration of therapy, chronic maintenance</td>\r\n            <td class=\"subtitle1\">Alternative therapy</td>\r\n            <td class=\"subtitle1\">Other options/issues</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p><strong>Preferred therapy for moderately severe to severe disseminated disease</strong></p>\r\n            <p><em>Induction therapy</em> (for 2 weeks or until clinically improved) </p>\r\n            <ul>\r\n                <li>Liposomal amphotericin B at 3 mg/kg IV daily </li>\r\n            </ul>\r\n            <p>&nbsp;</p>\r\n            <p><em>Maintenance therapy</em></p>\r\n            <ul>\r\n                <li>Itraconazole 200 mg PO tid for 3 days, then bid </li>\r\n            </ul>\r\n            <p>&nbsp;</p>\r\n            <p><strong>Preferred therapy for less severe disseminated disease</strong></p>\r\n            <p><em>Induction and maintenance therapy</em></p>\r\n            <ul>\r\n                <li>Itraconazole 200 mg PO tid for 3 days, then 200 mg PO bid </li>\r\n            </ul>\r\n            <p>Duration of therapy: at least 12 months</p>\r\n            <p>&nbsp;</p>\r\n            <p><strong>Preferred therapy for meningitis</strong></p>\r\n            <p><em>Induction therapy</em> (4-6 weeks)</p>\r\n            <ul>\r\n                <li>Liposomal amphotericin B 5 mg/kg/day </li>\r\n            </ul>\r\n            <p>&nbsp;</p>\r\n            <p><em>Maintenance therapy</em></p>\r\n            <ul>\r\n                <li>Itraconazole 200 mg PO bid-tid for &#8805;1 year and until resolution of abnormal CSF findings </li>\r\n            </ul>\r\n            <p>&nbsp;</p>\r\n            <p><strong>Preferred therapy for long term suppression therapy</strong></p>\r\n            <p>In patients with severe disseminated or CNS infection and in patients who relapse despite appropriate therapy (CIII)</p>\r\n            <ul>\r\n                <li>Itraconazole 200 mg PO daily </li>\r\n            </ul>\r\n            </td>\r\n            <td>\r\n            <p><strong>Alternative therapy moderately severe to severe disseminated disease </strong></p>\r\n            <p><em>Induction therapy</em> (for 2 weeks or until clinically improved) </p>\r\n            <ul>\r\n                <li>Amphotericin B deoxycholate 0.7 mg/kg IV daily </li>\r\n                <li>Amphotericin B lipid complex 5 mg/kg IV daily </li>\r\n            </ul>\r\n            <p>&nbsp;</p>\r\n            <p><em>Maintenance therapy</em></p>\r\n            <p>Same as \"Preferred therapy\"</p>\r\n            </td>\r\n            <td>\r\n            <p>Itraconazole levels should be obtained in all patients to ensure adequate absorption. Serum concentrations of itraconazole + hydroxyitraconazole should be &#62;1 mcg/mL. </p>\r\n            <p>Itraconazole oral solution is preferred over capsule by certain specialists because of&nbsp;improved absorption</p>\r\n            <p>Acute pulmonary histoplasmosis in HIV- infected patients with CD4+ count &#62;300 cells/microL should be managed as non-immunocompromised host</p>\r\n            </td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2009; 58:1.</div><div id=\"graphicVersion\">Graphic 82973 Version 2.0</div></div></div>"},"82975":{"type":"graphic_picture","displayName":"Endometrial tissue on the thoracic surface of the diaphragm ","title":"Endometrial tissue on the thoracic surface of the diaphragm ","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Endometrial tissue on the thoracic surface of the diaphragm </div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/PULM/82975_Endotissthoracdiaph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thoracoscopic image of endometrial tissue on the thoracic surface of the diaphragm.</div><div class=\"graphic_reference\">From: Ciriaco P, Negri G, Libretti L, et al. Surgical treatment of catamenial pneumothorax: a single centre experience, Interact Cardiovasc Thorac Surg 2009; 8:349. By permission of the European Association for Cardio-Thoracic Surgery. Copyright © 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 82975 Version 11.0</div></div></div>"},"82985":{"type":"graphic_figure","displayName":"Aortic coarctation children PI","title":"Aortic coarctation in a child","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Aortic coarctation in a child</div><div class=\"cntnt\"><img style=\"width:541px; height:633px;\" src=\"images/PI/82985_Aortic-coarctation-children-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The aorta is the main artery that delivers blood from the heart to the body. Aortic coarctation is a heart defect that causes the aorta to narrow (see arrow).</div><div id=\"graphicVersion\">Graphic 82985 Version 1.0</div></div></div>"},"82990":{"type":"graphic_picture","displayName":"Seborrheic dermatitis peds PI","title":"Seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:315px; height:498px;\" src=\"images/PI/82990_Seborrheic_dermatitis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In babies, seborrheic dermatitis is commonly called \"cradle cap\" when it happens on the scalp.<BR>(B) Seborrheic dermatitis can affect the scalp, face, ears, neck, and diaper area.</div><div class=\"graphic_reference\">Reproduced with permission from: Kenneth Greer, MD.</div><div id=\"graphicVersion\">Graphic 82990 Version 1.0</div></div></div>"},"82991":{"type":"graphic_picture","displayName":"Seborrheic dermatitis face PI","title":"Seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:350px; height:247px;\" src=\"images/PI/82991_Seborrheic_dermatitis_face_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seborrheic dermatitis can cause redness and flaky patches on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's photoguide of common skin disorders, 2nd ed., Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82991 Version 3.0</div></div></div>"},"82992":{"type":"graphic_picture","displayName":"Seborrheic dermatitis scalp PI","title":"Seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PI/82992_Seborrheic_derma_scalp_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dandruff is a mild form of seborrheic dermatitis. It causes white scales or flakes on the head or hair.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82992 Version 4.0</div></div></div>"},"82993":{"type":"graphic_picture","displayName":"Allergic contact dermatitis hand","title":"Allergic contact dermatitis of the hand","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis of the hand</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/82993_Allerg_contact_dermat_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema, vesiculation, and weeping in a patient with acute allergic contact dermatitis of the hands.&nbsp;</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 82993 Version 5.0</div></div></div>"},"82995":{"type":"graphic_table","displayName":"Clinical breakpoints for common Candida spp","title":"Clinical breakpoints for common Candida species","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical breakpoints for common Candida species</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Organism</td>\r\n            <td class=\"subtitle1\" colspan=\"4\">Clinical breakpoints (in mcg/mL)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2\">Susceptible</td>\r\n            <td class=\"subtitle2\">Susceptible dose-dependent</td>\r\n            <td class=\"subtitle2\">Intermediate</td>\r\n            <td class=\"subtitle2\">Resistant</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"5\">C. albicans</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Caspofungin</td>\r\n            <td>&#8804;0.25</td>\r\n            <td>-&nbsp;</td>\r\n            <td>0.5</td>\r\n            <td>&#8805;1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Anidulafungin</td>\r\n            <td>&#8804;0.25</td>\r\n            <td>-&nbsp;</td>\r\n            <td>0.5</td>\r\n            <td>&#8805;1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Micafungin</td>\r\n            <td>&#8804;0.25</td>\r\n            <td>-&nbsp;</td>\r\n            <td>0.5</td>\r\n            <td>&#8805;1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Fluconazole&nbsp;</td>\r\n            <td>&#8804;2.0&nbsp;</td>\r\n            <td>4.0&nbsp;</td>\r\n            <td>-&nbsp;</td>\r\n            <td>&#8805;8&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Itraconazole&nbsp;</td>\r\n            <td>&#8804;0.12&nbsp;</td>\r\n            <td>0.25-0.5&nbsp;</td>\r\n            <td>-&nbsp;</td>\r\n            <td>&#8805;1&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Voriconazole</td>\r\n            <td>&#8804;0.12</td>\r\n            <td>-</td>\r\n            <td>0.25-0.5</td>\r\n            <td>&#8805;1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"5\">C. parapsilosis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Caspofungin</td>\r\n            <td>&#8804;2</td>\r\n            <td>-&nbsp;</td>\r\n            <td>4</td>\r\n            <td>&#8805;8</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Anidulafungin</td>\r\n            <td>&#8804;2</td>\r\n            <td>-&nbsp;</td>\r\n            <td>4</td>\r\n            <td>&#8805;8</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Micafungin</td>\r\n            <td>&#8804;2</td>\r\n            <td>-&nbsp;</td>\r\n            <td>4</td>\r\n            <td>&#8805;8</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Fluconazole&nbsp;&nbsp;&nbsp;&nbsp;</td>\r\n            <td>&#8804;2&nbsp;</td>\r\n            <td>4.0&nbsp;</td>\r\n            <td>-&nbsp;</td>\r\n            <td>&#8805;8&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Voriconazole</td>\r\n            <td>&#8804;0.12</td>\r\n            <td>-</td>\r\n            <td>0.25-0.5</td>\r\n            <td>&#8805;1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"5\">C. tropicalis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Caspofungin</td>\r\n            <td>&#8804;0.25</td>\r\n            <td>-&nbsp;</td>\r\n            <td>0.5</td>\r\n            <td>&#8805;1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Anidulafungin</td>\r\n            <td>&#8804;0.25</td>\r\n            <td>-&nbsp;</td>\r\n            <td>0.5</td>\r\n            <td>&#8805;1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Micafungin</td>\r\n            <td>&#8804;0.25</td>\r\n            <td>-&nbsp;</td>\r\n            <td>0.5</td>\r\n            <td>&#8805;1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Fluconazole&nbsp;</td>\r\n            <td>&#8804;2.0&nbsp;</td>\r\n            <td>4.0&nbsp;</td>\r\n            <td>-&nbsp;</td>\r\n            <td>&#8805;8&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Voriconazole</td>\r\n            <td>&#8804;0.12</td>\r\n            <td>-</td>\r\n            <td>0.25-0.5</td>\r\n            <td>&#8805;1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"5\">C. glabrata</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Caspofungin</td>\r\n            <td>&#8804;0.12</td>\r\n            <td>-&nbsp;</td>\r\n            <td>0.25</td>\r\n            <td>&#8805;0.5</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Anidulafungin</td>\r\n            <td>&#8804;0.12</td>\r\n            <td>-&nbsp;</td>\r\n            <td>0.25</td>\r\n            <td>&#8805;0.5</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Micafungin</td>\r\n            <td>&#8804;0.06</td>\r\n            <td>-&nbsp;</td>\r\n            <td>0.12</td>\r\n            <td>&#8805;0.25</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Fluconazole&nbsp;</td>\r\n            <td>-&nbsp;</td>\r\n            <td>&#8804;32&nbsp;</td>\r\n            <td>-&nbsp;</td>\r\n            <td>&#8805;64&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"5\">C. krusei</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Caspofungin</td>\r\n            <td>&#8804;0.25</td>\r\n            <td>-&nbsp;</td>\r\n            <td>0.5</td>\r\n            <td>&#8805;1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Anidulafungin</td>\r\n            <td>&#8804;0.25</td>\r\n            <td>-&nbsp;</td>\r\n            <td>0.5</td>\r\n            <td>&#8805;1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Micafungin</td>\r\n            <td>&#8804;0.25</td>\r\n            <td>-&nbsp;</td>\r\n            <td>0.5</td>\r\n            <td>&#8805;1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Fluconazole*&nbsp;</td>\r\n            <td>-&nbsp;</td>\r\n            <td>-&nbsp;</td>\r\n            <td>-&nbsp;</td>\r\n            <td>-&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Voriconazole</td>\r\n            <td>&#8804;0.5</td>\r\n            <td>-</td>\r\n            <td>1</td>\r\n            <td>&#8805;2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"5\">C. guilliermondii</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Caspofungin</td>\r\n            <td>&#8804;2</td>\r\n            <td>-</td>\r\n            <td>4</td>\r\n            <td>&#8805;8</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Anidulafungin</td>\r\n            <td>&#8804;2</td>\r\n            <td>-</td>\r\n            <td>4</td>\r\n            <td>&#8805;8</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Micafungin</td>\r\n            <td>&#8804;2</td>\r\n            <td>-</td>\r\n            <td>4</td>\r\n            <td>&#8805;8</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_lgnd\">24-h 100 percent, MIC endpoints read as 100 percent inhibition at 24-h incubation; 24-h 50 percent, MIC endpoints read as 50 percent inhibition at 24-h incubation.</div><div class=\"graphic_footnotes\">WT: wild-type.<br />* Fluconazole breakpoints are not available for C. krusei since this species is considered intrinsically resistant to this compound. All strains should be reported as resistant.</div><div class=\"graphic_reference\">Data compiled from:<br /><OL>&#xD;&#xA;<LI>Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13:180.</LI>&#xD;&#xA;<LI>Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14:164.</LI>&#xD;&#xA;<LI>Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011; 70:330.</LI>&#xD;&#xA;<LI>Pfaller MA, Boykem L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 2010; 48:52.</LI>&#xD;&#xA;<LI>Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J Clin Microbiol 2011; 49:630.</LI>&#xD;&#xA;<LI>Pfaller MA, Castanheira M, Diekema DJ, et al. Triazole and echinocandin wild-type MIC distributions with epidemiological cutoff values for six uncommon species of Candida. J Clin Microbiol 2011; 49:3800.</LI>&#xD;&#xA;<LI>Pfaller MA, Espinel-Ingroff A, Canton E, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012; 50:2040.</LI></OL></div><div id=\"graphicVersion\">Graphic 82995 Version 3.0</div></div></div>"},"82996":{"type":"graphic_figure","displayName":"Application of tissue adhesive","title":"Application of tissue adhesive to a superficial laceration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Application of tissue adhesive to a superficial laceration</div><div class=\"cntnt\"><img style=\"width:363px; height:427px;\" src=\"images/EM/82996_Applicationtissueadhesive.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The wound edges are held in apposition with the fingers of the nondominant hand, and adhesive is applied evenly across the entire wound, including a margin of at least 5 to 10 mm on either side of the wound. The left-lower panel depicts incorrect placement of adhesive into the wound, which should be avoided.</div><div class=\"graphic_reference\">Reproduced with permission from: Hollander JE. Use of tissue adhesives in laceration repair. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 82996 Version 6.0</div></div></div>"},"82997":{"type":"graphic_figure","displayName":"Superior view female pelvis","title":"Superior view of the female pelvis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Superior view of the female pelvis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/OBGYN/82997_Sup_view_fem_pelvis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">View of female pelvis during laparotomy. Pelvic posterior cul-de-sac (pouch of Douglas) is well visualized.</div><div id=\"graphicVersion\">Graphic 82997 Version 2.0</div></div></div>"},"82998":{"type":"graphic_figure","displayName":"Sagittal view female pelvis","title":"Sagittal view of female pelvis","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Sagittal view of female pelvis</div><div class=\"cntnt\"><img style=\"width:608px; height:417px;\" src=\"images/OBGYN/82998_Sagittal_view_female_pelvis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal view of the female pelvis. The peritoneal sac drapes over the ovary, reproductive organs, and rectum. The thick body of the uterus transitions to the vagina through a cervix. An archway, or fornix, at the upper end of the vaginal canal surrounds the cervix and brushes into contact with the peritoneum posteriorly.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Baltimore 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 82998 Version 1.0</div></div></div>"}};